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Preface
in French by Professor Dr. Liliane Schnitzler
C’est pour moi un honneur de préfacer la thèse du docteur H. de Koning sur le syndrome qui 
porte mon nom. 
Le 28 octobre 1972, nait l’histoire du cas princeps dans notre service au CHU d’Angers, présenté 
à la journée nationale comme cas pour diagnostic. 
En 1987, à l’hôpital St. Louis de Paris, ce cas est baptisé syndrome de Schnitzler par M. Janier et 
B. Aguenier. 
En mai 2012, il est adopté par un groupe de dermatologistes et immunologistes internationaux 
à l’instigation de l’école de Strasbourg (D. Lipsker) et de Nimègue (A. Simon et H. de Koning). 
Essayons de brosser à gros traits cette observation durant près de 20 ans…
En 1968, au décours d’une prostatectomie pour adénome confirmé histologiquement, un 
agriculteur retraité souffre de douleurs articulaires et surtout osseuses du bassin et des jambes, 
par crises, la radiographie  révélant  une ostéocondensation de l’aile iliaque droite et des tibias qui 
ne sont pas des métastases. Les douleurs s’intensifient, rebelles aux antalgiques. 
A partir de la fin 1971, des lésions de type urticarien non prurigineuses et durables conduisent à 
une hospitalisation en dermatologie: chez ce patient de 62 ans, les mêmes crises se multiplient, 
faites de douleurs osseuses excruciantes, avec fièvre désarticulée, adénomégalies, hépatomégalie, 
amaigrissement, durant de quelques jours à quelques semaines, puis disparaissent spontanément.
De multiples explorations complémentaires reviennent négatives mais la VS est à plus de 100, 
la  fibrine à 10 g/l, et un pic d’IgM kappa avec protéinurie de Bence Jones se dessine qui ira 
croissant. On pourra constater par la suite une anémie inflammatoire avec courant granuleux au 
fond d’œil par hyperviscosité sanguine, des phosphatases alcalines augmentées, des IgE basses, 
et l’extension de l’ostéocondensation au fémur droit.   
Sur les diverses biopsies cutanées, existe un infiltrat perivasculaire polymorphe avec histiocytes, 
polynucléaires neutrophiles, mastocytes et plasmocytes normaux, sans vascularite.
En mai 1974, après une 2ème présentation à Paris en raison de cas semblables retrouvés notamment 
au CHU de Nantes, et bien que les biopsies ganglionnaires et médullaires (crête iliaque) n’aient 
pas révélé d’envahissement plasmocytaire et que la sécrétion plasmocytaire soit  polyclonale 
en IFD, dans la crainte d’une maladie de Waldenström atypique, sont prescrits 12 mg/jour de 
chlorambucil et 20 mg/jour de prednisone.
Les résultats cliniques sont si spectaculaires que le patient reprend une vie quasi normale et que 
les doses de prednisone sont diminuées à 5 mg/jour et le chlorambucil arrêté en 1986. Il sera suivi 
régulièrement dans le service par J.L. Verret après mon départ en 1982.
De 1974 à 1991, pourtant, à bas bruit, la VS reste entre 93 et 124, on retrouve à la biopsie 
cutanée un dense infiltrat riche en polynucléaires neutrophiles autour de vaisseaux à endothélium 
turgescent sans nécrose fibrinoïde et par endroits des polynucléaires pycnotiques en exocytose (IFD 
négative). Les lésions osseuses s’étendent à l’aile iliaque gauche puis aux fémurs, l’hyperfixation 
est diffuse à la scintigraphie, l’IgM s’élève à 1580 mg/dL (IgG 735 mg/dL et IgA 82 mg/dL).
En 1988, J.H. Saurat (Genève) émet l’hypothèse du rôle de l’IL-1 dans l’induction des principaux 
signes cliniques et en effectue le dosage dans les cas publiés. 
En 1991 se situe l’épilogue: à 81 ans, le patient est hospitalisé d’urgence pour une pancytopénie 
sévère dont il décède en quelques jours. Une IgG kappa s’est associée à l’IgM, inchangée. 
L’autopsie découvre une infiltration tumorale médullaire monoclonale au prélèvement de crête 
iliaque, une dysmyélopoïése, et un même aspect de lymphome dans la rate, le foie, les reins, les 
ganglions lymphatiques latéro-trachéaux et une zone ostéocondensante iliaque. 
Comment ce cas, isolé et provincial, a-t-il pu se diffuser au pays et sortir de ses frontières? 
Parce que les signes cliniques, curieusement associés, étaient comme les éléments incomplets 
d’un puzzle difficile à comprendre et qu’aucune lecture bibliographique ne faisait état de cas 
semblable antérieur.   
Parce que, présente fortuitement à une consultation de J. Civatte à l’hôpital St. Louis en 1986, 
j’ai pu authentifier un des cas présentés ce jour là, tout-à-fait superposable à celui d’Angers, et 
resté sans diagnostic depuis des mois. 
Ont alors suivi deux publications et une thèse, que les auteurs, M. Janier et B. Aguenier, ont 
intitulées syndrome de Schnitzler. 
Cela m’a permis de connaître les médecins présents au 1er meeting international de Strasbourg 
en Mai 2012, en particulier Heleen de Koning, dont le sourire et la compétence ont conquis 
l’auditoire. 
Que pour son travail, débuté en 2003 à l’initiative de professeur J.W.M. van der Meer et docteur 
A. Simon à partir de deux cas et que pour sa participation au traitement par anakinra dès 2004, à 
la revue générale des cas publiés en 2007 et au meeting de mai 2012, cette jeune dermatologue 
clinicienne et scientifique en reçoive les compliments mérités.
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Figure 1.1. Structure of normal human skin
The epidermis consists of the following layers: 
A) stratum corneum, (stratum lucidum), B) stratum 
granulosum, C) stratum spinosum and D) stratum basale. 
It consists predominantly of keratinocytes (95%), while 
Langerhans cells and melanocytes are the most common 
non-keratinocytic resident cells.
The underlying dermis contains hair follicles, sweat 
glands, sebaceous glands, E) collagen and elastin fibers,
F) fibroblasts, G) blood vessels, nerve endings, and a 
variable number of resident and circulating bone-marrow-
derived cells, such as mast cells, macrophages and 
lymphocytes. 
The subcutis (not shown) mainly consists of adipo-
cytes, blood vessels, and a variable number of resident 
and circulating bone-marrow-derived cells.
This thesis focuses on innate immunity in the inflammatory skin diseases psoriasis and atopic 
dermatitis and in particular in the autoinflammatory disorder Schnitzler’s syndrome (SchS). In 
the latter, we also studied systemic inflammation, using various methodologies ranging from 
next-generation sequencing to a clinical drug trial: a true bedside-to-bench story – and vice versa. 
Here, I will briefly introduce these topics along with basic knowledge of the skin and immu-
nity. 
1.1 The skin
A true multitasker, the skin serves many purposes. It protects the internal environment from 
harmful substances and radiation, prevents water loss, and is involved in thermoregulation and 
vitamin D production, to name a few. Surrounded by trillions of microorganisms, the skin is also 
pivotal as a physical and chemical barrier to tissue invasion by pathogens. Figure 1.1 shows the 
structure of the skin and summarizes the constituents of the epidermis, dermis and subcutis. 
Physically, the tightly packed corneocytes (terminally differentiated dead keratinocytes) impair 
inward microbial migration. This was illustrated by our study in which we showed that upon re-
moval of the stratum corneum by means of tape stripping, no bacteria could be detected in the 
deepest stratum corneum layers.1 The epidermis is capable of rapid regeneration upon wounding, 
thereby minimizing the exposure to microbes. Keratinocytes do not solely constitute a physical 
barrier, but also a chemical barrier, as they are capable of producing many immunological sub-
stances, such as antimicrobial proteins. Moreover, various kinds of leukocytes are present in or 
can be attracted to the skin, and in concert with the keratinocytes, they constitute an effective 
chemical and cellular barrier against pathogens. Recent findings indicate that hosts can actually 
benefit from the presence of several species of microorganisms, and the study of interactions 
between host factors and the skin (and gut) microbiome is gaining momentum. It appears that 
hosts not only benefit from commensals because of their physical competition with pathogens 
for a niche on the skin, but also because of their immune-modulating effects. In patients with 
certain genetic susceptibilities, however, commensal-derived molecular patterns are thought to 
contribute to chronic inflammatory conditions, such as Crohn’s disease.2
1.2  Immunity, the basics
1.2.1 Cells 
Leukocytes of multiple subtypes are the professionals of the immune system. In-depth discussion 
of immunity is beyond the scope of this introduction, so we will focus on the cells and factors 
that were studied in this thesis. Roughly, the immune system is divided into innate and adaptive 
immunity, a paradigm that was recently challenged by the identification of intermediates such as 
innate lymphoid cells as well as by the concept of trained immunity.3 Innate immune responses 
are fast and do not require previous encounters with the eliciting factors. The cells involved are 
natural killer (NK) cells, neutrophils, eosinophils, basophils, mast cells, monocytes/macrophages 
Chapter  1
14
and dendritic cells. Subsets of the latter are defined by maturity, location and specific subtype, 
such as the epidermis-residing Langerhans cells. Importantly, several non-specialized cell types 
were found to be able to exert innate immune functions too, as will be discussed in Chapters 3, 
4, 5, 6, 7 and 15 of this thesis. Neutrophils are the most abundant leukocytes in the circulation. 
They are short-lived innate immune cells and are among the first cells to migrate towards sites of 
inflammation. Neutrophils fight bacteria by means of phagocytosis, the secretion of antimicrobial 
proteins, and the formation of neutrophil extracellular traps. Monocytes are innate immune cells 
capable of producing large amounts of proinflammatory cytokines, including interleukin-1 (IL-1), 
IL-6 and tumor necrosis factor alpha (TNFa). In tissues, they transform into macrophages or den-
dritic cells, which are capable of phagocytosis and elicitation of an adaptive immune response, 
respectively. 
T- and B-lymphocytes are the prototypical cells of the adaptive immune system, which acts 
slower than innate immunity but enables immunological memory. Multiple subsets of T-lympho-
cytes have been described. CD8+, or cytotoxic T cells, kill cells that express epitopes on their 
surface that are recognized as foreign by the particular T cell receptor (TCR). These cells are im-
portant for the elimination of virus-infected or tumor cells. CD4+, or T helper (Th) cells, facilitate 
immune responses against a plethora of pathogens by producing a large variety of cytokines 
upon activation via the TCR. Th1 cells predominantly produce interferon gamma (IFNg), Th2 cells 
IL-4 and IL-13, Th17 cells IL-17, and Th22 cells IL-22. Regulatory T cells (Tregs) have been reported 
to exert crucial immunomodulatory functions in health and disease. The various innate lymphoid 
cells and other sublineages will not be discussed here. B-cells have antigen presenting properties, 
produce antibodies once differentiated into plasma cells, and secrete a number of cytokines.
1.2.2 Antigen processing and presentation 
This topic is only briefly touched upon in Chapter 16. The specificity of T-cell activation relies upon 
the unique properties of the major histocompatibility complex (MHC), also known as the human 
leukocyte antigen (HLA) system. HLA proteins present small peptides on the cell surface, and 
this HLA-peptide complex can only be recognized by a highly specific TCR. HLA type I proteins 
(HLA-A, HLA-B and HLA-C) present peptides derived from cytoplasmic (e.g. viral, tumor or nor-
mal human) proteins, whereas HLA type II proteins (HLA-DO, HLA-DP, HLA-DR, HLA-DQ) present 
peptides derived from endocytosed (e.g. microbial or human) proteins from outside the cell. To 
prevent autoimmunity, the TCR repertoire is strictly regulated in the thymus where autoreactive T 
cell clones are eliminated. The HLA classes can be further subdivided, and the many allele combi-
nations and polymorphisms contribute to the genetic variability in the HLA region. HLA subclasses 
and polymorphisms have been associated with several autoimmune diseases.2,4-8 Psoriasis, for 
example, is associated with HLA-C*06 and a single nucleotide polymorphism of endoplasmatic re-
ticulum aminopeptidase 1 (ERAP1), which processes peptides prior to antigen presentation.4,7,9,10 
1.2.3 Pattern recognition receptors and inflammasomes
Several decades ago, T- and B-cell receptors were presumed to be the only specific receptors of 
the immune system, but it was the late Charles Janeway who in 1996 reported that fruit flies defi-
cient in the protein Toll succumbed to infections with Aspergillus.11 This led to the identification of 
multiple mammalian toll-like receptors (TLRs) that recognize a multitude of pathogen-associated 
molecular patterns (PAMPs) and endogenous damage-associated molecular patterns (DAMPs). 
Moreover, several other classes of pattern recognition receptors (PRRs) were identified, including 
the RIG-like helicase receptors (RLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs), 
and absent in melanoma 2 (AIM2)-like receptors (ALRs). 
The roles of PRRs in infectious skin diseases and immune disorders of the skin are reviewed 
in Chapters 4 and 5, respectively. Figure 4.1 schematically shows the location and simplified 
signaling pathways of most currently identified PRRs (Chapter 4). Some PRRs, such as NLRP3, 
NLRP1, NLRC4 and AIM2, can form inflammasomes, which are multiprotein complexes that can 
activate the potent proinflammatory cytokines IL-1b, IL-18 and IL-33 (Chapter 5). In this thesis, 
AIM2, NLRP3 and dectin-1 play crucial roles (Chapters 6, 7, 8, 14). 
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1.2.4 Cytokines at a glance
Cytokines are intercellular mediators and can act in an autocrine, paracrine or endocrine fashion. 
Multiple variables define the net effect of a certain cytokine, including its extracellular abun-
dance, the presence and quantities of its specific receptor and receptor blockers, the avidity of re-
ceptor binding, the presence and potency of downstream signaling pathways, and the enhancing 
or interfering effect of concomitant activation of other signaling pathways by other agents. 
Several cytokines can exert similar functions or even bind to similar receptors, such as IL-1b that 
binds to the same IL-1 receptor as IL-1a and the IL-1 receptor antagonist (IL-1ra). IL-1b turned out 
to be the key cytokine in SchS and hence in this thesis (Part 3). Cytokines can be subdivided into 
proinflammatory or anti-inflammatory activity. IL-1b is one of the major proinflammatory cyto-
kines, like IL-6, IL-17, IL-18 and TNFa, whereas IL-1ra and IL-10 are the major anti-inflammatory 
cytokines. Interferons are specialized in antiviral responses and are produced upon activation of 
PRRs that sense viral particles, and TCRs that recognize a specific viral epitope in an HLA molecule. 
Some cytokines are readily excreted, but other require prior processing, such as IL-1b (Chapter 5).
1.2.5 Antimicrobial proteins
Antimicrobial proteins or peptides (AMPs) are endogenously produced antibiotics that are rapid-
ly induced in epithelia and leukocytes by inflammatory and infectious triggers.12 AMPs include 
defensins, cathelicidins, C-type lectins, ribonucleases, WAP-domain proteins, S100 proteins and 
psoriasin. Their antimicrobial specificities depend on the properties of the specific proteins. Human 
beta defensin 2 (hBD-2), for example, exhibits potent antimicrobial activity against Gram-negative 
bacteria and Candida, but not against Staphylococcus aureus.13 AMPs influence other processes 
as well, such as chemotaxis, cytokine production, angiogenesis, antigen presentation, and wound 
healing.12 
hBD-2 and several other AMPs are strongly increased in the epidermis in lesional skin of the 
chronic inflammatory skin disease psoriasis. As psoriasis is associated with skin barrier disruption, 
we studied the effect of experimental skin barrier disruption on the expression of several AMPs in 
both healthy controls and patients (Chapter 3). AMPs also appeared to be upregulated in lesional 
epidermis of SchS patients, hence showing that the inflammatory process in the neutrophilic 
urticarial dermatosis of these patients is not confined to the dermis (Chapter 15).
1.3 Diseases
1.3.1 Psoriasis
Psoriasis is a chronic inflammatory skin disease with a prevalence of 1-2% in the general popula-
tion. Psoriasis vulgaris is the most common phenotype, and is characterized by erythematosqua-
mous plaques with a predilection for extensor surfaces, ears and scalp. Other subtypes, that 
sometimes overlap, include guttate psoriasis, generalized pustular psoriasis and palmoplantar 
pustular psoriasis. Patients suffer most from social stigma and embarrassment, the dispersion of 
scales in their houses, time-consuming therapies with various potential side effects, and variable 
degrees of pruritus and pain. Also, psoriasis has been associated with cardiovascular risk factors 
such as obesity, but any causality and especially the direction of causality remain to be identified.14 
Histopathological features of psoriatic lesional skin include acanthosis and elongated rete ridges, 
a thin suprapapillar epidermis, hyperparakeratosis, Munro’s abcesses, and a cellular infiltrate in-
cluding neutrophils, Th1 and Th17 lymphocytes (Figure 1.2B). The etiology of psoriasis is multifac-
torial. Recent genome-wide association studies have identified a number of genetic risk factors, 
including HLA-C*06, polymorphisms in ERAP1 and in several adaptive and innate immunity-
related genes, copy number variation of defensin beta 4 (DEFB4), which encodes hBD-2, and the 
deletion of late cornified envelope proteins (LCE) 3B and 3C.10,15-17 Environmental factors also play 
a role, and the prototype is the elicitation of guttate psoriasis by streptococcal pharyngitis. The 
eventual phenotype results from the interplay between genetic and environmental risk factors. 
Better insight in the involved pathways enables targeted treatment, which I will not address here. 
In this thesis, we studied PRR expression and function in human keratinocytes, normal epider-
mis and psoriasis vulgaris lesional skin (Chapter 6). We also examined the effect of skin barrier 
disruption in non-lesional skin of psoriasis patients (Chapters 2 and 3).
Chapter  1
16
Figure 1.2. Histopathology of normal skin and skin lesions of patients with psoriasis, atopic 
dermatitis and Schnitzler’s syndrome
A. Normal skin
B. Psoriatic plaque: acanthosis, elongated rete ridges, hyperparakeratosis, mixed dermal cellular infiltrate
C. Atopic dermatitis lesion: acanthosis, spongiosis, mixed dermal cellular infiltrate
D. Schnitzler’s syndrome urtica: dermal infiltrate of neutrophils and macrophages
(images courtesy of Ivonne van Vlijmen-Willems, Dermatology, Radboudumc)
1.3.2 Atopic dermatitis
Atopic dermatitis, or atopic eczema, is the most prevalent inflammatory skin disease in children, 
but many adults remain or become affected too. Allergic rhinitis (hay fever), asthma and atopic 
dermatitis form the atopic triad, which is often familial. Skin lesions are very itchy and typically 
involve the flexural surfaces of the extremities, periorbital areas, and in infants the face, but any 
skin part can be affected. The erythematosquamous plaques may be moist and secondary bacte-
rial infection with Staphylococcus aureus is common. Histopathological examination shows acan-
thosis and spongiosis of the epidermis, and a variable cellular infiltrate that typically involves Th2 
cells and eosinophils (Figure 1.2C). The pathogenesis has been partially elucidated, and involves 
both epidermal and immunological factors. Importantly, common loss-of-function variants of the 
epidermal barrier protein filaggrin were identified as a major risk factor for atopic dermatitis.18 
It is postulated that the resulting impairment of the skin barrier results in increased exposure 
of the skin cells to allergens and PAMPs, which induce inflammation. The induction of AMPs is 
partially thwarted by the Th2 cytokines, whereas in psoriasis AMPs are induced by Th1 and Th17 
cytokines. Supposedly, this could explain the high rate of secondary bacterial infections in atopic 
dermatitis and the low rate seen in psoriatic lesional skin. 
We examined the effect of skin barrier disruption in non-lesional skin of atopic dermatitis 
patients, and compared in-vitro responsiveness of keratinocytes from healthy controls, psoriasis 
patients and atopic dermatitis patients (Chapters 2 and 3).
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1.3.3 Schnitzler’s syndrome
In 1972, Professor Dr. Liliane Schnitzler described the first case of the syndrome that was later 
given her name. She describes the evolution of disease in this index patient in the Preface of this 
thesis. SchS is a disabling autoinflammatory disorder, characterized by a chronic urticarial rash, 
monoclonal gammopathy, fever, arthralgia or arthritis and bone pain.19-22 SchS is considered as 
rare, but it is highly underdiagnosed, and many patients have consulted rheumatologists, derma-
tologists and internists for years with unexplained joint and bone pain, fever and skin symptoms 
before a diagnosis is made. Histopathologically, skin lesions typically feature a dermal infiltrate of 
neutrophils and macrophages without clear vasculitis (Figure 1.2D). 
Part 3 of this thesis comprises our findings regarding the clinical features and follow-up, treat-
ment effects and pathophysiology of SchS.
1.4 Research questions addressed in this thesis
This thesis deals with three major themes: skin barrier disruption, cutaneous PRRs, and SchS. 
The following research questions are addressed:
In Part 1 we show the effect of superficial skin barrier disruption on epidermal expression of 
genes and proteins involved in the physical (Chapter 2) and immunological (Chapter 3) barrier 
function of the skin. We investigate whether there is a difference in response between keratino-
cytes derived from healthy controls, psoriasis patients and AD patients.
In Part 2 we provide an overview of the current knowledge concerning PRRs in infectious (Chap-
ter 4) and immunological (Chapter 5) skin diseases, and compare the epidermal expression of 
PRRs in psoriatic plaques, atopic dermatitis lesions and healthy skin (Chapter 6). We address the 
questions which cells express AIM2 in the skin; whether AIM2 expression in the skin is influenced 
by inflammation (Chapter 7); and if AIM2 is differentially expressed in skin tumors (Chapter 8).
In Part 3 we review the current knowledge of SchS (Chapter 9, updated in Chapter 17); assess the 
efficacy and safety of novel treatment modalities (Chapters 10-12); and address multiple aspects 
of the pathophysiology of SchS by investigating both the hematological and skin compartments, 
and the role of IL-1b in particular (Chapters 13-16).
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Abstract 
Recent studies have emphasized the importance of heritable and acquired skin barrier 
abnormalities in common inflammatory diseases such as psoriasis and atopic dermatitis (AD). 
To date, no comprehensive studies on the effect of experimental barrier disruption on cornified 
envelope protein expression have been performed. Here we analyzed the effect of experimental 
skin barrier disruption on the expression of cornified envelope structural proteins and keratinocyte 
differentiation-regulating proteins.
We examined mRNA (day 1, 3 and 7) and protein (day 1, 2, 4 and 9) expression levels of 
structural proteins and regulatory molecules after sodium dodecyl sulphate (SDS) application on 
normal skin, and tape stripping of uninvolved epidermis of psoriasis patients, AD patients and 
healthy controls.
Upon tape stripping, several structural molecules were significantly downregulated (at the 
mRNA level as well as the protein level), including LCE5A, LCE2B, FLG, FLG2, and LOR, whereas 
others were upregulated: IVL, SPRR1, SPRR2, HRNR, and most notably LCE3A. The epidermal 
crosslinking enzymes transglutaminase (TGM)1, TGM3 and TGM5 were all upregulated, whereas 
proteases involved in the desquamation process (CTSV, KLK5 and KLK7) were downregulated or 
unaffected. Most results were similar in SDS-instigated irritant contact dermatitis. There was no 
significant difference in response between normal epidermis and non-lesional skin of psoriasis 
and AD patients.
Skin barrier disruption induces a temporary barrier repair response composed of increased 
expression of several cornification-related proteins, and decreased expression of some structural 
and desquamation-related proteins.
The balance between cornification and desquamation during skin barrier repair
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Introduction
There are many skin diseases with a Mendelian pattern of inheritance that are caused by 
mutations in genes involved in cornification, such as ichthyosis vulgaris (MIM 146700), X-linked 
recessive ichthyosis (MIM 308100), lamellar ichthyosis (TGM1, MIM 242300)1,2, and Netherton 
syndrome (SPINK5, MIM 256500).3 The impaired skin barrier function of these diseases is thought 
to contribute to the co-occurrence of atopic dermatitis (AD) in some of them, including ichthyosis 
vulgaris and Netherton syndrome.4,5 Recent genetic studies on common inflammatory diseases 
such as AD, psoriasis, asthma and Crohn’s disease have underscored the importance of epithelial 
function in many organs such as skin, lung and gut. The finding that null alleles of the epidermis-
expressed gene encoding filaggrin (FLG) are a major risk factor for AD has caused a paradigm shift 
for multifactorial inflammatory diseases.6 We and others have demonstrated that copy number 
variation of genes that encode keratinocyte-derived proteins predispose to psoriasis. These 
include the antimicrobial proteins of the beta-defensin family, and the late cornified envelope 
(LCE) proteins.7,8 It was found that deletion of the LCE3B and LCE3C genes (LCE3C_LCE3B-
del) is a strong psoriasis risk factor which has now been replicated world-wide in many ethnic 
backgrounds.9,10 After a decades-long dominance of the immunological paradigm in psoriasis 
and AD, these findings sparked a reappraisal of the role that epidermal biology and stratum 
corneum homeostasis play in these diseases. Currently the notion is held that skin barrier defects 
and aberrant immune responses jointly instigate the vicious circle of inflammation in chronic 
psoriasis and AD lesions.11,12
Skin barrier function results from the physical properties of the stratum corneum that consists 
of terminally differentiated keratinocytes, called corneocytes. At the end stages of epidermal 
differentiation, involucrin (IVL), envoplakin and periplakin form a scaffold on the inner plasma 
membrane for cornified-envelope assembly.13 Subsequently, other structural proteins are 
crosslinked to this scaffold by the transglutaminases (TGM), later followed by loricrin and small 
proline-rich proteins, and lipids complete the corneocyte backbone.14 Finally, desquamation 
ensues upon proteolytic degradation of the corneodesmosomes.15 Meanwhile, epidermal stem 
cells contribute to epidermal homeostasis by continuously adapting the supply of new epidermal 
cells.16 The effect of experimental barrier disruption on some cornified envelope genes has been 
reported. FLG and IVL protein expression was shown to be upregulated upon barrier disruption by 
means of tape stripping 17, and increased mRNA levels of FLG, IVL, TGM1 and lipid-metabolizing 
enzymes upon application of sodium dodecyl sulphate (SDS) were described.18,19 However, these 
effects have not been investigated comprehensively as yet, nor is it known if cornification-related 
proteins are expressed differently in psoriasis and AD skin after experimental barrier disruption. 
In this study, we examined expression levels of structural, cornification- and desquamation-
related elements at the mRNA and protein level upon tape stripping of uninvolved epidermis 
of psoriasis and AD patients and healthy controls. Morphology of the barrier-disrupted skin 
was studied by light microscopy and electron microscopy. In addition to mechanical skin barrier 
disruption, we studied SDS-induced irritant contact dermatitis in normal skin of healthy volunteers 
as a model for chemically induced skin barrier dysfunction.
Materials and Methods
Skin biopsies
Twenty-three healthy volunteers, nine chronic plaque-type psoriasis patients and ten chronic AD 
patients were included in the study upon written informed consent. All patients had moderate 
to severe disease. The study was approved by the local medical ethical committee and conducted 
according to the Declaration of Helsinki principles. 
Irritant contact dermatitis was induced by application of a patch with 5% SDS solution on 
the lower back of ten healthy controls, as previously described.20 After 4 or 8 hours the SDS-
containing patch was removed and 24 hours (for mRNA) or 48 hours (for IHC) after exposure, 
3-mm biopsies were taken from the erythematous exposed areas and from healthy control skin. 
For stratum corneum removal, two areas on the lower back measuring 3x2 cm each were 
tape stripped until the surface became slightly shining after repeated (20-70 times) application 
and removal of adhesive tape. Tape stripping was performed in 13 healthy controls, and on non-
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lesional skin of nine chronic plaque-type psoriasis patients and ten chronic AD patients. At several 
time points after tape stripping, 3-mm biopsies were taken from the tape-stripped area and from 
healthy skin from the same individual for both RNA isolation (day 1, 3 and 7) and histology (day 
1, 2, 4 and 9).
Isolation of epidermal sheets, RNA isolation and real-time quantitative PCR
Isolation of epidermal sheets for mRNA isolation was performed as previously described.21 
RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany), and a DNase I treatment 
was performed according to manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Reverse 
transcriptase reactions and qPCR were performed as described previously.22 The amount of 
mRNA for a given gene in each sample was normalized to the amount of mRNA of the human 
ribosomal phosphoprotein P0 (RPLP0) reference gene in the same sample. Primers for qPCR 
(Biolegio, Nijmegen, the Netherlands) were only accepted if their efficiency was 100 ± 10 % and 
corrections were made for primer efficiency. Relative mRNA expression levels were calculated 
with the delta-delta cycle threshold (∆∆Ct) method 23 and each value was compared to its intra-
individual healthy control sample (SDS-treated skin N=6, normal tape-stripped skin N=9, non-
lesional tape-stripped skin of psoriasis patients N=7, and of AD patients N=8). 
Immunohistochemistry and immunofluorescence
Paraffin-embedded formalin-fixed skin sections were blocked with 20% normal goat serum 
(for LCE2 and FLG2) or normal horse serum (CTSV, IVL) and subsequently incubated with either 
CTSV mouse monoclonal antibody (1:2000, Mab 2080, R&D Systems Europe, Abingdon, UK), 
IVL mouse antibody (1:20, antigen retrieval 10 minutes at 95°C in 10 mM citrate buffer pH 6,0, 
homemade MON-150 24), or LCE2 rabbit antibody (1:1000, home made by J-Y.T. 25) for 1 hour at 
room temperature or with either FLG2 rabbit antibody (1:100, antigen retrieval 40 min at 95°C in 
glycine 50 mM, pH 3.5, homemade by M.S. 26) or HRNR rabbit antibody (1:50, antigen retrieval 
40 min at 95°C in glycine 50 mM, pH 3.5, homemade by M.S. 27) overnight at 4°C. Next, sections 
were incubated for 30 minutes with a secondary antibody (biotinylated horse anti-mouse (IVL) or 
biotinylated goat anti-rabbit (LCE2 and FLG2) IgG in PBS containing 1% BSA, Vector laboratories, 
Burlingame, CA) and incubated for 30 minutes with Avidin-Biotin complex (Vector Laboratories). 
For CTSV, secondary staining was performed with an HRP-conjugated anti-mouse IgG antibody 
(EnVision+System, K4004, Dako North America, Carpinteria, CA). For HRNR, anti-rabbit IgG 
secondary antibodies were labeled with Alexa-FluorR 555 (Invitrogen). Eventually, sections were 
treated with 3-amino-9-ethyl carbazole (Calbiochem, San Diego, CA) for 10 minutes.
Transglutaminase-1 immunofluorescence and in-situ activity assay
Our previously described in-situ TGM1 activity assay was here performed on unfixed cryostat 
skin sections of two healthy individuals (normal skin, tape-stripped skin and SDS-treated skin 
of each).28 The tissue sections were incubated under a coverslip for 90 min at 37°C with 100 
µl TGM1 in-situ-assay buffer, in the presence of TGM1 rat anti-mouse antibody (1:5 29). The 
TGM1 in-situ-assay buffer contained 0.1 M Tris-HCl (pH 8), 1 mM DTT, 1 µM FITC-K5 30, and 5 
mM CaCl2 or 1 mM EDTA as a negative control. Next, tissue sections were incubated with the 
secondary antibody (1:200, Alexa-Fluor 594 goat anti-rat IgG highly cross-absorbed, Molecular 
Probes, Eugene, OR), and nuclei-staining DAPI (1:3000).
Electron microscopy
For conventional transmission electron microscopy, 2-mm biopsies from normal skin and tape-
stripped skin of two healthy individuals were fixed in half-strength Karnovsky fixative, followed 
by further fixation in 1% osmium tetroxide in distilled water. After en bloc staining with uranyl 
acetate, specimens were dehydrated in ethanol and embedded in Epon812 (Taab, Berkshire, 
UK).31 The corneodesmosome density was calculated as a percentage of the membrane length, 
and different layers were compared in normal and tape-stripped skin.
The balance between cornification and desquamation during skin barrier repair
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Statistical analysis
A repeated-measures analysis of variance using SPSS v16.0 (SPSS Inc) was performed on the ∆Ct 
values of the qPCR data corrected for primer efficiency. ∆Ct is the difference between the Ct 
of the target gene and the reference gene (RPLP0). For the corneodesmosome density on the 
electron microscopic images, the p-value was calculated by means of an unpaired 2-tailed t-test.
Results
Barrier disruption strongly influences expression of barrier repair and maintenance 
genes in human epidermis
mRNA expression levels in purified epidermal sheets of SDS-treated and tape-stripped skin 
were normalized to those in control epidermis of the same individual. Upon tape stripping, 
the expression of several structural cornified envelope genes was significantly downregulated, 
including LCE5A, LCE2B, FLG2, LOR and FLG, whereas others were upregulated: IVL, SPRR1, 
SPRR2 and most notably LCE3A (Table 2.1). The epidermal crosslinking enzymes TGM1, TGM3 and 
TGM5 were all upregulated, whereas expression levels of proteases involved in the desquamation
Table 2.1. Relative epidermal mRNA expression levels of structural, cornification- and 
desquamation-related genes upon SDS application or tape stripping
HUGO 
gene 
symbol
Protein Fold change1 P-value compared to US6
SDS2 TS 
NS3
TS
 PS4
TS 
AD5
SDS TS 
NS
TS 
PS
TS
 AD
Structural proteins
LOR Loricrin      0,48     0,13     0,41     0,24 0,07 0,00 0,03 0,00
IVL Involucrin      1,2   11     7,1   10 0,91 0,00 0,00 0,00
FLG Filaggrin      0,80     0,24     0,44     0,33 0,20 0,00 0,02 0,00
FLG2 Filaggrin-2 / Ifapsoriasin      0,27     0,17     0,23     0,13 0,01 0,00 0,01 0,00
HRNR Hornerin    52     9,1     7,7     2,6 0,01 0,79 0,45 0,70
RPTN Repetin      0,85     0,98     0,75     0,82 0,14 0,38 0,01 0,16
EVPL Envoplakin      0,74     1,4     0,90     0,97 0,17 0,67 0,25 0,33
PPL Periplakin      0,85     1,6     1,3     0,94 0,32 0,09 0,25 0,32
SPRR1 Small proline-rich protein 1    13   50   47   62 0,00 0,00 0,00 0,00
SPRR2 Small proline-rich protein 2    13   32   35   16 0,01 0,00 0,00 0,00
LCE2B Late cornified envelope 2B      0,49     0,10     0,39     0,17 0,05 0,00 0,01 0,00
LCE3A Late cornified envelope 3A  210 571 466 214 0,00 0,00 0,00 0,00
LCE5A Late cornified envelope 5A      0,08     0,01     0,09     0,06 0,00 0,00 0,00 0,00
Cornification enzymes
TGM1 Transglutaminase 1     1,2   12     5,1     6,3 0,73 0,00 0,00 0,00
TGM3 Transglutaminase 3     1,2     4,7     3,5     3,9 0,64 0,00 0,00 0,00
TGM5 Transglutaminase 5     0,88     1,9     2,4     2,3 0,20 0,02 0,04 0,07
Desquamation enzyme (inhibitor)
CTSV Cathepsin V     0,71     0,64     0,57     0,35 0,13 0,02 0,01 0,00
KLK5 Kallikrein 5     1,36     1,47     1,15     1,07 0,51 0,37 0,91 0,92
KLK7 Kallikrein 7     1,57     2,17     1,42     1,42 0,48 0,05 0,18 0,02
CST6 Cystatin M/E     0,34     0,46     0,56     0,49 0,02 0,01 0,02 0,00
1Mean relative epidermal mRNA expression levels after 24 hours. First, the ratio of each treated sample and 
its intra-individual control sample was calculated using Livak’s ∆∆Ct method. 2Mean ratio in SDS-treated skin 
(N=6), 3tape-stripped healthy skin (TS NS, N=9), 4tape-stripped non-lesional skin of psoriasis patients (TS PS, 
N=7), and 5tape-stripped non-lesional skin of atopic dermatitis patients (TS AD, N=8). 6P-value of ∆Ct of 
treated samples compared to intra-individual control samples of untreated skin (US).
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process of the skin were decreased (cysteine protease cathepsin V (CTSV)) or unaffected (the 
serine proteases kallikrein 5 and 7 (KLK5 and KLK7)). Furthermore, a decreased mRNA expression 
of the cysteine-protease inhibitor cystatin M/E (CST6) was observed. Interestingly, there was no 
significant difference in response between normal epidermis and non-lesional skin of psoriasis 
and AD patients (statistical data not shown). 
SDS-application induced overall similar responses as tape stripping, but its effects were 
significantly smaller on IVL, SPRR1, TGM1, TGM3 and TGM5 mRNA expression levels (Table 2.1).
Barrier disruption induces TGM1 and IVL and reduces FLG2, LCE2 and CTSV protein 
expression in human epidermis
Skin biopsies for histology were taken 48 hours after SDS application on normal skin or after tape 
stripping of normal skin or uninvolved skin of psoriasis and AD patients. Structural, crosslinking- 
and desquamation-related proteins were selected for immunohistochemical analysis. Treated skin 
biopsies were compared to intra-individual healthy control skin and most biopsies were taken 
from the same individuals that provided the biopsies for mRNA measurement. LCE2 and CTSV 
stainings were strongly reduced in all conditions, which was consistent with the mRNA data 
(Table 2.1, Figure 2.1). Both TGM1 and IVL protein expression levels were notably increased in the 
stratum granulosum, extending into the stratum spinosum. Whereas SDS did not induce TGM1 
and IVL mRNA expression levels after 24 hours, it did induce protein expression levels after 48 
hours (Table 2.1 and Figures 2.1 and 2.4). 
Figure 2.1. Barrier disruption induces IVL and reduces LCE2 and CTSV protein expression in human 
epidermis. Immunohistochemical staining of normal skin, and skin 48 hours after barrier disruption by 
means of either SDS application or tape stripping of normal skin. Treated skin was compared to intra-
individual non-lesional skin. Each picture is representative for data from six individuals. Bar: 100 µm.
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FLG2 protein expression levels were similarly reduced in normal skin and non-lesional skin of 
psoriasis and AD patients upon barrier disruption (Figure 2.2).
Barrier-associated protein expression levels remain aberrant for over a week after acute 
barrier disruption
We next set out to determine the time course of altered expression levels upon experimental 
skin barrier disruption. Gene expression levels of the majority of skin barrier-associated genes 
had normalized 3 days after tape stripping and remained normal at 7 days (data not shown). 
The only exception was hornerin (HRNR), a protein that was recently identified as part of the 
cornified envelope 27, with highly upregulated mRNA levels at day 3 that were largely normalized 
at day 7 (data not shown). The effects of both tape stripping and SDS application were studied 
at the protein level. IVL, TGM1, LCE2 and FLG2 protein expression levels were changed after 12 
hours with a peak at 48 hours for IVL and TGM1, followed by their gradual normalization during 
the next week. LCE2 and FLG2 were still decreased at day 9 (data not shown). HRNR protein 
expression levels peaked between days 2 and 4 and were still elevated at day 9 (Figure 2.3). 
Figure 2.2. Reduced FLG2 protein expression upon experimental barrier disruption in normal skin 
and nonlesional skin of psoriasis and atopic dermatitis patients. Immunohistochemical staining of 
normal skin, and skin 48 hours after barrier disruption by means of either SDS application on normal skin, 
or tape stripping of normal skin (TS NS) or uninvolved skin of psoriasis (TS PS) and atopic dermatitis (TS AD) 
patients. Treated skin was compared to intra-individual healthy control skin. Each picture is representative 
for data from six individuals. Bar: 100 µm.
Figure 2.3. Sustained upregulation of HRNR protein expression upon tape stripping 
Immunofluorescence staining of untreated normal skin, and normal skin at various time points following 
tape stripping. Tape-stripped skin was compared to intra-individual healthy control skin. Each picture is 
representative for data from four individuals. Bar: 100 µm.
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TGM1 activity is increased upon experimental skin barrier disruption 
Increased levels of membrane-bound TGM1 protein were demonstrated by immunofluorescent 
staining in the upper layers of the epidermis (Figure 2.4). To corroborate this, a recently developed 
activity-based probe for TGM1 was exploited for cytochemical in-situ staining.28,30 We used fresh 
frozen skin biopsies taken 48 hours after tape stripping or SDS application. Immunofluorescence 
staining showed increased TGM1 activity in the stratum granulosum and upper stratum spinosum 
layers upon barrier disruption, which co-localized with TGM1 protein expression (Figure 2.4).
Electron microscopy reveals alterations in corneodesmosome density upon skin barrier 
disruption
The cohesion of the stratum corneum and desquamation of the individual corneocytes depend 
on a number of factors including the corneodesmosome number and integrity. Histopathology 
of tape-stripped and SDS-treated skin showed that skin barrier disruption induces hyperkeratosis 
and parakeratosis (Figure 2.1). Next, electron microscopy of the stratum corneum revealed subtle 
morphological differences only in parakeratotic areas (Figure 2.5). Corneodesmosome density, 
calculated as the percentage of the corneocyte membrane occupied by corneodesmosomes, was 
29% in normal skin and 22% 2 days after tape stripping in the first two corneocyte layers adjacent 
to the stratum granulosum (p 0,01). In the consecutive layers (layer 3 and 4), the density increased 
upon tape stripping from 16% to 26% (p 0,001). In orthokeratotic areas, corneodesmosome 
numbers did not differ between tape-stripped and normal skin.
Figure 2.4. Increased TGM1 protein expression correlates with increased TGM1 activity upon 
epidermal barrier disruption. Immunofluorescence staining of TGM1 protein expression and activity in 
normal skin (NS), and skin 48 hours after SDS application on or tape stripping (TS) of normal skin. Treated 
skin was compared to intra-individual healthy control skin. Each picture is representative for data from two 
different individuals. Bar: 100 µm.
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Discussion
This study shows that acute skin barrier disruption, either chemically or mechanically induced, 
elicits an epidermal repair response composed of increased expression of several structural and 
cornification-related proteins, and decreased expression of some structural and desquamation-
related proteins. This temporary imbalance between cornification and desquamation results in 
hyperkeratosis and parakeratosis and ensures rapid skin barrier repair. Bearing in mind the skin 
barrier-related genetic risk factors for AD 6 and psoriasis 7,32, and their association with impaired 
epidermal barrier function in lesional skin 33-36, we wondered if the repair response would differ 
between healthy skin and non-lesional skin of psoriasis or AD patients. Interestingly, expression 
levels of structural, cornification- or desquamation-related genes and proteins were similarly 
influenced by experimental barrier disruption in all subjects, implying an intact mechanism that 
boosts an initial common barrier repair response in all groups. Likewise, we previously found no 
difference in host response gene expression levels between healthy controls and psoriasis and AD 
patients upon acute barrier disruption.20 
Previously, it was shown that tape stripping induces transient barrier disruption that peaks 
at day 0 and normalizes during the following week as measured by the trans-epidermal water 
loss (TEWL).37,38 SDS application removes the lipids from the stratum corneum and the ensuing 
TEWL peaks at day 4 and is almost normalized at day 14.39 Based on data of time courses of 
some structural proteins in previous papers 19,37, we selected 24 hours as the time point at which 
changes in most gene expression levels would appear. For the protein expression, we assessed 
multiple time points, but at 48 hours, most protein expression levels peaked. IVL and TGM1 
protein expression levels were induced upon application of SDS, peaking at day 3 19,40, which is 
in line with our results. In hairless mice, skin barrier disruption by means of aceton, SDS and tape 
stripping influenced expression of several keratins, but not loricrin (LOR). LOR expression was not 
affected by aceton application on human skin either.40 We found no difference in LOR expression 
upon SDS application, but reduced expression upon tape stripping, which may be accounted for 
by the more drastic barrier impairment caused by the total removal of the stratum corneum. In 
a large-scale microarray analysis of the effect of tape stripping, FLG was reduced and IVL and 
SPRR1B were induced, which is in line with our data.37 They also found upregulation of several 
host response genes of the S100A protein family, which we previously validated at the protein 
level.20,37
We did not take the genotypes (for FLG or LCE3C_LCE3B-del) of the healthy volunteers or 
patients into consideration, as the numbers would be far too small to draw any meaningful 
conclusions from it. Interestingly, a recent study showed that skin barrier function in AD patients 
was disturbed irrespective of FLG status 41, suggesting a general barrier failure in these patients, 
Figure 2.5. Corneo-
desmosome density aber-
rances upon experimental 
barrier disruption
Electron microscopic images 
of stratum corneum of 
A) normal skin, and B) a 
parakeratotic area  48 hours 
after of tape stripping (TS) 
of normal skin. Treated skin 
was compared to intra-
individual healthy control 
skin. 
Arrows: corneodesmosomes.
Nu: nucleus in a para-
keratotic cell.  C1, C2, C3, 
C4: the first, second, third 
and fourth layers of the 
stratum corneum. 
Bar: 500 nm.
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unrelated to one particular genetic defect. Others have shown that skin barrier proteins are 
strongly downregulated in lesional AD skin but also, albeit weakly, in non-lesional skin of AD 
patients, compared to healthy controls.26,42 In the present study we did not observe a significant 
difference between non-lesional skin of AD or psoriasis patients compared to healthy controls.
The most strikingly upregulated gene was LCE3A, a member of the LCE3 group that contains 
the psoriasis risk-associated deletion genes LCE3B and LCE3C. We recently reported that the 
LCE3 genes respond opposite to the other LCE genes upon acute (tape stripping of normal 
skin) or chronic (psoriatic lesional skin) barrier disruption. LCE3 expression levels were increased, 
whereas LCE1, LCE2, LCE5 and LCE6 expression levels were decreased, suggesting that the latter 
groups are involved in normal skin barrier function, whereas LCE3 genes encode proteins involved 
in barrier repair.25 Our current data show a similar upregulation of LCE3A and downregulation of 
LCE2B and LCE5A upon tape stripping of non-lesional skin of psoriasis or AD patients, as well as 
upon SDS application. SPRR1 and SPRR2 were also strongly upregulated. These structural proteins 
are cross-linked by transglutaminases to become part of the cornified envelope.14 Recently, 
fascinating new properties of SPRRs were identified, since they appeared to be efficient cell-
protective proteins, linking reactive oxygen species (ROS) detoxification with cell migration, which 
are pivotal processes for optimal tissue repair and wound healing.43 However, prior to such a 
stress response, barrier perturbation induces an immediate differentiation response characterized 
by corneocyte formation and deposition of lamellar bodies.44
Transglutaminases, which catalyze cross-linking of structural proteins and thereby induce 
epidermal cornification, were also upregulated upon barrier disruption. We found that during 
the repair phase, the protein expression and activity of TGM1 extended deeply into the stratum 
spinosum, which may result in faster barrier repair and account for the hyperkeratosis and 
parakeratosis. The pivotal function of TGM1 in proper cornification and thereby barrier repair 
is illustrated by the association of mutations in the TGM1 gene with autosomal recessive skin 
disease lamellar ichthyosis.1,2,45
FLG2 is a recently identified member of the S100 fused-type protein family, which is encoded 
in the epidermal differentiation complex.26,46 FLG2 is located with proFLG in keratohyalin granules 
and with FLG in the lower corneocyte matrix. In addition both proteins are deiminated and 
substrates of calpain 1, and they concomitantly disappear in the upper cornified layer. FLG2-
derived amino acids are probably involved in the formation of the natural moisturizing factor.26 
FLG2 expression kinetics were shown to be similar to that of FLG. Indeed, our data show a 
reduction of both FLG2 and FLG upon barrier disruption in all subject groups, correlating with 
the reduction of LCE2B and LCE5A expression levels. Possibly, FLG and FLG2 exert their function 
rather in barrier maintenance than in barrier repair, like most of the LCE gene family members. 
Hornerin is the latest described cornified envelope protein.27 Interestingly, this was the only 
gene of which mRNA levels displayed a delayed peak at day 3. Protein levels were still increased 
in the upper epidermis at day 9. We speculate that in view of its reported additional antimicrobial 
properties 47, this prolonged increase in hornerin expression contributes to both barrier repair and 
local antimicrobial defense.
Our electron microscopic analysis revealed subtle alterations in corneodesmosome densities 
upon barrier disruption, only in parakeratotic areas. Speculatively, corneodesmosome numbers 
are influenced by the accelerated cell turnover and altered protease-antiprotease balance which 
is presumed to facilitate desquamation by means of corneodesmosome disintegration. The dis-
rupted corneodesmosome density and the prolonged alterations in cornified envelope-related 
proteins may add to the sustained deviations from normal skin barrier properties that were found 
upon tape stripping. E.g. TEWL was increased up to 6 days after tape stripping.48
Although the available literature is not always consistent regarding expression of skin barrier 
proteins in lesional psoriasis and AD skin, a general picture based on these and previous findings 
emerges.6,7,22,49 The upregulation of SPRR1A, SPRR2B and IVL and downregulation of LOR and 
FLG (in AD) and induction of IVL, SPRR and TGM1 and downregulation of FLG (in psoriasis) are 
similar to the expression patterns found following skin barrier disruption.50 
Altogether, skin barrier disruption induces a temporary imbalance between cornification 
and desquamation in the upper epidermal layers, resulting in barrier recuperation and transient 
hyperkeratosis and parakeratosis. These responses were similar in healthy skin and non-lesional 
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skin of psoriasis or AD patients, and correlate with data of lesional psoriatic and AD skin, in which 
the epidermis is trapped in a chronic barrier repair phase. Hence, therapies directed at improving 
barrier function should aim at resolving the imbalance between cornification and desquamation. 
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Abstract
Recent genetic studies have indicated that skin barrier abnormalities contribute to the pathogenesis 
of atopic dermatitis (AD) and psoriasis. Deficiencies in skin barrier formation or repair may expose 
epidermal cells to environmental stimuli such as microbial components which could in turn evoke 
an immune response, shaped by the genetic background of the host. 
Here we investigated the effect of experimental skin barrier disruption on the expression of 
host defense genes in uninvolved epidermis of psoriasis and AD patients and healthy controls. 
Skin barrier disruption, either induced by tape stripping of the stratum corneum or by 
SDS-application, only marginally affected the mRNA expression levels of pattern recognition 
receptors (PRRs). We observed, however, strongly elevated mRNA and protein expression levels of 
antimicrobial proteins (AMPs), which were of similar magnitude in psoriasis and AD patients and 
healthy controls. In cultured keratinocytes from the three groups, Th2 cytokines partly reduced 
the Th1 cytokine-mediated induction of several AMPs. 
We conclude that skin barrier disruption induces AMP expression similarly in uninvolved skin 
of AD and psoriasis patients without requiring transcriptional upregulation of PRRs. Our data 
indicate that the expression of AMPs in human epidermis is a complex process driven by many 
factors including skin barrier integrity, cytokine environment and genetic predisposition.
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Introduction
The common chronic inflammatory skin conditions psoriasis and atopic dermatitis (AD) are 
both associated with impaired epidermal barrier function in lesional skin, the degree of which 
correlates with the extent of inflammation.1-5 However, psoriasis and AD differ considerably in 
clinical presentation, gene expression profiles, and involvement of immune cells.6-9 Recently, 
epidermal barrier-associated genetic risk factors were found for both diseases. Filaggrin null 
alleles were identified as a major risk factor for developing AD.10 Mutations in the serine protease 
inhibitor Kazal type 5 (SPINK5) gene encoding an epidermis-expressed protease inhibitor were 
also found to confer susceptibility to AD.11 Copy number variation of genes that are involved in 
chemical skin barrier function (beta-defensins) 12 and repair of the physical barrier (late cornified 
envelope genes LCE3B and LCE3C) were found to be associated with psoriasis.13-15 Shaped by the 
genetic background of the host, deficiencies in skin barrier formation or dysfunctional repair will 
expose epidermal cells to environmental stimuli such as microbial components which could evoke 
an inflammatory response, and possibly a chronic inflammatory skin condition.4,16,17 
Here, we used two widely applied models of skin barrier disruption: tape stripping of the 
stratum corneum, which rids the skin of its physical corneocyte barrier, and irritant contact 
dermatitis induced by the anionic surfactant sodium dodecyl sulphate (SDS) which distorts 
the lipid compartment of the stratum corneum.18,19 Pattern recognition receptors (PRRs) and 
antimicrobial proteins (AMPs) are at the frontline of innate immune responses as sensors and 
effector molecules, respectively. Recently, upregulation of psoriasin and to a lesser extent hBD-2, 
hBD-3 and RNase 7 protein was reported after tape stripping of normal skin.20,21 
Studies by Giustizieri et al. and our lab suggested that epidermal keratinocytes from psoriasis 
and AD patients and healthy controls are intrinsically different.22,23 In vitro, these cells show 
distinct transcriptional responses upon stimulation with pro-inflammatory cytokines. Further, 
the AD-specific Th2 cytokines IL-4 and IL-13 were found to downregulate AMP expression in 
keratinocytes.8,24,25 Epidermal AMP levels are high in psoriatic plaques and relatively low in AD 
lesions.6,9,23,26 This prompted us to investigate if patients and controls display different immune 
responses upon skin barrier disruption of non-lesional skin. 
Materials and Methods
Skin biopsies
Nineteen healthy volunteers, 13 chronic plaque-type psoriasis patients and 13 chronic AD patients 
were included in the study and had given written informed consent. The study was approved 
by the local medical ethical committee and conducted according to the Declaration of Helsinki 
principles. To induce irritant contact dermatitis, 400 µl 5% SDS solution was applied on a 2x2 cm 
patch of fabric (Medicomp, Hartmann, Heidenheim, Germany), which was applied to the lower 
back of six healthy volunteers and covered with Tegaderm and Soft Cloth Surgical Tape (3M 
Health care, Neuss, Germany). After 4 or 8 hours the SDS-containing patch was removed and 
48 hours after exposure, 3-mm biopsies were taken from the exposed areas and from healthy 
control skin of the same individual. Skin reactions to SDS application were variable and biopsies 
were only taken from strong erythematous reactions. For stratum corneum removal, two areas 
on the lower back measuring 3x2 cm each were tape stripped until the surface became slightly 
shining after repeated (20-40 times) application and removal of adhesive tape. 24 and 48 hours 
after tape stripping, 3-mm biopsies were taken from the tape-stripped area and from healthy skin 
of the same individual for both RNA isolation and histology, respectively.
Isolation of epidermal sheets, RNA isolation and real-time quantitative PCR
Isolation of epidermal sheets for mRNA isolation was performed as previously described.27 
RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany), and a DNase I treatment 
was performed according to manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Reverse 
transcriptase reactions and qPCR were performed as described previously.6 The amount of mRNA 
for a given gene in each sample was normalized to the amount of mRNA of the human ribosomal 
phosphoprotein P0 (RPLP0) reference gene in the same sample. Primers for qPCR (Biolegio, 
Nijmegen, the Netherlands) were only accepted if their efficiency was 100 ± 10 % and corrections 
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were made for primer efficiency. Relative mRNA expression levels were calculated with the delta-
delta cycles times (∆∆Ct) method.28 For graphic representation of mRNA data, all data are plotted 
relative to 1 untreated sample of DEFB4 (Figure 3.1) or TLR3 (Figure 3.3).
Immunohistochemistry
Skin biopsies were immediately fixed in a 10% formalin solution (Baker Mallinckrodt, Deventer, 
The Netherlands) for 4 hours and subsequently embedded in paraffin. Sections were blocked 
for 15 minutes with 20% normal rabbit serum (for hBD-2) or normal goat serum (elafin, 
S100A7/psoriasin and S100A8/MRP8) in PBS and subsequently incubated with anti-hBD-2 
(Abcam, Cambridge, UK) (1:100), anti-elafin (1:500), anti-S100A7/psoriasin (kind gift of Dr P. 
Madsen, University of Aarhus, Denmark) (1:10000), and anti-S100A8/MRP8 (kind gift of Dr G. 
Siegenthaler, University Hospital, Geneva, Switzerland) (1:10000) for 1 hour at room temperature. 
Next, sections were incubated for 30 minutes with a secondary antibody (biotinylated rabbit anti-
goat or biotinylated goat anti-rabbit in PBS containing 1% BSA, Vector laboratories, Burlingame, 
CA). After 30 minutes incubation with Avidin-Biotin complex (Vector Laboratories), sections were 
treated with 3-amino-9-ethyl carbazole (Calbiochem, San Diego, CA) for 10 minutes.
Cell culture
Primary human epidermal keratinocytes from skin biopsies of psoriasis patients (N=7), AD patients 
(N=7) and healthy volunteers (N=7) were cultured and induced to differentiate by growth factor 
depletion as described before.23 At 100% confluency, differentiated cell cultures were stimulated 
with Th1 cytokines (IFNg 10 U/ml, TNFa 30 ng/ml and IL-1a 30 ng/ml), Th2 cytokines (IL-4 50 ng/
ml and IL-13 50 ng/ml), both, or left untreated. Cytokines were obtained from Peprotech. After 
48 hours the supernatant was collected and the cells were harvested for mRNA isolation. ELISA 
assays for elafin were performed as described previously 29 and for hBD-2 using antisera against 
recombinant hBD-2 (Peprotech).30
Statistics
A repeated-measures analysis of variance using SPSS v16.0 (SPSS Inc) was performed on the 
∆Ct values of the qPCR data corrected for primer efficiency and on the absolute values of the 
ELISAs. ∆Ct is the difference between the Ct of the target gene and the reference gene (RPLP0). A 
Bonferroni post-hoc test was used to test the significance of the difference between each sample 
and its intra-individual control as well as between the models and the patient groups.
Results
Barrier disruption strongly induces AMP mRNA expression in human epidermis
mRNA expression levels in purified epidermal sheets of SDS-treated and tape-stripped skin were 
normalized to those in control epidermis of the same individual. We found highly significant, 
markedly induced expression levels of AMPs in all conditions of skin barrier disruption, including 
the tape-stripped uninvolved skin of psoriasis and AD patients (Figure 3.1C, Table 3.1).
In contrast to the robust AMP response, expression profiles of PRRs and inflammasome-
related signaling genes were hardly affected by barrier disruption, irrespective of the subject 
group (Figures 3.1A and B, Table 3.1). There were some significant and notable exceptions, such 
as the downregulation of toll-like receptor 3 (TLR3) in all conditions (Figure 3.1A, Table 3.1). The 
following genes had such low mRNA expression levels in all conditions that they could not be 
further analyzed: TLR4, TLR9, NLRP3, caspase recruitment domain family member 8 (CARD8), NLR 
family CARD domain containing 4 (NLRC4), and mannose receptor 1 (MRC1). The sole significant 
difference between normal and patient skin was downregulation of TLR3 in non-lesional skin of 
psoriasis and AD patients. 
As certain cytokines control the expression of AMPs, we analyzed the response of several 
psoriasis- and AD-associated cytokines upon skin barrier disruption. Whereas the Th2 cytokines 
IL4 and IL13 were expressed in purified epidermal sheets of AD lesions, they were absent after 
barrier disruption in all conditions in this study, including the tape-stripped uninvolved skin of AD 
patients. IL17 was also absent and no significant differences in expression of IFNG, TNFA and IL1B 
were seen (data not shown).
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Table 3.1. Relative epidermal mRNA expression levels of host defense genes after SDS 
application or tape stripping 
HUGO 
gene 
symbol
Protein / synonym Fold change1 P-value compared to US6
SDS2 TS 
NS3
TS
 PS4
TS 
AD5
SDS TS 
NS
TS 
PS
TS
 AD
Toll-like receptors (TLRs)
TLR2 1,1 0,6 0,7 0,8 0,92 0,02 0,08 0,15
TLR3 0,6 0,4 0,1 0,2 0,03 0,00 0,00 0,00
TLR5 0,6 0,9 0,8 0,9 0,20 0,31 0,14 0,26
C-type lectin receptors (CLRs)
CLEC2B CLECSF2 6,8 3,3 2,7 2,2 0,00 0,01 0,15 0,35
CLEC7A Dectin-1 1,4 1,6 2,3 2,0 0,68 0,20 0,00 0,03
NOD-like receptors (NLRs)
NLRP1 NALP1 0,3 0,4 0,6 0,4 0,01 0,01 0,02 0,01
NLRP2 NALP2 3,3 1,3 0,4 0,3 0,58 0,06 0,05 0,01
NOD1 CARD4 0,6 0,9 2,3 1,3 0,02 0,36 0,05 0,36
NOD2 CARD15 1,1 5,7 6,8 4,9 0,74 0,32 0,01 0,02
RIG-like helicase receptors (RLRs)
DDX58 RIG-I 1,6 0,9 2,6 1,7 0,31 0,37 0,31 0,13
IFIH1 MDA5 1,6 1,9 4,1 3,1 0,01 0,22 0,10 0,03
Diverse
RIPK2 RIP2 1,2 1,2 1,9 2,0 0,46 0,17 0,18 0,05
PYCARD ASC 2,7 3,0 1,6 2,1 0,01 0,01 0,31 0,05
ICEBERG Caspase-1 inhibitor 0,8 0,4 0,4 1,3 0,29 0,06 0,01 0,99
CASP1 ICE 1,6 0,8 0,7 1,2 0,06 0,10 0,00 0,65
IL1RN IL-1RA 2,5 2,7 2,3 3,3 0,75 0,47 0,20 0,06
IL1A IL-1a 4,9 1,1 2,3 9,6 0,63 0,71 0,27 0,42
IL1B IL-1b 8,3 1,8 9,2 2,4 0,19 0,93 0,05 0,12
IL18 IL-18 1,2 2,0 0,8 0,7 0,03 0,39 0,28 0,05
Antimicrobial peptides (AMPs)
DEFB4 hBD-2  1901 21760  9394  9359 0,00 0,00 0,00 0,00
DEFB103A hBD-3      12       43      43      41 0,03 0,01 0,03 0,00
PI3 Elafin    368     597    780    627 0,00 0,00 0,00 0,00
S100A7 Psoriasin    120     113      77    136 0,00 0,00 0,00 0,00
S100A8 MRP8    941     333    139    655 0,00 0,00 0,00 0,00
S100A9 MRP14  1548   2018    781  1739 0,00 0,00 0,00 0,00
SLPI SLPI 6,3 5,8     3,2       4,8 0,00 0,00 0,00 0,00
LYZ Lysozyme 7,9 3,1 2,6       7,4 0,05 0,03 0,00 0,05
CAMP LL-37      15    123    357      85 0,09 0,00 0,00 0,00
1Relative epidermal mRNA expression levels calculated by taking the mean of the treated samples each 
divided by the relative mRNA expression level of its intra-individual control sample as calculated by Livak’s 
delta-delta qPCR cycle times method. 2Mean ratio in SDS-treated skin, 3tape-stripped healthy skin (TS NS), 
4tape-stripped non-lesional skin of psoriasis patients (TS PS), and 5tape-stripped non-lesional skin of atopic 
dermatitis patients (TS AD). 6P-value of ∆Ct of treated samples compared to intra-individual control samples 
of untreated skin (US). 
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Barrier disruption strongly induces AMP protein expression in human epidermis
Figure 3.2 shows the striking increase in protein expression of elafin, psoriasin, MRP8 and hBD-2 
after skin barrier perturbation. Protein expression was rather similar in the different conditions of 
barrier disruption, even though there seemed to be a tendency towards stronger staining in the 
SDS-treated samples. No differences in staining were observed between tape-stripped normal 
skin and uninvolved skin of psoriasis or AD patients.
Figure 3.1. qPCR data of innate immunity genes in epidermal sheets after SDS application or tape 
stripping. Relative mRNA expression levels of innate immunity genes 48 hours after sodium dodecylsul-
phate application on normal skin (SDS, N=5) or tape stripping of normal skin (TS NS, N=6) or uninvolved skin 
of psoriasis patients (TS PS, N=6) or atopic dermatitis patients (TS AD, N=6), normalized to intra-individual 
control epidermis. A. Pattern recognition receptors; B. Signaling molecules; C. Effector molecules. P-values 
are indicated in Table 3.1.
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Th2 cytokines partly inhibit Th1-induced AMP upregulation in cultured primary 
keratinocytes
Keratinocytes from healthy subjects and patients with psoriasis and AD were stimulated with 
IFNg, TNFa and IL-1a (hereafter referred to as Th1 cytokine mix), Th2 cytokines (IL-4 and IL-13), or 
both. Most Th1 and Th2 data were published previously 23 and only serve as comparative values 
for the combined Th1 and Th2 stimulation data. AMP mRNA expression levels revealed significant 
Th2-mediated suppression of the Th1-mediated induction of DEFB4, DEFB103A, PI3, and SLPI in 
all groups. S100A7 data followed this trend, but S100A8 and S100A9 transcription remained 
stable (Figure 3.3A, data not shown). When comparing the three subject groups, several AMPs 
were expressed at significantly lower levels in AD-patient-derived keratinocytes compared to both 
healthy subjects and keratinocytes from psoriasis patients upon concomitant stimulation with Th1 
and Th2 cytokines (Figure 3.3). On the protein level, Th1-mediated induction of hBD-2 secretion 
was significantly suppressed by Th2 cytokines (Figure 3.3B).
Figure 3.2. Protein expression of psoriasin, MRP8, elafin and hBD-2 after SDS application or tape 
stripping of human skin. Immunohistochemical staining of normal skin (NS), and skin 48 hours after barri-
er disruption by means of either sodium dodecylsulphate application of normal skin (SDS), or tape stripping 
of normal skin (TS NS) or uninvolved skin of psoriasis (TS PS) and atopic dermatitis (TS AD) patients. Treated 
skin was compared to intra-individual healthy control skin. Each picture is representative for data from six 
different individuals.
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In vivo, TLR3 stood out as the sole PRR that was distinctly downregulated upon skin barrier 
disruption in uninvolved psoriasis and AD patient skin compared to their own untreated controls 
and tape-stripped normal skin. In vitro, however, stimulation with the combination of Th1 and 
Th2 cytokines resulted in upregulation of TLR3 in keratinocytes from psoriasis and AD patients, 
which was significant compared to intra-individual unstimulated samples, but not compared to 
healthy subjects.
Discussion
This study shows that skin barrier disruption, either chemically or mechanically induced, elicits a 
striking increase in mRNA and protein expression levels of many AMPs, whereas the expression 
levels of PRRs and some inflammasome-related signaling molecules were largely unaltered except 
for a few genes. Interestingly, almost all examined host defense gene expression levels were 
similarly influenced by barrier disruption in healthy skin and non-lesional skin of psoriasis or AD 
patients.
Figure 3.3. Relative expression levels of innate response genes in cultured keratinocytes from 
healthy controls and psoriasis and atopic dermatitis patients after cytokine stimulation. Cultures 
of primary human keratinocytes from healthy skin (NKCs) and uninvolved skin from patients with psoriasis 
(PKCs) or atopic dermatitis (AKCs) (each N=7) were stimulated for 48 hours with a Th1 cytokine mixture 
(IFNg, TNFa and IL-1a), Th2 cytokines (IL-4 and IL-13) or both. A. Relative mRNA expression levels of antimi-
crobial proteins and TLR3. B. Protein levels of hBD-2 (DEFB4 gene) and elafin (PI3 gene) in the supernatants 
were measured by ELISA. Bars: mean +/- SEM. 
Enhanced antimicrobial protein expression upon skin barrier disruption
41
 3
This proves that non-lesional AD patient epidermis is equally capable of producing massive 
amounts of AMPs upon skin barrier perturbation as psoriasis patient epidermis. This is remarkable 
in view of the lower AMP levels in cultured keratinocytes from AD patients, either or not stimulated 
with Th1 or Th2 cytokines 23 or both cytokine mixtures (this study). Previous studies showed 
that, depending on the specific AMP, these molecules are expressed at equal or higher levels 
in lesional AD skin than in normal skin, but these expression levels are exceeded considerably 
by those in lesional psoriasis skin.6,21,31,32 We show that apart from cell-autonomous (genetically 
programmed) low AMP expression levels in lesional AD keratinocytes, the particular local cytokine 
environment (Th1/Th17 versus Th2) may also be involved, as demonstrated by the Th2-mediated 
partial inhibition of Th1-induced AMP expression in keratinocytes from healthy subjects and 
patients with AD and psoriasis. 
Altogether, our data show that enhanced expression levels of epidermal AMPs in vivo can 
be induced by barrier disruption, irrespective of the genetic predisposition of the keratinocytes 
(normal, psoriasis or AD background). This phenomenon may depend on the massive damage-
induced release of preformed cytosolic stimuli, such as IL-1a. Modifying factors such as genetic 
programming (e.g. Filaggrin or LCE3B/C deficiency, differential sensitivity to cytokines) and 
cytokine environment could play a role in the repair process, which may be qualitatively different 
in psoriasis and AD. Continued barrier deficiency will stimulate production of factors that induce 
inflammation and recruitment of immune cells, eventually including Th1/Th17 cells in psoriasis and 
mainly Th2 cells in AD. This process will also determine epidermal host defense gene expression 
levels: a full-blown antimicrobial defense in psoriasis or a dampened antimicrobial response that 
promotes skin colonization and superinfection as observed in AD lesions.
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Abstract 
During the last decade, multiple pattern recognition receptors (PRRs) have been identified. These 
are involved in the innate immune response against a plethora of pathogens. However, PRR 
functioning can also be detrimental, even during infections. 
This review discusses the current knowledge on PRRs that recognize dermatotropic pathogens, 
and potential therapeutical implications.
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Introduction
Recent studies have shown that the human microbiome not only protects us from pathogens by 
simply occupying the gut and skin epithelial surfaces, but also actively modulates the immune 
system.1-3 Most studies focused on the gut microbiome and provided evidence that intestinal 
microbiota influence host immune development, immune responses, and susceptibility to human 
diseases such as inflammatory bowel disease, diabetes mellitus, and obesity.3,4 Conversely, host 
factors can affect microbe populations and behavior, which in turn modulate disease susceptibility. 
A well-established example in the gut is the association of loss-of-function polymorphisms in 
the nucleotide oligomerization domain containing 2 (NOD2) gene with Crohn’s disease.5,6 Nod2 
deficient mice have an increased load of resident intestinal microbiota in the terminal ileum 
and increased susceptibility to intestinal pathogens such as Listeria monocytogenes, Salmonella 
typhimurium, and Helicobacter hepaticus.4 NOD2 was found to be present in human epidermis 
and functional in primary keratinocytes.7,8 Here, we focus on the current knowledge of the role 
of pattern recognition receptors (PRRs) like NOD2 in skin infections.
Figure 4.1. Subcellular location of pattern recognition receptors (PRRs). PRRs are classified in subgroups, 
including the Toll-like receptors (TLRs), C-type lectin receptors (CLRs), nucleotide-binding oligomerization 
domain (NOD) leucine-rich-repeat–containing receptors (NLRs), and retinoic acid–inducible gene I protein 
(RIG-I) helicase receptors (RLRs). TLR1,2,4,5,6,10,11 are located on the cell membrane and recognize a 
plethora of mainly bacterial pathogen-associated molecular patterns (PAMPs), whereas TLR3,7,8,9 survey 
the endosomes for nucleic acids of e.g. viral origin. In the cytosol, nucleic acids are recognized by RLRs and 
other sensors including absent in melanoma 2 (AIM2). The transmembrane CLRs mainly, but not exclusively, 
recognize fungal PAMPs. The cytosolic NLRs recognize PAMPs and damage-associated molecular patterns 
(DAMPs) from various sources. Most PRR signaling pathways converge on activation of NF-κB, which results 
in transcription of proinflammatory cytokines. Activation of RLRs, endosomal TLRs, IFI16 and TLR4 also leads 
to activation of interferon regulatory factors (IRF) 3 and 7, resulting in the production of type I interferons. 
Upon activation, some NLRs, AIM2 and IFI16 form inflammasomes, protein complexes that lead to caspase-
1-mediated IL-1b activation. The major PRR ligands are depicted in italic bold.
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Whereas variation in major histocompatibility complex proteins, T-cell receptors and 
immunoglobulin specificity shape adaptive immune responses, PRRs evolved as an innate 
immunity tool to fight infections with a plethora of microorganisms. The Toll-like receptors (TLRs) 
were the first identified PRRs.9,10 Other PRRs followed suit, such as different NOD-like receptors 
(NLRs)11, RIG-like helicase receptors (RLRs)12, and C-type lectin receptors (CLRs).13 These PRRs sense 
specific ligands called pathogen-associated molecular patterns (PAMPs) or damage-associated 
molecular patterns (DAMPs). The former are of microbial origin, the latter are potentially harmful 
endogenous factors, such as uric acid and b-amyloid. Activation of a particular PRR initiates a 
specific cascade which eventually leads to a tailored immune response against the recognized 
agent. Strictly, parts of the complement system can also be regarded as PRRs, but this is beyond 
the scope of this review. 
Table 4.1 lists the PRRs that were identified to date and Figure 4.1 shows their subcellular 
location. Baseline expression levels of most PRRs are low in normal epidermis. For example, the 
potent LPS receptor TLR4 and the important inflammasome-related protein NLRP3 are hardly 
detectable. TLR2, TLR3, TLR5, NLRP1, DDX58 and IFIH1 are the highest expressed PRRs.7
PRRs are a vital part of our antimicrobial defense system, but genetically predisposed or 
pathogen-induced excessive PRR signaling can be very harmful. Some reviews described the role 
of TLRs in skin disease 14-19, but an overview of the role of all PRRs in skin infections is lacking. 
This review summarizes the roles PRRs can play in infectious skin diseases, including therapeutical 
implications.
Table 4.1. PRRs and their ligands 
PRR Synonym1 PAMPs and DAMPs2 Source PAMPs and DAMPs
Toll-like receptors
TLR1/TLR2 Triacyl lipopeptides
Lipoprotein
Glycosylphosphatidylinositol
Bacteria
Mycobacteria
Plasmodium falciparum
TLR2 Peptidoglycans
Lipoprotein
Glycolipids
Phosphatidylinositol
 dimannoside
Phospholipomannan
Glycosylphosphatidylinositol
Leishmania donovani-like   
  lipophosphoglycans
Tc52
PorB (porin) protein
Envelope proteins
Gram-positive bacteria, e.g. S. aureus
Gram-positive bacteria, e.g. S. aureus
Treponema maltophilum; Mycobacteria
Mycobacteria
Candida albicans
Toxoplasma gondii; Trypanosoma cruzi
Leishmania major; L. donovani
Trypanosoma cruzi
Neisseria meningitidis
Human cytomegalovirus; Measles virus; Herpes 
simplex virus type I
TLR3 dsRNA Viruses
TLR4 Lipopolysaccharide
Envelope proteins
Mannan
Glucuronoxylomannan
Glycoinositolphospholipids /
  Glycosylphosphatidylinositol
F protein
HSPgp96; HSP60; HSP70
Calprotectin (MRP8/MRP14)
Gram-negative bacteria
Viruses
Fungi, e.g. Saccharomyces cerevisiae, 
  C. albicans
Cryptococcus neoformans
Trypanosoma cruzi; Plasmodium falciparum; 
  Toxoplasma gondii
Respiratory syncytial virus
Endogenous
Endogenous
TLR5 Flagellin Flagellated bacteria
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PRR Synonym1 PAMPs and DAMPs2 Source PAMPs and DAMPs
Toll-like receptors, continued
TLR6/TLR2 Diacyl lipopeptides
Phenol-soluble modulin
Lipoteichoic acid
Zymosan
GPI anchor
Mycoplasma; bacteria
S. epidermidis
Bacteria
Fungi, e.g. Saccharomyces cerevisiae
Trypanosoma cruzi
TLR7 ssRNA
Imidazoquinolones
Loxoribine; Bropirimine
Viruses, e.g. influenza, HIV-1; T. gondii
Medication
Medication
TLR8 ssRNA
Imidazoquinolones
Viruses, e.g. HIV-1
Medication
TLR9 CpG DNA
DNA
Hemozoin
Bacteria
Bacteria; DNA viruses; T. cruzi, T. brucei
Plasmodium falciparum
TLR10 Not known Bacteria
TLR11 Profilin-like protein Toxoplasma gondii
C-type lectin receptors
CLEC4E Mincle a-mannose, glycolipids C. albicans; Malassezia spp;
  M. tuberculosis             
CLEC6A Dectin-2 High mannose, a-mannans C. albicans; C. neoformans; 
  S. cerevisiae; M. tuberculosis
CLEC7A Dectin-1 b-1,3 glucan Fungi, e.g. C. albicans; Mycobacteria
MRC1 CLEC13D High mannose, Fucose Fungi, e.g. C. albicans, C. neoformans;
  M. tuberculosis; F. tularensis, 
  S. pneumonia, Leishmania spp, 
  dengue virus, HIV-1
CD207 Langerin Fucose, Mannose, b-glucan, 
  N-acetylglucosamine
Candida spp; Saccharomyces spp; 
  Malassezia furfur; HIV; M. leprae
CD209 DC-SIGN High mannose
Fucose
HIV; measles virus; dengue virus; 
  SARS; Mycobacterium spp; 
  Leishmania spp; C. albicans
H. pylori; P. acnes
Galectin-3 Glycosylphosphatidylinositol Toxoplasma gondii; C. albicans
RIG-like helicase receptors
IFIH1 MDA5 Poly:IC; Long dsRNA Viruses, e.g. Picornaviridae; 
  Flaviviridae; Vaccinia virus
DDX58 RIG-I Short dsRNA; ssRNA Viruses, e.g. Paramyxoviridae; Rhabdoviridae; 
  Orthomyxoviridae; Filoviridae; Arenaviridae; 
  Flaviviridae; Bunyaviridae; Coronaviridae; 
  Caliciviridae; Epstein-Barr virus
DHX9 DNA HSV-1
DHX36 DNA HSV-1
NOD-like receptors
NOD1 CARD4 iE-DAP;    
  GM-tripeptide
  mesolanthionine
Bacteria, e.g. Helicobacter pylori; Shigella 
  flexneri; Campylobacter jejuni; 
  Listeria monocytogenes; Enteropathogenic 
  Escherichia coli; Pseudomonas aeruginosa; 
  Chlamydia pneumoniae; Bacillus spp  
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PRR Synonym1 PAMPs and DAMPs2 Source PAMPs and DAMPs
NOD-like receptors, continued
NOD2 CARD15 MDP; M-TRILys Bacteria, e.g. S. aureus; Streptococcus
  pneumoniae; S. flexneri; Salmonella 
  typhimurium; L. monocytogenes; 
  M. tuberculosis
NLRC4 IPAF / 
CARD12
Flagellin Bacteria, e.g. S. typhimurium; 
  L. pneumoniae; P. aeruginosa; 
  S. flexneri; L. monocytogenes
NAIP Flagellin Bacteria, e.g. L. pneumophila; Listeria spp; 
  P. aeruginosa; Salmonella spp
NLRP1B NALP1 Anthrax lethal toxin Bacillus anthracis  
NLRP2 NALP2
NLRP3 NALP3 / 
CIAS1
MDP; DNA; RNA; toxins; 
Hemozoin; 
ATP; uric acid; amyloid-b
UV-B
Bacteria, e.g. L. monocytogenes, S. aureus; 
  viruses 
P. falciparum 
Endogenous
Sun
Other receptors
AIM2 PYHIN4 dsDNA Francisella tularensis, L. monocytogenes;   
  vaccinia virus; endogenous
IFI16 PYHIN2 dsDNA L. monocytogenes; vaccinia virus; HSV-1
ZBP1 DAI dsDNA Herpesviridae
1. Old gene terminology or protein name
2. Pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPS)
PRRs in skin infections: heroes with a few flaws
PRRs evolved as innate immune sensors of pathogenic agents. Several PRRs have been implicated 
in skin infections with varying degrees of in-vivo or in-vitro evidence (Table 4.2).
PRRs in fungal skin infections
Most of the studies of fungal (skin) infections concerned Candida albicans. Transient 
mucocutaneous Candida infections are common in the general population. A host of disease-
associated single nucleotide polymorphisms (SNPs) can be found in patients that fail to clear these 
fungal infections.20 These include mutations in PRRs, such as dectin-1 (CLEC7A) 21 and CARD9, an 
intracellular adaptor molecule of dectin-1 22, in patients with chronic mucocutaneous candidiasis.
Dectin-1 is a member of the CLR family that is specialized in sensing fungal components, in 
this case b-glucan. Candida spp. contain multiple other PAMPs including chitin, mannan, proteins, 
and nucleic acids, which are recognized by several PRRs (Table 4.2).20,23 TLR2, TLR4 and TLR9 
are the principal TLRs involved in sensing fungal PAMPs, such as phospholipomannan, O-linked 
mannans and fungal DNA (Table 4.1).24 The exact role of TLRs in the antifungal response remains 
controversial and seems to vary depending on the microbial characteristics and host environment 
conditions. For example, Tlr2-mediated recognition of Candida spp. was deleterious to the host 
in some mouse experiments, but other studies suggest a protective or dispensable role of Tlr2.23 
Similarly, in some studies, Tlr4-deficient mice were more susceptible to C. albicans infection than 
control mice, but others reported that Tlr4 deficiency does not influence susceptibility to Candida 
yeast and that Tlr4-deficient mice survive longer than control mice when systemically infected 
with Candida hyphae.23 Antifungal responses are likely shaped by the available array of PAMPs 
and functioning PRRs. For example, dectin-1 synergizes with both TLR2 and TLR4 pathways in 
human primary PBMCs and monocyte-derived macrophages.25,26 Galectin 3 and MRC1 support 
TLR2-mediated innate and T helper cell responses to C. albicans.23 Another example of this 
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necessary synergy was shown in a murine model of chromoblastomycosis, a chronic skin infection 
caused by the fungus Fonsecaea pedrosoi. The fungus was recognized by CLRs, but failed to 
activate TLRs, which led to defective induction of proinflammatory cytokines; addition of TLR2, 
TLR4 or TLR7 ligands in this model helped to clear the F. pedrosoi infection.27 
In mouse models, inflammasome-dependent caspase-1 activation and IL-1b production were 
detected in response to PAMPs from C. albicans, Aspergillus fumigatus, and Saccharomyces 
cerevisiae.28 Inflammasomes are multi-protein complexes that assemble upon activation of a subset 
of PRRs and result in IL-1b activation by caspase-1.29 NLRP3 is one of the few inflammasome-
related PRRs. Mice deficient in Nlrp3 were found to be hypersusceptible to C. albicans in several 
infection models. The host response against C. albicans is a classic example of PRR cooperation, 
since TLR2 and dectin-1 are required to drive the transcription of the pro-form of IL-1b, whereas 
NLRP3 is required for caspase-1-induced IL-1b processing.28 In addition, ATP drives the NLRP3 
inflammasome activation in response to zymosan.30 
Not only primary immune cells, but also keratinocytes can respond to PAMPs, although data 
are still scarce. One report showed that keratinocytes secreted IL-8 in a TLR2- and TLR4-dependent 
manner in response to incubation with C. albicans and that keratinocytes had Candida killing 
activity.31,32 However, TLR4 is almost absent in normal epidermis, and no response of primary 
human keratinocytes was found to b-glucan, mannan or heat-killed C. albicans, nor a synergistic 
effect of b-glucan and TLR2 or TLR5 ligands.7 Others reported a synergistic effect of histamine, 
high calcium, ATP and poly:IC on dectin-1 signaling in keratinocytes.33,34 
Fungi have evolved several ways to evade immune responses, one of which is deceiving PRRs 
by concealing PAMPs on the dynamic fungal cell wall. For example, b(1,3)-glucans are exposed 
in the bud scar of C. albicans yeasts but are masked on hyphae, thus favoring fungal escape 
from recognition by dectin-1. This may also explain why patients with chronic mucocutaneous 
candidiasis and dectin-1 mutations do not suffer from invasive fungal infections.35 Conversely, 
fungi can promote excessive inflammation and autoimmunity by propagating continuous PRR 
signaling. Indeed, dectin-1 and fungal b-glucans have been implicated in the induction of 
psoriasis 36 and autoimmune arthritis.37
Table 4.2. PRRs implicated in the recognition of cutaneous pathogens
Infection Genetic association PRR-mediated effect on 
immune response to 
pathogen in human cells
Functional association in mice
Fungal skin infections
Candida 
  albicans
CLEC7A mutation:  
  increased susceptibility
CARD9 mutation: 
  increased susceptibility
Stimulation via NLRP3,
  TLR2,4,6,7,9, CLEC7A, 
  CLEC4E, MRC1, CD209, 
  galectin-3
Tlr2-/-: increased susceptibility 
  or no effect
Tlr4-/-: increased susceptibility 
  or increased survival
Nlrp3-/-: increased susceptibility
Malassezia spp Stimulation via CLEC4E Clec4E-/-: increased susceptibility
Fonsecea
  pedrosoi
Synergistic immune response of 
  Clec4e with TLR2,4, or 7
Bacterial skin infections
Staphylococcus
  epidermidis
Stimulation or inhibition 
  via TLR2
Tlr2 activation by LTA inhibits
  Tlr3-induced inflammation
Staphylococcus 
  aureus
MyD88 deficiency: 
  increased susceptibility
IRAK4 deficiency:
  increased susceptibility
TLR2 SNP in two patients 
  with S. aureus sepsis
Stimulation via TLR2, 
  TLR1/2, TLR2/6, NOD2, 
  NLRP3
Myd88-/-: increased susceptibility
Irak4-/-: increased susceptibility
Tlr2-/-: impaired IL-1b production
Nod2-/-: impaired IL-1b 
  production
Streptococcus 
  pyogenes
Stimulation via NLRP3 Nlrp3-/-: impaired IL-1b
  production
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Infection Genetic association PRR-mediated effect on 
immune response to 
pathogen in human cells
Functional association in mice
Bacterial skin infections, continued
Pseudomonas
  aeruginosa
Stimulation via TLR5/NAIP/
    NLRC4?
Propionibacte-
  rium acnes
Stimulation via TLR2,4, 
  NOD1,2, CD209
Tlr2-/-: impaired IL-6 production
Treponema
  pallidum
Stimulation via TLR1/2
Stimulation via TLR5/NAIP/
    NLRC4?
Borrelia
  burgdorferi
Stimulation via TLR2/6
TLR2 A253G SNP trans-
  fected: less stimulation
Mycobacterial skin infections
Mycobacterium
  tuberculosis
Stimulation via TLR2,4,9, 
  CLEC7A, CLEC4E, MRC1, 
  CD209
Myd88-/- or Card9-/-: increased 
  susceptibility
Tlr2-/- or Tlr4-/- or Tlr9-/-: 
  increased susceptibility or no 
  effect
Nod2-/-: impaired cytokine 
  production
Mycobacterium
  ulcerans
Stimulation via TLR2,4, 
  CLEC7A
Mycobacterium 
  leprae
TLR1 T1805G SNP: 
  impaired immune 
  response
TLR2 C597T SNP: more 
  severe immune
  response
TLR4 D299G and T399I 
  SNP: increased 
  susceptibility
Stimulation via TLR1/2,4, 
  CD209
Viral skin infections
Herpes viruses TLR2 R753Q SNP in 
  transplant recipients:
  elevated CMV 
  replication
TLR2 haplotypes 2&4:  
  increased susceptibility
  to genital HSV-2
TLR3 homozygous
  mutation in 2 cases
  with HSV-1 encephalitis
Stimulation via TLR2,3,7,9, 
  AIM2, IFI16, DHX9, 
  DHX36, MDA5, RIG-I
Myd88-/-: increased susceptibility
Tlr2-/-: increased susceptibility to
  CMV, HSV-2
Tlr3-/-: impaired cytokine 
  production
Tlr9-/-: no effect, or increased
  susceptibility to mCMV, HSV-1
Aim2-/-: increased susceptibility 
  to mCMV
Vaccinia virus Stimulation via TLR2,3,4, 
  MDA5, RIG-I
Aim2: stimulation in murine cell 
  line
Parasitic skin infections
Leishmania Stimulation via TLR2,3,4 Myd88-/- or Tlr4-/- or Tlr9-/-: 
  increased susceptibility
Trypanosoma
  cruzi
Stimulation via TLR7,9
Stimulation or inhibition via 
  TLR2
Myd88-/- or Tlr4-/- or Tlr9-/-: 
  increased susceptibility
Tlr2-/-: increased cytokine 
  production
Unc93b1-/- (defective Tlr3,7,9):
  increased susceptibility
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PRRs in bacterial skin infections
The skin microbiome
The human skin microbiome varies greatly among individuals and contains many different bacterial 
species with distinct predilection for certain body sites.1 In general, sebaceous skin areas harbor 
predominantly Propionibacterium spp, whereas Staphylococcus and Corynebacterium spp. are 
the most abundant organisms colonizing moist areas. The dry skin areas have a more diverse 
microbiome, with Actinobacteria, Proteobacteria, Firmicutes and Bacteriodetes as the main 
phyla.38,39 Instead of constantly fighting the entire resident microbiota, the skin can discriminate 
between harmless commensal microorganisms and harmful pathogenic microorganisms. Recent 
studies have begun to shed light on the underlying mechanisms and point towards the induction 
of immune tolerance by commensals. Inhibition of PRR signaling is a means of achieving immune 
evasion, as was shown for fungi. For example, TLR function may be impaired by prolonged 
exposure to commensal microorganisms, either through decreased TLR expression or by activation 
of the TLR pathway inhibitors interleukin-1 receptor-associated kinase 3 (IRAK3) and suppressor 
of cytokine signaling 1 (SOCS1).40,41 Also, the requirement of a specific combination of PAMPs for 
PRR signaling may contribute to immune tolerance. It was recently shown that lipoteichoic acid 
from the commensal bacterium Staphylococcus epidermidis can inhibit TLR3 signaling in a TLR2-
dependent manner, whereas lipoteichoic acid derived from S. aureus can not.42 S. epidermidis 
can also trigger keratinocyte expression of AMPs via TLR2.43 These data show that commensal 
bacteria actively shape innate immune responses, among others through modulation of PRR 
signaling.
Staphylococcus aureus
Fifty percent of the general population is intermittently colonized with S. aureus, and 20% even 
persistently. Even though S. aureus often colonizes skin uneventfully, it is commonly involved 
in skin infections, including impetigo and folliculitis.44 Moreover, methicillin-resistant S. aureus 
(MRSA) strains are posing an increasing health threat.45 Staphylococci contain PAMPs, such 
as the TLR2/TLR6 ligand bacterial lipoprotein, the TLR2/TLR2 ligand lipoteichoic acid, and the 
NOD2 ligand peptidoglycan.46-49 The importance of TLR function in preventing infection was 
shown when Tlr2- and Myd88-deficient mice were highly susceptible to S. aureus infection.50 
In humans, genetic deficiencies in MyD88 or IRAK4 result in increased susceptibility to S. aureus 
skin infections.51,52 MyD88 and IRAK4 are indispensable adaptor proteins for signaling of the 
TLR and IL-1 receptor (IL-1R) families that are important for neutrophil recruitment during S. 
aureus infections (Figure 4.1). These receptor families include almost all TLRs (except for TLR3, 
which signals through TRIF), as well as the IL-1R family members IL-1R, IL-18R and IL-33R.53,54 
To identify the exact pathway responsible for the increased susceptibility to infection seen in 
MYD88- or IRAK4-deficient patients, defects in TLR2 and IL1R signaling were studied. Whereas 
TLR2/TLR1 and TLR2/TLR6 heterodimers recognize S. aureus lipopeptides and lipoteichoic acid 
54, IL-1R is activated by endogenous IL-1a and IL-1b. Miller et al. found that IL1R-deficient mice, 
but not Tlr2-deficient mice, had similar defects in bacterial clearance and neutrophil recruitment 
to Myd88-deficient mice, indicating a more prominent role for IL-1R in host defense against 
infections.55 Still, Tlr2-deficient mice had impaired production of IL-1b during S. aureus infection. 
In another study, S. aureus-derived diacylated lipopeptide upregulated the expression of thymic 
stromal lymphopoietin (TSLP) and other proinflammatory molecules via TLR2/TLR6 signaling.56 
Also, the TLR2 homodimer recognizes S. aureus lipoprotein.57 Hypothetically, TLR2 mutations may 
predispose to bacterial infections. In two patients with staphylococcal sepsis, a TLR2 Arg753Gln 
polymorphism was found, but large scale studies are required to determine if there is an actual 
association, and functional studies to establish if the SNP is disease-causing.58 Finally, it remains 
to be determined if TLR2 polymorphisms are relevant to the susceptibility of skin colonization 
with S.aureus. Reduced pro-IL-1b during cutaneous S. aureus infection was also seen in mice 
deficient in Nod2, an NLR that recognizes muramyl dipeptide, a breakdown product of S. aureus 
peptidoglycan.59 S. aureus was also shown to induce IL-1b secretion in an NLRP3-dependent 
manner.60 More specifically, S. aureus alpha-hemolysin activated NLRP3 in human and mouse 
monocytic cells.61  Altogether, both IL-1R and TLR2 signaling are implicated in protective immune 
responses against S. aureus.
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Streptococcus pyogenes
The group A streptococcus S. pyogenes causes the skin diseases erysipelas and necrotizing 
fasciitis. S. pyogenes activates the NLRP3 inflammasome in a streptolysin O (SLO)-dependent 
manner. Interestingly, NLRP3 was essential for IL-1b production but Nlrp3 knockout mice were 
equally susceptible to S. pyogenes infection as wild-type mice.62 NLRP3 can be activated via 
the ATP channel P2X7R 60, but several pathogens bypass this channel through the formation 
of membrane pores. S. pyogenes, for example, activates NLRP3 inflammasome in a P2X7R-
independent manner, which was suggested to be due to the poreforming SLO.62 Similarly, S. 
aureus hemolysins and lipoproteins trigger NLRP3 activation independently of P2X7R.63
Pseudomonas aeruginosa
In keratinocyte cultures, TLR5 was shown to recognize the Gram-negative bacterial component 
flagellin, which induced the upregulation of S100A8/S100A9 and several proinflammatory 
molecules.36,64 Others reported that rhamnolipids of the opportunistic Gram-negative bacterium 
P. aeruginosa mediate the crossing of the outer skin barrier by flagellin, thereby enabling it to 
induce the antimicrobial protein psoriasin without direct contact of bacteria and responding 
cells.65 
Propionibacterium acnes
Commensals can possess a pathogenic potential, as was shown for S. aureus. Another example 
is acne vulgaris, in which P. acnes is causally involved in pustule formation. A few studies indicate 
a role for TLRs in the P. acnes-induced inflammation. P. acnes is a Gram-positive bacterium and 
therefore has a cell wall rich in the TLR2 ligand peptidoglycan. Kim et al. found that TLR2 was 
abundantly expressed on perifollicular and peribulbar macrophages, and that the number of 
TLR2-positive cells increased with the evolution of acne lesions.66 Also, P. acnes-induced IL-12 and 
IL-8 production by primary human monocytes could be inhibited by anti-TLR2 blocking antibodies. 
And finally, peritoneal macrophages from Tlr2 knockout mice failed to produce IL-6 in response 
to P. acnes, whereas IL-6 production was not impaired in wild-type, Tlr6 knockout, and Tlr1 
knockout mice. In human keratinocytes, P. acnes-induced DEFB1 and IL8 gene expression could 
be inhibited by blocking TLR2 and TLR4.67 Human sebocytes express TLR2 and TLR4 as well.68 The 
inflammatory response of human sebocytes to P. acnes could well be mediated by PRR stimulation 
69, but this needs to be verified by inhibition studies. Of note, TLR2 and TLR4 polymorphisms are 
not associated with acne vulgaris.68 In macrophages, the CLR CD209 was shown to mediate an 
immune response against P. acnes.70 Tanabe et al. found that intracellular P. acnes activated NF-κB 
in both NOD1- and NOD2-dependent manners in HEK293 cells.71
Treponema pallidum 
Syphilis is a sexually transmitted systemic infection caused by Treponema pallidum. Lipopeptides 
derived from T. pallidum induce dendritic cell (DC) maturation, proinflammatory cytokine 
production and phagocytosis in a TLR2-dependent manner.72,73 T. pallidum lipopeptides also 
induce T helper 1 cell responses by engaging TLR2.74 As a flagellated spirochete, T. pallidum is rich 
in the potent PAMP flagellin, a ligand of TLR5, NLRC4 en NAIP. These PRRs could therefore well 
be involved in the resulting immune response to the spirochete. For instance, binding of flagellin 
to TLR5 leads to production of proinflammatory cytokines, such as TNFa.75
Borrelia burgdorferi 
Borrelia burgdorferi, another spirochete, causes Lyme disease. The outer surface protein lipoprotein 
A of B. burgdorferi was shown to induce TLR2/TLR6 dependent NF-κB activation.76 In patients 
with erythema migrans, peripheral monocytes had higher surface expression levels of TLR1 and 
TLR2, and monocytoid dendritic cells of TLR2 and TLR4.77 Also, 293T cells transfected with TLR2 
containing the Arg753Gln polymorphism were significantly less responsive to bacterial peptides 
derived from both B. burgdorferi and T. pallidum 58, suggesting that TLR2 genetic variations 
influence susceptibility or resistance to infections.53
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PRRs in mycobacterial skin infections
Mycobacterium tuberculosis
The data on the role of PRRs in mycobacterial skin infections are scarce. Pivarcsi et al. found that 
M. tuberculosis induced NF-κB activation and TLR2- and TLR4-dependent IL8 gene expression in 
keratinocytes.31 Myd88 and Card9 knockout mice had increased susceptibility to M. tuberculosis. 
M. tuberculosis was shown to activate TLR2, TLR4 and TLR9 signaling, but knockout mice models 
of all of these TLRs had conflicting outcomes. In some studies, Tlr2, Tlr4 or Tlr9 knockout mice had 
increased susceptibility to infection, but in others, there was no difference with wildtype mice. 
Nod2 knockout mice displayed impaired cytokine production during M. tuberculosis infection, 
but they were not more susceptible than wild type mice.78
Mycobacterium ulcerans
TLR2, TLR4 and dectin-1 were found to actively participate in the innate immune response 
of keratinocytes to M. ulcerans, which causes Buruli ulcer. M. ulcerans was shown to induce 
the internalization of bacteria, production of reactive oxygen species (ROS), and expression of 
chemokines and LL-37.79 In this study, neonatal foreskin keratinocytes were used, that tend to 
have a more inflammatory phenotype than adult human primary keratinocytes.80
Mycobacterium leprae 
Mycobacterium leprae causes the chronic debilitating disease leprosy, which ranges from 
tuberculoid to disseminated lepromatous disease. Several studies have implicated a role of PRRs in 
leprosy. The TLR1/TLR2 heterodimer, which senses microbial triacetylated lipoproteins, mediates 
cell activation by M. leprae. In addition, TLR1 and TLR2 are more abundantly expressed in lesions 
of tuberculoid patients compared with lepromatous patients.81 The notion of TLR1 involvement 
was strengthened by the finding that monocytes from people homozygous for the TLR1 SNP 
T1805G (I602S) had an impaired TLR1 response to lipoproteins in vitro.82,83 Bochud et al. found a 
significant association between the C597T SNP in TLR2 and the occurrence of an increased cell-
mediated response to M. leprae antigens, but not with susceptibility in patients with leprosy.84 In 
a Korean population, a SNP in TLR2 was associated with lepromatous leprosy susceptibility 85, but 
the true nature of the SNP was questioned by a validation study in a cohort from India.86 Others 
identified an association between polymorphisms in TLR4 and protection against leprosy.87
Further, the CLR CD209 that recognizes high mannose moieties, was reported to mediate the 
uptake of M. leprae by tissue macrophages and Schwann cells.88,89
PRRs in viral skin infections
As viruses bear numerous different PAMPs, they are readily recognized by PRRs. Interactions of 
several dermatotropic viruses with PRRs have been studied in cell lines and different kinds of 
primary human cells. We describe a number of viruses that were mechanistically linked to PRR 
function; see also Table 4.2.
Human herpes viruses
The involvement of several PRRs in the immune recognition of human herpes viruses was subject 
of an excellent review recently published by Paludan et al.90 Briefly, the herpes virion is sensed by 
TLR2, which presumably recognizes the viral glycoproteins. The viral genomic DNA is sensed by 
TLR9 in endosomes, and by DNA-dependent activator of IFN-regulatory factors (DAI), absent in 
melanoma 2 (AIM2) 91 and IFNg-inducible protein 16 (IFI16) in the cytoplasm.92 DNA is also sensed 
indirectly by the RNA polymerase III (Pol III) and retinoic acid-inducible gene I (RIG-I) system.93 Viral 
RNAs are sensed either in the cytoplasm by melanoma differentiation associated gene 5 (MDA5) 
and RIG-I or in endosomes by TLR3 and TLR7.94 Eventually, activation of these receptor pathways 
leads to proinflammatory cytokine production. 
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Vaccinia virus
Vaccinia virus is a member of the family of poxviruses. TLR2 signaling is critical for NK cell acti-
vation, CD8+ T cell expansion and memory formation in response to vaccinia viral infection.93,94 
In the immortalized murine macrophage cell line B6-MCL, vaccinia-derived dsDNA induced the 
AIM2 inflammasome, resulting in IL-1b processing.92 
Poxviruses are notorious for their multiple strategies to evade and downregulate the host 
immune response. For example, in mouse keratinocytes, the dsRNA-binding domain of the viral 
protein E3 sufficed to prevent activation of the innate immune response, whereas an E3 mutant 
virus induced an immune response that depended on mitochondrial antiviral signaling protein 
(MAVS, an adaptor for the cytoplasmic viral RNA sensors RIG-I and MDA5) and the transcription 
factor IRF3.95 In addition, E3 inhibits recognition of dsDNA via the RNA polymerase III-mediated 
dsDNA-sensing pathway.96 Also, the vaccinia virus proteins A46R and A52R share similarity with 
the human Toll-like/IL-1R domain and interfere specifically with IL-1 signal transduction. Both 
proteins blocked IL-1-mediated activation of NF-κB, and A52R also blocked TLR4- and TLR3-me-
diated NF-κB activation.91,97 A46R targets multiple Toll-like/IL-1R adaptors and contributes to viru-
lence.98 Altogether, vaccinia virus can be recognized by several PRRs, but has also evolved multiple 
ways to sabotage PRR signaling.99
PRRs in parasitic skin infections
Leishmania
Leishmaniasis is a protozoan infection transmitted by sand flies. Several studies have shown 
that in-vivo control of Leishmania parasites requires MyD88.100-102 As noted above, MyD88 is 
an indispensable adaptor protein for the signaling of most TLRs (Figure 4.1). TLR2, TLR3 and 
TLR4 are implicated in the immune response of NK cells, macrophages and mice to Leishmania 
parasites.102-104 Others found that Leishmania-induced IL-12 and type I IFN release by mDCs and 
pDCs was strictly dependent on TLR9 signaling.105,106 In vivo, the phenotype of L. major infection 
was more severe in Tlr9 knockout mice than in normal controls. Still, these mice were ultimately 
capable of containing the infection, proving that other immune pathways exist beside TLR9.105 
Trypanosoma
Trypanosoma cruzi is a flagellated protozoon that is transmitted by insects and causes the potentially 
life threatening Chagas disease. TLR-mediated recognition of Trypanosoma spp. was proposed 
when mice deficient for Myd88 were found to be highly susceptible to infection with T. brucei, T. 
cruzi, and T. gondii, and to have an impaired Th1 response during infection.107-109 T. cruzi-derived 
glycosylphosphatidylinositol (GPI) anchors are TLR2 ligands and induce inflammatory cytokine 
production by macrophages through TLR2.110,111 The T. cruzi protein Tc52 is also a TLR2 ligand and 
induces human dendritic cell maturation and confers protection against lethal infection.112 TLR4 
recognizes T. cruzi-derived glycoinositolphospholipids and confers higher resistance to infection 
with T. cruzi.113,114 Similarly, TLR2 and/or TLR4 are involved in the recognition of GPI anchors from 
T. gondii, L. major, and P. falciparum.112 The involvement of TLR9 was reported by Bafica et al, 
who found that T. cruzi-derived DNA stimulates cytokine production by antigen presenting cells in 
a TLR9-dependent manner. Moreover, they found that this TLR9 ligand synergizes with parasite-
derived GPI anchor in the induction of cytokine production by macrophages. TLR2 and TLR9 also 
cooperated in the control of parasite replication.115 
The evidence is growing that TLR2 has ambiguous roles in inflammation, and that it is rather 
immunomodulating than purely stimulating. Indeed, Tlr2 knockout mice produced enhanced 
levels of cytokines upon in-vivo challenge with T. cruzi parasites. In addition, pretreatment of 
macrophages with GPI significantly reduced cytokine release in response to T. cruzi in a TLR2-
dependent manner, indicating an immunoregulatory role of TLR2.116 Recently, it was shown that 
mice lacking functional Unc93B1, which consequently lack functional endosomal Tlr3, Tlr7, and 
Tlr9, show decreased IL-12 production by DCs upon stimulation with T. gondii, and are highly 
susceptible to infection with T. gondii. TLR7 was identified the main PRR involved in recognition 
of parasite RNA, IL-12 production by DCs, and IFNg by T lymphocytes.117  Altogether, multiple 
PRRs seem to play in concert in the immune response against infection with Trypanosoma spp. 
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PRRs as therapeutic target
The potential applications of immunomodulation are thoroughly investigated in many fields, 
including oncology, autoimmunity, and infectious diseases. The best known example of a 
PRR-targeting drug in the field of dermatology is imiquimod, a TLR7 and TLR8 ligand that is a 
recognized therapy for genital warts, and for superficial basal cell carcinoma and actinic keratosis 
in particular.15 Here, we will focus on the role of PRRs in the treatment of infectious skin disorders.
Retinoids have been used in the treatment of acne for many years. Treatment with the 
retinoid all-trans retinoic acid (ATRA) results in downregulation of TLR2 and CD14 expression 
in monocytes and in skin explants of acne and normal skin.118,119 This suggests that part of the 
therapeutic effect of ATRA could be mediated by decreased TLR signaling. Also, addition of ATRA 
directly induced differentiation of monocytes into CD209(+) macrophages and enhanced the P. 
acnes-mediated differentiation of the CD209(+) subset.70
In many infections, synergy of PRRs is indispensible for a proper immune response. This is 
also the case in chromoblastomycosis, the abovementioned chronic skin infection caused by the 
fungus F. pedrosoi. In a murine model, exogenous administration of TLR ligands helped to clear 
F. pedrosoi infection in vivo, which suggested that PRR agonists may be used therapeutically in 
infectious diseases.27 
Vaccination is the most widely applied form of immunomodulation, and several PAMPs hold 
great promise as adjuvants. The aluminium salt alum, which activates NLRP3, is one of the most 
common adjuvants in human vaccines.120 Among others, the TLR4 ligand monophosphoryl lipid 
A, TLR9 ligand CpGDNA, and TLR7 and TLR8 ligands imidazoquinolines are currently assessed as 
potential vaccine adjuvants against infectious diseases, allergies, and tumors, but TLR2 and TLR5 
ligands are promising as well.121 A combination of adjuvants may be the most successful approach, 
as was shown for a Leishmania vaccine. Co-stimulation of TLR1/TLR2 with DNA induced provided 
protection against Leishmania, whereas DNA alone did not.122 Besides, conventional adjuvants 
such as Freund’s complete adjuvant and Freund’s incomplete adjuvant contain TLR ligands, even 
though TLR signaling was shown to be dispensable for the induction of adaptive immunity.123 
Conclusion
PRRs play an important role in host defense against a plethora of dermatotropic pathogens. 
In this review, we attempted to clarify the different levels of evidence upon which the various 
presumed associations are based. Even though a large number of studies address the role of 
PRRs in skin diseases, an even greater challenge awaits since the exact mechanisms often remain 
unknown, or need to be verified in models with primary human cells or in vivo. Also, interactions 
of PRR signaling pathways during infections need to be investigated in depth to provide insight 
in the overall response in vivo. However, research on PRRs in skin has started to provide increased 
insight in disease mechanisms and offers promising new therapeutic targets. 
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Abstract 
Pattern recognition receptors (PRRs) evolved to protect organisms against pathogens, but 
excessive signaling can induce immune responses that are harmful to the host. Putative PRR 
dysfunction is associated with numerous immune disorders that affect the skin, such as systemic 
lupus erythematosus, cryopyrin-associated periodic syndrome, and primary inflammatory skin 
diseases including psoriasis and atopic dermatitis. As yet, the evidence is often confined to 
genetic association studies without additional proof of a causal relationship. However, insight in 
the role of PRRs in the pathophysiology of some disorders has already resulted in new therapeutic 
approaches based on immunomodulation of PRRs.
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Introduction
Pattern recognition receptors (PRRs) are a vital part of innate host defense. In several diseases, 
however, PRR signaling can be harmful to the host. Tissue damage can be inflicted by excessive 
pathogen-induced PRR signaling. Yet during the last decade several diseases were identified in 
which profuse PRR signaling was caused by endogenous factors. The cryopyin-associated periodic 
syndrome (CAPS) is an example of genetically predisposed nucleotide oligomerization domain 
(NOD), leucin-rich repeat- and pyrin domain-containing 3 protein (NLRP3) overactivation, result-
ing in mild to debilitating systemic inflammation.1,2 Multiple complex disorders have been linked 
to NLRP3 dysfunction, including gout, type 2 diabetes mellitus and atherosclerosis.1,3,4 Although 
NLRP3 is the best-characterized inflammasome-related PRR, and it was shown to respond to an 
impressive array of endogenous and exogenous stimuli ranging from ATP to reactive oxygen 
species, the exact ligand-sensing mechanism of NLRP3 remains unknown. NLRP3 is part of an 
inflammasome. Inflammasomes are multiprotein complexes that upon ligand binding by certain 
PRRs activate caspase-1, which in turn activates the potent proinflammatory cytokines IL-1b, IL-18 
and IL-33 (Figure 5.1). 
Figure 5.1. The inflammasomes. Inflammasomes are protein complexes that activate caspase-1, which in 
turn activates interleukin-1 beta (IL-1b). IL-1b production requires two signals. First, activation of multiple 
PRRs may lead to NF-κB activation, resulting in the production of the precursor pro-IL-1b. Second, activation 
of an inflammasome results in activation of caspase-1, which in turn cleaves pro-IL-1b into the active 
cytokine. The pattern recognition receptors (PRRs) that associate with inflammasomes are NLRP1, NLRP3, 
NLRC4, AIM2, IFI16 and RIG-I, each recognizing particular pathogen- and damage-associated molecular 
patterns (PAMPs and DAMPs). The adaptor protein ASC is required in all inflammasome complexes to 
bridge the interaction between upstream PRRs and inflammatory caspases through its amino-terminal pyrin 
domain (PYD) and carboxy-terminal caspase-recruitment domain (CARD), respectively. 
The major ligands of the PRRs are depicted in italic bold. Adaptor and signaling proteins: MyD88, TIRAP, 
IRAK, SYK, ASC, NF-κB. Ligands: dsDNA, ssRNA, dsRNA, MDP, UV-B.
Chapter  5
64
Since IL-1b is an extremely potent inflammatory cytokine, its activation is strictly regulated and 
requires more than inflammasome activation. The two-step model of IL-1b activation holds that 
prior to inflammasome activation the precursor of IL-1b (pro-IL-1b) needs to be transcribed, for 
which priming with TLR ligands or the cytokine tumor necrosis factor alpha (TNFa) is required 
(Figure 5.1).5,6 This is one of the many cases in which PRR cooperation is imperative. The PRRs 
that associate with inflammasomes are the NLRs NLRP1, NLRP3, NOD-, leucin-rich repeat- and 
caspase-associated recruitment domain (CARD)-containing 4 (NLRC4) 7, the DNA sensors absent 
in melanoma 2 (AIM2) 8-10 and interferon, gamma-inducible protein 16 (IFI16) 11, and retinoic-acid-
inducible gene I (RIG-I).12
The levels of evidence for associations between diseases and PRRs differ greatly. In some, 
there is a clear causal relationship between a mutation in a PRR gene and excessive inflammation, 
whereas in other diseases, only differences in expression levels of certain PRRs or associations with 
single nucleotide polymorphisms (SNPs) in genome-wide association studies were reported. This 
review summarizes the detrimental roles PRRs can play in primary inflammatory skin diseases and 
systemic diseases with skin manifestations.
PRRs as villains in primary skin disorders
Despite the fact that these disorders principally affect the skin, several of them can also give 
systemic symptoms, and can display abnormalities in circulating immune cells or inflammatory 
mediators. The inflammatory skin disorders that are associated with PRRs are listed in Table 5.1.
Table 5.1. PRRs implicated in immune disorders affecting the skin 
Disease Genetic association Endogenous 
expression in 
affected human 
tissues
PRR-mediated effect 
on immune response 
to ligands in human 
cells
Functional 
association in mice
Primary skin disorders
Primary skin disorders in which a role of PRRs is suspected
Psoriasis Increased: AIM2, 
  dectin-1, MRC1
In keratinocytes:
TLR2: induction of 
  hBD-2 and TNFa
TLR3: induction of 
  TNFa
TLR4: induction of 
  TNFa or no effect
TLR5 or TLR9: induction 
  of hBD-2
Dectin-1: no effect of 
  b-glucan +/- TLR2 or 
  TLR5 or MRC1 ligands
AIM2: IL-1b activation
In monocytes:
Dectin-1: induction of 
  IL-23
Tlr7 / Tlr8: imiquimod 
  induced psoriasis-like 
  disease
Atopic 
dermatitis
TLR2 A-16934T 
  promotor SNP: 
  disease severity
TLR2 R753Q SNP: 
  disease severity and   
  increased coloniza-
  tion with S. aureus
TLR9 C-1237T 
  promotor SNP: asso-
  ciation in subgroup
NOD1 SNPs: 
  association in some
Increased: AIM2, 
  dectin-1, 
  MRC1, TLR1
Normal or 
  decreased: TLR2
In keratinocytes:
TLR2/TLR6: induction 
of TSLP
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Disease Genetic association Endogenous 
expression in 
affected human 
tissues
PRR-mediated effect 
on immune response 
to ligands in human 
cells
Functional 
association in mice
Primary skin disorders
Primary skin disorders in which a role of PRRs is suspected, continued
Allergic 
contact 
dermatitis
MyD88 or TLR4 RNAi: 
  inhibited nickel-
  induced inflammation
IRAK1 RNAi: reduced 
  nickel-induced 
  inflammation
Caspase-1: mediated 
  IL-1b activation upon 
  TNCB or SDS
Tlr2-/-,Tlr4-/-: impaired 
  TNCB-induced ACD
Tlr4-/-: no effect on 
  TNCB-induced ACD
hTLR4, not mTlr4: 
  mediated nickel-
  induced ACD
Asc-/- or Nlrp3-/-: 
  reduced TNCB-
  induced ACD
Nlrp12-/-: reduced 
  oxazolone or FITC-
  induced ACD
Primary skin disorders in which a role of PRRs is speculative
Rosacea Increased: TLR2 TLR2: induction of 
  kallikrein 5
Vitiligo NLRP1 SNPs: 
  association with 
  generalized vitiligo
Stevens-
Johnson 
syndrome
TLR3 SNPs: 
  association
Systemic immune disorders affecting the skin
Monogenic disorders directly linked to a mutation in a PRR gene
CAPS NLRP3 mutations: 
  autosomal 
  dominant, 
  disease-causing
NLRP3 mutants: 
  excessive endogenous 
  and PAMP-induced 
  IL-1b activation
NLRP12AD NLRP12 mutations: 
  autosomal 
  dominant(?), 
  disease-causing
NLRP12 mutants: 
  impaired inhibition 
  of NK-κB signaling in 
  some; increased IL-1b 
  and ROS activation in 
  others
Blau 
syndrome
NOD2 mutations: 
  disease-causing
NOD2 mutants: 
  constitutive activation 
  of NK-κB
Disorders caused by overstimulation of PRR by endogenous ligands
Gout NLRP3: excessive 
  uric-acid-induced 
  IL-1b activation, 
  provided LPS is 
  present
Nlrp3-/- or Asc-/-: 
  no gout upon urate 
  injection
Pseudo-
gout
NLRP3: excessive 
  calcium pyrophos-
  phate dihydrate-
  induced IL-1b 
  activation, provided 
  LPS is present
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Disease Genetic association Endogenous 
expression in 
affected human 
tissues
PRR-mediated effect 
on immune response 
to ligands in human 
cells
Functional 
association in mice
Systemic immune disorders affecting the skin, continued
Systemic immune disorders in which a role of PRRs is suspected
Behçet’s 
disease
TLR4 SNP: more 
  prevalent in 
  HLA-B51+ patients
TIRAP SNP: associated 
  in one population
SLE TLR5 SNP: protective
TIRAP SNP: decreased 
  susceptibility
HSP70 SNPs: 
  association in some, 
  but controversial 
TLR2, TLR7, 
  TLR9, AIM2 
  and IFI16: 
  mRNA 
  increased in 
  PBMCs
TLR2, TLR4 and / or 
  TLR9: in serum 
  increased HMGB1 
  (ligand) protein and 
  anti-HMGB1 anti-
  bodies
TLR7: overexpression 
 induced autoimmunity
Tlr2-/-: impaired auto-
  antibody production 
  induced by 
  nucleosomes 
  containing HMGB1
Tlr7 overexpression: 
  induced autoimmunity
TLR9-/-: decreased or 
  increased disease in 
  SLE mouse model
Graft-
versus-
host-
disease
NOD2 SNPs: increased 
  susceptibility
Recipient Tlr9-/-: 
  reduced GVHD
Donor Tlr9-/- or 
  Nod2-/-: no effect
Tlr9 blocking by iODN: 
  reduced GVHD
Recipient Myd88-/-, 
Trif-/- or Tlr2-/-: no 
  effect
Recipient Tlr4-/-: no 
  effect or more severe 
  GVHD
Donor Tlr4-/-: no 
  effect or reduced 
  GVHD
Recipient Nod2-/-: 
  more severe GVHD
Systemic immune disorders in which a role of PRRs is speculative
Sarcoidosis NOD2 SNPs: 
  association with 
  severe pulmonary 
  disease, not in 
  general
Schnitzler’s 
syndrome
NLRP3 V198M SNP 
  in a single patient, 
  to date not in 
  others*
Inflammasome: 
  increased IL-1b 
  activation upon 
  stimulation of 
  PBMCs with 
  LPS*
*Novel data are reported in Chapter 14 (myeloid-lineage-restricted mosaicism of NLRP3 mutations in two 
patients with variant Schnitzler’s syndrome) and Chapter 16 (more LPS-induced IL-1b production in peripheral 
blood mononuclear cells of patients during a symptomatic episode; and less TLR2/6- and TLR3-mediated 
induction of inflammation) of this thesis.
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Primary skin disorders in which a role of PRRs is suspected
Psoriasis
Psoriasis is a chronic inflammatory skin disease characterized by erythematosquamous plaques, 
and is associated with skin barrier abnormalities and T helper cell 1 (Th1) and Th17 immune 
responses. More recently, the innate immune system was found to play a role too. The expres-
sion of multiple antimicrobial proteins (AMPs), including human b-defensin-2 (hBD-2), is strongly 
increased in psoriatic plaques, which could well be a downstream effect of PRR signaling.13,14 
Several groups investigated PRR expression in psoriatic lesions. Lesional TLR2 mRNA and protein 
expression levels are similar to those in normal skin 15,16, although two older studies suggested dif-
ferently.17,18 Transforming growth factor alpha, which is induced in psoriasis, increases TLR5 and 
TLR9 expression and function in keratinocytes. TLR2, TLR5 and TLR9 ligands induce the expres-
sion of human b-defensins in primary keratinocytes.15,19 Also, TLR2, TLR3 and TLR4 ligands were 
shown to induce the psoriasis-associated cytokine TNFa in human keratinocytes.18 It is, however, 
controversial whether TLR4 is expressed in primary human keratinocytes, because several authors 
did not find TLR4 expression or effects of lipopolysaccharide (LPS) stimulation in these cells.15,20
Interestingly, topical application of imiquimod, a ligand for both TLR7 and TLR8, has been 
described to aggravate psoriatic lesions, but also to induce de novo psoriasis.21-24 TLR7 and TLR8 
signaling leads to a type I interferon (IFN) response. IFNa-producing plasmacytoid dendritic cells 
(pDCs) are thought to be important in the induction of psoriasis.25 Moreover, psoriasis was repor-
ted to be induced or exacerbated by treatment with IFNa or IFNb for various indications (hepatitis 
C 26, chronic myeloid leukemia 27 or multiple myeloma 28). In a mouse model, daily application of 
imiquimod induced psoriasis-like lesions with increased epidermal expression of IL-23, IL-17A and 
IL-17F, and an increase in splenic Th17 cells. However, this phenotype was prevented in mice defi-
cient in the IL-23 or IL-17 receptor. This study provided a link between TLR7 or TLR8 signaling and 
the IL-23/IL-17 axis, which is important in the pathogenesis of psoriasis.29 The role of other type 
I IFN-inducing PRRs is unclear, since in one study RIG-I and melanoma differentiation-associated 
gene 5 (MDA5) were slightly upregulated 30, while others did not find any difference in RIG-like 
helicase receptor family (RLR) expression levels.15
A meta-analysis demonstrated a lack of association between NOD2 polymorphisms and pso-
riasis and psoriatic arthritis, suggesting that this NLR is not a susceptibility gene for psoriasis.31
Compared to normal skin, the CLR dectin-1 is increased in the epidermis in psoriatic plaques at 
both the mRNA and protein level. Macrophage mannose receptor 1 (MRC1) mRNA expression 
was also upregulated.15 In monocytes and macrophages, dectin-1 signaling induces IL-23, which 
in turn promotes differentiation of Th17 cells.32 As a sensor of fungal b-glucan, dectin-1 signaling 
stimulates immune cells to produce antifungal AMPs, which are highly expressed in psoriasis 
lesions. Stimulation of primary human keratinocytes with b-glucan or heat-killed Candida, how-
ever, did not induce proinflammatory cytokines or AMPs, either with or without TLR2, TLR5 or 
MRC1 costimulation.15 Possibly, dectin-1 expression levels were too low for proper functioning, 
or costimulation with other ligands is required.
LL-37, one of the upregulated AMPs in psoriasis, forms aggregates with extracellular self-DNA 
that can enter pDCs, activate TLR9 and trigger type I IFN production.33 Recently, LL-37 was repor-
ted to neutralize cytosolic DNA in keratinocytes and block activation of the AIM2 inflammasome. 
The authors found upregulation of AIM2 in psoriatic lesional skin and a 3-fold induction of IL-1b 
secretion by keratinocytes upon stimulation with double-stranded DNA (dsDNA).34
Atopic dermatitis
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that mainly affects children 
and is characterized by pruritus, eczematous plaques and xerosis. AD is associated with skin barri-
er abnormalities and a Th2 immune response.13 AD lesions display lower levels of AMPs than pso-
riatic plaques 35,36, and are often infected with Staphylococcus aureus, which is associated with 
AD flares and severity.37,38 Herpes simplex virus (HSV) infections can also exacerbate AD and Can-
dida species often colonize atopic skin.38 Defects in the innate immune system were hypothesized 
to predispose to AD development and to colonization with these pathogens. Hence, differences 
in PRR expression and function became research targets. S. aureus-diacylated lipoproteins were 
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shown to induce expression of thymic stromal lymphopoietin (TSLP), which is highly expressed by 
keratinocytes in skin lesions of patients with AD. This process required signaling of the TLR2/TLR6 
heterodimer and was enhanced by Th2 cytokines.39 The role of TLR2 in AD is controversial, as is 
the case in other diseases. One study reported the association of the TLR2 A-16934T promoter 
polymorphism with severe AD, which did not affect TLR2 mRNA expression and resulted in de-
creased TLR2-induced IL-6, but not TNFa production.40 In one population the TLR2 R753Q poly-
morphism was associated with AD disease severity and increased colonization with S. aureus.41 
Previously, this polymorphism had been implicated in S. aureus infections.42 The TLR2 R753Q 
polymorphism led to decreased cell surface expression of TLR2 in CD3/CD28-activated CD4+ 
T cells, and impaired TLR2-mediated IL-8 secretion by monocytes.43 In other populations, no as-
sociations between TLR1, TLR2, TLR4 and TLR6 polymorphisms and AD were found.44,45 The data 
on TLR2 protein expression levels in AD lesions are also conflicting, since one study reported no 
difference with normal skin 16, whereas another study reported decreased TLR2 and increased 
TLR1 expression in AD lesions. In this study, TLR4 and TLR9 protein expression levels were similar 
in AD lesions and normal skin.46 The C-1237T polymorphism in the TLR9 promoter was signifi-
cantly associated with AD in a subgroup of patients, and resulted in significantly higher promoter 
activity. This association was not seen in a case-control cohort in the same study, so it may only 
apply to some cases of AD.47 One genetic study revealed an association of NOD1 polymorphisms 
with AD 48, but in other studies, genetic associations of AD with NOD1, NOD2 or NLRP12 were 
only slightly significant, which renders the pathophysiological implications questionable.49,50
A comprehensive study on epidermal PRR mRNA expression showed that expression of the 
majority of PRRs was similar in psoriasis, AD and normal skin. In AD, CLEC7A (dectin-1) was up-
regulated 6-fold and MRC1 10-fold.15 Progenitor-derived mast cells from AD patients were shown 
to display lower dectin-1 expression, but the implications are yet to be determined.51
Allergic contact dermatitis
Allergic contact dermatitis (ACD) is a type IV delayed hypersensitivity reaction in the skin typically 
after sensitization by haptens.52 In mice, the concomitant absence of Tlr2 and Tlr4 prevented 
the induction of ACD to 2,4,6-trinitro-1-chlorobenzene (TNCB). Also, in Tlr4/IL-12Rb2 double 
knockout mice, DC-mediated sensitization, generation of effector T cells, and the subsequent 
contact hypersensitivity response to TNCB, oxazolone, and fluorescein isothiocyanate were ab-
sent. This was not the case in Tlr4 or IL12 single knockout mice.53 Epicutaneous immunization 
with protein antigen is applied as desensitization because it induces suppression of subsequent T 
cell-dependent contact hypersensitivity reactions after active immunization. Ptak et al. found that 
this suppression can be reversed by crude bacterial components and purified TLR2, TLR3, TLR4, 
and TLR9 ligands.54 Also, the effect of TLR4 ligand LPS was not observed in Tlr4 mutant C3H/
HeJ mice, which indicates that this effect was dependent upon intact TLR4 signaling. The inflam-
matory response in nickel ACD is TLR4 dependent. Interestingly, mouse Tlr4 could not generate 
this response, but transgenic expression of human TLR4 in Tlr4-deficient mice allowed efficient 
sensitization to nickel and elicitation of ACD.55
Watanabe et al. showed involvement of the inflammasome in ACD. In primary human kera-
tinocytes, TNCB and SDS induced IL-1b activation in a caspase-1-dependent manner. In Asc and 
Nlrp3 knockout mice, TNCB-induced ACD was reduced.56
NLRP12 is one of the latest identified NLRs. In two models of ACD (oxazolone and FITC), 
Nlrp12-deficient mice exhibited attenuated inflammatory responses. Nlrp12 knockout DCs were 
less capable of migrating to draining lymph nodes, and both Nlrp12 knockout DCs and neutro-
phils failed to respond to chemokines in vitro.57
Primary skin disorders with speculative associations with PRRs
In other skin disorders, the evidence for a role of PRRs is still more speculative, although it may 
have important implications. We will mention three examples of these.
Rosacea
Rosacea is a common skin disease that is characterized by facial inflammation, abnormal vascular 
dilatation and proliferation, and formation of granulomas. Symptoms are exacerbated by external 
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triggers, such as UV light, heat, and a variety of microbes. TLR2 stimulation induced expression of 
kallikrein 5, a critical protease involved in the pathogenesis of rosacea, since it processes catheli-
cidin.16 The increased TLR2 expression in rosacea may cause increased susceptibility to pathogen- 
and damage-associated molecular patterns (PAMPs and DAMPs) that trigger disease.
Vitiligo
Vitiligo is an autoimmune disease characterized by the destruction of melanocytes in the epider-
mis, resulting in depigmented macules. It is associated with several other autoimmune disorders 
including autoimmune thyroid disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), 
and diabetes.58 NLRP1 genetic variants have been associated with vitiligo 58-60, which is interesting 
from a pathophysiological point of view, since NLRP1 is part of an inflammasome that activates 
IL-1b and can result in apoptosis. The functional aspects require further investigation.
Stevens-Johnson syndrome
Stevens-Johnson syndrome and the related toxic epidermal necrolysis are severe acute-onset mu-
cocutaneous disorders that can be induced by drugs or pathogens. In Japanese patients, TLR3 
polymorphisms were associated with Stevens-Johnson syndrome and toxic epidermal necrolysis 
61, while in another population TLR9 polymorphisms were not.62
PRRs in systemic inflammatory disorders with skin manifestations
PRRs are implicated in many systemic disorders, such as the autoinflammatory syndromes, which 
are characterized by a predisposition towards excessive innate immune activation, often affecting 
the skin.63 Several autoinflammatory diseases somehow affect PRR signaling pathways, but in this 
review we chose to discuss those that are directly linked to PRRs. We will also discuss examples of 
multifactorial diseases in which PRRs were implicated, as listed in Table 5.1.
Monogenic disorders directly linked to a mutation in a PRR gene
Cryopyrin-associated periodic syndrome
CAPS refers to a spectrum of autoinflammatory diseases, previously known as familial cold asso-
ciated periodic syndrome, Muckle-Wells syndrome, and the debilitating chronic infantile neuro-
logic, cutaneous, articular syndrome. The latter was also known as neonatal-onset multisystem 
inflammatory disease.1,2 CAPS is clinically characterized by urticarial-like skin rashes which may be 
cold-induced, recurrent fevers, arthralgia or arthritis, ocular symptoms, sometimes amyloidosis, 
and, in severely affected patients, severe neurological symptoms.64 These diseases were collec-
tively classified as CAPS upon recognition that all three were caused by heterozygous mutations 
in NLRP3, previously referred to as NALP3 or cryopyrin.65,66 These are regarded as gain-of-function 
mutations, resulting in a hyperactive or constitutively active inflammasome, leading to systemic 
IL-1b-induced inflammation. Monocytes and macrophages from Muckle-Wells syndrome patients 
display a basal secretion of mature IL-1b in the absence of any external stimulus.67 Together, 
these data formed the rationale for trials with IL-1 blocking therapies. Indeed, the IL-1 receptor 
antagonist anakinra, the IL-1 receptor-Fc fusion protein rilonacept, and the human IgG1 anti–IL-
1b monoclonal antibody canakinumab are all successful in preventing inflammation in CAPS.1,68-70 
NLRP12-associated periodic syndrome
A very rare hereditary periodic fever syndrome results from mutations in the NLRP12 gene, and 
manifests with mainly cold-induced recurrent fevers, arthralgia, and in some cases urticarial rash-
es or abdominal pain.71-73 The pathophysiology is not completely clear yet. NLRP12 was previously 
shown to inhibit nuclear factor-κB (NF-κB) signaling 74, and in some of the NLRP12 mutations a 
clear reduction of these inhibitory properties could be found, in keeping with a loss of function 
72, but this was not true in all cases.75 In another family, monocytes produced more IL-1b and 
reactive oxygen species upon stimulation with PAMPs.71 Altogether, NLRP12 mutations cause an 
autoinflammatory syndrome through increased NF-κB and/or IL-1b signaling.
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Blau syndrome
Blau syndrome, also known as early-onset sarcoidosis, is a rare autosomal dominant disorder 
which is characterized by granulomatous arthritis, uveitis and skin rash. Various mutations in 
the NOD2 gene were found in patients with Blau syndrome, and all mutations were associated 
with constitutive activation of the transcription factor NF-κB.76 These mutations confer a gain of 
function to NOD2, while Crohn’s disease-associated NOD2 variants impair NF-κB activation.77,78
Systemic immune disorders in which a role of PRRs is suspected 
Gout and pseudogout
Monosodium urate and calcium pyrophosphate dihydrate crystals were long known to cause 
arthritis in gout and pseudogout, respectively. In the so-called tophi, uric acid depositions induce 
inflammation in the skin. Both monosodium urate and calcium pyrophosphate dihydrate crystals 
were shown to be able to activate the NLRP3 inflammasome in vitro, provided there was costi-
mulation with LPS, resulting in excessive IL-1b production.79 The authors showed that macro-
phages from mice deficient in various components of the inflammasome, such as pro-caspase-1, 
ASC or NLRP3, did not respond to injection of urate crystals. The excessive production of IL-1b 
provides a rationale for IL-1b blocking therapies. Indeed, anakinra and rilonacept proved highly 
effective in clinical trials in gout patients.80,81
Behçet’s disease
Behçet’s disease (BD) is a multisystem disease characterized by recurrent oral and genital ulcers, 
relapsing uveitis, and articular, neurologic, vascular, intestinal and pulmonary manifestations. 
Several groups studied NOD2 polymorphisms in BD patients, but found no association.82-84 SNP 
analyses of TLR2, TLR4, CD14 and TLR9 in BD patients was also negative.85-89 However, the S180L 
polymorphism in Toll/interleukin receptor 1 domain-containing adaptor protein (TIRAP), a protein 
involved in TLR2 and TLR4 signaling, was significantly associated with BD patients in the UK, but 
not in the Middle East.89 Also, a TLR4 variant was significantly more prevalent in HLA-B51-posi-
tive, but not HLA-B51-negative BD patients, compared with healthy control participants, which 
suggests a synergistic increase in susceptibility of BD in this population.90 Thus, most genetic 
studies on PRRs in BD showed no association.
Systemic lupus erythematosus
SLE is predominantly regarded as a disorder of the adaptive immune system, but recent studies 
point towards a concomitant role of innate immune responses.91 In murine SLE models, autoan-
tibodies bind DNA or chromatin released from dying cells, forming complexes that can stimulate 
IFNa production by DCs via TLR9.92-95 In addition, TLR9/MyD88 (myeloid differentiation factor 88) 
signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in autore-
active B cells in SLE, resulting in a pathogenic loop.96 The role of TLR9 is controversial, however, 
since others found that TLR9 knockdown resulted in exacerbation of autoimmunity rather than 
reduction.97 Moreover, Tlr9 was found to regulate Tlr7- and Myd88-dependent autoantibody 
production and disease in a murine SLE model.52 Possibly, differences between mouse strains 
account for these discrepancies. TLR9 polymorphisms were associated with lupus nephritis in a 
Chinese Han population, but the functional consequences of the polymorphisms are unclear.98 
Patients with active SLE displayed an increased number of TLR9-positive B cells, which correlated
with elevated titers of autoantibodies against dsDNA. In vitro, serum from patients with SLE 
upregulated expression of TLR9 on plasma cells.99 Tian et al. showed that B cells and pDCs can 
be activated by immune complexes that contain DNA and high mobility group box (HMGB)-1 
in a TLR9- and MyD88-dependent manner involving the receptor for advanced glycation end 
products (RAGE).100 HMGB1 is also recognized by TLR2 and TLR4.101 In the sera of SLE patients, 
HMGB1 and anti-HMGB1 antibodies are often found 102, as are HMGB1-containing nucleosomes. 
These HMGB1-containing nucleosomes stimulated the production of proinflammatory cytokines 
in macrophages, and induced autoantibody production in BALB/c mice, both in a TLR2-depen-
dent manner.103
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Activation of TLR7 and TLR8 by RNA and RNA-containing immune complexes is also implicated 
in the pathogenesis of SLE.92,93,104,105 TLR7 and TLR8 are encoded on the X chromosome, which is 
intriguing since 90% of SLE cases occur in women. Hypothetically, a copy number increase of the 
TLR7 or TLR8 genes could account for this predominance. Indeed, overexpression of TLR7 trig-
gered autoimmune responses in mice and transgenic cell lines.106 In peripheral blood mononucle-
ar cells (PBMCs) of patients with SLE, mRNA expression levels of TLR2, TLR7 and TLR9 were eleva-
ted, whereas TLR3, TLR4, TLR5 and TLR8 remained the same.107 A TLR5 stop codon polymorphism 
abrogating TLR5 function was associated with resistance to SLE.108 Polymorphisms of some, but 
not all investigated heat shock protein 70 (HSP70) genes were associated with SLE.109,110 Some 
studies suggest HSP70 is an endogenous TLR2 and TLR4 ligand.111,112 These associations are con-
troversial, however, since some argue that contaminating PAMPs are responsible for the reported 
in-vitro cytokine effects of HSPs, as highly purified HSPs do not show any cytokine effects.113
TLR3, which recognizes dsRNA, is absent in B cells, but its activation on glomerular mesangial 
cells and antigen-presenting cells aggravated lupus nephritis in a mouse model.114 However, TLR3 
costimulation did not influence TLR7-induced complex glomerulonephritis in this mouse model. 
The S180L polymorphism in the TLR2 and TLR4 pathway adaptor protein TIRAP decreased suscep-
tibility to SLE in a Colombian population.115 The majority of studies investigated the role of TLRs in 
SLE, but other PRRs may well be involved too. Kimkong et al. found increased mRNA expression 
levels of IFI16 and AIM2 in PBMCs of SLE patients. Since these are cytosolic dsDNA receptors, they 
may well be involved in the immune reactions against host-derived DNA.116
Graft-versus-host disease
Graft-versus-host disease (GVHD) occurs when donor cells from a bone marrow transplant at-
tack healthy tissues of the host. The adaptive immune system is thought to be the main culprit, 
but recent findings implicate the host innate immune system as well. In the case of intestinal 
GVHD, microbiota may modulate innate immune response via PRRs.117 For example, in murine 
experimental GVHD models, Tlr9 deficiency in the host but not the donor reduced intestinal 
immunopathology and GVHD-related mortality. GVHD was also reduced in mice upon treatment 
with synthetic inhibitory oligodeoxynucleotide (iODN) that blocks TLR9 signaling. However, it is 
not clear whether TLR9 inhibition impairs the graft-versus-tumor response too, which would be 
highly undesirable.116 
No increased GVHD was seen in recipient mice deficient in the crucial TLR adaptor proteins 
Myd88 or Toll-interleukin 1 receptor-domain-containing adapter-inducing IFNb (Trif). Recipient 
Tlr2 deficiency did not affect GVHD outcome in mice. Recipient Tlr4 deficiency did not affect 
GVHD in two murine studies, and more severe GVHD was seen in another. Donor Tlr4 deficiency 
did not affect GVHD in one murine study, but decreased GVHD severity in two others, while 
graft-versus-leukemia activity was preserved in one.117 NOD2 polymorphisms were associated 
with GVHD in human transplant recipients.118,119 In mouse models, Nod2-deficient transplant 
recipients developed more severe GVHD, which was suggested to be caused by an increased ac-
tivation status of DCs. NOD2 may therefore inhibit DC activation. Nod2 knockout in donor mice 
did not affect GVHD.120
Systemic immune disorders in which a role of PRRs is speculative
Sarcoidosis
Sarcoidosis is characterized by granulomas affecting multiple organs. In one study, severe pul-
monary sarcoidosis was associated with NOD2 polymorphisms 121, but no NOD2 association was 
found in sarcoidosis in general.122 In a Japanese population, an association between NOD1 gene 
polymorphisms and sarcoidosis susceptibility was found. The polymorphism was associated with 
reduced NOD1 expression and impaired NF-κB activation upon infection with Propionibacterium 
acnes.123
Schnitzler’s syndrome
Schnitzler’s syndrome is an acquired syndrome characterized by a chronic urticarial rash and para-
proteinemia with signs and symptoms of systemic inflammation, such as arthralgia and recurrent 
fever.124 It has similarities to the hereditary syndrome CAPS (see above), and IL-1b has been shown 
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to be a central mediator in this disorder as well.125,126 The exact pathophysiology is unknown. In 
one patient, the common variant V198M was found in the NLRP3 gene 127, but not in others.128 
The success of IL-1 inhibition as treatment in Schnitzler’s syndrome supports the suspicion of a 
role of PRRs in the pathophysiology of this rare syndrome.125,128,129 (See comment under Table 5.1)
PRRs as therapeutic targets in immune disorders
In view of their potential detrimental role in a multitude of immune disorders, inhibition of PRR 
pathways may be a promising therapeutic approach. Conversely, PRR triggering has become a 
prominent topic in research on the immunomodulation of tumors, which we will discuss sepa-
rately below.
Immunomodulation of PRRs by established treatments in immune disorders
Calcineurin inhibitors
Calcineurin inhibitors, such as cyclosporin A, tacrolimus and pimecrolimus, are used in the treat-
ment of psoriasis and AD, and to prevent rejection in transplant patients. These agents suppress 
T cell-mediated immune responses, especially the production of proinflammatory cytokines in T 
cells, but recently evidence emerged that these calcineurin inhibitors also directly affect PRRs. In 
an immunohistochemical analysis of AD lesions, tacrolimus was found to reverse the increased 
TLR1 and decreased TLR2 expression levels.46 In normal human epidermal keratinocytes, pimecro-
limus enhanced TLR2/TLR6-induced expression of antimicrobial peptides. Interestingly, pimecroli-
mus also increased the functional capacity of keratinocytes to inhibit growth of S. aureus, which 
often colonizes the skin of AD patients and causes superinfections of AD lesions.130
Chloroquine
The antimalarial drugs chloroquine and hydroxychloroquine have been applied as therapeutic 
agents for SLE for many years, although the mechanism of action is unclear. A direct role of 
modulation of PRRs is suggested by studies which show that they inhibit stimulation of TLR3, 
TLR8 and TLR9, presumably by direct binding to nucleic acids, thereby masking the TLR-binding 
epitopes.131,132
Immunomodulation of PRRs in experimental models of immune disorders
TLR9 agonists
Not only inhibition, but also stimulation of PRRs might be of benefit in a therapeutic setting. 
Applications of TLR9 agonists, also referred to as CpG oligodeoxynucleotides (ODN), are investi-
gated in mouse models of allergy, since the Th1-biased immune response upon TLR9 activation 
may improve desensitization strategies in allergy treatment. Indeed, CpG ODN inhibited the Th2 
response in allergic mice, preventing inflammatory disease manifestations. In human clinical trials 
with a conjugate of CpG ODN and part of the ragweed allergen as an allergy vaccine, selective 
redirection of the allergic Th2 response towards a Th1 response occurred, and reduced allergic 
symptoms.132 Even though these studies were mainly on murine asthma models, they could have 
implications for the treatment of allergic cutaneous diseases.
Of note, CpG ODN also accelerates wound healing in mice and rhesus macaques, which 
could have therapeutic implications for chronic wounds in humans.133,134 
Combined TLR7/TLR9 inhibition
TLR7 signaling is involved in the pathophysiology of SLE, while results on the role of TLR9 
are conflicting. A specific inhibitor of TLR7 and TLR9, immunoregulatory sequence (IRS) 954, 
inhibited the induction of IFNa by human pDCs upon stimulation with DNA and RNA virus-
es and isolated immune complexes from SLE patients.92 In SLE-prone mice, IRS 954 prevented 
progression of disease.135 Recently, TLR7 and TLR9 signaling was shown to hamper glucocorticoid 
efficacy in SLE. Triggering of TLR7 and TLR9 by nucleic acid-containing immune complexes or by 
synthetic ligands enhanced survival of IFNa-producing pDCs.136 The role of TLR9 is controversial, 
however, since others found that TLR9 knockdown resulted in exacerbation of autoimmunity 
rather than reduction.97
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Antitumor immunomodulation of PRRs by established treatments
Imidazoquinolines
The prototype of a PRR-targeting therapy is imiquimod, an imidazoquinoline compound which 
is a synthetic agonist of TLR7 and to a lesser extent TLR8.137,138 In contrast, imidazoquinolines 
were found to inhibit TLR3 and TLR9 signaling.131 Imiquimod has potent antitumor and antiviral 
properties and is an approved topical therapy for superficial basal cell carcinoma, actinic keratosis 
and genital warts.139,140 There are multiple off-label indications for imiquimod, including HSV 
infections, verruca vulgaris, molluscum contagiosum, keloids, squamous cell carcinoma, Bowen’s 
disease, lentigo maligna, cutaneous T cell lymphoma, Kaposi’s sarcoma, and Paget’s disease.141,142 
Imiquimod induces the production of several proinflammatory cytokines, stimulates T cell re-
sponses, and instigates the migration of Langerhans cells and pDCs to the lymph nodes.138,143-145 
Moreover, at higher concentrations imiquimod induced apoptosis in basal cell carcinomas and 
melanoma metastases, but it is not clear whether this is a direct or indirect effect on the tumor 
cells.138 
Because of its immunomodulating properties, imiquimod has been tested as an adjuvant in 
antitumor vaccines. In a murine model, topical imiquimod significantly enhanced the protective 
antitumor effects of a live, recombinant Listeria vaccine against melanoma.149 In melanoma pa-
tients, the combination of a NY-ESO-1 vaccine with topical imiquimod elicited both humoral and 
cellular responses in a significant fraction of patients, but the additive effect of imiquimod was 
unclear since a vaccine-only control arm was lacking.150 The downside of immunomodulation by 
TLR7 agonists is excessive immune responses. Indeed, imiquimod often induces local skin inflam-
mation at the application site, but it was also reported to aggravate psoriatic lesions and even to 
induce de novo psoriasis.21-24
Resiquimod is a more potent TLR7- and TLR8-activating imidazoquinoline which was reported 
to be effective in the treatment of actinic keratosis 146 and genital HSV-2 infections.147,148
Investigational antitumor immunomodulation of PRRs
Loxoribine
Loxoribine, another TLR7 agonist, enhances the production of IFN, activates NK cells and B cells 
151, and was recently found to induce maturation of human monocyte-derived DCs and to stimu-
late their Th1- and Th17-polarizing capability.152 Hence, loxoribine has been under investigation 
for antiviral and antitumor properties 153, although not as intensively as imiquimod.
TLR9 agonists
CpG ODN directly induce the activation and maturation of pDCs and enhance differentiation of 
B cells into antibody-secreting plasma cells.132 As an adjuvant, CpG ODN were shown to induce 
strong CD4+ and CD8+ T cell responses and rapid production of antigen-specific antibodies to 
many types of antigen.154 They are therefore considered as promising adjuvants in anticancer vac-
cines, e.g. in the treatment of melanoma.132,155-157 In mice with cutaneous melanoma, combina-
tion therapy of topical CpG ODN with systemic dacarbazine inhibited tumor growth significantly 
more than with monotherapy with either agent.156 Importantly, TLR9 expression patterns differ 
between mice and humans, and CpG DNA are less stimulating in humans than in mice; therefore 
these results cannot automatically be extrapolated to humans.154 In patient trials, monotherapy 
with the TLR9 agonist PF-3512676 induced immune responses, but for optimal clinical efficacy 
CpG ODN are currently under investigation as antimelanoma vaccine adjuvants.155
Conclusion
PRRs have been implicated in the pathophysiology of multiple immune disorders that affect the 
skin. Once evolved to protect us from pathogens, at which they are quite successful, they can 
become detrimental if signaling is excessive. Indications that PRRs are involved in the patho-
physiology of multifactorial immune disorders are mainly based on genetic association studies 
and murine knockout models. Comprehensive endogenous expression analyses and functional 
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studies are urgently needed to determine their actual contribution to the pathophysiology. This 
will also lead to more targeted therapies, since immunomodulation of PRRs seems a promising 
therapeutic approach to various immune disorders and malignancies.
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Abstract 
Human epidermis plays an important role in host defense by acting as a physical barrier and 
signaling interface between the environment and the immune system. Pattern recognition 
receptors (PRRs) are crucial to maintain homeostasis and provide protection during infection, but 
are also causally involved in monogenic autoinflammatory diseases. 
This study aimed to investigate the epidermal expression of PRRs and several associated host 
defense molecules in healthy human skin, psoriasis and atopic dermatitis. 
Using microarray analysis and qPCR we found that many of these genes are transcribed in 
normal human epidermis. Only a few genes were differentially induced in psoriasis (CLEC7A 
(dectin-1), TLR4 and MRC1) or atopic dermatitis (MRC1, IL1RN and IL1B) compared to normal 
epidermis. A remarkably high expression of dectin-1 mRNA was observed in psoriatic epidermis 
and this was corroborated by immunohistochemistry. In cultured primary human keratinocytes, 
dectin-1 expression was induced by interferon-g, interferon-a and Th17 cytokines. Keratinocytes 
were unresponsive, however, to dectin-1 ligands such as b-glucan or heat-killed Candida albicans, 
nor did we observe synergy with TLR2/TLR5 ligands. 
In conclusion, upregulation of dectin-1 in psoriatic lesions appears to be under control of 
psoriasis-associated cytokines. Its role in the biology of skin inflammation and infection remains 
to be explored.
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Introduction
Psoriasis and atopic dermatitis (AD) are common chronic inflammatory skin conditions with dis-
tinct transcriptional programs in keratinocytes.1 In psoriasis, antimicrobial proteins are strongly 
upregulated, in contrast to AD, which was proposed to account for the increased susceptibility to 
skin infections in AD.1-5 This raises the question which signaling cascades precede these distinct 
expression profiles of innate response genes in psoriasis and AD. At the very frontline of innate 
immune surveillance are the pattern recognition receptors (PRRs) that in humans comprise four 
main groups: Toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like re-
ceptors (NLRs), RIG-like helicase receptors (RLRs), and C-type lectin receptors (CLRs).6 Together, 
TLRs can sense a wide array of bacterial, viral, fungal and protozoan ligands. The endosomal TLRs 
3,7,8 and 9 mainly recognize viral nucleic acids, whereas the remaining TLRs, located on the plas-
ma membrane, harbor mostly bacterial specificity.7 NLRs mainly recognize bacterial components, 
but NLR family pyrin domain containing 3 (NLRP3) recognizes numerous stimuli. Viral single- (ss) 
and double-stranded (ds) RNA are sensed by the RLRs, but dsRNA also by TLR3. C-type lectin do-
main family 7 member A (CLEC7A), or dectin-1, is the best-known CLR and recognizes the fungal 
cell wall component b-glucan.8,9 PRR activation initiates a specific cascade that eventually leads 
to a tailored immune response against the recognized agent, as was also established in kerati-
nocytes.10 Cytokines and type I interferons are the downstream signaling molecules that mediate 
leukocyte chemotaxis, secretion of antimicrobial proteins and vascular effects. Recent findings 
show that activation of innate PRRs shapes adaptive immune responses, e.g. by attracting specific 
kinds of T helper cells.11
Reports on PRR mRNA and protein expression in human skin are scarce and have mainly 
focused on TLRs.12-20 TLR1-3,5 and 9 are present in normal human skin in vivo and responsive 
to ligands in vitro in primary human keratinocytes. Reports on TLR4 in skin are conflicting: some 
did, others did not find in-vivo expression or response after lipopolysaccharide (LPS) stimulation. 
Epidermal expression of TLR6 and TLR10 was often detected, whereas TLR7 and TLR8 expression 
and function were absent in most studies. NOD1 and NOD2 were functionally expressed 16,21, as 
were dsRNA receptors.22,23 Dectin-1 was upregulated by Mycobacterium ulcerans and mediated 
its internalization in human keratinocytes.24 In another in-vitro study on dectin-1 in keratinocytes, 
data were inconsistent.16
The downside of the extensive immune surveillance properties of PRRs is that several 
autoinflammatory diseases are directly or indirectly related to malfunctioning PRRs.25,26 Keeping 
in mind the distinct expression profiles of cytokines and effector molecules in psoriasis and AD 
2,3, some PRRs might play a pathophysiological role in these inflammatory disorders. In psoriasis, 
stronger IHC staining of TLR2 was found compared to normal skin 13 and TLR expression patterns 
appeared to differ.12 A more diffuse epidermal expression of TLR5 and TLR9 was found in psoriasis, 
and these TLRs are upregulated and functionally potentiated by TGFa.20
In the current study we performed a comprehensive real-time quantitative PCR (qPCR) 
analysis on PRR expression and we provide protein data of selected molecules, while comparing 
expression in normal skin, psoriatic plaques and AD lesions. Dectin-1 was highly upregulated in 
psoriatic epidermis. Expression and functionality of dectin-1 were studied in vitro by engagement 
of its natural ligand b-glucan and cytokine stimulation of primary human keratinocytes.
Materials and Methods
Subjects
Four-millimeter punch biopsies were taken from chronic lesions of moderate to severe plaque 
psoriasis (N=15) and AD (N=12). Exclusion criteria were systemic or UV-B-therapy or topical 
steroids locally two weeks before the biopsy. Skin biopsies of healthy volunteers (N=11) served 
as control samples. In advance, approval of the Medical ethics committee region Arnhem-
Nijmegen, and individual written informed consent were obtained. The study was conducted 
according to the Declaration of Helsinki principles. RNA from different organs was available from 
autopsy material of one individual (Department of Pathology, Radboud university medical center, 
Nijmegen, the Netherlands).
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RNA isolation and quantitative real-time PCR
Purified epidermal sheets from healthy volunteers (N=5), psoriasis patients (N=9) and AD 
patients (N=6) were collected for mRNA analysis and cDNA was generated and PCR-amplified 
as previously described.2 Specific qPCR primers were designed with Primer Express 1.0 Software 
(Applied Biosystems), purchased from Biolegio (Nijmegen, The Netherlands) and validated on 
skin, some on blood. Primers were only accepted if their efficiency was 100 +/- 10%. Using the 
comparative delta-delta (∆∆)Ct-method and RPLP0 as reference gene, relative mRNA expression 
levels were calculated.27
Immunohistochemistry
Full-thickness skin biopsies of healthy controls, psoriatic plaques and AD lesions were forma-
lin-fixated and embedded in paraffin or directly frozen and embedded in TissueTek (Sakura 
Finetek Europe) (N=3 per condition). Sections were processed for IHC staining with the avidin-bi-
otin complex method. The following primary antibodies were used, all dissolved in 1% bovine 
serum albumin: polyclonal goat antibody to MDA5 (Imgenex, IMG-3202) (1:30), polyclonal goat 
antibody to ICEBERG (Santa Cruz, sc-14207) (1:10), monoclonal mouse antibody to dectin-1 
(R&D systems, MAB 1859) (1:50), and monoclonal mouse antibody to NLRP3 (Alexis, ALX-804-
819-C100) (1:50). Dectin-1 staining was only possible on frozen sections. 
Cell culture
Primary human epidermal cells were isolated from the dermis and cultured in keratinocyte growth 
medium (KGM).1 At 100% confluency, the cells were stimulated with different cytokine mixtures 
at concentrations that were optimized in previous experiments: IL-4 50 ng/ml with IL-13 50 ng/ml, 
IL-17 30 ng/ml with IL-22 30 ng/ml, IL-1a 30 ng/ml with TNFa 30 ng/ml and IL-6 2*104 U/ml, IFNa 
10-500 U/ml, IFNg 10-500 U/ml (PeproTech Inc, Rocky Hill, NJ) or 5% fetal calf serum. A dose-
response study was performed with b-glucan 2-50 µg/ml and heat-killed Candida 0,2-5*106/ml. 
In the final ligand-stimulation study, cells were preincubated with IFNg 500 U/ml for 24 hours 
and stimulated with b-glucan 50 µg/ml or heat-killed Candida 5*106/ml with or without addition 
of Pam3Cys-SKKKK (EMC microcollections) 10 µg/ml or flagellin (Brunschwig chemie) 1 µg/ml. 
Cells and supernatants were harvested after 24 and 48 hours, and cells were stored in Trizol for 
RNA extraction. The following enzyme-linked immunosorbent assays (ELISAs) were performed 
on the supernatants: IL-1b (R&D, DY 201E), IL-6 (Sanquin, M9316), IL-8 (Sanquin, M9318), IL-23 
(Bioscience, 88-7237-88), and hBD-2 using a goat hBD-2 antibody (Abcam, ab9871) and a rabbit 
hBD-2 antiserum.28
Statistics
For the qPCR experiments, statistical analysis by ANOVA was performed on ∆Ct values corrected 
for primer efficiency, followed by a Bonferroni (in vivo data) or LSD (in vitro data) post-hoc test 
using SPSS v16.0 (SPSS Inc). Delta-Ct is the difference between the target gene and reference 
gene (RPLP0) Ct. Note that relative expression levels are graphically shown (Figure 6.1).27
Results
mRNA expression of innate immunity genes
Our previous microarray analyses and qPCR validation studies revealed significant epidermal ex-
pression of several PRRs and related signaling molecules.2,29 To further investigate PRR expression 
in normal and inflamed skin, we designed and validated qPCR assays for multiple innate immu-
nity signaling molecules (Table 6.1).
We observed large differences in basal expression levels. RLRs, TLR2 and TLR3 show higher 
expression levels compared to other PRRs. Only a limited number of signaling molecules showed 
differential expression between normal and inflamed skin. CLEC7A (dectin-1) mRNA levels were 
induced the most in psoriatic epidermis, also compared to uninvolved skin of psoriatic patients. 
TLR4, TLR10 and mannose receptor C type 1 (MRC1) were significantly induced in psoriasis, 
although the expression levels were low (Figure 6.1 and Table 6.1). In AD skin, NOD2, MRC1, 
TLR10, pyrin domain and caspase recruitment domain-containing protein (PYCARD), IL-1 recep-
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tor antagonist (IL1RN, or IL-1ra) and IL1B were significantly induced. When comparing AD to 
psoriasis, NLRP3, PYCARD, IL1RN, IL1A and IL1B were expressed at significantly higher levels in 
AD, and CLEC2B, CLEC7A and ICEBERG in psoriasis.
Figure 6.1. Relative mRNA expression levels of pattern recognition receptors and related signaling 
molecules in human epidermis. mRNA expression data from human epidermal sheets of normal skin 
(N=5), psoriatic plaques (N=9), and atopic dermatitis lesions (N=6). TLR4 in normal skin was used as a 
reference value (relative quantity of 1) in calculating the relative quantities of all gene expression levels. 
Note that the relative quantity is presented in a log10 scale. Bars: mean +/- SEM. * p < 0,05 compared to 
normal skin.
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Table 6.1. qPCR data on PRRs and signaling molecules in human epidermis
HUGO Synonym mRNA in vivo P value5 Relative quantity
gene 
symbol
(protein) dCt1 
NS2
dCt 
PS3
dCt 
AD4
PS/NS AD/NS PS/AD PS/NS AD/NS PS/AD
Toll-like receptors (TLRs)
TLR1 14,0 13,2 13,2 0,75 0,98 1,00 2,1 1,9 1,1
TLR2 9,3 7,5 7,8 0,37 0,77 1,00 3,4 2,8 1,2
TLR3 9,4 9,0 9,6 1,00 1,00 0,63 1,4 0,9 1,5
TLR4 21,7 16,5 17,6 0,05 0,12 1,00 16,5 13,9 1,2
TLR5 12,0 11,6 11,2 0,56 0,36 1,00 1,6 1,7 0,9
TLR6 12,2 11,5 11,5 1,00 1,00 1,00 1,8 1,8 1,0
TLR7 18,5 16,2 17,6 0,23 1,00 0,11 5,2 1,8 2,8
TLR8 17,0 14,0 13,8 0,18 0,14 1,00 8,6 9,7 0,9
TLR9 14,6 14,1 13,3 0,19 0,06 0,60 0,7 1,1 0,7
TLR10 17,0 15,0 15,7 0,01 0,04 0,86 3,7 1,8 2,0
C-type lectin receptors (CLRs)
CLEC2B CLECSF2 4,9 4,0 5,9 1,00 0,65 0,03 1,9 0,5 3,6
CLEC7A Dectin-1 10,9 7,0 8,5 < 0,01 0,05 0,02 17,3 5,9 2,9
NOD-like receptors (NLRs)
NLRP1 NALP1 10,1 11,1 10,5 1,00 0,91 0,61 0,5 0,7 0,7
NLRP2 NALP2 10,3 10,5 7,6 1,00 0,85 0,07 1,4 6,6 0,2
NLRP3 NALP3 20,7 16,0 14,2 1,00 0,09 < 0,01 7,4 25,4 0,3
NOD1 CARD4 11,6 12,7 12,1 1,00 1,00 0,44 0,5 0,6 0,7
NOD2 CARD15 11,3 10,3 9,7 0,06 0,01 0,09 1,9 3,0 0,6
NLRC4 CARD12 18,9 16,7 16,1 0,18 0,03 0,22 3,0 4,3 0,7
CARD8 15,5 14,4 14,4 1,00 1,00 1,00 2,1 2,0 1,0
RIG-like helicase receptors (RLRs)
DDX58 RIG-I 7,5 6,1 7,4 0,65 1,00 0,13 2,9 1,1 2,8
IFIH1 MDA5 8,7 7,5 8,0 1,00 1,00 1,00 2,5 1,5 1,7
DHX58 LGP2 12,0 12,0 11,0 1,00 1,00 0,65 1,6 2,0 0,8
Diverse
MRC1 15,2 11,4 11,5 < 0,01 < 0,01 1,00 10,0 10,1 1,0
CHIT3L1 5,5 5,0 5,7 0,89 1,00 0,30 1,4 0,9 1,6
PKR 11,6 9,6 9,0 0,53 0,36 1,00 5,3 6,0 0,9
P2RX7 8,8 9,9 8,2 1,00 0,14 0,11 0,3 1,5 0,2
CARD9 14,0 15,3 15,9 0,07 0,38 1,00 0,3 0,5 0,6
SYK 8,0 8,1 7,4 1,00 0,26 0,01 0,8 1,4 0,6
RAF1 6,0 6,8 6,0 0,02 1,00 0,01 0,5 1,0 0,5
RIPK2 RIP2 6,6 7,5 6,4 1,00 1,00 0,12 0,6 1,1 0,5
PYCARD ASC 6,9 7,0 6,0 0,06 0,01 0,04 0,9 1,7 0,5
ICEBERG casp1 inh. 7,6 6,3 7,9 1,00 1,00 0,02 2,4 0,9 2,7
CASP1 ICE 6,7 5,4 6,2 0,14 0,93 0,17 2,5 1,4 1,8
IL1RN IL-1RA 10,2 8,7 6,6 0,11 0,00 < 0,01 2,9 13,5 0,2
IL1A IL-1a 14,7 14,9 11,5 1,00 0,23 < 0,01 0,9 15,9 0,1
IL1B IL-1b 14,9 12,7 10,4 0,18 < 0,01 < 0,01 3,6 40,8 0,1
IL18 IL-18 4,8 4,8 4,5 1,00 0,58 0,60 1,0 1,1 0,9
1 dCt: Delta PCR cycle time. 2 mRNA expression data from epidermal cells of normal skin (NS, N=5), 3 psori-
atic plaques (PS, N=9), and 4 atopic dermatitis lesions (AD, N=6). All data are corrected for primer efficiency. 
5 P-values of ANOVA and Bonferroni post-hoc test.
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Protein expression of innate immunity genes
To confirm our qPCR results we investigated protein expression by means of IHC staining of skin 
sections of normal skin, psoriatic plaques and AD lesions (Figure 6.2). We selected four proteins 
that were not previously stained in skin: one CLR (dectin-1), one RLR (DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 58 (DDX58), or melanoma differentiation-associated gene-5 (MDA5)), one NLR 
(NLRP3), and the caspase-1 inhibitor (ICEBERG). Dectin-1 and NLRP3 were of particular interest 
in view of their relatively high transcription levels in psoriasis and AD, respectively. Indeed, mRNA 
data of dectin-1 were confirmed, since strong membrane staining was seen in psoriasis and inter-
mediate staining in AD compared to normal skin (Figure 6.2). Scattered dectin-1 positive stained 
Langerhans cells (LC) were occasionally observed, although the strong keratinocyte staining for 
dectin-1 makes them difficult to distinguish at first sight. Immunofluorescence double staining 
showed that our dectin-1 antibody positively stained keratinocyte membranes as well as LC that 
are present in the psoriatic epidermis (Figure S6.1). NLRP3 protein levels were extremely low in 
skin, whereas a strong staining was found in the positive control tissue esophagus (not shown). 
Protein expression of the cytoplasmic proteins ICEBERG and MDA5 was similar in the three dif-
ferent conditions (Figure 6.2).
mRNA expression of dectin-1 in human tissues
As dectin-1 stood out as a robustly upregulated PRR in psoriatic epidermis both at the mRNA and 
protein level, we decided to investigate this receptor in more detail. To compare the observed 
high expression in lesional psoriatic epidermis with other tissues we performed qPCR analysis of 
Figure 6.2. Protein expression of dectin-1, MDA5 and ICEBERG in human epidermis. 
Immunohistochemical staining of normal skin, psoriatic plaques and atopic dermatitis lesions. Each picture 
is representative for data from three different individuals. Bar: 100 µm.
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dectin-1 in a large panel of hu-
man tissues, including various 
epithelia (Figure 6.3). Relatively 
low CLEC7A mRNA expression 
levels, comparable to those in 
normal epidermis, were found 
in gastrointestinal and genito-
urinary tissues. Compared to 
normal skin, more than ten-
fold higher expression rates 
were seen in gingiva, trachea, 
mammary gland, aorta and 
foot sole, whereas the highest 
transcription levels were found 
in tissues rich in immune cells: 
tonsil, spleen, lung and espe-
cially peripheral blood mono-
nuclear cells (PBMCs).
CLEC7A expression in cultured keratinocytes is induced by interferons and Th17 
cytokines
Next, we set out to study dectin-1 expression and
function in vitro in previously validated epidermal 
model systems.1,30 In differentiated keratinocyte 
cultures that exhibit a normal skin phenotype, 
CLEC7A mRNA expression levels were low. In order 
to induce dectin-1 expression for subsequent ligand 
stimulation, we incubated keratinocytes with several 
cytokines including IFNa or IFNg, Th2 cytokines (IL-
4 and IL-13), Th17 cytokines (IL-17 and IL-22) and 
a proinflammatory cytokine mixture (IL-1a, IL-6 and 
TNFa). After 24 hours, CLEC7A mRNA levels increased 
the most (twelvefold) following stimulation with 
IFNg (Figure 6.4), which was dose-dependent (not 
shown). Interestingly, the Th17 mixture induced 
CLEC7A transcription tenfold, but this effect ap-
peared only after 48 hours. CLEC7A was induced 
fivefold by IFNa and sixfold by the proinflammatory 
mixture after 48 hours. Stimulation with Th2 cyto-
kines (Figure 6.4) or fetal calf serum (not shown), a 
known inducer of stress signaling in keratinocytes, 
did not affect CLEC7A expression.
Figure 6.3. Relative mRNA 
expression levels of CLEC7A 
(dectin-1) in a panel of human 
tissues. Equal amounts from 
each tissue were analyzed by 
qPCR. CLEC7A expression levels 
in normal skin, psoriasis and 
atopic dermatitis were taken 
from Figure 6.1. Normal skin was 
used as a reference value (relative 
quantity of 1) in calculating the 
relative quantities of all gene 
expression levels.
Figure 6.4. Cytokine-mediated induction 
of CLEC7A (dectin-1) transcription in 
cultured primary keratinocytes. Confluent 
cell cultures (N=4-8) were stimulated for 24 
and 48 hours with IL-4 (50 ng/ml) and IL-13 
(50 ng/ml); IL-17 (30 ng/ml) and IL-22 (30 ng/
ml); IFNa (500 U/ml); or IFNg (500 U/ml). 
* p < 0,05, ** p < 0,001.
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Stimulation of keratinocytes by dectin-1 ligands
In order to obtain higher a priori dectin-1 levels we preincubated primary human keratinocytes 
from four different donors for 24 hours with IFNg before stimulation with the dectin-1 ligands 
b-glucan (50 µg/ml) or heat-killed Candida (5*106/ml). Since dectin-1 reinforces TLR2 and TLR5 
responses in monocytes and macrophages 31,32, co-stimulation of their respective ligands Pam-
3Cys (10 µg/ml) and flagellin (50 µg/ml) with b-glucan or heat-killed Candida was also performed. 
Ligand addition hardly influenced mRNA levels of CLEC7A itself (not shown). As a functional 
readout for dectin-1-mediated stimulation, we examined the expression of proinflammatory cy-
tokines and antimicrobial proteins with known anti-fungal activity (hBD-2, secretory leukoprote-
ase inhibitor (SLPI), elafin and S100A8). b-glucan caused significant, moderate upregulation of 
IL23 mRNA after 48 hours, but neither b-glucan nor heat-killed Candida had significant effect 
on the expression of the other cytokines or antimicrobial proteins. In contrast, flagellin induced 
IL23, IL8 and IL1B mRNA, especially after 24 hours. Flagellin strongly induced DEFB4 and weakly 
PI3 and S100A8, most notably after 48 hours. Pam3Cys induced IL23 and IL8 transcription to a 
small extent at this concentration. After 48 hours, addition of b-glucan to flagellin or Pam3Cys 
significantly induced IL23 and IL8 mRNA levels, respectively. Such synergy was not seen after the 
addition of heat-killed Candida (Figures 6.5A and S6.2A; 48- and 24-hour data respectively).
ELISAs were performed for IL-1b, IL-6, IL-8, IL-23 and hBD-2 in supernatants. Even though 
IL23 mRNA was clearly present, no IL-23 protein could be detected in the supernatants and only 
very low secreted IL-1b levels. The transcriptional induction of IL23, IL8 and DEFB4 (hBD-2) by 
flagellin or Pam3Cys was reflected by strongly increased protein levels of IL-6, IL-8 and hBD-2 
(Figures 6.5B and S6.2B). The small synergistic effects of b-glucan with Pam3Cys or flagellin as 
determined by qPCR were not observed at the protein level. 
Figure 6.5. Host response gene expression in cultured primary keratinocytes upon stimulation 
with dectin-1, TLR2 and TLR5 ligands. After 24-hour preincubation with IFNg, confluent keratinocyte 
cultures (N=4) were stimulated for 48 hours with b-glucan (50 µg/ml) or heat-killed Candida (5*106/ml) with 
or without addition of Pam3Cys-SKKKK (10 µg/ml) or flagellin (1 µg/ml). Grey versus white bars indicate the 
(synergistic) effect of dectin-1 stimulation and black versus white bars the (synergistic) effect of concerted 
fungal receptor stimulation. (Figure S6.2 shows 24-hour stimulation data). A. Relative quantity (RQ) of 
mRNA levels. B. Protein levels of IL-8, IL-6 and hBD-2 in the supernatants are measured by ELISAs. Note that 
the data are presented in a log scale. Bars: mean +/- SEM. * p < 0,05.
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Discussion
In this study we show that many PRRs and other host defense genes are expressed in human 
epidermis, albeit to a different extent. RLRs, TLR2 and TLR3 were more abundant than other PRRs. 
Interestingly, PRR and signaling gene expression profiles in epidermal sheets of psoriasis and AD 
were rather similar to those in healthy skin, in contrast to effector molecule expression levels.1,2 
However, MRC1 was upregulated in both disorders and dectin-1 was the most notable exception 
with higher expression levels in psoriasis.
The reason for the relatively high constitutive expression levels of TLR2, TLR3, CLEC2B, 
DDX58 and IFIH1 in skin remains elusive. Possibly, their respective specificities are vital to the 
immunological epidermal barrier function, whereas other PRRs can be upregulated in response 
to specific microbes. It is remarkable that viral dsRNA sensors (TLR3, DDX58 and IFIH1) are all 
constitutively strongly expressed in epidermis, unlike endosomal ssRNA receptors TLR7 and TLR8 
and DNA receptor TLR9. Interestingly, pathophysiological roles of TLR7 and TLR9, but not TLR3, 
have been implicated in several autoimmune diseases, such as systemic lupus erythematosus.33,34 
Still, it was previously unclear why keratinocytes are highly sensitive to TLR3 ligands, since viruses, 
the major source of dsRNA, are not among the most prevalent causes of skin infection. Recently, 
TLR3 was demonstrated to be crucial in the initiation of inflammation in wound healing and TLR2 
in dampening of the TLR3-mediated inflammatory response.35 Indeed, TLR3 has been implicated 
as a mechanism for detection of cell death by sensing self-RNA.36,37
Previous studies reported high epidermal expression levels of effector molecules in psoriasis 
and lower ones in AD, which raised the question whether these differences resulted from distinct 
PRR or signaling gene expression profiles.2,4,38,39 Here, we demonstrate that epidermal PRR mRNA 
expression levels in healthy skin and psoriatic and AD skin lesions are rather similar, apart from 
a few exceptions. MRC1, which binds high-mannose surface structures of viruses, bacteria, and 
fungi, was significantly and equally upregulated in psoriasis and AD, indicating that this might 
be a general response of inflamed skin to sense pathogens in the context of compromised skin 
barrier function. We recently reported that MRC1 is the sole receptor able of directly inducing IL-
17 production in human PBMCs, and that this pathway is amplified by dectin-1/TLR2 signaling.40 
TLR4 is borderline-significantly upregulated in psoriasis, but its functional relevance is questionable 
seeing its very low expression. NLRP3 expression was strongly induced in atopic dermatitis, but 
only low mRNA levels and no protein expression could be detected while esophageal epithelium 
stained strongly. Indeed, strong IHC staining of NLRP3 was previously found in non-keratinizing 
squamous epithelium (oral cavity, esophagus, and ectocervix) and transitional epithelium 
(bladder), whereas it was absent in skin.41 The NLRP3 inflammasome is implicated in recognition 
of  many different stimuli, ranging from ATP and RNA to uric acid, b-amyloid, asbestos, and even 
ultra-violet (UV) light.6,42 The latter was also reported in keratinocytes, even though baseline 
NLRP3 expression levels were barely detectable.43 Surprisingly, we found increased expression 
levels of IL1RN, IL1A and IL1B in AD. Reports about IL-1 in AD are scarce, whereas more research 
has focused on IL-1 in psoriasis. For example, overexpression of IL1RN was found in psoriatic 
epidermis compared with normal epidermis.44 In a clinical setting, treatment with the IL-1 receptor 
antagonist anakinra proved only hardy effective in psoriasis 45, in contrast to the widely applied 
TNF antagonists.46 Still, the upregulation of IL1RN, IL1A and especially IL1B in our AD samples 
requires further investigation.
The highest upregulated PRR in psoriasis was dectin-1. Although CLEC7A (dectin-1) 
mRNA is also expressed by LC (M. Teunissen, Academic Medical Center, Amsterdam, personal 
communication), we confirmed its increased protein expression levels on keratinocytes in psoriatic 
plaques with IHC and immunofluorescence (Figures 6.2 and S6.1). Dectin-1 senses b-glucans, 
cell-wall components of fungi such as Candida, Pneumocystis and Aspergillus, and is mainly 
expressed on monocytes, macrophages and neutrophils, and in small amounts on dendritic 
cells, eosinophils, B- and T-cells.47 Dectin-1 signaling can reinforce immune responses driven by 
TLR2,4,5,7 and 9.8,48,49 Dectin-1-deficient mice are more susceptible to Candida albicans and 
Pneumocystis carinii infections 9,50 and dectin-1 appeared to be crucial in pulmonary defense 
against Aspergillus fumigatus.47 In a human family, however, we found that functional dectin-1 
deficiency was associated with recurrent vulvovaginal candidiasis and onychomycosis, but not 
invasive fungal infections. Functional dectin-1 deficiency did not impair fungal phagocytosis and 
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fungal killing, which underlined the specific function of dectin-1 in human mucosal antifungal 
defense and the important role of other Candida receptors in preventing invasion.31 Examples 
are MRC1 and TLR4 that recognize Candida cell-wall-derived mannans and TLR2 that binds 
phospholipomannan.8,49 Previously, elevated IL-8 expression levels were found after stimulation 
of keratinocytes with heat-killed Candida albicans and this was shown to increase the Candida 
killing activity by keratinocytes.52,53 Since fungal colonization is absent in psoriatic plaques, ligand-
induced upregulation of dectin-1 is unlikely. We deem it plausible that dectin-1 upregulation in 
psoriatic plaques results from local lesional elevated IFNg concentrations and thus is coincidental. 
However, this upregulation can result in improved immune responses against fungi that happen 
to land on a plaque and are thus eliminated more effectively.
Recently, the IL-23/Th17 pathway has become a focus of attention in both psoriasis and 
Candida research.40,54,55 Therefore, the increase of IL23 mRNA we found in keratinocytes after 
co-stimulation of dectin-1 and TLR5 seemed an interesting link between dectin-1 function and 
psoriasis pathophysiology. IL-23 protein levels, however, were below the detection level of our 
assay so this association remains unclear. The ability of dectin-1 to trigger immune responses is 
cell-type dependent. In dendritic cells, for example, dectin-1 signaling induces TNF production 
directly, whereas this response requires additional TLR co-stimulation in macrophages.56,57 Such 
cell-specific co-stimulation requirement might account for the limited effects we found upon 
stimulation with dectin-1 ligands. Therefore, keratinocytes might need concomitant signaling 
through receptors other than TLR2 or TLR5 in order for proper dectin-1 signaling. For TLR5 and 
TLR9 functioning for example, TGFa was identified as an important synergizing factor in kerati-
nocytes and a pathophysiological role in psoriasis was suggested.20 Another possible explanation 
is that optimal stimulation of dectin-1 requires specific spatial cell wall distribution of b-glucans. 
Absence of adaptor proteins could also account for defective dectin-1 signaling, as was illustrated 
by a human recessive disorder caused by a homozygous CARD9 mutation.58 We therefore tested 
CARD9, SYK and RAF1 gene expression in our in-vivo and in-vitro samples and found that these 
genes are transcribed in normal epidermis and psoriatic and AD lesions to a similar extent (Table 
6.1). CARD9, SYK and RAF1 were also transcribed in unstimulated primary human keratinocytes 
in vitro. Moreover, none of the ligands (b-glucan, heat-killed Candida, Pam3Cys or flagellin) sig-
nificantly influenced the mRNA expression levels of these genes. IFNg, however, induced CARD9 
significantly 5,8 times after 24 hours (not shown).
Finally, we examined if selective expression of a non-functional isoform of dectin-1 in kera-
tinocytes could explain our findings. The qPCR primers cover exon 1 and 2 that are present in all 
isoforms. The antibody we used for IHC recognizes the full length protein (isoform A) and the 
major alternatively spliced isoform B that lacks the stalk region but possesses the cytoplasmic, 
transmembrane and extracellular carbohydrate recognition domains, which determine function.59 
Previously, dectin-1 staining of LC, not keratinocytes, was reported in normal skin and psoriatic 
lesions.60 However, the applied antibody was raised against a peptide from the stalk region and 
by means of PCR we identified the stalk-lacking isoform as the dominant dectin-1 isoform in 
keratinocytes (Figure S6.3). This affects antibody specificity, but not function, since both major 
isoforms are functional.
In conclusion, many PRRs are expressed in normal human epidermis, but only a few show 
significant differences in expression levels between normal epidermis and psoriasis or AD lesions. 
Dectin-1 is remarkably upregulated in psoriatic lesions, but its function in the biology of skin in-
flammation and infection remains to be further explored.
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 Supplemental figures
Figure S6.1. Human dectin-1 protein is predominantly expressed on keratinocyte cell membranes
and Langerhans cells present in psoriatic epidermis. Immunofluorescence staining of dectin-1 (green), 
CD1a (Langerhans cell (LC) marker, red), and double staining (yellow-orange merge) for both proteins in 
psoriatic epidermis. Frozen sections prepared from psoriatic skin were double stained with a monoclonal 
mouse antibody (1:50) IgG2b to human dectin-1 (R&D Systems) and a monoclonal mouse antibody 
IgG1 (1:4000) against CD1a (DakoCytomation, Carpinteria, CA), which is a surface marker for LC. For 
immunofluorescence analysis, the following secondary reagents were used: Alexa-Fluor 488 mouse IgG2b 
labeling kit, and Alexa-Fluor 594 mouse IgG1 labeling kit (Molecular Probes, Eugene, OR). Nuclei were 
stained with 4’,6-diamine-2’-phenylindole dihydrochloride (DakoCytomation). Bar: 100 µm.
Figure S6.2 Host response gene expression in cultured primary keratinocytes upon stimulation 
with dectin-1, TLR2 and TLR5 ligands. After 24-hour preincubation with IFNg, confluent keratinocyte 
cultures (N=4) were stimulated for 24 hours with b-glucan (50 µg/ml) or heat-killed Candida (5*106/ml) 
with or without addition of Pam3Cys-SKKKK (10 µg/ml) or flagellin (1 µg/ml). (Figure 6.5 shows 48-hour 
stimulation data). A. Relative quantity (RQ) of mRNA levels. B. Protein levels of IL-8, IL-6 and hBD-2 in the 
supernatants are measured by ELISAs. Note that the data are presented in a log scale. Bars: mean +/- SEM.
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Figure S6.3. Dectin-1 isoform mRNA expression. In order to investigate whether keratinocytes 
predominantly produce stalk-lacking dectin-1 isoforms, we designed specific primers on either site of the 
stalk region (CLEC7A forward primer 5’-ACTCTCAAAGCAATACCAGGATAG-3 in exon 1 and CLEC7A 
reverse primer ‘5’-GCTGAATAGATAACAGCTCTTCTC-3 in exon 4) and performed PCR with the optimized 
program 94°C for four minutes, 35 repeats of 94°C, 58°C and 72°C (one minute each), and five minutes 
72°C. The reagents were 5 µl Green Gotaq Flexi buffer (Promega), 0,2 µl Taq Polymerase (Promega), 3 µl 
25 mM MgCl2, 1 µl dNTPs, 1 µl 10µM forward primer, 1 µl 10 µM reverse primer, 11 µl MilliQ and 3 µl 20 
times diluted cDNA. The cDNA was generated from RNA and obtained as described in the materials and 
methods section from normal (NS), psoriatic (PS) and atopic dermatitis (AD) lesional epidermis, cultured 
primary keratinocytes of donor 1 (KC1) and donor 2 (unstimulated (KC2) or stimulated with 500 U/ml IFNg 
for 24 hours (KC2+)), monocyte-derived unstimulated dendritic cells (DC), unstimulated PBMCs (PB) and 
human tonsil (Ton). The agarose gel shows the relative expression of stalk-containing (upper band of 345bp: 
isoforms A,C,G,H) and stalk-lacking (lower band of 207bp: isoforms B,D) isoforms. The functional isoform 
B is much stronger expressed than the non-functional isoform D.59 Therefore, the functional isoform B is 
predominantly expressed in all samples, including the pure keratinocyte samples. The relative expression 
levels in NS, PS and AD correspond with our qPCR and IHC data.
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Abstract 
Absent in melanoma 2 (AIM2) is a double-stranded DNA receptor and its activation initiates 
an interleukin-1-beta-processing inflammasome. AIM2 is implicated in host defense against 
several pathogens, but could hypothetically also contribute to autoinflammatory or autoimmune 
diseases, such as is the case for NLRP3. 
Using thoroughly characterized antibodies we analyzed AIM2 expression in human tissues 
and primary cells. 
A strong epidermal upregulation of AIM2 protein expression was observed in several acute 
and chronic inflammatory skin disorders, such as psoriasis, atopic dermatitis, venous ulcera, 
contact dermatitis, and experimental wounds. We also found AIM2 induction by interferon-
gamma in submerged and three-dimensional in-vitro models of human epidermis. 
Our data highlight the dynamics of epidermal AIM2 expression, showing Langerhans-
cell- and melanocyte-restricted expression in normal epidermis but a pronounced induction in 
subpopulations of epidermal keratinocytes under inflammatory and proliferative conditions. 
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Introduction
Absent in melanoma 2 (AIM2) was recently identified as a cytosolic receptor for double-stranded 
DNA (dsDNA), which interacts with apoptosis speck-like protein (ASC) to form a caspase-1 
activating inflammasome, leading to interleukin-1 beta (IL-1b) activation.1-3 AIM2 is a member 
of the hemopoietic interferon-inducible nuclear proteins containing a 200 amino acid repeat 
(HIN-200) family, which also includes interferon-inducible protein 16 (IFI16), IFIX and myeloid cell 
nuclear differentiation antigen (MNDA).4,5 AIM2 is one of the few pattern recognition receptors 
(PRRs) that are known to bind dsDNA and it is unique in the sense that it induces an IL-1b 
response rather than interferon production.6 In view of the important role of nucleic acid PRRs 
in mainly anti-viral immunity 7, AIM2 was likely to be involved in host defense reactions against 
infections that would cause cytoplasmic exposure to dsDNA. This was indeed shown for Francisella 
tularensis 8-10, Listeria monocytogenes 9,11-15, Vaccinia virus 3 and mouse cytomegalovirus 9, but not 
Varicella zoster virus 16 and Salmonella typhimurium.8
Interestingly, AIM2 also recognizes endogenous DNA, which could imply a role for this dsDNA 
receptor in sterile inflammation, such as in autoinflammatory or autoimmune diseases. Indeed, 
a recent study by Dombrowski et al. demonstrated AIM2-dependent inflammasome-mediated 
IL-1b production by epidermal keratinocytes. The authors suggest that cytosolic DNA triggers 
keratinocyte activation and IL-1b processing in psoriatic lesions.17 Others reported increased AIM2 
mRNA expression in leukocytes from patients with systemic lupus erythematosus.18 
In this study, we investigated AIM2 expression in several inflammatory skin conditions such as 
psoriasis, atopic dermatitis (AD), experimental skin barrier disruption, experimental full-thickness 
wounds and skin ulcers. As the cellular source and immunolocalization of endogenous AIM2 
had not been assessed so far, we generated well-characterized, specific antibodies against 
AIM2. Our data highlight the dynamics of epidermal AIM2 expression, showing Langerhans-
cell- and melanocyte-restricted expression in normal epidermis but a pronounced induction in 
subpopulations of epidermal keratinocytes under inflammatory and proliferative conditions. 
Materials and methods
Subjects and skin biopsies
The study was approved by the local medical ethical committee and conducted according to 
the Declaration of Helsinki principles. Upon written informed patient consent, 3- to 4-mm 
punch biopsies were taken from healthy volunteers, patients with chronic venous ulcera, chronic 
plaque-type psoriasis patients and chronic AD patients, none on systemic or UV-B-therapy. For 
experimental skin barrier disruption, two areas on the lower back measuring 3x2 cm each were 
tape stripped until the surface became slightly shining after repeated (20-70 times) application 
and removal of adhesive tape. Tape stripping was performed in 25 healthy controls, and on 
non-lesional skin of nine chronic plaque-type psoriasis patients and ten chronic AD patients. At 
several time points after tape stripping, 3-mm biopsies were taken from the tape-stripped area 
and from healthy skin of the same individual for both RNA isolation and immunohistochemistry 
(IHC). Irritant contact dermatitis (ICD) was induced by application of a patch with 5% sodium 
dodecyl sulphate (SDS) solution on the lower back of ten healthy controls, as previously described 
19, and allergic contact dermatitis (ACD) by means of application of a perfume mixture-containing 
patch in two perfume-sensitive subjects. After 4 to 8 hours the patch was removed and 24 hours 
(for mRNA) or 48 hours (for IHC) after exposure, 3-mm biopsies were taken from the exposed 
areas and from healthy control skin. Experimental wounds were induced with 3-mm punches and 
sampled with a 4-mm punch after 1, 2, 4, 7, and 14 days. RNA and paraffin-embedded sections 
from a variety of tissues was available from autopsy material (Department of Pathology, Radboud 
university medical center, Nijmegen, The Netherlands).
Isolation of epidermal sheets, RNA isolation and quantitative real-time PCR
Epidermal sheets were isolated, RNA was extracted and cDNA was generated by reverse 
transcription as previously described.20,21 Specific qPCR primers were designed with Primer Express 
1.0 Software (Applied Biosystems) and purchased from Biolegio (Nijmegen, The Netherlands). Two 
different primer pairs for full-length AIM2 gave similar results and were validated by sequencing 
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the cDNA products. Primers were only accepted if their efficiency was 100 +/- 10% and 
corrections were made for primer efficiency (Table 7.1). The amount of mRNA for a given gene in 
each sample was normalized to the amount of mRNA of the human ribosomal phosphoprotein 
P0 (RPLP0) reference gene in the same sample. By means of the comparative delta-delta (∆∆)
Ct method, relative mRNA expression levels of all examined genes were calculated 22 and each 
value was compared to normal controls, or to its intra-individual healthy or unstimulated control 
sample in case of tape stripping, ICD, and in-vitro cytokine stimulations.  
Table 7.1. Primer sequences and efficiency
Gene Set Forward primer 5’-3’ Reverse primer 5’-3’ Efficiency1
AIM2 Full length set 1 gatcaacacgcttcaaactca ttctaacccccagtacttcca 1,87
AIM2 Full length set 2 ttgtttgtagtccagaaggt catttcattgtgtcctcgt 2,08
AIM2 Part of AIM2 for 
fusion protein2
ggatccgataacatcactgatgagga gaattcctactttgctttcagtaccat X
IFI16 ttaaaagtaaaaggaccagccctatc gagtctgttcctcggacacctta 2,05
IFIX gactactgttgaagaaattccc tgatgacctctaatcctttcag 1,93
MNDA taaacttcgactcttctgcc cattcattggtccttccttg 2,02
1Efficiency as fold increase in fluorescence per PCR cycle.
2Forward primer including BamH1 site, reverse primer including EcoR1 site
Production of rabbit anti-human AIM2 antiserum
Prior to our decision to generate an anti-AIM2 antibody ourselves, we had tried two commercial 
antibodies and one personally provided antibody without success. Anti-AIM2 antibodies from 
Abcam ab76423-50 and Abnova H00009447-B01P resulted in non-specific diffuse staining of 
the epidermis, and a monoclonal mouse anti-human antibody (3B10) kindly provided by Dr. John-
stone did not result in any staining. Hence, we selected amino acid sequence D15 to K162 of 
the AIM2 cDNA (reference sequence NP_004824.1) to prepare a recombinant fragment of AIM2 
protein as immunogen. This part of the molecule shows the least homology with other AIM2 
family members, thus minimizing the chance of crossreacting antibodies. The partial cDNA was 
amplified by PCR (Table 7.1) and the PCR product was ligated into a TOPO vector and cloned 
in TOP10 cells (Invitrogen, Carlsbad, CA). All constructs were verified by sequence analysis. For 
protein production, the cDNA was ligated into both a pET-32a vector (Novagen, Madison, WI, 
USA) and pGEX-2T vector (Amersham Pharmacia Biotech, Uppsala, Sweden), and expressed in 
Escherichia coli (BL21 cells, Invitrogen) as TRX-AIM2 and GST-AIM2 fusion proteins, respectively. 
TRX-AIM2 was affinity-purified using Ni-NTA beads (Invitrogen) and GST-AIM2 using glutathione 
Sepharose 4B beads (GE Healthcare Bio Sciences, Uppsala, Sweden). These preparations were 
dialyzed against phosphate-buffered saline and emulsified with complete Freund’s adjuvant to 
immunize a rabbit and a guinea pig with TRX-AIM2 and a rabbit and a guinea pig with GST-AIM2, 
to generate polyclonal sera. Animals were boosted with TRX-AIM2 or GST-AIM2, and blood was 
obtained for serum preparation. Prior to the study, the local animal ethical committee had ap-
proved of the protocol.
Purification and characterization of AIM2 antibodies
We obtained three high-titered anti-AIM2 sera that were used for further study. Affinity-purified 
polyclonal anti-AIM2 antibodies were obtained by purifying TRX-AIM2 antisera on GST-AIM2-
coupled CNBr-activated Sepharose 4B beads (GE Healthcare Bio Sciences, Uppsala, Sweden) and 
vice versa, and were stored in 1% bovine serum albumin and 0,1% sodium azide at 4°C or 
-80°C. On immunohistochemical staining, a subset of cells was positive in the positive controls 
spleen and lymph node. Also, the strong widespread cytoplasmic staining of keratinocytes in 
psoriatic lesions and the very low number of positive cells in normal skin corresponded with the 
mRNA data. The staining patterns of three out of four antisera were identical and we selected 
the rabbit antibodies raised against TRX-AIM2 for further experiments. The strong epidermal 
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staining in psoriasis could be inhibited in competition experiments, by incubating the antiserum 
with GST-AIM2-coupled beads or TRX-AIM2-coupled beads for 1 hour prior to the experiment 
(Figures S7.1A,B). Moreover, pre-incubation of the antibodies with an irrelevant competing 
immunogen (GST-LCE3-coupled beads) did not inhibit the staining (Figure S7.1C). Our purified 
AIM2 antibodies could detect recombinant human GST-AIM2 (Sino Biological Inc, Beijing, China) 
on Western blots (Figure S7.2), but the sensitivity was not sufficient for detection of AIM2 in 
lysates of peripheral blood mononuclear cells (PBMCs), interferon gamma (IFNg)-stimulated 
keratinocytes, or epidermal extracts of normal skin, chronic psoriasis plaques or AD lesions.
Immunohistochemistry and immunofluorescence
Formalin-fixed paraffin-embedded (FFPE) skin sections were blocked with 20% normal goat or 
swine serum and subsequently incubated for 3 hours with our polyclonal affinity-purified rabbit 
or guinea pig AIM2 antisera at a 1:50 dilution in 1% BSA. Next, sections were incubated for 30 
minutes with biotinylated goat anti-rabbit IgG or swine anti-guinea pig in PBS containing 1% BSA 
(Vector laboratories, Burlingame, CA) and incubated for 30 minutes with Avidin-Biotin complex 
(Vector Laboratories). 
For immunofluorescence (IF), we used the secondary antibody donkey anti-rabbit labeled 
with Alexa-FluorR 488 (Invitrogen) and double-stained with either the melanocyte marker Melan 
A (clone A103, M7196, DakoCytomation, Glostrup, Denmark), or the macrophage marker CD68 
(clone KP1, M0814, DakoCytomation), for which we used the secondary anti-mouse antibody 
labeled with Alexa-FluorR 594 (Invitrogen). Eventually, sections were treated with 3-amino-9-ethyl 
carbazole (Calbiochem, San Diego, CA) for 5 minutes.
Keratinocyte cultures
Primary human epidermal cells were isolated from skin biopsies and stored as described 
previously.23 Cells were thawed and cultured in keratinocyte growth medium (KGM).24 At 100% 
confluency, the cells were stimulated with different cytokine mixtures at concentrations that were 
optimized in previous experiments: IL-4 50 ng/ml with IL-13 50 ng/ml, IL-17 30 ng/ml with IL-22 
30 ng/ml, IL-1a 30 ng/ml with tumor necrosis factor alpha (TNFa) 30 ng/ml and IL-6 2*104 U/ml 
or IFNg 10 U/ml, IFNa 10-500 U/ml, or IFNg 10-500 U/ml (PeproTech Inc, Rocky Hill, NJ). Cells were 
harvested after 24 and 48 hours and stored in Trizol for RNA extraction. Samples were compared 
to the unstimulated samples of the same keratinocyte donor.
Three-dimensional reconstructed skin 
Reconstructed skin generated from human adult abdominal keratinocytes and de-epidermized 
human dermis was generated as described previously with minor modifications.25 Briefly, de-
epidermized human dermis of 0,8 mm thickness and 8 mm diameter was placed in transwells in 
a 24-well culture plate and seeded with 105 keratinocytes. After three days of submerged culture, 
the medium level was lowered and constructs were cultured at the air-liquid interface to induce 
terminal differentiation. After seven days of culture at the air-liquid interface, the culture medium 
was supplemented for three days with a mixture of the pro-inflammatory cytokines IL-1a (10 ng/
ml), TNFa (5 ng/ml) and IL-6 (5 ng/ml) or with indicated concentrations of IFNg alone. Thereafter, 
the constructs were processed for routine histology or qPCR with the only difference that for skin 
equivalents, 2-hour dispase treatment (Roche Diagnostics, Mannheim, Germany) at 4°C suffices 
for separation of the epidermis. Samples were compared to the unstimulated samples of the 
same keratinocyte donor.
Statistics
A repeated-measures analysis of variance using SPSS v16.0 (SPSS Inc) was performed on the ∆Ct 
values of the qPCR data corrected for primer efficiency. ∆Ct is the difference between the Ct of 
the target gene and the reference gene (RPLP0). Note that for graphical representation of the 
data we used the relative expression levels.22
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Results
Strong increase in epidermal mRNA expression of AIM2 in psoriatic and atopic 
dermatitis lesions
In a previously performed microarray analysis of epidermal sheets from lesional psoriasis and AD 
skin, AIM2 was among the ten most upregulated genes in psoriatic lesional skin.20 qPCR analysis 
of purified epidermal sheets showed that AIM2 is hardly present in normal skin. Compared to 
normal controls, AIM2 mRNA was massively increased in psoriatic lesional skin (331-fold) and 
Figure 7.1. AIM2 expression in normal skin, psoriasis and atopic dermatitis. A. Relative epidermal 
mRNA expression levels of AIM2 in normal skin (NS, N=7), psoriasis lesional (PS, N=9) and uninvolved skin 
(PSun, N=4), atopic dermatitis lesional (AD, N=6) and uninvolved skin (ADun, N=4), compared to the mean 
of NS. B. Relative epidermal mRNA expression levels of IFI16, IFIX and MNDA in NS (N=5), PS (N=9), and AD 
(N=6), compared to the mean of NS. C. IHC of AIM2 in NS, AD and PS. D. IHC of AIM2 in the marginal zone 
of a PS lesion, with active inflammation with Munro’s abscesses on the left and normal skin on the right. E. 
Immunofluorescence double staining of AIM2 with the Langerhans cell marker CD1A or F. the melanocyte 
marker Melan A. * p < 0,005. Bar = 100 µm (D) or 25 µm (C, E ,F).
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in AD (68-fold). Interestingly, it was also increased in non-lesional skin of psoriasis (28-fold) and 
AD patients (11-fold) (Figure 7.1A). mRNA levels of the other IFI family members IFI16, IFIX and 
MNDA were also significantly increased in both psoriasis and AD, but only at a maximum of 15-
fold, Figure 7.1B).
Increased cytoplasmatic AIM2 protein expression in keratinocytes of psoriasis 
and atopic dermatitis lesions 
Despite multiple different IHC approaches (cryopreserved sections, FFPE sections, several antigen 
retrieval techniques), several commercial anti-AIM2 antibodies failed to yield a reliable and spe-
cific staining of positive control tissue (lymph node) or psoriatic plaques. We therefore generated 
well-characterized, specific rabbit anti-AIM2 antiserum for subsequent experiments. Affinity-pu-
rified anti-AIM2 antibodies from three different animals yielded similar staining patterns. Af-
ter characterization and validation of the antisera by competition experiments (Figure S7.1) and 
Western blotting (Figure S7.2), we selected one of the rabbit anti-AIM2 antisera for subsequent 
experiments. 
In normal skin, only scant cells stained positive, in concordance with the low mRNA levels (Fi-
gures 7.1A,C). AIM2 double staining with CD1A and Melan A showed that most, if not all of the 
positive cells in normal skin are Langerhans cells and melanocytes, respectively (Figures 7.1E,F). In 
lesional psoriatic skin, however, there was clear cytoplasmic staining of keratinocytes with distinct 
intensity in different layers. Staining was found at variable levels in all layers, but was most intense 
in the basal layer and in proximity of a Munro’s abscess (Figures 7.1C,D). At the marginal zone of 
a psoriasis lesion, decreasing intensity of AIM2 staining towards the non-lesional skin was found 
(Figure 7.1D). In AD lesional skin, there was cytoplasmatic staining of keratinocytes as well, but 
the intensity was lower than in psoriasis (Figure 7.1C).
Figure 7.2. AIM2 expression in human tissues
A. Relative epidermal mRNA expression levels of AIM2 in several human tissues (N=1), compared to the 
mean of normal epidermis. PBMCs: peripheral blood mononuclear cells. 
B. Immunofluorescence (IF) double staining of AIM2 with the macrophage marker CD68 in lung tissue. 
C. IF double staining of AIM2 with CD68 in lymph node. 
D. Immunohistochemical staining of AIM2 in gingiva. Bar = 50 µm.
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Distinct AIM2 expression in a variety of human tissues
AIM2 expression has almost exclusively been studied in immune cells, so we were interested in its 
expression in a larger panel of human tissues. Most tissues exhibited low AIM2 mRNA expression 
levels, including various epithelia (Figure 7.2A). However, AIM2 mRNA expression levels were high 
in PBMCs and in tissues rich in immune cells, such as the spleen, lymph node and tonsil (Figure 
7.2A). 
On IHC of sections from different tissues, a subset of cells was positive for AIM2. In lung tissue 
(Figure 7.2B) and lymph nodes (Figure 7.2C), CD68-positive macrophages were strongly positive 
for AIM2. In gingiva, basal epithelial cells were positive (Figure 7.2D).
Experimental skin barrier disruption induces AIM2 expression
Since psoriasis and AD are inflammatory diseases associated with skin barrier impairment 26-
28, we investigated AIM2 expression in two experimental models of skin barrier disruption and 
inflammation in vivo. The stratum corneum was removed by means of tape stripping of normal 
skin and non-lesional skin of psoriasis and AD patients. After 24 hours, there was a modest 
increase in AIM2 mRNA levels in epidermal sheets (Figure S7.3). Protein expression levels were 
strongly induced after 48 hours with a steady increase over the preceding hours and decline 
during the following days (Figure 7.3A). The results were similar in controls and patients with 
psoriasis or AD (Figure 7.3B). 
In models of acute ICD and acute ACD caused by 4 to 8 hours application of SDS or a 
perfume mixture, respectively, AIM2 protein expression was also upregulated in the epidermis 
(Figure 7.3B).
Figure 7.3. AIM2 expression upon skin barrier disruption and during wound healing. IHC staining 
of AIM2 (A) at several time points after tape stripping of normal skin (NS), B. 48 hours after tape stripping 
of uninvolved skin of atopic dermatitis (TS AD) or psoriasis (TS PS) patients, or 48 hours after SDS or perfume 
application on normal skin to induce irritant contact dermatitis (ICD) or allergic contact dermatitis (ACD), 
respectively. C. IHC of AIM2 at several time points during wound healing (d = day). D. IHC of AIM2 in an 
ulcer margin. Bar: 100 µm.
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Epidermal AIM2 protein expression at wound and ulcer margins
Considering the upregulation of AIM2 upon skin barrier disruption and inflammation, we 
wondered whether AIM2 expression would be increased in full-thickness wounds as well. We 
therefore stained sections of experimental excisional wounds that were biopsied at 1, 2, 4, 
7 and 14 days after wounding. AIM2 protein expression was increased in the wound edges, 
predominantly in the keratinocytes of the basal layer (Figure 7.3C). The rise in AIM2 expression 
started at day 1, peaked at day 2 and persisted throughout the first week (Figure 7.3C), while 
wound healing was in progress, and returned to normal levels at day 14 when the wound had 
healed (not shown). AIM2 expression was also increased in chronic wounds, as in venous leg 
ulcers, AIM2 was present in the basal layers of the adjacent epidermis (Figure 7.3D). 
IFNg and IFNa induce AIM2 mRNA in primary human keratinocytes 
In view of the epidermal upregulation of AIM2 in psoriasis and AD, we stimulated differentiated 
primary human keratinocytes with several psoriasis- or AD-associated cytokines or mixtures 
thereof. At baseline, AIM2 mRNA was not or hardly present. AIM2 mRNA upregulation was most 
profound upon stimulation with IFNg. IFNa stimulation resulted in an increase in AIM2 expression, 
albeit lower than for IFNg. TNFa, IL-1a, Th2 cytokines and Th17 cytokines mixtures did not induce 
AIM2 (Figure 7.4A). The addition of other cytokines to IFNg had no synergistic effect, singling out 
IFNg as the predominant AIM2 inducer.
Figure Figure 7.4. AIM2 expression in submerged keratinocyte cultures and three-dimensional 
epidermal constructs. A. Relative AIM2 mRNA expression levels in differentiated keratinocyte cultures 
at 24 or 48 hours after stimulation with several cytokines or cytokine mixtures, compared to unstimulated 
samples of the same donor (N=2-5, error bars: mean +/- SEM). IFNg 10: 10 U/ml. B. Relative AIM2 mRNA 
expression levels in differentiated keratinocyte cultures of healthy controls (NS KC, N=35), psoriasis patients 
(PS KC, N=17), and atopic dermatitis patients (AD KC, N=11) with and without 24-hour stimulation with 
IFNg 500 U/ml, IL-1a 30 ng/ml and TNFa 30 ng/ml (PS mix). All data are compared to mean NS KC = 1; error 
bars: mean +/- SEM. C. Relative AIM2 mRNA expression levels in a 3D-reconstructed epidermis, either or not 
stimulated with several cytokines of cytokine mixtures, compared to the unstimulated sample of the same 
cell donor (N=3, error bars: mean +/- SEM). For comparison, AIM2 expression in unstimulated submerged 
keratinocytes is shown (N=8). D. IHC of 3D-reconstructed epidermis shows AIM2 protein expression in the 
basal layers of unstimulated epidermis (left), and induction of AIM2 protein in both suprabasal and basal 
layers upon stimulation with IFNg 500 U/ml (right). Bar: 50 µm.
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Similar IFNg-primed induction of AIM2 in primary human keratinocytes of 
healthy controls, patients with psoriasis and patients with AD 
Next, we investigated if primary keratinocytes from healthy controls, psoriasis patients and 
AD patients were intrinsically different regarding IFNg-dependent AIM2 induction. Primary 
keratinocytes from a large panel of healthy controls, patients with psoriasis and patients with 
AD were allowed to differentiate in vitro and stimulated with a mixture of TNFa, IL-1a, and 
IFNg. Baseline AIM2 mRNA levels were low or absent in all unstimulated samples. The cytokine 
mixture induced AIM2 mRNA expression to a similar extent in keratinocytes from healthy controls, 
patients with psoriasis and patients with AD (Figure 7.4B).
AIM2 mRNA and protein induction by IFNg in a 3D skin model 
Subsequently, we examined the effect of different cytokines in an in-vitro 3D model of 
differentiated human epidermis. Interestingly, baseline AIM2 mRNA expression levels were higher 
than in submerged keratinocytes (Figure 7.4C). IHC staining verified the presence of AIM2 protein 
in the 3D-reconstructed epidermis, mainly in the basal layer (Figure 7.4D). Upon stimulation with 
cytokines, IFNg was the sole cytokine responsible for AIM2 mRNA induction (Figure 7.4C) in both 
the basal and suprabasal layers (Figure 7.4D). 
Discussion
Our data highlight the dynamics of epidermal AIM2 expression, showing Langerhans-cell- 
and melanocyte-restricted expression in normal epidermis but a pronounced induction in 
subpopulations of epidermal keratinocytes under inflammatory and proliferative conditions. 
The exact (sub)cellular localization of endogenous AIM2 in primary human cells has not been 
decisively demonstrated in previous studies.2,3,9-12,14,15,29,30 Most studies used mice or induced 
overexpression of tagged AIM2 in transfected cell lines, followed by detection of the protein 
by antibodies directed against the tag. Our antibodies yielded a strong signal in IHC staining of 
FFPE material, that paralleled mRNA induction and specificity, and was verified in competition 
experiments with recombinant protein. 
Recently, Dombrowski et al. found a 3-fold increase in IL-1b protein secretion by keratinocytes 
upon priming by IFNg and TNFa, followed by stimulation with poly:dAdT.17 In full-thickness skin 
biopsies, they found a 2,5-fold increase of AIM2 mRNA levels in psoriatic plaques versus normal 
skin, whereas we found a 331-fold increase in separated epidermal sheets of psoriatic lesional 
skin. Their immunolocalization data of AIM2 showed uniform staining of suprabasal cells in 
the epidermis. The discrepancy with our results may be caused by technical issues or by the 
properties of their antiserum, which was not characterized. Kopfnagel et al. reported comparable 
epidermal AIM2 protein expression in normal skin, psoriasis and AD lesions, in contrast to the 
large differences we found at both the mRNA and protein level, and data from Dombrowski et 
al.17,31,32 This is probably due to lack of specificity of the antibody they used (Abcam ab 76423), 
since we and others had also found aspecific staining with this antibody. This paper also reported 
poly:dAdT-mediated IL-1b release that did not require IFNg priming. In view of the presence of 
other poly:dAdT receptors (RIG-I, IFI16) in keratinocytes, and the very low baseline AIM2 levels, 
we feel this IL-1b release can not be caused by AIM2 activation. Also, their keratinocytes were 
derived from epidermal stem cells from human hair follicles, which may respond differently in 
vitro than those derived from skin biopsies.
The increased epidermal AIM2 expression levels in inflammatory skin conditions could 
imply a role for AIM2 in epidermal barrier disruption-related skin inflammation. Possibly, AIM2 
upregulation serves as a first line of defense against invading pathogens upon skin barrier 
disruption in view of its role as a PRR.2,3,8-11,13-15,33 This is beneficial during wound healing, in which 
it is temporary. However, in case of prolonged barrier impairment, AIM2-induced IL-1b activation 
could contribute to a vicious circle of inflammation in chronic inflammatory skin diseases, such 
as psoriasis, AD and even venous leg ulcers. The fact that AIM2 expression is predominantly 
upregulated in the basal layer in the various conditions could reflect a concentration gradient of 
IFNg or IFNa from the dermis, since we identified these to be responsible for AIM2 upregulation in 
primary human keratinocytes. In psoriasis, IFNa could well be derived from dermal plasmacytoid 
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dendritic cells that are implicated in its pathogenesis.34 Of note, this study also shows that there 
are no cell-autonomous differences in AIM2 induction in primary keratinocytes from healthy 
controls and patients with psoriasis or AD.
In contrast to an earlier report, we did not find evidence of DNA in the cytosol of epidermal 
keratinocytes in psoriasis lesions 17, nor did we find cytosolic DNA in keratinocytes in AD lesions 
or wound edges. We did however, find extracellular DNA in Munro’s microabcesses in psoriasis 
lesions, and abundantly in wound edges (data not shown).
The fact that AIM2 is principally expressed in the basal epidermal layer in various inflammatory 
skin conditions could also imply an association of AIM2 with proliferation, either in a cause-effect 
relationship or as a bystander effect. Intriguingly, prior to its identification as a PRR, AIM2 was 
linked to control of tumorigenesis in several studies.4,35-44 In studies on microsatellite instability in 
gastrointestinal carcinomas, for example, AIM2 was consistently mutated in high percentages in 
gastric, small intestinal or colorectal cancers.37-39,41,42,44 However, the hypothesis that AIM2 could 
have a tumor-suppressive role is contradicted by the fact that no increased incidence of tumors 
was reported in two Aim2 knockout mouse models. In contrast, these mice do not seem to have 
an apparent phenotype.9,29 Based on our results, there may be an association between AIM2 
expression and proliferation of keratinocytes, but the exact relationship remains to be determined.
Interestingly, nearly all inflammasome-associated PRRs show only low levels of expression in 
normal keratinocytes in vivo.45 Also, IFI16 is located in the nucleus under normal conditions, and 
it can only exert its function as a PRR upon translocation to the cytosol.3,46 Speculatively, these 
low expression levels of PRRs may cause a high threshold for responding to normal environmental 
and endogenous stimuli (e.g. nucleic acids derived from commensal bacteria or the host), thereby 
preventing normal skin from unwanted inflammatory responses. 
In conclusion, this study shows a striking AIM2 increase in keratinocytes at sites of acute and 
chronic skin barrier disruption-related inflammation and proliferation, suggesting a role for AIM2 
in both antimicrobial defense and possibly also sustained chronic inflammation.
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Supplemental figures
Figure S7.1. Specific inhibition of AIM2 staining by competition with recombinant AIM2 
IHC staining of psoriasis lesional skin sections with purified AIM2 antisera raised against GST-AIM2 (B) or 
TRX-AIM2 (A and C) in rabbits. In A and B, antibodies were immunoprecipitated by GST-AIM2- and TRX-
AIM2-coupled CnBr Sepharose A beads, which resulted in inhibition of subsequent staining with the super-
natant. Such inhibition did not occur when the antibodies were preincubated with GST-LCE3 coupled CnBr 
Sepharose A beads (C), proving the specificity of the antibodies for AIM2. Bar: 100 µm.
Figure S7.2. AIM2 antiserum stains recombinant GST-AIM2 on Western blot
On Western blot we did not succeed in staining endogenous AIM2 in cell lysates 
of PBMCs and IFNg-stimulated keratinocytes, but the purified AIM2 antiserum did 
stain 0,1 µg recombinant human GST-AIM2 that was produced in a baculovirus 
system (Sino Biological Inc, Beijing, China). The band corresponds with the 
molecular weight of 65,2kD. 
Method: 0,1 µg recombinant human GST-AIM2 was boiled in an lithium do-
decyl sulphate buffer with reducing agent and loaded onto a Tris polyacrylamide 
gel. After electrophoresis, the protein was transferred to a membrane by Western 
blotting, stained with 1:1000 of our rabbit anti-(TRX-)AIM2 antibody for 1 hour, 
followed by 30-minute incubation with 1:1000 goat anti-rabbit. The blot was incu-
bated for 1 minute with Lumiglo (7003, Cell Signaling Technology, Dancers, MA).
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Figure S7.3. Relative epidermal AIM2 mRNA 
expression upon experimental barrier disruption
SDS application on normal skin (SDS, N=6), tape stripping 
of normal skin (TS NS, N=9) and non-lesional skin of pso-
riasis (TS PS, N=7) and atopic dermatitis (TS AD, N=8) pa-
tients. RNA extraction from separated epidermis was per-
formed as described in the materials and methods section. 
Each sample was compared to an untreated sample of the 
same individual. 
After 24 hours, there was a modest increase in AIM2 
mRNA levels in epidermal sheets in all conditions, which 
was significant in TS PS (p 0,028). * p < 0,05.
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Abstract 
Since 2009, research on absent in melanoma 2 (AIM2) has predominantly focused on its function 
as an inflammasome-activating pattern recognition receptor. Initially, however, AIM2 was linked 
to tumor suppression. Here we assessed AIM2 expression and its possible correlation with 
proliferation and differentiation in benign and malignant keratinocytic and melanocytic skin 
tumors.
Sections of normal skin, psoriasis lesional skin, genital warts, palmoplantar warts, well-
differentiated cutaneous squamous cell carcinoma (CSCC), poorly differentiated CSCC, local 
CSCC metastases, common melanocytic nevi, cutaneous melanoma, local cutaneous melanoma 
metastases, and nodal melanoma metastases were stained with a specific, purified anti-AIM2 
antibody. Proliferation of keratinocytes was assessed by MIB-1 staining.
AIM2 is present in most common melanocytic nevi and cutaneous melanomas, but is 
downregulated in melanoma metastases. AIM2 is also expressed in proliferating keratinocytes in 
warts, genital warts, and well-differentiated CSCC, whereas it is absent or scarcely expressed in 
poorly differentiated CSCC and in CSCC metastases.
AIM2 is predominantly present in benign cutaneous melanocytic and keratinocytic tumors 
and in primary melanoma and primary CSCC, but largely absent in metastases of both tumors. 
Hence, its putative tumor-suppressive role needs further investigation in these tumors.
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Introduction
Since the identification of absent in melanoma 2 (AIM2) as an inflammasome-activating double-
stranded DNA receptor, research has mainly focused on this property of the protein.1-5 Previously, 
however, AIM2 was linked to control of tumor growth.6-17 In studies on microsatellite instability in 
gastrointestinal carcinomas, for example, AIM2 was consistently mutated in high percentages in 
gastric, small intestinal or colorectal cancers.9-11,13,14,16 The name AIM2 is derived from the initial 
finding that it was absent in the tumorigenic UACC-903 melanoma cell line, but upregulated 
in a subline of this cell line in which tumorigeniticy was suppressed.17 We previously reported 
upregulation of AIM2 in acute and chronic inflammatory skin conditions, some of which are 
also characterized by keratinocyte proliferation, such as psoriasis. We also found strong AIM2 
expression in melanocytes in normal skin.18
In view of the putative tumor-suppressive role, we studied AIM2 expression in several benign 
and malignant keratinocytic and melanocytic hyperproliferative and neoplastic lesions, including 
metastases of cutaneous squamous cell carcinoma (CSCC) and cutaneous melanoma.
Materials and methods
Skin samples
We used sections of biopsies or excised samples of normal skin (N=3), psoriasis lesional skin 
(N=3), genital warts (N=3), palmoplantar warts (N=3), well-differentiated CSCC (N=10), poorly 
differentiated CSCC (N=9), skin metastases of primary CSCC (N=7), common melanocytic nevi 
(N=6), primary cutaneous melanoma (N=6; all with a Breslow thickness > 2 mm), skin metastases 
of cutaneous melanoma (N=6), and nodal metastases of cutaneous melanoma (N=5). Written 
informed consent was obtained from non-anonymous patients, and the other samples were 
anonymous residues.
Immunohistochemistry 
Formalin-fixed paraffin-embedded (FFPE) skin sections were blocked with 20% normal goat se-
rum and subsequently incubated for 3 hours with our polyclonal affinity-purified rabbit AIM2 an-
tiserum at a 1:50 dilution in 1% BSA.18 Next, sections were incubated for 30 minutes with bioti-
nylated goat anti-rabbit IgG in PBS containing 1% BSA (Vector laboratories, Burlingame, CA) and 
incubated for 30 minutes with Avidin-Biotin complex (Vector Laboratories). Eventually, sections 
were treated with 3-amino-9-ethyl carbazole (Calbiochem, San Diego, CA) for 5 minutes. Parallel 
sections to the AIM2-stained ones were stained for MIB-1. Upon antigen retrieval with Citrate pH 
6,0, sections were incubated for 1 hour with MIB-1 antibody (M7240, DAKO), incubated for 30 
minutes with polymer HRP, and finally for 7 minutes with 3-3-di-aminobenzidine.
Scoring of AIM2 protein expression and MIB-1 was performed in a quantitative way (see 
below), and by its location (basal or suprabasal for keratinocytic lesions; superficial to deep for 
melanocytic lesions, and peripheral or central within metastases). Psoriasis was used as a positive 
control, and the keratinocytes in normal skin as a negative one, as established in our previous 
study.18
Quantification and Statistics 
Immunohistochemical staining of cells was quantified using Image J software by dividing the 
intensity of the AIM2 staining by the intensity of the haematoxylin staining (mostly nuclei) in 
each sample. Next, the groups were compared. Using SPSS statistics software, significance was 
calculated by means of a two-tailed independent Student’s T test, equal variances not assumed.
Results
Strong increase in epidermal AIM2 expression in benign and malignant 
hyperproliferative keratinocytic conditions
Whereas keratinocytes in normal epidermis hardly express any AIM2, strong induction of cyto-
plasmic AIM2 expression was found in the basal layers of keratinocytes in palmoplantar warts 
(median induction compared to normal skin 18-fold, p < 0,001), genital warts (median 6-fold, 
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Figure 8.1. Increased AIM2 expression in psoriasis lesions, common warts and genital warts. 
Immunohistochemical staining (IHC) of AIM2 in normal skin (NS) (A), psoriasis lesional skin (PS) (C), 
genital wart (E) and plantar wart (G). Panel I, J, K and L show details of panel A, C, E, and G, respectively. 
Keratinocyte proliferation as assessed with MIB-1 staining is shown in Figure B (NS), D (PS), F (genital wart) 
and H (plantar wart). Bar: 200 µm (A-H) or 50 µm (I-L).
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Figure 8.2. AIM2 is 
upregulated in squamous 
cell carcinoma, but down-
regulated in squamous 
cell carcinoma metastases 
IHC of AIM2 in normal skin 
(NS) (A), well-differentiated 
cutaneous squamous cell 
carcinoma (CSCC) (C, E), 
poorly differentiated CSCC 
(G) and skin metastases of 
CSCC (I). Panel K, L, M and 
N show details of panel 
A, C, G and I, respectively. 
Keratinocyte proliferation as 
assessed with MIB-1 staining 
is shown in Figure B (NS), D&F 
(well-differentiated CSCC), H 
(poorly differentiated CSCC), 
and J (CSCC metastases). 
Bar: 200 µm (A-J) or 50 µm 
(K-N).
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p 0,09), and to a variable degree in psoriasis (median 3-fold, p 0,07) (Figures 8.1 and S8.1, and 
Table S8.1). In the latter, AIM2 expression was also increased surrounding a Munro’s abscess, as 
we previously reported.18 MIB-1 staining showed that AIM2 expression generally correlated with 
keratinocyte proliferation in the basal cell layers (Figure 8.1), overall Pearson correlation 0,71 (p 
0,032).  
In view of the putative tumor suppressive function of AIM2, we hypothesized that 
AIM2 would be upregulated in well-differentiated CSCC, and downregulated in poorly 
differentiated CSCC and metastases of CSCC as a result of loss of control. Indeed, in 
well-differentiated CSCC, AIM2 was strongly expressed in mainly the basal cell/
peripheral layers of the infiltrating tumor nests (median induction compared to normal skin 
13-fold, p < 0,001), while in poorly differentiated CSCC and in metastases of CSCC, AIM2 
expression was absent or low and significantly downregulated compared to well-dif-
ferentiated CSCC (respectively, median 7-fold, p 0,004, and median 29-fold, p 0,001).
Interestingly, this was irrespective of the proliferative state of the tumors (Figures 
8.2 and S8.1, and Table S8.1).
AIM2 is present in melanocytic nevi and most melanomas, and 
downregulated in most melanoma metastases 
As we previously found robust AIM2 expression in melanocytes, and the name AIM2 implies its 
absence in melanoma, we investigated AIM2 expression in benign and malignant melanocytic 
tumors. 
We found strong cytoplasmic AIM2 expression in common melanocytic nevi (median induction 
compared to normal skin 6-fold, p 0,085), and in most primary melanomas (median 10-fold, 
p 0,033) (Figures 8.3A,B and S8.2, and Table S8.2). In some melanomas, there seemed 
to be a steady decrease in expression towards the deeper parts of the lesions (Figure 8.3B); 
one sample was AIM2-negative. In the periphery of cutaneous melanoma metastases,
AIM2 expression was weak to strong (Figure 8.3C), but it was absent in the center 
of half of them (Figure 8.3D). Moreover, in most nodal melanoma metastases, AIM2 expression 
was absent, with weak AIM2 expression in the periphery in some of them (Figure 8.3E), while in 
the center no AIM2 was found (Figure 8.3F). Hence, compared to primary melanomas, AIM2 expres-
sion was significantly lower in nodal metastases (median 5-fold, p 0,05) (Figure S8.2 and Table S8.2).
Discussion
In this study, we show that absent in melanoma 2 (AIM2) is present in most common melanocytic 
nevi and primary cutaneous melanomas, but is downregulated in nodal melanoma metastases. 
We also found that AIM2 is upregulated in proliferating keratinocytes in common warts, genital 
warts, and CSCC. Compared to their well-differentiated counterparts, AIM2 expression was lower 
in poorly differentiated CSCC, and absent or poorly expressed in their metastases. Hence, in the 
latter two, proliferating cells had at least partially lost AIM2 expression. Thus, AIM2 is absent in 
metastases, rather than in melanoma, as its name implies. 
The limitation of this study is the small sample size, but our findings and previous reports on 
the putative tumor-suppressive function of AIM2 support the hypothesis that in both epithelial 
and melanocytic proliferative lesions, AIM2 may have a role in suppression of proliferation and 
metastasis.6-17 For example, lack of AIM2 expression was closely associated with poor outcome 
in colorectal cancer.19 Interestingly, a recent in-vitro study on oral SCC cells suggested that AIM2 
has both a tumor-suppressive and an oncogenic potential, depending on the presence of p53.20 
Knockdown of AIM2 resulted in suppression of cell growth and apoptosis, but in cells bearing 
wild-type p53, the expression of AIM2 resulted in suppressed cell growth. 
The hypothesis that AIM2 could have a tumor-suppressive role is not supported by animal 
experiments, since no increased incidence of tumors was reported in two Aim2 knockout mouse 
models. In contrast, these mice do not seem to have an apparent phenotype.1,21 Still, Aim2 could 
be redundant for tumor suppression in mice, or perhaps tumor development would be revealed 
during longer follow-up. Also, to our knowledge, no human germ-line AIM2 mutations or other 
genetic aberrations were reported to date. In GEO Profiles of NCBI, varying expression levels 
AIM2 in keratinocytic and melanocytic skin tumors
111
 8
Figure 8.3. High AIM2 expression in common melanocytic nevi and most melanomas, and lower 
to absent expression in melanoma metastases. IHC of AIM2 in common melanocytic nevi (A), primary 
melanoma of the skin (B), periphery (C) and center (D) of cutaneous melanoma metastases, periphery 
(E) and center (F) of nodal melanoma metastases. Panel G shows a detail of AIM2 expression in benign 
melanocytic cells, panel H-J show heterogeneous AIM2 expression in melanoma, and K and L show details 
of cutaneous and nodal melanoma metastases, respectively. Bar: 200 µm (A-F) or 50 µm (G-L).
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of AIM2 in melanoma and melanoma metastases are depicted (e.g. ID.74488239). These data 
have to be interpreted with caution, since the exact experimental setup is often unclear, and the 
mRNA samples are likely to contain mRNA derived from monocytes or dendritic cells too, which 
are AIM2 positive. For example, we found strongly AIM2-positive multinucleated giant cells in a 
CSCC metastasis that itself exhibited only faint expression of AIM2 (data not shown).
The mechanisms that cause AIM2 up- and downregulation need to be identified. As we only 
investigated AIM2 protein expression, it is yet unknown whether genetic or functional alterations 
of AIM2 occur in these skin tumors. 
Based on our data, one could speculate that AIM2 is only upregulated in keratinocytes to 
control proliferation once they become hyperproliferative, whereas this inhibitory effect may be 
constantly required in melanocytes. The high constitutive AIM2 expression in melanocytes might 
be a means of continuous growth control fuelled by the considerable migratory potential of 
melanocytes. The putative role of AIM2 in growth control in vivo and in vitro in different types of 
malignancies, and whether mutations, silencing, deletions or other mechanisms are involved, is 
at present largely unknown. In particular, future studies are needed to reveal whether the tumor-
suppressive role of AIM2 can be linked to its inflammasome-activating capacity.
Acknowledgments
HdK is supported by an AGIKO stipend from the Netherlands Organisation for Health Research 
and Development. We thank Mrs. M. Link from the Department of Pathology for technical as-
sistance.
Supplemental material
Table S8.1. Relative quantities and statistical significance of AIM2 staining in keratinocytic 
lesions
Skin condition Relative 
quantity
P value Relative 
quantity
P value
 compared to 
normal skin
compared to 
normal skin
compared to 
CSCC well-
differentiated
compared to 
CSCC well-
differentiated
Normal skin 1,0  
Psoriasis plaques 3,0 0,067
Palmoplantar warts 17,6 0,000
Genital warts 5,9 0,093
CSCC well-differentiated 12,6 0,000
CSCC poorly differentiated 1,7 0,285 0,14 0,004
CSCC metastases in skin 0,4 0,561 0,03 0,001
CSCC: cutaneous squamous cell carcinoma
AIM2 in keratinocytic and melanocytic skin tumors
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Table S8.2. Relative quantities and statistical significance of AIM2 staining in melanocytic 
lesions
Skin condition Relative 
quantity
P value Relative 
quantity
P value
 compared to 
normal skin
compared to 
normal skin
compared 
to primary 
melanoma
compared 
to primary 
melanoma
Normal skin 1,0  
Melanocytic nevi 6,0 0,085
Primary melanoma 10,2 0,033
Melanoma metastases in skin 6,1 0,126 0,60 0,709
Melanoma nodal metastases 2,0 0,429 0,19 0,051
Figure S8.1. Relative quantities of AIM2 
staining in keratinocytic lesions 
Relative intensity of AIM2 staining, boxes show 
median +/- interquartile range, whiskers show 
10th and 90th percentile. Statistical significance is 
indicated in Table S8.1.
CSCC: cutaneous squamous cell carcinoma
Figure S8.2. Relative quantities of 
AIM2 staining in melanocytic lesions
Relative intensity of AIM2 staining, 
boxes show median +/- interquartile 
range, whiskers show 10th and 90th 
percentile. Statistical significance is 
indicated in Table S8.2.
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beyond the case reports -
Review and follow-up of 94 
patients with an emphasis on 
prognosis and treatment
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Abstract 
Schnitzler’s syndrome is a rare disorder characterized by a chronic urticarial rash and monoclonal 
gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain, and 
lymphadenopathy. In this study, we systematically reviewed disease characteristics of Schnitzler’s 
syndrome, and collected follow-up information to gain insight into treatment efficacy and long-
term prognosis.
PubMed and MEDLINE databases (1966-2006) were searched, using the key words 
‘Schnitzler’s syndrome’, ‘Schnitzler syndrome’, and the combination of ‘urticaria’ with ‘monoclonal 
gammopathy’, ‘IgM’ or ‘paraproteinemia’, as well as secondary references. Data on a total of 94 
patients who met the criteria for Schnitzler’s syndrome were reviewed. Questionnaires sent to all 
authors retrieved additional follow-up data on 43 patients, resulting in a mean follow-up of 9,5 
years after onset of symptoms, and a follow-up of 20 years or more in 10 patients.  
Symptoms, signs and laboratory findings as found in the 94 patients are reviewed in detail. 
There have been promising developments in therapeutic options, especially anti-interleukin-1 
treatment, which induced complete remission in all eight patients treated so far. To date, no 
spontaneous complete remissions have been reported. Patients with Schnitzler’s syndrome show 
no increased mortality during the present follow-up. However, they do have a 10-year risk of 15% 
of developing a lymphoproliferative disorder, most notably Waldenström’s macroglobulinemia. 
Three cases of type AA amyloidosis associated with Schnitzler’s syndrome have been reported.
Schnitzler’s syndrome is a rare disabling disorder which affects multiple systems and which 
can be considered as an autoinflammatory syndrome. There are new, effective treatment options, 
but close monitoring remains warranted because of the increased risk of lymphoproliferative 
disease. 
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Introduction
Schnitzler’s syndrome (SchS) is a rare disabling disorder characterized by a chronic urticarial rash 
and a monoclonal immunoglobulin M (IgM) gammopathy, accompanied to varying degrees by 
intermittent unexplained fever, arthralgia or arthritis, bone pain, lymphadenopathy, hepato- 
or splenomegaly, leukocytosis and an elevated erythrocyte sedimentation rate (ESR).1 Because 
patients often present to different specialists with different symptoms, and because the disorder 
is little known, it can take years before the correct diagnosis is made. 
In 1972, the French dermatologist L. Schnitzler was the first to describe this constellation 
of symptoms and signs 2, and to date, 89 cases have been reported. However, these are mostly 
confined to case reports, written at the time of diagnosis of the patient, and yield relatively little 
information on long-term disease progression and prognosis. In the present study, we wanted 
to address this issue. We reviewed all 89 reported cases and five previously unpublished cases 
with SchS 2-73 (Nikolova, Akhras & Lachmann, Gül, Brinkman, personal communication (p.c.), and 
one of our own patients) and obtained follow-up data by contacting authors. Our main focus is 
treatment efficacy, course of disease and prognosis. 
Definition
Lipsker et al. introduced a set of diagnostic criteria for SchS.43 They proposed that a diagnosis of 
SchS could be made in a patient with a combination of an urticarial skin rash, a monoclonal IgM 
component and at least 2 of the following criteria: (recurrent) fever, arthralgia or arthritis, bone 
pain, lymphadenopathy, hepato- or splenomegaly, leukocytosis, an elevated ESR, and abnormal 
findings on bone morphologic investigations (Table 9.1).43 Importantly, other causes must have 
been excluded (see ‘Differential diagnosis’). In recent years, a variant SchS has been defined, 
characterized by an IgG monoclonal gammopathy instead of IgM 3,6,19,29,50,54,61 (Gül, p.c.). We 
follow these criteria in the present review.
Table 9.1. Diagnostic criteria for Schnitzler’s syndrome, adapted from Lipsker et al. 43
Major criteria Minor criteria
(Chronic) urticarial skin rash Intermittent fever
Monoclonal IgM (or IgG: variant type) Arthralgia or arthritis
Bone pain
Lymphadenopathy
Hepato- and/or splenomegaly
Elevated ESR and/or leukocytosis
Bone abnormalities (on radiological or histological investigation)
A patient can be diagnosed with Schnitzler’s syndrome when there is a combination of both major criteria and 
two or more minor criteria, after exclusion of other causes (see ‘Differential diagnosis’).
Methods
We performed a literature search of MEDLINE and PubMed (1966-2006), using the key words 
‘Schnitzler’s syndrome’, ‘Schnitzler syndrome’, and the combination of ‘urticaria’ with ‘monoclonal 
gammopathy’, ‘IgM’ or ‘paraproteinemia’. References revealed many additional articles in mostly 
English and French literature. Personal communication yielded four additional unpublished cases 
from Bulgaria, the United Kingdom, Turkey and the Netherlands (Nikolova, Akhras & Lachmann, 
Gül, and Brinkman), and we included an unpublished case of our own. We set up a database 
with patients’ characteristics, signs and symptoms, treatment effects and course of disease, in 
which we included all patients who met the above-mentioned definition of SchS. Patients with 
other diseases that might explain the findings were excluded. This database contains data on 
94 patients at present. We sent questionnaires to the authors in order to collect more follow-up 
data, which we obtained on 43 patients. Mean duration of follow-up from start of symptoms 
in the 94 patients is 9,5 years. In five patients follow-up was less than one year, and in 10 of 
94 patients it was 20 years or more. Survival analysis was performed using the Kaplan-Meier 
method, by GraphPad Prism version 4.02 for Windows, GraphPad Software, San Diego, USA.
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Epidemiology
During the seventies to early nineties, SchS was reported solely in western European countries, 
especially in France. The majority of reported cases is still of French origin (Table 9.2). This is 
presumably due to the fact that the disorder was originally published in French by a French 
physician.74 In the last decade, however, cases have been reported in countries all over the world, 
ranging from Australia 68 to the Czech Republic.51 As shown in Table 9.2, the vast majority of 
reported patients are western Europeans of Caucasian 
descent, but three Japanese cases are known as 
well.3,49,67 The reason for the relatively low number of 
patients reported from the USA is unknown. SchS is 
likely to be highly underdiagnosed.  
Of the 94 cases, 57 are male (male:female ratio 
1,6). The mean age of onset is 51 years (SD 12 years). 
The youngest patient reported had the first attack 
of urticaria at the age of 13.34 However, she is an 
exception, as in only four other patients symptoms 
started before the age of 35 years 5,15,53 (Gül, p.c.). 
There is a significant delay in diagnosis, ranging from 
several months up to 20 years. In most cases the 
diagnostic delay exceeds five years.43
No risk factors have been identified to date, nor 
are there indications that SchS is a familial disorder. 
There is only one patient known to have a relative with 
a monoclonal IgM, in this case the patient’s father 
(Clauvel, p.c.).
Etiology/pathophysiology
The exact etiology of SchS remains unknown. Several hypotheses have been proposed, most of 
which suggest the involvement of autoreactive antibodies. Lipsker et al. showed monoclonal 
IgM deposits in the skin of SchS patients along basement membranes or in capillary walls, and 
suggested that in-situ IgM-mediated complement activation and subsequent tissue damage 
might cause the urticarial skin lesions.75 However, these IgM skin deposits were only detected 
in approximately 25% of SchS patients, and were also found in patients with Waldenström’s 
macroglobulinemia without urticaria, which strongly suggests that this phenomenon plays no 
major pathophysiological role. De Castro et al. found heterogeneous histopathological changes 
in a study of 15 cases, although most cases demonstrated neutrophilic urticaria.17 Sperr et al. 
reported the detection of IgG3 autoantibodies directed against cellular proteins, and IgG2 
antibodies specific for the a-chain of the FcεRI in one patient’s serum. They suggested that 
preferential Th1 autoimmune reactions played a pathophysiological role.66 In addition, Saurat 
et al. reported the detection of IgG autoantibodies directed against the cytokine interleukin (IL)-
1a.76 However, other groups could not confirm these findings in their patients 8,20,39,45,49,58,66 and 
these anti-IL-1a antibodies are present in about 18% of the general population.76 
Considerations regarding potential pathophysiological mediators in SchS include the role of 
several cytokines. For example, an elevated concentration of IL-6 was found in some patients.18,49 
As a major modulator of the acute phase response, IL-6 could be involved in the systemic 
features, and it was suggested that its effects on B-cell differentiation could form the link to the 
monoclonal gammopathy.76 However, increased levels of cytokines are not sufficient evidence for 
a causal relationship.77 
The recent success of treatment with the IL-1 inhibitor anakinra, which invariably leads to 
complete remission (see ‘Treatment’) 19,46 (Akhras, p.c.), seems to indicate a role for IL-1b as an 
important mediator in the pathophysiology of SchS. IL-1b can cause both systemic inflammation 
and inflammation of the skin and is also a potent stimulator of bone resorption.78 The exact 
involvement of IL-1b, initiating factors and cause of SchS remain to be identified. 
Table 9.2. Epidemiology: country of 
origin of reported patients
Country of origin Number of patients
France 38
Germany 12
Italy 8
Spain 7
The Netherlands 6
United Kingdom 4
United States 4
Japan 3
Canada 2
Bulgaria 2
Others 8
Total 94
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Medical history and physical examination
The main clinical findings and the frequencies that were reported in patients with SchS are shown 
in Table 9.3.
Table 9.3. Prevalence of clinical findings in Schnitzler’s syndrome patients
Characteristic Number of cases Frequency
present reported*
Chronic urticarial rash 94 94 100%
Pruritus 29 64 45%
Periodic fever 73 83 88%
Arthralgia / arthritis 58 71 82%
Bone pain 50 69 72%
Weight loss 16 25 64%
Lymphadenopathy 30 68 44%
Hepatomegaly 18 63 29%
Splenomegaly 8 65 12%
Angioedema 4 88 5%
* Number of cases in which this information was available
Chronic urticaria
The hallmark of SchS is a chronic, recurrent urticarial rash, which is usually the first symptom to 
occur. Chronic urticaria is defined as episodes of urticarial outbreaks that persist between 4 and 
36 hours and recur for a duration of at least 6 weeks.79,80 The frequency of urticarial eruptions 
differs greatly among patients. It ranges from daily to twice a year, but in most cases the rash is 
continuously present. Individual lesions last 12-36 hours and resolve completely without scarring, 
while new ones appear daily. The urticarial rash consists of annular erythematous maculopapular 
lesions that are 0,5-3 cm in diameter and sometimes confluent. 
In SchS, pruritus is usually absent at 
disease onset, but lesions became pruritic 
in approximately 45% of patients after several 
years. Severe antihistamine-resistant pruritus 
has been reported in only a few cases.57,66 
The rash affects primarily the trunk and the 
extremities, sparing the palms, the soles, and 
the head and neck areas (Figure 9.1). Some 
patients report aggravating factors, such 
as alcohol, spicy food and stress.19,43 One 
publication reported the onset of SchS in a 
patient within three months after a severe 
maxillary sinusitis complicated by mycotic 
sepsis, and the authors suggested that this 
might have been an immunological trigger.5 
Angioedema occurred in four cases.15,61
Periodic fever
Recurrent spiking fever is the second most common symptom, affecting 88% of patients. Like 
the urticarial eruptions, the frequency of febrile episodes differs greatly among patients, ranging 
from daily to twice a year. The episodes usually resolve within a few hours, but can persist for 
up to 24-48 hours. Peaks over 40ºC are common, though chills are rare. The fever and skin rash 
usually, but not always, appear simultaneously.
Figure 9.1. Urticarial rash on the lower arm 
of a Schnitzler’s syndrome patient
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Musculoskeletal symptoms
About 80% of patients complain of relapsing arthralgias. Commonly, the large joints are affected, 
including hips, knees, wrists and ankles, although other joints may be involved as well. The 
aching joints often appear normal. Frank arthritis was reported in three patients, one of which 
experienced a flare-up of SchS with oligoarthritis after a two-year remission on corticosteroids 29,56 
(Gül, p.c.). Joint destruction or deformities have not been reported.
Bone pain has been reported in 72% of cases, typically in tibia and ilium. Other bones were 
incidentally affected, including the femur, forearm, spine and clavicle. Some patients report 
myalgias, which may be hard to differentiate from bone pain.
Other symptoms
Lymphadenopathy was found in 44% of patients, usually in the axillary and inguinal regions. The 
enlarged lymph nodes can be persistent, multiple and up to 3 cm large. This may necessitate a 
biopsy to exclude lymphoma. Hepatomegaly is also a common feature, and splenomegaly was 
found in 12% of patients. Many patients suffer from malaise and fatigue. Weight loss is common. 
Incidentally reported symptoms include chronic inflammatory demyelinating polyneuropathy 9, 
pseudoxanthoma elasticum 30,45,69, headache, depression and vertigo.30 Peripheral neuropathy 
associated with anti-MAG (myelin-associated glycoprotein) serum activity was seen in two 
patients.39,60 Monoclonal IgM antibodies against MAG can cause a chronic demyelinating 
polyneuropathy in which deposits of IgM are found on skin myelinated nerve fibers 81, but the 
relationship with the paraprotein in SchS is unclear. One patient developed severe thrombophilia 
with antiphospholipid syndrome and hyperhomocysteinemia.24 Another patient reported hearing 
loss; intriguingly, this resolved completely on treatment with an IL-1 inhibitor.19
Laboratory, histological and radiological investigations
A monoclonal IgM component must be present to meet the diagnostic criteria. Alternatively, in 
case of variant SchS, it is a monoclonal IgG component (9% of the present cohort). However, it has 
to be kept in mind that at the time of presentation, the M component can still be undetectable, 
only exceeding the threshold later in the course of disease. At the time of diagnosis, IgM 
concentrations do not exceed 10 g/L in more than two thirds of cases. 
Table 9.4. Prevalence of laboratory and imaging findings in Schnitzler’s syndrome 
patients
Characteristic Number of cases Frequency
present reported*
Laboratory
monoclonal gammopathy 94 94 100%
- IgMκ (1 case: + IgA) 81 94 86%
- IgMl 5 94 5%
- IgGκ 7 94 7%
- IgGl 1 94 1%
Elevated ESR 81 84 96%
Leukocytosis 48 70 69%
Anemia 31 55 56%
Bence-Jones proteinuria 10 35 29%
Histology (skin biopsy)
Vasculitis 22 87 25%
Radiographic imaging
abnormal bone morphology 36 75 48%
* Number of cases in which this information was available
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In 94% of cases, light chains are of the kappa type (Table 9.4, Figure 
9.2). Agarose gel electrophoresis followed by immunofixation is 
recommended for recognition of a paraprotein.82 IgM levels can 
either remain stable or show a progressive increase of about 0,5-
1,0 g/L per year.43 A very high concentration of IgM may be an 
indication of Waldenström’s disease. In one case, a monoclonal IgA 
gammopathy was reported in conjunction with a monoclonal IgMκ 
gammopathy.45 Bence-Jones proteinuria was reported in 29% (10 
of 35) of patients. IgA and IgG levels are decreased in approximately 
25% of patients.
Signs of systemic inflammation will also be found: elevated ESR, 
elevated concentrations of acute phase proteins, leukocytosis and 
sometimes anemia of chronic disease. ESR and C-reactive protein 
(CRP) concentrations are continuously increased throughout the 
course of disease, peaking during exacerbations. Complement 
factors are normal or increased. Decreased concentrations of 
complement could indicate either an alternative diagnosis or 
possibly a genetic complement factor 4a (C4a) deficiency, which has 
been reported in two patients.60 Leukocytosis was found in 69%, 
although lymphopenia was reported in three cases 4,63 (Nikolova, 
p.c.).
The evaluation of a patient with recurrent fever and urticaria should also include tests to 
exclude hematological, infectious, and autoimmune diseases (see “Differential Diagnosis”), e.g. 
a complete blood count, blood cultures, serology for hepatitis C and streptococcal antibodies, 
tests for rheumatoid factor, antinuclear antibodies, cold agglutinins, cryoglobulins and ferritin. 
Skin biopsies of urticarial lesions show heterogeneous histopathological findings, ranging 
from neutrophilic urticaria (most common) to spongiotic dermatitis.17 Vasculitis, predominantly 
described as leukocytoclastic, was found in 25% (22 of 87 patients).
On radiological examination of the skeleton, bone densification is the most frequent finding 
(48%). If present, it is often related to the sites of bone pain, but bone pain without obvious 
bone abnormalities occurs as well. Bone-marrow examination is normal in 80% of patients at the 
time of diagnosis. Non-specific polyclonal lymphocytic or plasmocytic infiltrates were found in the 
remaining cases. Biopsy of lymph nodes shows non-specific inflammation.
In one patient, an ultrasound scan of the abdomen performed because of mild gamma-
glutamyl-transferase (gGT) elevation disclosed multiple hepatic lesions. The liver histology showed 
incipient nodular regenerative hyperplasia, as is often found in patients with autoimmune or 
hematological disorders.38 Although hepatomegaly was found in 29% of cases, hepatological 
findings were non-specific in these cases. 
Differential diagnosis
Before the diagnosis SchS can be made, a number of disorders have to be excluded (Table 9.5); 
we will discuss a few of them in more detail.
Chronic urticaria
The relevant differential diagnosis of the chronic urticarial rash includes chronic idiopathic 
urticaria.83 SchS can be distinguished by the presence of the accompanying features, particularly 
the paraprotein, and the inefficacy of antihistamines. Recently, a useful guideline for classification 
and diagnosis of urticaria was published as a result of the second international consensus meeting 
on urticaria.84 In delayed-pressure urticaria, fever, arthralgias and myalgia can accompany the 
urticaria in severe cases. In contrast to SchS, this is not associated with a paraprotein, elevated 
ESR, anemia, or leukocytosis.85
An urticarial skin rash can sometimes also accompany systemic lupus erythematosus (SLE). 
Many of the systemic features of SchS, such as fever, arthralgias and anemia are also seen in 
SLE. However, in SLE, the skin eruptions tend to be more persistent and to appear in a specific 
shape, such as the butterfly-shaped facial rash, and there is often specific organ-involvement in 
Figure 9.2. Monoclonal 
IgMκ (A) and IgGκ (B) 
bands on serum protein 
electrophoresis with 
immunofixation
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SLE which is absent in SchS. Antinuclear antibodies, which are common in SLE, can be detected 
in only 10% or fewer of SchS cases. A monoclonal gammopathy is not found in SLE.41
In acquired C1 esterase inhibitor deficiency (AC1ID), angioedema is much more common 
than in SchS, and it is often associated with B-cell lymphoproliferative disorders. Low C4 and 
C1-inhibitor levels are typical. The skin eruptions and vasculitis that might appear in AC1ID differ 
from those in SchS.85
Table 9.5. Differential diagnosis
Autoimmune disorders
Adult-onset Still’s disease (AOSD)
Systemic lupus erythematosus (SLE)
Acquired C1 esterase inhibitor deficiency
Hematological disorders
Monoclonal gammopathy of unknown significance (MGUS)
Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) 
syndrome
Waldenström’s macroglobulinemia (WM)
Lymphoma
Multiple myeloma (MM)
Hereditary auto-inflammatory syndromes
Cryopyrin-associated periodic syndrome (CAPS)
- Familial cold urticaria (FCAS)
- Muckle-Wells syndrome (MWS)
- Chronic infantile neurologic cutaneous and articular syndrome (CINCA/NOMID)
Infectious diseases 
Hepatitis B,C 
Chronic meningococcemia
Other
Idiopathic chronic urticaria
Hypocomplementic urticarial vasculitis
Delayed pressure urticaria 
Cryoglobulinemia
Behçet’s disease
Mastocytosis
Periodic fever 
Adult-onset Still’s disease (AOSD) resembles SchS in being a disorder of unknown origin 
characterized by recurrent fever, rash, arthralgia and/or myalgia. Diagnosis of AOSD can also only 
be made by exclusion; the only somewhat specific finding is an elevated serum concentration 
of ferritin. However, the rash in AOSD is more maculopapular or erythematous of appearance, 
rather than the urticarial lesions seen in SchS. Bone pain with hyperostosis, and especially the 
monoclonal gammopathy are not found in AOSD 67. 
The combination of urticaria and recurrent fever is also strikingly found in certain types of the 
cryopyrin-associated periodic syndrome (CAPS). This is a hereditary autoinflammatory syndrome 
with intermittent fever episodes, caused by mutations in NLRP3, which can result in at least 
three recognized phenotypes, with some overlap between them. One of these phenotypes, 
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also known as familial cold autoinflammatory syndrome (FCAS), is characterized by an urticarial 
skin rash, which however typically appears after exposure to cold. Another, known as Muckle-
Wells syndrome (MWS), is often accompanied by amyloidosis and deafness. Features which may 
distinguish these two phenotypes of CAPS from SchS include onset of symptoms at a younger 
age, a family history of the disease and the absence of a paraprotein.86 The third clinical phenotype 
associated with cryopyrin mutations is chronic infantile neurologic cutaneous and articular 
(CINCA) syndrome (also known as neonatal-onset multisystemic inflammatory disorder (NOMID)). 
The severe complications of this syndrome, which include chronic sterile meningtitis, progressive 
visual and severe auditory defects, and abnormal growth and neurologic development distinguish 
it very clearly from SchS. 87
Another hereditary autoinflammatory syndrome that is often mentioned in the differential 
diagnosis of SchS is the hyper-IgD and periodic fever syndrome (HIDS). However, the clinical 
presentation of HIDS is very distinct from that of SchS. In more than 90% of classic HIDS patients, 
the recurrent fever episodes start in the first year of life, and all of them have had their first 
symptoms before the age of 12 years old. The skin rash which can accompany the fever in HIDS 
is not urticarial, but rather erythematous of character, with petechiae and purpura. Between the 
fever attacks HIDS patients are generally symptom-free. A monoclonal gammopathy has never 
been detected in HIDS; the IgD elevation is always polyclonal.88
Paraproteins
Theoretically, monoclonal gammopathy of undetermined significance (MGUS), an isolated 
asymptomatic gammopathy, could exist beside chronic urticaria due to other causes and thereby 
mimic the syndrome. However, the particular combination of symptoms in SchS is quite specific. 
Also, MGUS and SchS differ in the associated type of lymphoproliferative disorder; when a 
malignancy develops, in the case of MGUS this is mostly multiple myeloma, whereas in SchS it is 
typically Waldenström’s macroglobulinemia.82
Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes 
(POEMS) syndrome is a rare multisystemic disease of unknown origin that occurs in the setting 
of plasma cell dyscrasia. Circulating M components of POEMS syndrome consist mainly of IgG or 
IgA-lambda, in contrast to the IgM of SchS. Instead of urticaria, the most common dermatologic 
changes in POEMS include hyperpigmentation and plethora.89 Endocrinopathy is not associated 
with SchS.
An IgM monoclonal gammopathy is also found in Waldenström’s macroglobulinemia (WM), 
a hematological malignancy further characterized by the infiltration of lymphoplasmacytic cells 
into bone marrow.90 As shown under “Prognosis”, there is a remarkable relationship between 
SchS and WM. 
Treatment 
Table 9.6 shows the effects of the main therapies tried as reported in the literature. For many 
years, no treatment option had proved to be satisfactory. Antihistamines have often been tried, 
but they were never effective in controlling the skin rash, so they are not indicated. The fact that 
antihistamines are ineffective, and that the urticarial rash in SchS is non-pruritic in more than half 
of the cases, seems to imply a histamine-independent etiology of the rash.
Corticosteroids are able to decrease symptoms significantly in 39% of patients. However, as 
almost invariably high-dose regimens are needed, their use is limited by the unavoidable side-
effects. Colchicine has been reported to be highly effective in some (four of 19 patients) 11,12,28,39, 
but ineffective in most of the cases.
In recent years a few promising therapeutic options have emerged, although the numbers 
of treated patients are still small. Initially, interferon alpha (IFNa) seemed to be a promising 
option.63,91 In one patient, after several other therapies had failed to improve symptoms, IFNa2b 
caused a major regression in urticarial lesions and bone pain during an 18-month follow-up. 
Only three times urticaria relapsed, two times of which were induced by attempts to stop IFNa 
therapy. In this patient, the therapy was well tolerated.63 Later, it proved ineffective in five out of 
11 patients, and only partly effective in another two. Furthermore, in view of the potential side 
effects, it has to be used with caution. 
Chapter  9
126
Table 9.6. Therapeutic options studied in Schnitzler’s syndrome
Treatment Reported Efficacy (# patients) Overall References
 # 
patients
Highª Mode-
rateb
Highª 
efficacy
corticosteroids 64 25 21 39%
3-8,10,12-15,17-24,26-28,30,31,
34,35,39,41-51,53-68,71,93 
(Akhras, Gül, Brinkman, Nikolova)c
cox-inhibitors1 44 6 16 14%
5,6,8,11,12,17-19,21-24,28-30,
33,35,37,39,40,42,43,45,46,49,
50,53-58,60,61,65,66,68,70,71,
93 (Akhras, Nikolova)
alkylating agents2 31 3 9 10% 4,6-10,13,15,20,30,35,41,43-46,48,49,54,57-59,68 (Akhras, Gül)
antihistamines 42 0 1 0%
3,7,8,11,14,15,19,24,26,27,30,
33,35,40,42,43,45,50,54,55,
57-59,61-63,68,71,93 (Akhras, 
Brinkman, Nikolova)
colchicine 19 4 4 21% 8,11,12,18,19,24,28,33,35,39,42,43,45,49,54,57,60 (Akhras)
IFNa3 11 4 2 36% 10,30,34,35,43,46,61,63 (Akhras)
IL-1Ra4 8 8 0 100% 19,46,(Akhras, and the authors)
thalidomide 6 3 1 50% 19,71,72,(Akhras, Brinkman)
cyclosporine 10 2 1 20% 19,24,30,41,46,54,57 (Akhras, Brinkman, Gül)
azathioprine 9 0 0 0% 11,30,46,50,52,54,55,58 (Akhras)
plasmapheresis 9 0 3 0% 8,10,30,42,50,52,54,63 (Akhras)
i.v. immunoglobulins 6 0 2 0% 30,39,46,50,57 (Akhras)
dapsone 12 0 1 0% 10-12,19,24,30,33,43,45,52,62 (Akhras)
pefloxacine 2 1 1 50% 25 (Clauvel)
psoralene 4 0 0 0% 39,42,43,63
PUV-A5 8 5* 1 63%* 14,43,46,48,58 (Akhras)
UVB phototherapy 2 1 0 50% 27 (Akhras)
UVA phototherapy 1 0 0 0% 63
bisphosphonates 5 3** 0 60%** 41,46,51,56 (Akhras)
anti-TNF6 2 0 0 0% 46 (Akhras)
chloroquine 4 0 0 0% 8,33,55 (Akhras)
hydroxychloroquine 2 1 0 50% 42,56
doxepine 3 0 1 0% 30,54,63
dihydroergotamine 1 0 1 0% 11
rituximab 3 0 2 0% 42,46,72
e.c. immunoadsorption7 1 1 0 100% 10
sulfasalazine 1 0 0 0% 42
a. High efficacy: complete remission of urticaria, fever and musculoskeletal symptoms.
b. Moderate efficacy: partial or temporary remission of symptoms.
c. Names of physicians that communicated patient data personally.
1. Cyclooxygenase inhibitors; 2. Alkylating agents: cyclophosphamide, methotrexate; 3. Interferon-a; 
4. IL-1Ra: interleukin-1 receptor antagonist: anakinra; 5. Psoralene UV-A; 6. Anti-tumor necrosis factor: 
etanercept; 7. Extracorporal immunoadsorption
* Reduced urticaria only; ** Reduced bone pain only
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A few years ago, thalidomide appeared to be very effective as it induced complete remission in three 
out of three cases, although it had to be stopped in two of them because of polyneuropathy.19,71 
However, recently, two patients did not improve on thalidomide at all (Akhras and Brinkman, 
p.c.), and another improved only temporarily.72 In addition, the potential of serious side effects 
make thalidomide a less preferable option. Pefloxacine may also be a promising option, although 
its use has only been reported in two patients so far 25 (Clauvel, p.c.).
A new development was seen on treatment with IL-1 inhibitors. Anakinra, which is a synthetic 
analogue of the endogenous IL-1 receptor antagonist, caused complete remission in eight out of 
eight patients 19,46 (Akhras, p.c., and AS, personal observation). Complete remission was induced 
within 24 hours in both classical and variant SchS with 100 mg s.c. anakinra, and could be 
sustained with daily injections. The longest follow-up is now three years, with persistent complete 
remission. Some patients only require on-demand administration after variable intervals. However, 
in three patients whose treatment was stopped temporarily, a flare-up of symptoms appeared 
within one day, but symptoms faded as soon as they were restarted on anakinra.19 A similar 
experience was observed in a patient who unintentionally missed two doses of anakinra, leading 
to dramatic worsening of symptoms within 48 hours with rigors, fever, and recurrence of the 
rash. However, as soon as the drug was restarted, symptoms subsided (Akhras, p.c.). The sole side 
effect of anakinra in SchS reported to date is an erythematous painful lesion at the injection site. 
At present, anakinra appears to be the treatment of choice in case of severe symptoms.
Prognosis 
Overall, SchS has a favorable prognosis in terms of mortality, with 91% survival after 15 years 
(Figure 9.3). Since the average age of onset is 51 years, this does not seem to differ from the 
general population at this age (e.g. 89% 15-year survival rate in the general Dutch population; 
Statistics Netherlands 2005, www.cbs.nl). 
SchS does require long-term follow-
up due to the potential development of 
lymphoproliferative disorders, in particular 
WM. In the group of 94 patients, 11 patients 
developed WM 4,6,9,13,16,34,59,68,92,93 (Nikolova, 
p.c.). A survival analysis of the occurrence of 
WM is given in Figure 9.4. Ten years after 
the onset of symptoms, WM had occurred 
in 15% of cases. However, this might be 
an underestimation because of the limited 
number of patients at risk after a decade.
Development of other lymphoprolifera-
tive disorders has been identified in three 
cases: one had a lymphoplasmocytic 
lymphoma of which bone marrow 
involvement (required for the diagnosis 
of WM) is unclear 60, another patient 
developed a myeloma 32 and recently, Dalle 
et al. reported the first known case of 
SchS that developed a marginal zone B cell 
lymphoma.72 
Overall, the risk of development of a lymphoproliferative disorder as found in this SchS cohort 
is very similar to that found by Kyle et al. in a cohort of patients with IgM MGUS (18% in 10 
years).94
An evidence-based follow-up scheme for the M component in SchS has not been reported 
yet, as it has been for example for MGUS by Kyle et al.82 It is not known whether this can 
be applied equally to SchS. Symptoms that should prompt further investigation for possible 
malignant evolution include easy bleeding of mucous membranes, dizziness and blurred vision – 
all part of the so-called hyperviscosity syndrome.90 This occurs in WM at high IgM levels: a steady 
increase in the paraprotein levels should raise suspicion. 
Follow-up (years) 0 5 10 15 20
# at risk 94 71 40 16 9
Survival proportion (%) 100 96 94 91 75
Figure 9.3. Survival in Schnitzler’s syndrome 
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Interestingly, no reports have been made of 
the development of type AL amyloidosis, 
even after decades of a monoclonal 
gammopathy. However, to date, three cases 
with AA type amyloidosis have been reported 
40,53 (Lozano Gutierrez, p.c.). In one of them, 
renal and cardiac involvement caused renal 
failure and cardiac complications 53; another 
patient died of progressive renal failure 
(Lozano Gutierrez, p.c.). Development 
of type AA amyloidosis is associated with 
prolonged elevation of acute phase protein 
concentrations, specifically serum amyloid 
A (SAA) protein. 
No spontaneous remissions have been 
reported, and most of the sparse treatment-
induced remissions failed to last after dose 
reduction or stopping treatment.19,63 The 
long-term effects of the different therapies 
on symptoms, paraprotein level, and 
incidence of WM are still unclear. 
Discussion
The analysis of follow-up data on 94 patients with SchS in the present review reveals new 
information on the long-term prognosis and complications of this disorder. For this review, we 
adopted the definition of SchS from Lipsker et al.43 This raises a problem for SchS-like cases which 
lack one of the two major criteria. For example, one patient presented with bone pain, bone 
densification and a monoclonal IgMκ gammopathy, in the absence of urticaria.95 There have also 
been reports of patients with a typical clinical phenotype resembling SchS, but without the M 
component.96,97 This last group of patients could well contain SchS patients, as the monoclonal 
gammopathy can become detectable even several years after the onset of symptoms. Still, as the 
official definition stands, the diagnosis can only be made at the time both a chronic urticarial rash 
and a monoclonal gammopathy are detected. Therefore, we did not include the aforementioned 
cases in our database.
SchS does not seem to be an inherited disorder, but the fact that the father of the youngest 
case had MGUS leaves open the possibility of a genetic predisposition to other B-cell disorders. 
In view of the potential development of WM or other lymphoproliferative disorders, it is interesting 
that Treon et al. recently reported that of 257 patients with WM, 48 (18,7%) had at least one 
first-degree relative with either WM (5,1%), or another B-cell disorder including MGUS (1,9%). 
Patients with a family history of WM or a plasma cell disorder were diagnosed at a younger age 
and with greater bone marrow involvement.98 
Some observers feel that SchS may be an indolent presentation of a slowly developing 
lymphoproliferative disorder which becomes clinically apparent after several years. In some 
early reports, SchS was thought of as a paraneoplastic phenomenon.13 Indeed, 11 patients in 
the present data set developed WM in the long term, but clear evidence for this hypothesis is 
lacking, and we have shown that most patients survive for many years without developing a 
lymphoproliferative disorder. Since WM is characterized by a monoclonal component of the IgM 
type, and all SchS patients who developed WM had this type of paraprotein, the risk of malignant 
development in the IgG type SchS cases is unclear. To date, none of the eight cases with the IgG 
variant have developed a lymphoproliferative disorder, at a maximum follow-up of 21 years.54 
Whereas the results of a wide range of treatments had been disappointing for a long time, recent 
developments seem promising. The striking effects of IL-1 inhibition may indicate a new era in 
which patients with SchS do not have to suffer from this chronic disease. Anti-IL-1 therapy still 
has to be tried in more patients with long-term follow-up in order to establish its long-term effect 
on clinical symptoms and the development of WM or amyloidosis. 
Follow-up (years) 0 5 10 15 20
# at risk 94 68 38 16 9
WM proportion (%) 0 5 15 18 27
Figure 9.4. Incidence of Waldenström’s 
macroglobulinemia in Schnitzler’s syndrome 
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SchS remains an enigmatic disorder, which is hard to categorize. Is it primarily an immunological, 
hematological or dermatological disease? Central to the clinical phenotype is a systemic 
inflammatory response to an unknown trigger. In this, it resembles the hereditary periodic fever 
syndromes, and most especially among these, the cryopyrin-associated periodic syndrome. In 
addition to a similarity in clinical phenotype, the impressive response to treatment with IL-1 
blockers in several of these syndromes resembles that seen in SchS.99-101 These hereditary periodic 
fever syndromes have been relabeled “hereditary autoinflammatory syndromes”.102 This name 
aptly reflects the similarities to autoimmune disorders, while at the same time setting them 
apart. In the autoinflammatory syndromes it appears to be the innate immune system that is 
malfunctioning, while in the autoimmune disorders the fault lies primarily in the adaptive or 
acquired immune system. 
We and others have previously suggested that SchS should be regarded as an acquired 
autoinflammatory syndrome.46,103 It is our hypothesis that the main pathophysiological defect 
should be sought for in the innate immune system. This however is yet to be elucidated. 
To increase our understanding of this rare syndrome, it is necessary to collect the experience 
of physicians around the world. We have made a start by collecting patient data in this present 
review. Another initiative is the website, www.schnitzlersyndrome.com, which offers a reference 
list of scientific literature on SchS, and aims to be a platform for clinical and/or research initiatives 
on the subject of this elusive disorder.
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Abstract 
Schnitzler’s syndrome is an inflammatory disorder characterized by a chronic urticarial rash and 
monoclonal gammopathy, accompanied by periodic fever, arthralgia or arthritis, and bone pain. 
The cause and treatment are still unknown. 
Here we assessed the therapeutic effect of thalidomide and anakinra, an interleukin-1 
receptor antagonist, in Schnitzler’s syndrome.
Three patients with Schnitzler’s syndrome are described, one with IgM gammopathy, two with 
IgG type. In one patient, thalidomide induced complete remission, but was stopped because of 
polyneuropathy. Anakinra 100 mg daily led to disappearance of fever and skin lesions within 24 
hours in all three patients. After a follow up of 6–18 months, all patients are free of symptoms.
Anakinra proved to be effective in three patients with Schnitzler’s syndrome. This treatment 
is preferable to thalidomide, which induced a complete remission in one of our patients, as 
anakinra has fewer side effects.
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Introduction
Schnitzler’s syndrome (SchS) is a rare disabling disorder characterized by a chronic urticarial rash 
and a monoclonal IgM gammopathy, accompanied by at least two of the following features: 
intermittent unexplained fever, arthralgia or arthritis, bone pain, lymphadenopathy, hepato- or 
splenomegaly, an acute phase response, and abnormal findings on bone morphological investi-
gations.1,2 In most cases, the syndrome follows a chronic, benign course, but at least 15% will 
develop a lymphoproliferative disorder in the long term.1 The pathophysiology is still unknown, 
although different autoantibody-mediated mechanisms have been proposed.3 Treatment remains 
a challenge and to date, no spontaneous complete remissions have been reported. We report the 
cases of three patients with SchS, two of whom have the variant form with an IgG gammopathy 
instead of IgM, and our observations on treatment with thalidomide as well as with the interleu-
kin-1 receptor antagonist (IL-1Ra), anakinra. All patients were informed in detail about the nature 
of the treatment and possible side effects, and gave their informed consent.
Case reports
Case No. 1
A 55-year-old woman with a 16-year history of chronic urticaria was referred to our outpatient 
clinic. She experienced daily episodes of pruritic urticarial lesions on the extremities, trunk, and 
face. Her medical history disclosed iritis as well as hearing loss and tinnitus due to otosclerosis. 
Since one year she experienced recurrent episodes of fever (39°C). She also complained 
of pain in both shins, and arthralgia in the hands, knees, and ankles. Physical examination 
showed a generalized urticarial rash (Figure 10.1A), splenomegaly, and axillary and inguinal 
lymphadenopathy. Laboratory investigations showed an increased C reactive protein (CRP) (92 
mg/L) and leukocytosis (12,5*109/L). She has a monoclonal IgG kappa (IgGκ) component. Further 
examinations showed no autoimmune disease, cryoglobulinemia or malignancy. DNA analysis 
showed no evidence for cryopyrin-associated periodic syndrome (CAPS).4 The combination of 
generalized urticaria, bone pain, arthralgia, recurrent fever, and a monoclonal IgG gammopathy 
allowed us to make the diagnosis of variant-type SchS.5,6 Earlier, treatment with cyclooxygenase 
inhibitors, antihistamines, cyclosporine, colchicine, and dapsone had been ineffective. High-
dose corticosteroids caused only a partial remission of symptoms. Administration of 100 mg 
thalidomide daily strikingly improved her condition: the fever and arthralgia vanished, urticarial 
lesions disappeared almost entirely, and the CRP level and leukocyte count normalized. 
Unfortunately, after seven weeks she developed severe polyneuropathy, which was reversible 
when thalidomide was stopped. Soon afterwards, her symptoms relapsed. Combination therapy 
of corticosteroids and thalidomide 50 mg improved symptoms, but complete remission was not 
obtained. We started anakinra treatment at a daily dose of 100 mg subcutaneously (s.c.). This 
caused the urticarial rash and fever to disappear within 24 hours (Figures 10.1B and 10.2) with 
a normalization of CRP level and leukocyte count. Interestingly, the tinnitus disappeared, but the 
audiogram did not change. Bone pain and arthralgia slowly diminished over the next weeks until 
complete remission was reached, which has lasted for more than 18 months.
Case No. 2
The second patient, a 58-year-old man, had a 15-year history of cold-induced urticaria and IgGκ 
paraproteinaemia. In the past year this had been accompanied by attacks of fever, myalgia, and 
arthritis of the ankles. These episodes of fever occurred in varying frequency from several times 
each week to once every two weeks. He had developed a weight loss of 8 kg during this year. He 
also had a perceptive hearing loss and bilateral distal mononeuropathy of the communal peroneal 
nerve. Detailed diagnostic examination showed no signs of cryoglobulinemia, multiple myeloma 
or other malignancy. A diagnosis of variant-type SchS was made, and during an episode of fever, 
treatment of the patient with anakinra (100 mg s.c. daily) was started. Within one day, the fever 
subsided, the skin lesions decreased in intensity, and the leukocyte count normalized. The CRP 
concentration dropped from 103 to 48 mg/L 48 hours after starting anakinra. The fever did not 
recur. Six months later the patient is still free from fever and urticaria, has gained weight, and is 
back at work.
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Case No. 3
A 60-year-old man presented with a three-year history of chronic urticaria. The moderately 
pruritic lesions were confined to his trunk and extremities and usually resolved within a few days 
(Figure 10.1C). He complained of arthralgia of the knees and feet. He had recurrent episodes of 
fever and bone pain affecting his pelvis and both shins. Physical examination showed urticarial 
lesions on his trunk and extremities. No hepatosplenomegaly or lymphadenopathy was found. 
Laboratory investigations demonstrated an increased CRP (143 mg/l), leukocytosis (13.5*10^9/l), 
and a monoclonal IgMκ. Examination of blood, urine, bone marrow, and radiographs showed no 
evidence of autoimmune disease, cryoglobulinemia, malignancy or CAPS, and the diagnosis SchS 
was made. Treatment with cyclooxygenase inhibitors and corticosteroids improved his symptoms 
only partially. After starting treatment with anakinra 100 mg s.c. daily, complete remission was 
reached, which has now lasted for one year (Figure 10.1D).
Figure 10.1. Skin manifestations in Schnitzler’s syndrome. Urticarial skin rash in the first (A) and third 
(C) patient, and the remarkable improvement 24 hours after administration of anakinra (B, D).
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Discussion
In this report we describe three patients with SchS who showed a remarkable clinical response 
to treatment with the IL-1Ra anakinra. In our first patient, thalidomide had also been effective, 
but treatment had to be stopped as it caused severe polyneuropathy. Our patients fulfilled the 
diagnostic criteria for SchS.1 Whereas most patients with SchS reported have an IgM paraprotein, 
our first two patients belong to the rare cases with a monoclonal IgG gammopathy. To date, 
five other patients with the IgG variant SchS have been described.5,6 The clinical manifestations 
of the variant-type syndrome do not differ from those of the typical syndrome. Treatment of 
SchS remains a challenge. No consistent effectiveness was reported for non-steroidal anti-
inflammatory drugs, antihistamines, colchicine, and several immunosuppressive drugs. At low 
doses, oral corticosteroids are usually ineffective in controlling the urticarial rash. Only high-dose 
corticosteroids can improve the urticarial rash as well, but this regimen was not effective in our 
first patient and cannot be sustained for prolonged periods.1,3 
Recently, Worm and Kolde reported the efficacy of thalidomide in two patients with SchS, 
in whom complete resolution of urticarial skin rash and marked improvement of fever attacks 
and bone pain were achieved.7 A similar remarkable response was seen in our first patient, but 
treatment had to be stopped because of severe polyneuropathy. Combination therapy with low 
dose thalidomide (50 mg) and corticosteroids subsequently induced a partial response. In our 
search for a more effective treatment we tried anakinra. Anakinra is a recombinant form of 
human IL-1ra, which competitively inhibits binding of IL-1a and IL-1b to the IL-1R type 1. IL-1 is 
a key proinflammatory cytokine mediating cellular responses during inflammation. Anakinra has 
proved to be effective in the treatment of rheumatoid arthritis and recently, it induced complete 
remission in the hereditary autoinflammatory disorder Muckle-Wells syndrome.4 Anakinra has 
Figure 10.2. Temperature curves and acute phase response. Body temperature (black line) and CRP 
serum levels (dotted line) in a patient with variant Schnitzler’s syndrome (Case No. 1) before and during 
treatment (grey areas) with thalidomide (left panel) and, subsequently, anakinra (right panel).
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also been successful in other autoinflammatory syndromes such as TNF-receptor-associated 
periodic syndrome and hyper-IgD syndrome.8,9 In our patients with SchS we observed a rapid 
and complete remission after starting treatment with 100 mg anakinra s.c. daily. After a follow 
up of 6–18 months, they are still in remission. Our first patient had the commonly reported 
adverse effect of painful, erythematous lesions at the site of injection, but this was only during 
the first few weeks of treatment and no other adverse effects were noted. The pathophysiological 
mechanism of SchS is still unclarified, but autoantibody-mediated mechanisms involving the 
paraprotein have been proposed.3 The remarkable responses we observed support the theory 
that IL-1 has an important role in the pathogenesis of SchS. This is corroborated by recent reports 
on successful treatment with interferon-a, which induces high levels of endogenous IL-1ra.10,11 
Saurat et al. reported the presence of anti-IL-1a antibodies in SchS.12 These autoantibodies are 
believed to prolong the half life, change tissue distribution, and enhance the systemic effects of 
IL-1. However, these anti-IL-1a antibodies could not be detected in other patients, nor were the 
serum concentrations of TNFa, IL-1b or IL-1ra increased.13-15 
In conclusion, anakinra (IL-1Ra) proved to be very effective in our three patients with SchS. 
This treatment is preferable to thalidomide, which induced a complete remission in one of our 
patients, as anakinra has fewer side effects. The effect of IL-1Ra underlines the important role of 
IL-1 in the pathogenesis of the disorder.
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Abstract 
The long-acting IL-1b antibody canakinumab induces sustained suppression of systemic 
inflammation in Schnitzler’s syndrome. Hence, IL-1b, not IL-1a, is pivotal in the pathophysiology 
of Schnitzler’s syndrome.
Canakinumab is highly effective in Schnitzler’s syndrome
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Schnitzler’s syndrome (SchS) is a chronic disabling autoinflammatory disorder, characterized by 
the association of chronic urticaria and paraproteinemia with symptoms and signs of systemic 
inflammation, such as fever, bone pain, arthralgia or arthritis, and elevated inflammatory 
markers.1,2 Over 160 cases have been reported to date, but it is likely to be highly underdiagnosed. 
The effectiveness of the interleukin-1 receptor antagonist (IL-1Ra) anakinra in over 40 cases to 
date implies a crucial pathophysiological role of IL-1, but does not discriminate between IL-1a 
and IL-1b.3-5 The burden of painful daily injections raised the need for longer-acting agents, 
and in-vitro findings hinted at IL-1b as the principal proinflammatory cytokine involved in the 
pathophysiology.6 Canakinumab is a human monoclonal anti-human IL-1b antibody which 
generally requires administration only once every four to eight weeks. It is effective in cryopyrin-
associated periodic syndrome (CAPS), a rare hereditary autoinflammatory disorder caused by 
increased IL-1b activation, which has phenotypical similarities to SchS.7,8 We therefore investigated 
whether canakinumab is effective in SchS.
Upon approval of the local and national ethical committees and patients’ informed consent, 
we started treatment with canakinumab (150 mg subcutaneously once every four weeks) in 
three patients with SchS. A 66-year-old male, a 51-year-old male, and a 67-year-old female had 
suffered from SchS for fourteen, five and six years with classical symptoms (fever, arthralgias, 
urticaria) and an IgM or IgG paraproteinemia, and had been asymptomatic on daily anakinra 
injections for 4½, 2½ and 1/3 years, respectively. In order to enter the study, the patients would 
stop their treatment with anakinra and report to us at the time of recurrence of symptoms.
Within 36 hours after stopping anakinra, the patients fell ill and gradually developed general 
malaise, pruritic to burning urticaria, fever (patients 2 and 3) and arthralgia, as before initiation 
of anakinra. Four to five days after discontinuing anakinra, they presented with disseminated 
Figure 11.1. Rapid resolution of urticaria and arthritis upon first canakinumab injection
Pictures show urticarial rash in patients 1 and 2, and arthritis of the left hand in patient 3 before canakinumab 
administration, and resolution of symptoms four days after injection. 
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urticaria (Figure 11.1), arthralgia (arthritis in patient 3), strongly elevated serum C-reactive protein 
(CRP) concentrations (Figure 11.2) and neutrophilic leukocytosis. Upon a single subcutaneous 
injection of 150 mg canakinumab, their symptoms started to abate within 6-16 hours, and all 
were asymptomatic after two days. CRP concentrations dropped dramatically within the first 
week and remained low or undetectable (Figure 11.2). Patient 1 reported scarce, short-lived faint 
non-pruritic urticaria-like lesions in the fourth and eight week, without any rise in inflammatory 
markers. Adverse events in patient 1 were localized non-pruritic erythema at the injection site 
(once after the first injection), fleeting light-headedness when rising up in week eight, and a single 
spell of palpitations in week five, all of which were not considered as serious adverse events. 
Patient 2 received acenocoumarol anticoagulation therapy because of aortic valve replacement 
due to a calcified bicuspid valve in 2007. His acenocoumarol dose needed to be adjusted after 
start of canakinumab possibly due to interaction with canakinumab. Patient satisfaction is high 
and follow-up of complete or clinical remission is now twelve, seven and eight weeks, respectively. 
These data suggest that monthly injection with canakinumab is an effective long-acting 
treatment of SchS. We have initiated a six-month trial of canakinumab in SchS (ClinicalTrials.
gov NCT01276522) which will determine the long-term safety and efficacy in more patients. 
Whereas anakinra blocks the action of both IL-1a and IL-1b, canakinumab specifically blocks IL-
1b. Consequently, these data single out IL-1b as the key cytokine responsible for inflammation 
in SchS, thereby providing a pivotal pathophysiological clue for this enigmatic disorder and 
corroborating the evidence for its autoinflammatory nature.
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Abstract 
Schnitzler’s syndrome is a chronic disabling autoinflammatory disorder, characterized by a chronic 
urticarial rash, paraproteinemia and systemic inflammation. The interleukin-1 receptor antagonist 
anakinra is a very effective treatment, but requires daily injections. Canakinumab is a human 
monoclonal anti-IL-1b antibody with a long half-life. We investigated long-term efficacy and 
safety of canakinumab in Schnitzler’s syndrome. 
In an open-label, single treatment arm trial (ClinicalTrials.gov: NCT01276522), eight patients 
with Schnitzler’s syndrome received monthly injections with 150mg canakinumab s.c. for six 
months, followed by a three-month observation period. Primary outcome was complete or clinical 
remission at Day 14. Secondary outcome measures included inflammatory markers, quality of life, 
time to relapse, safety and tolerability.
After stopping anakinra, patients developed moderate to severe clinical symptoms. 
Canakinumab induced complete or clinical remission at Day 14 in all eight patients. Median 
CRP concentrations decreased from 169 mg/L at baseline to < 10 mg/L on Day 14 and remained 
low or undetectable. One patient discontinued participation on Day 39 because of return of 
symptoms while all others remained in complete or clinical remission during the six-month 
treatment period. Relapse after the last canakinumab dose occurred within three months in four 
patients. For two patients, remission continued several months post-study. Five patients reported 
at least one adverse event, predominantly mild upper respiratory tract infections. One patient 
died in a traffic accident. 
In this nine-month study, monthly 150 mg canakinumab injection was an effective and well-
tolerated treatment for Schnitzler’s syndrome. Our data demonstrate that IL-1b plays a pivotal 
role in this disease.
Canakinumab trial in Schnitzler’s syndrome
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Introduction
Schnitzler’s syndrome (SchS) is a chronic disabling autoinflammatory disorder, characterized by 
a chronic urticarial rash, paraproteinemia and systemic inflammation. Patients are affected to 
different degrees by fever, bone pain and arthralgias or arthritis, and are at risk of developing a 
lymphoproliferative disorder and AA amyloidosis in the long term.1-3 Over 160 cases have been 
reported to date, but the actual prevalence is probably much higher. The etiology of SchS is 
unknown. Numerous immunosuppressive therapies had failed, but the interleukin-1 receptor 
antagonist anakinra was found to be effective in over 45 cases to date, implying a pivotal 
pathophysiological role of IL-1, either IL-1a, IL-1b, or both.4-6 The short half-life of anakinra 
requires daily subcutaneous (s.c.) injections, which occasionally lead to strong local injection site 
reactions.
Canakinumab is a fully human selective monoclonal anti-IL-1b antibody with a half-life of 
approximately 28 days. It is effective in the cryopyrin-associated periodic syndrome (CAPS), a rare 
hereditary autoinflammatory disorder caused by IL-1b-activating NLRP3 mutations.7,8 Phenotypical 
similarities to CAPS and in-vitro findings in SchS patients’ cells suggest that IL-1b is the principal 
pathophysiological cytokine in SchS as well.9 We have previously reported short-term successful 
treatment with canakinumab in three patients with SchS.10 Here we report efficacy and safety 
data of a nine-month trial of canakinumab in eight patients with SchS. 
Methods
Design overview
The design was an open-label, single-arm nine-month trial comprising six months of 150mg 
canakinumab s.c. injections every four weeks and three months of follow-up (ClinicalTrials.
gov registration number: NCT01276522). Dose adjustment to 300 mg was possible in case of 
incomplete response at Day 7. The study was approved by the local medical-ethical board and 
patients’ informed consent was obtained according to the principles of the Declaration of Helsinki.
Patients and Intervention
The trial took place in a single academic centre. Patients were eligible if they had active SchS as 
defined by the adapted Lipsker criteria 1,2, responded well to anakinra therapy, and fulfilled the 
other inclusion and exclusion criteria (Table S12.1). After discontinuation of anakinra treatment 
and the return of symptoms of SchS, patients entered the study to receive their first s.c. dose of 
150 mg canakinumab. Patients were then evaluated 3, 7, 14, and 28 days later and subsequently 
every four weeks, and received a canakinumab injection every four weeks for a total of six months. 
After the last injection, patients were followed until disease relapse or until three months passed. 
Upon disease relapse, the patients were restarted on anakinra.
Outcome measures
The primary outcome measure was complete or clinical remission at Day 14 of the trial (definitions 
are outlined in Table S12.2). Complete remission was defined as absent or minimal clinical disease 
activity with normal C-reactive protein (CRP), and clinical remission as absent or minimal disease 
activity and > 75% improvement of CRP concentration from baseline, though still above 10 mg/L. 
Secondary outcome measures included prevention of disease relapse during the trial; 
change in inflammatory markers (CRP and serum amyloid A (SAA)), physician and patient global 
assessment of disease activity (PGA and PaGA, respectively, scale 0 (absent), 1 (minimal), 2 (mild), 
3 (moderate) to 4 (severe)), quality of life using the RAND-36 questionnaire 11; time to disease 
relapse after the last canakinumab dose; safety and tolerability. Paraprotein levels were measured 
throughout the trial.
Statistical analysis
The differences in quality of life measurements (RAND-36 data) under anakinra treatment versus 
without treatment (Baseline), under canakinumab treatment Day 14 versus Baseline and under 
anakinra treatment versus canakinumab treatment Day 14 were tested with a paired Student’s 
t test. Also serum concentrations of CRP and SAA at Baseline versus Day 7 after the first 
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canakinumab injection were tested with a paired Student’s T test. P < 0,05 was regarded as 
statistically significant. 
Role of the funding source
This is an investigator-initiated study, primarily funded by the Radboud university medical center, 
Nijmegen, and a VIDI grant of the Netherlands Organisation for Scientific Research. Novartis 
supplied canakinumab free of charge and provided some financial research support.
Results
Patients
All patients with SchS known to us in the Netherlands at the start of the trial (nine in total) 
were invited and screened for participation. One patient preferred not to discontinue anakinra 
treatment for personal reasons, but the others provided informed consent and were eligible. 
Therefore, eight patients aged 51 to 75 years (mean 64) with classical (IgM) or variant (IgG) type 
SchS were included in the trial. Baseline patient characteristics are shown in Table 12.1.
Within 35 to 96 (median 43) hours after stopping anakinra, the patients gradually developed 
general malaise, non-pruritic to burning urticaria, fever and arthralgia, as before initiation of 
anakinra. At the Baseline visit four to six days after discontinuing anakinra, they presented with 
disseminated urticaria and arthralgia. Five patients had arthritis in one to seven joints. Baseline 
SAA (median 974 mg/L, range 72 to 2390 mg/L) and CRP (median 169 mg/L, range 18 to 333 
mg/L) concentrations were elevated, and seven patients had a neutrophilic leukocytosis.
Table 12.1. Baseline patient characteristics (after discontinuation of anakinra)
Patient 1 2 3 42 5 6 7 8
Sex M F M M M M F M
Age (years) 66 67 51 63 67 75 63 59
Disease duration (years) 14 2,5 6 20 10 17 25 9
Anakinra use (years) 4,5 0,25 2,5 6 7 6,5 7 2
Paraprotein subtype IgMκ&
IgMl
IgGκ IgMκ IgGκ IgMκ IgMκ IgGκ3 IgGκ3
Physician global assessment1 3 4 3 3 3 4 4 4
CRP level (mg/L) 202 147 190 18 60 250 95 333
SAA level (mg/L) 1380 867 1840 72 109 1080 502 2390
Neutrophils (*109/ml) 11,1 7,5 12,1 4,9 10,4 8,3 15,6 11,3
1 Five-point score of disease activity from 0 (absent) to 4 (severe).
2 This patient required antihistamines for concomitant cold-induced urticaria during both anakinra and 
canakinumab treatment. The other patients did not use any concomitant anti-inflammatory drugs. 
3 Previously an unquantifiably low IgGκ paraprotein was found, but this is currently undetectable.
Primary outcome and disease activity
After the first s.c. injection of 150 mg canakinumab, symptoms in all patients started to abate 
within six to 16 hours, and all were asymptomatic after two to seven days. By Day 14, all eight 
patients met the primary outcome by achieving complete or clinical remission. Six patients were 
in complete remission and two in clinical remission due to slightly elevated CRP levels (18 and 28 
mg/L) (Figure 12.1A). 
Physician global assessment and patient global assessment were almost identical during the 
trial, and showed moderate to severe disease activity at Baseline (mean 3,5, on a scale from 
0 (absent) to 4 (severe activity)), which improved to minimal or no disease activity at Day 7 
(mean 0,8) (Figures 12.1B and S12.1). There was rapid resolution (median duration 18 hours, 
range 10 to 48 hours) of the typical urticarial rash after the first canakinumab administration as 
illustrated in Figure 12.1C. During the ensuing months, disease activity remained mild or absent 
in all patients except for Patient 8, as described below (Figures 12.1A,B).
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Serum CRP and SAA concentrations dropped dramatically within the first week (at Day 7: CRP 
median 13 mg/L (p 0,004), range < 5–46 mg/L; SAA median 9 mg/L (p 0,009), range 1-103 
mg/L) and remained low or undetectable during the ensuing months (e.g. after six months: CRP 
median < 5 mg/L, range < 5–20 mg/L; SAA median 5 mg/L, range 1-25 mg/L) (Figure 12.2). 
Paraprotein levels were stable throughout the trial and fluctuated less than 1 mg/L compared to 
the measurement prior to the trial (data not shown).
After an initial clinical remission and drop in CRP from 333 mg/L at Baseline to 18 mg/L at Day 
14, Patient 8 started experiencing symptoms at Day 18 and had a clear clinical and biochemical 
relapse at Day 27. The second canakinumab dose of 150 mg at that time again induced clinical 
remission, but symptoms reappeared at Day 37. The patient chose to discontinue with the trial at 
Day 39; return to anakinra treatment was successful in controlling disease activity.
Quality of life assessment
At each visit, quality of life (QoL) was assessed with the RAND-36 questionnaire. At Baseline 
during active disease, patients’ QoL had substantially decreased in all dimensions compared to 
QoL under anakinra treatment when their disease was inactive (Figure 12.3 and Tables S12.3 and 
Figure 12.1. Trial 
outcome and clinical 
assessments
A. Outcome during 
the trial in days after 
the first injection 
of canakinumab. 
Arrows indicate s.c. 
injection with 150 mg 
canakinumab. The 
single relapse at Day 28 
was seen in Patient 8.
B. Physician global 
assessment of disease 
activity (PGA) scores. 
Arrows indicate s.c. 
injection with 150 mg 
canakinumab.
C. Urticarial rash on 
thighs of patient 6 at 
baseline; urticae had 
almost vanished two 
days after the first 
canakinumab injection.
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S12.4). Pain and role impairment due to a physical problem were the most affected dimensions, 
whereas mental health remained relatively stable. Upon starting canakinumab treatment, 
patients’ QoL rapidly improved during the first week and remained stable during the whole trial 
(Figure S12.2 and Table S12.3). In the dimensions role impairment due to a physical problem and 
vitality, patients scored their QoL slightly, but statistically significantly better during canakinumab 
(Day 14) than during anakinra treatment (Table S12.4). 
Figure 12.2. 
Sustained
suppression of 
systemic 
inflammation 
A. Serum C-reactive 
protein (CRP) and 
B. Serum amyloid 
A (SAA) levels as a 
measure of systemic 
inflammation du-
ring the trial and 
during follow-up. 
Each line represents 
one patient. 
At Day -10, CRP 
and SAA levels 
under anakinra are 
shown. 
Upper limit of 
normal is 10 mg/L.
Figure 12.3. Quality of 
life assessment
Spidergram depicting 
seven dimensions of the 
RAND-36 quality of life 
questionnaire. Data are 
normalized to a scale of 
0 (center, the worst) to 
100 (periphery, excellent 
quality of life) and the 
lines indicate the mean 
scores during anakinra 
treatment, symptomatic 
episode upon stopping 
anakinra, and at 
Day 14 after the first 
canakinumab injection.
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Relapse of disease activity after last dose of canakinumab
Within the three-month follow-
up, four patients relapsed 
(definition of relapse in Table 
S12.2) and one died in a traffic 
accident while asymptomatic. 
In two patients, remission 
continued until seven and eight 
months after the last injection 
(Figure 12.4). Of the six patients 
who completed the trial, median 
time to relapse was 72 days after 
the last canakinumab (range 40-
234 days). All were restarted on 
anakinra, which quickly induced 
disease remission. Disease activity 
at relapse (Figure 12.4) was much 
milder than at study entry when 
they had discontinued anakinra 
and relapsed, as evidenced by 
the lower PGA and PaGA scores 
(Figures 12.1B and S12.1), lower 
CRP levels (Figure 12.2), and less 
pronounced drop in the quality 
of life, as shown for the most 
severely affected dimensions in 
Figure S12.2.
Adverse events
During the whole trial, blood pressure, weight, kidney function and liver enzymes remained 
unaffected. A total of 22 adverse events were reported by five patients and were predominantly 
upper respiratory tract infections. All but rhinitis, pharyngitis, lightheadedness, and vertigo (each 
N=2) were reported in one patient only. One fatality due to a traffic accident occurred during the 
follow-up phase, 45 days after the last injection of canakinumab (trial Day 185). There was no 
apparent relationship with the study drug. All adverse events are listed in Table 12.2.   
Table 12.2. Adverse events
# patients with 
AE (total N=5)
Serious adverse event
   Death in traffic accident 1
Adverse events 
  Infections
    Rhinitis 2
    Pharyngitis 2
    Sinusitis (H. parainfluenzae) 1
    Herpes labialis 1
  Injection site reaction 1
  Other
    Lightheadedness 2
    Hot flushes 1
Figure 12.4. Time to relapse 
The duration in days after the last canakinumab dose until relapse is 
shown for the seven patients that finished the six-month treatment 
part of the trial. Four patients (Patients 1, 2, 4 and 7) relapsed within 
the three-month follow-up period during the trial, whereas two 
patients (Patients 5 and 6) relapsed several months later. The cross 
indicates the patient who died in a traffic accident during the follow-
up phase. The duration from the beginning of symptoms to clear 
relapse (objectified by a physician) is indicated by light grey (PGA 
grade 2, mild disease activity at relapse visit) and dark grey (PGA 
grade 3, moderate disease activity) bar endings.
continued # patients with 
AE (total N=5)
    Headache 1
    Fatigue 1
    Palpitations 1
    Tinnitus 1
    Vertigo 2
    Anterior uveitis 1
    Diarrhoea 1
    Transient INR rise under 
      anticoagulation 1
    Numb feeling foot soles 1
    Transient increase hair loss 1
    Jaw luxation 1
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Discussion
This study shows that monthly s.c. injection with 150 mg canakinumab is an effective treatment 
in patients with SchS. All patients met the criteria for the primary outcome measure: clinical or 
complete remission of disease activity at Day 14. 
One patient relapsed after initial clinical remission. In view of his severe inflammation at 
Baseline, initial response to canakinumab, and relatively high body mass index, we hypothesize 
that he might have benefitted from higher dosing. 
The time to relapse after the trial’s end varied greatly among the patients. For two patients, 
canakinumab induced a long-term remission of this unremitting disease. Seemingly, a vicious 
circle of inflammation had been interrupted (IL-1b induces its own production) with canakinumab 
treatment, but the reason why this created such a long-term remission in these particular patients 
remains elusive. They both had had SchS for many years, and their disease activity at Baseline was 
intermediate compared to the other patients. 
The monthly dosing regimen was based on the report that in 24,1% of 109 CAPS patients 
who were injected bimonthly, an increase in dose or frequency was required.12 Based on our data, 
in some patients less frequent dosing may suffice, while others require more frequent or higher 
dosing. Pharmacokinetic studies with larger patient numbers may yield the optimal regimen. One 
option may be to use a higher dose or more frequent dosing for a short period of time (‘loading 
dose’) to induce a strong response followed by a lower or less frequent dosing regimen at some 
point to maintain that response. 
Apart from a fatal traffic accident that was unrelated to the study drug, adverse events were 
mild and were predominantly viral upper airway infections. 
To date, anakinra was the only therapy reported to be highly effective in almost all patients 
with SchS, but its daily injections raised the need for a more patient-friendly alternative.4-6 Recently, 
eight patients responded well to rilonacept, which requires weekly administration and is more 
expensive than canakinumab, which in turn is more expensive than anakinra.13 Both anakinra 
and rilonacept block IL-1a and IL-1b, but canakinumab specifically blocks IL-1b. Consequently, 
this study indicates that IL-1b is the key cytokine responsible for inflammation in SchS. Recently, 
IL-6 inhibition was also found effective in three patients with SchS.14 The patients in that study 
were the first in which IL-1 inhibition was reported to be ineffective, which is interesting from 
a pathophysiological point of view and could indicate that these patients constitute a distinct 
subset.
The serum paraprotein concentrations were not affected by canakinumab treatment in this 
trial. This mirrors the absence of an effect on paraprotein concentration by anakinra, even after 
years of treatment (personal observation). Long-term follow-up is needed to evaluate whether 
IL-1 inhibition has any effect on the progression to lymphoproliferative disorders, of which 
patients with SchS are at risk.1 
To conclude, in this trial, monthly 150 mg s.c. canakinumab was effective and well-tolerated 
in SchS. The study demonstrated that IL-1b is pivotal in the pathophysiology of this debilitating 
disease.
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Supplemental material
Table S12.1. Inclusion and exclusion criteria
Inclusion criteria
1 Patients with a diagnosis of Schnitzler’s syndrome as per criteria 1,2
2 Patients who have demonstrated a partial or complete clinical response with an associated 
normalization of their biomarkers of inflammation (CRP) upon treatment with anakinra
3 Male and female patients at least 18 years of age at the time of the screening visit
4 Patient’s informed consent
5 Negative QuantiFERON test or negative Purified Protein Derivative (PPD) test (< 5 mm induration) 
at screening or within 1 month prior to the screening visit, according to the national guidelines. 
Patients with a positive PPD test (≥ 5 mm induration) at screening may be enrolled only if they have 
either a negative chest x-ray or a negative QuantiFERON test (QFT-TB G In-Tube)  
6 Adequate contraception in females of childbearing potential
Exclusion criteria
1 Pregnant or nursing (lactating) women
2 History of being immunocompromised, including a positive HIV at screening (ELISA and Western 
blot)
3 Serologic evidence of hepatitis B or C infection
4 Live vaccinations within three months prior to the start of the trial, during the trial, and up to three 
months following the last dose  
5 History of significant medical conditions, which in the Investigator’s opinion would exclude the 
patient from participating in this trial
6 History of recurrent and / or evidence of active bacterial, fungal, or viral infection(s) 
7 Use of the following therapies: 
- Anakinra within 24 hours prior to Baseline visit
- Corticosteroids (oral prednisone (or equivalent)) > 1,0 mg/kg/day (or greater than the maximum of 
   60 mg/day for children over 60 kg) within three days prior to the Baseline visit
- Intra-articular, peri-articular or intramuscular corticosteroid injections within four weeks prior to the 
   Baseline visit
- Any other investigational biologics within eight weeks prior to the Baseline visit
- Any other investigational drugs, other than investigational biologic treatment, within 28 days 
   (or three months for investigational monoclonal antibodies) or five half-lives prior to the Baseline  
   visit, whichever is longer
8 History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
Table S12.2. Trial endpoints*
Primary endpoint
Complete or clinical remission at Day 14
Secondary endpoints
1 Complete or clinical remission at Day 3 and Day 7
2 Prevention of disease relapse in patients who demonstrated complete remission at Day 14
3 The change in biomarkers (CRP and SAA) and clinical parameters (physician and patient global 
 assessment of disease activity) during the treatment and follow-up periods
4 Time to relapse after the last canakinumab dose
Exploratory endpoints
1 Changes in patient quality of life by using: Medical Outcome Short Form (36) Health Survey (SF-36®)
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*Endpoint definitions:
Complete remission: a physician global assessment of disease activity of 0 or 1 (no or minimal symptoms/
signs, includes rash) and a normal CRP (< 10 mg/L) 
Clinical remission: a physician global assessment of disease activity score of 0 or 1 and CRP > 10 mg/L, but > 
75% reduction compared to baseline
Partial response: a new physician global assessment of disease activity score shows a decrease when compared 
to baseline physician global assessment by at least 1 point, but is not equal to 0 or 1 and / or a decrease from 
baseline CRP > 25% and < 75% (without explanation for elevated CRP other than Schnitzler’s syndrome).
Non-response: a physician global assessment of disease activity score unchanged or worsened as compared 
to baseline and / or CRP increased or < 25% reduced from baseline CRP 
Relapse: a physician global assessment of disease activity of 2 or 3, or a value for CRP > 30 mg/L (after an 
initial response)
Table S12.3. RAND-36 quality of life data
Quality of Life 
dimension
Ana-
kinra
Base-
line*
Day 
4**
Day 
7
Day 
14
Day 
28
Day 
56
Day 
84
Day 
112
Day 
140
Day 
168
Re-
lapse
Physical functioning 90 64 79 89 92 91 94 91 95 94 94 81
Social functioning 95 64 73 84 95 91 95 88 95 95 95 85
Role impairment 
(physical problem) 78 16 72 59 94 75 93 89 100 96 93 54
Role impairment 
(emotional problem) 100 63 96 71 100 83 100 90 100 100 100 78
Mental health 87 78 88 85 91 85 88 85 89 87 87 85
Vitality 74 36 66 72 79 74 81 76 83 83 78 67
Pain 90 53 75 88 92 85 92 89 96 95 92 78
General health 
perception 68 48 63 64 68 68 70 69 66 71 69 55
Health change 56 13 47 53 63 59 61 50 64 61 54 46
Mean RAND-36 data, transformed to a scale from 0 (worst quality of life) to 100 (excellent quality of life). 
Data from anakinra to Day 28 are from all eight patients, data from Day 56 to Day 168 are from the remaining 
seven patients, and relapse data are from the six patients who finished the entire trial.
For General health perception and Health change, a score of 50 indicates ‘the same as one year ago’. 
* Score at Baseline, so during symptoms. ** Day 4 after the first canakinumab injection.
Figure S12.1. Patient 
Global Assessment of 
Disease Activity
Arrows indicate s.c. 
injection with 150mg 
canakinumab.
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Table S12.4. Comparison quality of life outcomes
Quality of Life dimension Anakinra vs Baseline Canakinumab Day 
14 vs Baseline
Canakinumab Day 
14 vs anakinra
QoL 
change
P value QoL 
change
P value QoL 
change
P value
Physical functioning 1,4 0,02 1,4 0,01 1,0 0,40
Social functioning 1,5 0,05 1,5 0,06 1,0 1,00
Role impairment (physical 
problem)
5,0 0,01 6,0 < 0,01 1,2 0,05
Role impairment (emotional 
problem)
1,6 0,08 1,6 0,08 1,0 1,00
Mental health 1,1 0,13 1,2 0,06 1,0 0,09
Vitality 2,0 < 0,01 2,2 < 0,01 1,1 0,02
Pain 1,7 < 0,01 1,7 < 0,01 1,0 0,66
General health perception 1,4 0,04 1,4 < 0,01 1,0 0,91
Health change 4,5 < 0,01 5,0 < 0,01 1,1 0,17
Relative change in quality of life as measured with the RAND-36 questionnaire. The mean values of transformed 
outcomes (scale 0-100,  shown in Table S12.3) were divided by those during the other treatment conditions. 
Statistical significance of difference between the scores during anakinra, at Baseline (symptomatic), and at 
canakinumab Day 14 were calculated with a paired Student’s T-test and indicated in P-values. 
 
Figure S12.2. Quality of life assessment during the trial
RAND-36 data during the trial and during relapse, normalized to a 0 (the worst) to 100 (excellent quality of 
life) scale. Mean data of the four most affected dimensions are shown.
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Introduction
Schnitzler’s syndrome (SchS) is a disease characterized by chronic urticaria with intermittent 
fever, arthralgia, and a monoclonal gammopathy. Recently, the use of IL-1 inhibitors has been 
advocated on the basis of clinical observations.1 In this report, we examine the ex-vivo production 
of cytokines and effect of inhibition of IL-1 in SchS.
Case
A 50-year-old Caucasian woman with an eight-year history of increasingly severe urticaria 
presented for evaluation. She initially noticed intermittent, scattered, nonpruritic ‘‘hive’’-like 
rashes presenting for a few hours at a time. The rash gradually progressed to chronic persistent 
urticaria with significant pruritus, affecting her entire body with the exception of her face. She 
had a three-year history of intermittent fever up to 39°C, with associated fatigue, myalgia, and 
arthralgia affecting her lower limbs. She denied perioral edema or dyspnea. Previous trials of 
numerous medications, including antihistamines and montelukast, were unsuccessful; high doses 
of steroids resulted in temporary improvement. Past history included hypothyroidism for which 
she was on an adequate dose of levothyroxine.
On examination, she had indurated erythematous papules and plaques, ranging in size 
from 0,5 to 4 cm in diameter, with the most prominent involvement on the central body (Figure 
13.1A). No pigmentary disturbance, bruising, or epithelial change was noted. Laboratory tests 
revealed anemia (hemoglobin 101 g/L), thrombocytosis (platelets 749*109/L), and a white cell 
count of 6,9*109/L. Complement levels, including functional assays, were normal. Biochemistry 
was normal except for elevated alkaline phosphatase at 146 U/L and IgM gammopathy with a 
total IgM of 9,22 g/L on serum protein electrophoresis, with no paraprotein peak on urine protein 
electrophoresis. Bone marrow biopsy demonstrated no increase in lymphocytes, blast cells, or 
plasma cells. Flow cytometry showed no clonal population. Bone scintigraphy showed increased 
uptake in both tibiae. Biopsy of affected skin demonstrated a neutrophilic dermatosis with no 
evidence of vascular damage.
A diagnosis of SchS was made. This syndrome bears similarities to Muckle-Wells syndrome 
(MWS), an inherited disease in which symptoms usually begin in childhood and mutations in the 
CIAS1 gene are found. Sequencing of the entire gene in this patient revealed no mutations.
Within hours of the introduction of anakinra 100 mg daily, an IL-1 receptor antagonist, our 
patient had resolution of skin rash (Figure 13.1B), fevers, malaise, and bone pain. This effect 
has now been sustained for one year. Laboratory testing demonstrates normalization of her 
hematologic parameters and alkaline phosphatase, but the IgM gammopathy persists.
Ex-vivo experiments
PBMCs were isolated by Ficoll (MP Biomedicals LLC, Solon, Ohio) from this patient 48 hours after 
withdrawal of anakinra and from a healthy control following institutional review board approval 
Figure 13.1. A. Urticarial plaques on the trunk of a patient with Schnitzler’s syndrome. B. Within 24 hours 
of commencing anakinra, these lesions had resolved.
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and written informed consent. PBMCs were incubated with 100 pg/mL lipopolysaccharide (LPS; 
ultrapure Salmonella minnesota LPS, List Biological Laboratories, Campbell, Ca), with or without 
30 minutes preincubation with YVAD (Z YVAD-FMK; Kamiya Biomedical Company, Seattle, Wa), 
an inhibitor of caspase-1, IL-1 trap (Regeneron Pharmaceuticals,Tarrytown, NY), an inhibitor of 
IL-1, or adalimumab (Abbott Laboratories, North Chicago, Ill), an inhibitor of TNF. After 14 hours, 
we collected supernatant and determined concentrations of IL-1, IL-6, and TNF by a cytokine 
bead array (BD Biosciences, San Diego, Ca).
There was no spontaneous secretion of cytokines, but the concentration of all three cytokines 
upon stimulation with LPS was significantly elevated in the patient versus control (Figure 13.2A). 
Both the IL-1 trap and the caspase-inhibitor YVAD were effective in inhibiting the hypersecretion 
of all three cytokines, whereas adalimumab had only a very limited effect (Figure 13.2B). The 
effect of the IL-1 trap on IL-1 secretion cannot be directly demonstrated in this model as it 
interacts with this IL-1 detection assay.
Discussion
SchS is defined as a combination of chronic urticaria, IgM gammopathy, and at least two of 
the following criteria: recurrent fever, arthralgia or arthritis, bone pain, lymphadenopathy, 
hepatomegaly or splenomegaly, leukocytosis, an elevated erythrocyte sedimentation rate, and 
abnormalities in bone morphology.1,2 As in the present case, there is usually a diagnostic delay 
of years. Long-term follow-up is warranted because some patients progress to Waldenström’s 
macroglobulinemia.1 SchS is of unknown etiology; biopsy of skin lesions is generally in keeping 
with neutrophilic urticaria.3 The clinical response of patients with cryopyrinopathies such as 
MWS led to the use of anakinra in SchS. To date, anakinra has resulted in complete remission 
of symptoms in all patients with SchS; it does not seem to affect the IgM gammopathy.1,4,5 Most 
patients require daily dosing to prevent recurrence of symptoms, although intermittent dosing has 
sufficed in isolated cases. The safety of anakinra has been evaluated in a randomized controlled 
trial in patients with rheumatoid arthritis. Adverse events included injection site reactions and 
Figure 13.2. 
A. Cytokine produc-
tion by PBMCs on 
LPS stimulation is 
significantly increa-
sed in patient versus 
control cells (four-
fold for IL-6, 15-fold 
for IL-1). 
B. Caspase-1 inhibitor 
YVAD had the most 
profound effect on 
LPS-induced IL-1 and 
also on IL-6 and TNF 
(not shown), more 
than TNF inhibitor 
adalimumab.
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a 2% risk of serious infections in the anakinra arm compared to a 1% risk in those receiving 
placebo. The effect of IL-1 inhibition on the risk of developing malignancy is still unknown. There 
have been two reports on the use of TNF inhibitors in SchS: in one report, etanercept gave a partial 
remission 6; in another patient, inhibition of TNF by either adalimumab or etanercept seemed to 
result in an exacerbation of disease.7 Our ex-vivo results support these clinical observations (Figure 
13.2).
The case presented in this report highlights the advances that have transformed SchS from an 
incurable, incapacitating curiosity to a disorder with a successful and rational therapy. SchS should 
be considered in patients with chronic urticaria who fail to improve with standard therapies. A 
careful history with regard to systemic symptoms and serum protein electrophoresis can lead to a 
diagnosis. Monotherapy with an inhibitor of IL-1 is the treatment of choice. This report provides 
ex-vivo evidence to support clinical observations.
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Abstract
Schnitzler’s syndrome (SchS) is a late-onset autoinflammatory syndrome of unknown etiology, 
with clinical evidence of involvement of the interleukin-1 beta (IL-1b) pathway. Based on its late 
onset and absence of familial clustering, the syndrome was considered acquired rather than 
genetic. Here we applied deep sequencing techniques to address the possibility of a genetic cause 
in SchS.
Eleven patients with classical or variant SchS were included, and for the functional studies 
eight patients with SchS and age- and sex-matched controls. Exome sequencing of whole blood 
was performed, followed by targeted resequencing of NLRP3 in whole blood, different leukocyte 
subsets, keratinocytes and fibroblasts. Spontaneous production of IL-1b and IL-6 by peripheral 
blood mononuclear cells (PBMCs) was measured during symptomatic and treatment episodes, 
and compared to controls.
Exome sequencing, followed by targeted resequencing revealed NLRP3 mutations in whole 
blood DNA from two patients with IgG variant SchS. Remarkably, these mutations were exclusively 
present in neutrophils (13%/32%) and monocytes (6,5%/29%). Patient PBMCs showed excessive 
spontaneous in-vitro IL-1b production, consistent with the clinical response to IL-1b blockade. 
Identification of myeloid-lineage-restricted mosaicism of NLRP3 places SchS in the spectrum 
of cryopyrin-associated periodic syndrome, and explains the complete response to IL-1b-blocking 
therapy. This is the first report on myeloid-lineage-restricted mosaicism in a non-malignant 
disorder. Importantly, these findings suggest that other late-onset disorders may have a genetic 
(mosaic) basis.
Myeloid mosaicism of NLRP3 mutations in variant Schnitzler’s syndrome 
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Introduction
Schnitzler’s syndrome (SchS) is an elusive autoinflammatory disorder, characterized by a chronic 
(neutrophilic) urticarial rash, a monoclonal gammopathy and systemic inflammation.1 The etiolo-
gy is unknown, but a pathophysiological clue has been provided by the efficacy of anti-interleu-
kin-1 (IL-1) treatment 1, and IL-1b inhibition in particular.2 The lack of familial clustering and the 
late onset of the disease suggested an acquired rather than genetic nature. 
Phenotypical characteristics of SchS patients including responsiveness to anti-IL-1 therapy are 
also seen in the cryopyrin-associated periodic syndrome (CAPS). In CAPS, activating germline or 
somatic mutations of the NLRP3 gene result in increased spontaneous IL-1b production. Routine 
genetic screening of our SchS patients did so far not reveal pathogenic NLRP3 mutations.3 Here 
we applied next generation sequencing (NGS) technologies to further address the possibility of a 
genetic cause in SchS. 
Materials and methods
Ethics statement
The study complies with the guidelines of the Declaration of Helsinki, and patients’ informed 
consent was obtained.
Patients and sample collection
DNA was isolated from whole blood from 11 clinically characterized patients with classical (IgM) 
or variant (IgG) SchS (Table S14.1). None of the patients had affected family members. From two 
patients showing mosaicism in whole blood (patients 7 and 8) and two non-mosaic patients 
(patients 9 and 10), leukocyte subsets were isolated by ficoll gradient. Subsequently, fluores-
cence-activated cell sorting was performed based on cell size (granulocytes), CD14 (monocytes), 
CD3 (T-lymphocytes), and CD19 (B-lymphocytes), followed by DNA isolation. 
Skin biopsies were taken from lesional and uninvolved skin from patients 7 and 8 for immu-
nohistochemical staining and the isolation of keratinocytes and fibroblasts; these were cultured 
as previously described 4, followed by DNA isolation. 
For functional studies, peripheral blood mononuclear cells (PBMCs) were isolated from eight 
SchS patients (patients 1-8) and eight age- and sex-matched controls.
Whole exome sequencing (WES)
Total blood DNA from patients 1, 2 and 7 was analyzed by means of WES, which was performed 
on a 5500XL sequencing platform (Life Technologies). The exomes of the probands were enriched 
according to the manufacturer’s protocol using the SureSelect Human All Exon v2 XT Kit (50 Mb) 
(Agilent Technologies). LifeScope software v2.1 (Life Technologies) was used to map color space 
reads along the hg19 reference genome assembly. The DiBayes algorithm, with high-stringency 
calling, was used for single-nucleotide variant calling, and the small Indel Tool to detect small 
insertions and deletions. WES data were filtered as described previously.5
Sanger sequencing of the NLRP3 gene 
Exon-specific primers were used to amplify all coding exons including the flanking regions of 
the NLRP3 gene (NM_001243133.1), followed by Sanger sequencing. Each exon was amplified 
in duplicate and Sanger sequenced using BigDye Terminator v1.1 (Applied Biosystems). Sequence 
Pilot software (JSI Medical Systems) was used for the analysis of sequence data.
Targeted deep resequencing of the NLRP3 gene (MiSeq)
For deep targeted resequencing of the NLRP3 gene, library preparations were performed using 
the TruSeq library preparation protocol according to manufacturer’s instructions, followed by Mi-
seq sequencing using the MiSeq Reagent Kit v2 (500 cycles) (Illumina). Numbers of reads included 
all allele counts per position after BWA mapping.
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Immunohistochemical staining of skin sections
Sections of paraffin-embedded lesional and uninvolved skin of patients 7 and 8 were stained with 
mouse anti-human myeloperoxidase (R&D systems) as a marker for neutrophils and monocytes 
according to standard protocols. 
Functional studies
PBMCs from eight SchS patients (patients 1-8) with active disease or in remission during treat-
ment with anakinra (IL-1 receptor antagonist, IL-1Ra) or canakinumab (anti-IL-1b antibody) 2, and 
from eight age- and sex-matched healthy controls were isolated. Patient and control cells were 
cultured for 24 hours in the presence of no stimulus or anakinra (10 µg/ml). Cytokine concentra-
tions in the cell supernatants were measured by ELISA (IL-1b, R&D; IL-6, Sanquin)
Results
Variants in NLRP3 are associated with severe Schnitzler’s syndrome phenotype
Exome sequencing of whole blood DNA from three SchS patients revealed in patient 7 in 22/127 
reads (17%) a known missense mutation in the NLRP3 gene (c.1569C>G; p.F523L) (Tables S14.2, 
S14.3), which was previously reported as disease-causing in two neonates with severe CAPS.6 It 
had been missed by previous Sanger sequencing 3, but could now be confirmed as a small peak 
underlying the wildtype allele, potentially representing a somatic mosaicism (Fig. 14.1A). No fur-
ther plausible candidates have been identified yet in the exome data.
Next, we performed deep targeted MiSeq resequencing of the NLRP3 gene in whole blood 
DNA from 11 SchS patients, including the three exome-sequenced patients (Tables S14.1, S14.3). 
This analysis confirmed the presence of the p.F523L mutation in patient 7, and in addition re-
vealed in patient 8 in 27% of 930 reads a NLRP3 mutation (c.1303A>G; p.K435E) which is 
predicted to be pathogenic (Table 14.1). The mutation was confirmed by Sanger sequencing of 
whole blood DNA from patient 8 (Figure 14.1B), and his three healthy sisters did not show this 
variant. Remarkably, the two patients that carried the NLRP3 variants were the most severely 
affected individuals of our cohort, and the highest percentage of NLRP3 mutant alleles in whole 
blood was found in patient 8, who had the severest phenotype. Both patients were classified as 
variant (IgGκ) type SchS. 
Table 14.1. Mutation analysis of two patients with somatic mosaicism of NLRP3 variants
Patient 7 8
NLRP3 genetic variant c.1569C>G c.1303A>G
NLRP3 amino acid change p.F523L p.K435E
Variant reads in exome sequencing 
- whole blood 17% n.a.
Variant reads in Miseq resequencing
- whole blood 8% 27%
- granulocytes 13% 32%
- monocytes 6.5% 29%
- T-lymphocytes n.d. n.d.
- B-lymphocytes n.d. n.d.
- keratinocytes n.d. n.d.
- fibroblasts n.d. n.d.
Pathogenicity: prediction or known association NOMID/CINCA possibly damaging*
Percentages of NLRP3 mutants in different cell subsets from patient 7 and 8
n.a. = not assessed
n.d. = not detectable: below the 2% threshold for reliable detection
* predicted to be possibly damaging by SIFT, Align GVGD and PolyPhen-2
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NLRP3 mosaicism is confined to the myeloid lineage
Deep MiSeq resequencing of NLRP3 in DNA from purified granulocytes, monocytes, T-lympho-
cytes, B-lymphocytes, keratinocytes and fibroblasts showed that the mosaicism of the identified 
variants in both patients 7 and 8 was restricted to the granulocytes and monocytes (Table 14.1), 
and hence the myeloid lineage. These two cell types are the predominant cells in the dermal 
infiltrate of lesional skin, as is the case in all patients with SchS (Figure 14.1C). No NLRP3 genetic 
variants were found in any of the analyzed cell types derived from two SchS patients without 
NLRP3 variants in whole blood (Table 14.1). 
Figure 14.1.
A. Sanger sequencing patient 7. Chromatogram showing NLRP3 variant c.1569C>G (p.F523L) as well as 
the wildtype allele.
B. Sanger sequencing patient 8. Chromatogram showing NLRP3 variant c.1303A>G (p.K435E) as well as 
the wildtype allele.
C. Neutrophils and monocytes in lesional skin of Schnitzler’s syndrome patients. Immunohistochemical 
staining of skin sections with anti-myeloperoxidase, which is predominantly present in neutrophils and to 
a lesser extent in monocytes. Panels show uninvolved skin of patient 7, and lesional skin of patients 7 and 
8. Bar length 100 µm.
D. Spontaneous in-vitro production of IL-1b and IL-6 in PBMCs with NLRP3 mosaicism. PBMCs from pa-
tients with Schnitzler’s syndrome without NLRP3 mosaicism (SchS non-mosaics) and with NLRP3 mosaicism 
(SchS mosaics) sampled both during symptoms and during IL-1Ra or anti-IL-1b treatment, and PBMCs from 
healthy controls were cultured for 24 hours, either or not in the presence of IL-1Ra. Supernatant IL-1b and 
IL-6 were measured by means of ELISA. Results during anti-IL-1b treatment are shown; these were similar 
in the other conditions.
E. Positions of known and mosaicism-related mutations in NLRP3 gene in CAPS and Schnitzler’s syndrome. 
CAPS, cryopyrin-associated periodic syndrome; PYD, pyrin domain; NACHT domain; LRR, leucin-rich repeats.
Chapter  14
166
Spontaneous in-vitro production of IL-1b in PBMCs with NLRP3 mosaicism
As we have previously demonstrated that IL-1b is a pivotal mediator of the clinical signs of SchS 
2,7, we proceeded to investigate the functional consequences of the NLRP3 mosaic mutations on 
IL-1b and IL-6 production in PBMCs. PBMCs from SchS patients were collected during sympto-
matic episodes, and during treatment with IL-1Ra or anti-IL-1b antibodies. PBMCs of patients 
with NLRP3 mosaicism produced IL-6 and IL-1b constitutively, even during in-vivo anti-IL-1 thera-
py, while this was not seen in the other SchS patients. Interestingly, in PBMCs from these patients 
the spontaneous in-vitro production of IL-6 and IL-1b was largely to completely abolished by in-vi-
tro addition of IL-1Ra (Figure 14.1D). This implies a strong positive feedback loop, and that IL-6 
overproduction is entirely IL-1b-dependent in these patients. The excessive spontaneous in-vitro 
production of IL-1b in the NLRP3 mosaics correlates with their severe phenotype and the dramatic 
response to IL-1b inhibition in vivo.2 
Discussion
Somatic mosaicism of NLRP3 has been reported in neonatal-onset CAPS patients (Figure 14.1E).8,9 
In CAPS patients, there was no significant difference in mutation frequency between several 
leukocyte subsets and buccal mucosa.9 In contrast, in our two SchS patients, the mosaicism was 
restricted to the granulocytes and monocytes. We speculate that in the CAPS patients, the muta-
tion occurred rather early in embryogenesis, as both mesenchymal and ectodermal tissues were 
equally affected. In our patients, the mutational event took place soon after differentiation of the 
myeloid precursor cells, leading to mosaicism in both granulocytes and monocytes. 
The myeloid-confined NLRP3 mosaicism, late age of onset, lack of family history, and (tran-
sient) gammopathy differentiate these two SchS patients from the known spectrum of CAPS 
patients. However, as the name CAPS implies association with NLRP3 mutations, we propose that 
SchS patients with NLRP3 mosaicism should be added to the spectrum of CAPS, as ‘Schnitzler’s 
syndrome variant CAPS’.
The two patients with NLRP3 mosaicism had the most severe clinical phenotype of our patient 
group, and in both of them, an unquantifiably low IgGκ paraprotein was previously found, that 
is currently undetectable. The latter fact may be a mere coincidence, or alternatively, these two 
patients are part of a specific subgroup with NLRP3 mosaicism, transient paraproteinemia, and a 
severe phenotype. If disease severity is determined by the proportion of cells carrying a mutation, 
the frequency in the other patients may have been too low to allow detection. Alternatively, 
(mosaisicm of) mutations in other genes of the NLRP3-IL-1b pathway could be involved in the 
pathophysiology of SchS.2 
Previously, a p.V198M variant in NLRP3 has been detected in two patients with SchS, but both 
had unaffected family members carrying this variant.10,11 The population allele frequency of this 
variant is about 0,5%, and at present the pathophysiological significance of this variant remains 
to be determined.
Most of the known CAPS-associated mutations are localized in the NACHT domain of exon 3 
of the NLRP3 gene, as are the mutations of the CINCA/NOMID patients with NLRP3 mosaicism. 
The p.V198M variant found in CAPS patients, two patients with SchS, but also healthy controls, 
is localized in exon 3, however not in the NACHT domain. The p.F523L mutation found in patient 
7 was previously described in two severely affected NOMID/CINCA cases. The p.K435E variant 
found in patient 8 is novel, but localized in close proximity to known CAPS mutations, and 
the effect of the resulting amino acid change is predicted to affect protein functioning (Figure 
14.1E).8,9,12
To conclude, we found somatic mosaicism of NLRP3 mutations exclusively in the myeloid 
lineage in two patients with variant SchS. To our knowledge, this is the first report on somatic 
mosaicism confined to the myeloid lineage in a non-malignant disorder. Our identification of my-
eloid-lineage-restricted somatic mosaicism of NLRP3 mutations as the cause of SchS variant CAPS 
is not merely a step forward in our understanding of this particular disease, but also highlights the 
possibility that several other late-onset, sporadic diseases may have a genetic basis.
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Supplemental material
Table S14.1. Patient characteristics 
Patient 1 2 3 4 5 6 7 8 9 10 11
Sex M F M M M M F M F M M
Age of onset 
(years) 52 64 45 43 57 58 38 50 71 43 59
Disease dura-
tion (years) 15 3,5 6 21 11 18 26 10 2 21 6
Paraprotein 
subtype 
IgMκ,
IgMl IgGκ IgMκ IgGκ IgMκ IgMκ IgGκ
2 IgGκ2 IgMκ IgMκ IgMl
Physician 
global 
assessment1 
3 4 3 3 3 4 4 4 3 4 3
C-reactive 
protein level 
(mg/L) 
202 147 190 18 60 250 95 333 166 164 31
Further clinical characteristics of patients 7 and 8: chronic urticaria with in histology a dermal infiltrate of 
neutrophils and monocytes; severe arthralgias, bone pain, intermittent fever, severe malaise, weight loss.
1. Physician global assessment of disease activity (PGA). PGA during symptoms, assessed by clinician. PGA 
scores: absent (0), minimal (1), mild (2), moderate (3), severe (4).
2. Previously an unquantifiably low IgGκ paraprotein was found, but this is currently undetectable.
Table S14.2. Filtering of variants found in WES 
Patient 1 2 7
Total number of variants 46892 45753 45892
Coding +SS 18175 17596 17799
Non-synonymous 8936 8591 8730
Not seen before (in-house) 305 247 243
Nonsense 7 7 4
Canonical SS 9 6 10
Indels 40 29 32
Missense (phyloP>2.5) 109 87 84
Known variant (HGMD) 1 (KCNQ1) 0 1 (NLRP3)
Total number of variants: all variants detected by WES; 
Coding+SS: all variants that are located either in exonic regions or in canonical splice sites; 
Non-synonymous: variants that are leading to an amino acid change; 
Not seen before (in house): variants that have not been detected in 672 in-house sequenced whole exomes, 
Nonsense: nonsense variants; 
Canonical SS: variants located in a canonical splice site; 
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Indels: insertions or deletions;  
Missense (phyloP >2.5 13): highly conserved missense variants with a phyloP > 2,5, 
Known variant (HGMD): variant that has been described as pathogenic in the Human Gene Mutation 
Database (www.hgmd.org). 
We detected two known variants described in HGMD: 
- Patient 1 carried a variant in KCNQ1, which is associated with Long QT syndrome. The identified variant is 
considered as a benign polymorphism.14
- In patient 7, we detected a known missense mutation in the NACHT domain of the NLRP3 gene (c.1569C>G; 
p.F523L), which was previously reported as disease-causing in two infants with NOMID/CINCA, a severe, 
early-onset form of CAPS.6
Table S14.3. Next Generation Sequencing: numbers of reads of NLRP3 variants 
Patient 1 2 3 4 5 6 7 8 9 10 11
NLRP3 genetic 
variant in blood c.1569C>G c.1303A>G
NLRP3 amino acid 
change  in blood p.F523L p.K435E
Number of reads in exome sequencing
- whole blood n.d. n.d. - - - - 22/127 - - - -
Number of reads in Miseq resequencing
- whole blood n.d. n.d. n.d. n.d. n.d. n.d. 78/976 250/924 n.d. n.d. n.d.
- granulocytes - - - - - - 2103/15249 3102/9424 n.d. n.d. -
- monocytes - - - - - - 1304/19994 4232/14500 n.d. n.d. -
- T-lymphocytes - - - - - - 4/397 18/11814 n.d. n.d. -
- B-lymphocytes - - - - - - 17/849 59/12456 n.d. n.d. -
- keratinocytes - - - - - - 0/882 14/10163 - - -
- fibroblasts - - - - - - 0/563 19/11459 - - -
-  = not assessed
n.d. = not detectable: below the 2% threshold for reliable detection
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Abstract
Schnitzler’s syndrome (SchS) is an autoinflammatory disease characterized by a chronic urticarial 
rash, a monoclonal component, and signs of systemic inflammation. Interleukin-1 beta (IL-1b) 
is pivotal in the pathophysiology. Here we investigated the cellular source of pro-inflammatory 
mediators in skin of SchS patients.
Skin biopsies of lesional and non-lesional skin from eight SchS patients and from healthy 
controls and cryopyrin-associated periodic syndrome (CAPS), delayed-pressure urticaria (DPU) and 
cold contact urticaria (CCU) patients were used. We studied in-vivo IL-1b, IL-17 and antimicrobial 
protein (AMP) expression in resident skin cells and infiltrating cells. In addition we investigated the 
in-vitro effect of IL-1b, IL-17 and poly:IC stimulation on AMP production by cultured epidermal 
keratinocytes. 
Remarkably, we found IL-1b-positive dermal mast cells both in lesional and non-lesional 
skin of SchS patients, but not in normal control skin, CCU, and fewer in CAPS. IL-17-positive 
neutrophils were only observed in lesional SchS and DPU skin, whereas IL-17-positive mast cells 
were present in all skin samples. In lesional SchS epidermis, mRNA and protein expression levels of 
AMPs were strongly increased compared to non-lesional skin and that of healthy controls. When 
exposed to IL-1b, poly:IC, or IL-17, patient and control primary human keratinocytes produced 
AMPs in similar amounts.
To conclude, dermal mast cells of SchS patients produce IL-1b. This presumably leads to 
activation of keratinocytes and neutrophil influx, and further amplification of inflammation by 
IL-17 (from neutrophils and possibly mast cells) and epidermal AMP production leading to chronic 
histamine-independent neutrophilic urticarial dermatosis.
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Introduction
Schnitzler’s syndrome (SchS) is a chronic disabling autoinflammatory disorder, characterized 
by a chronic urticarial rash, a monoclonal component, fever and other signs of systemic 
inflammation.1-3 Recent advances in our understanding of the pathophysiology of SchS have 
focused on systemic IL-1b production 4-6, based on the successful suppression of inflammation by 
inhibition of interleukin-1 (IL-1) 4,5,7-14, IL-1b in particular.5,13,14 The cardinal skin features of SchS 
are erythematous macules or maculopapules that are often non-pruritic. Histopathologically the 
disease can be classified as neutrophilic urticarial dermatosis.15 SchS has clinical similarities to the 
cryopyrin-associated periodic syndrome (CAPS) which is caused by activating nucleotide-binding 
oligomerization domain–leucine-rich repeats containing pyrin domain 3 (NLRP3) mutations. 
In CAPS, dermal mast cells were identified as IL-1b producers and inducers of neutrophil 
recruitment.16 We recently described mosaicism of myeloid-lineage-restricted NLRP3 mutations in 
two patients with variant-type SchS.17 
Studies of SchS skin lesions have so far mainly been confined to histopathological description. 
The presence of IL-1b-positive cells in the dermis of one SchS patient was reported, without 
specification of the cell type.18 The epidermal compartment and the influence of IL-1b in SchS 
skin lesions have not been studied to date. In several skin diseases, both infiltrating inflammatory 
cells and resident skin cells like keratinocytes are an important source of proinflammatory 
mediators. Keratinocytes secrete large amounts of cytokines and antimicrobial peptides (AMPs), 
many of which have immunomodulatory properties. AMPs are increased in lesional epidermis in 
other inflammatory skin diseases, such a psoriasis, and can be induced by several cytokines. We 
hypothesized that AMPs were involved in the perpetuation of inflammation in SchS skin lesions, 
also because of the abundance of neutrophils, which are rich in AMPs. Taken together, this 
provided the rationale of the current study, which aims to analyze the expression of cytokines 
and AMPs in SchS skin.
Materials and methods
Patients and patient samples
Eight patients with SchS, four with IgM monoclonal gammopathy (classical type), and four 
with IgG (variant type), four patients with cold contact urticaria (CCU), two CAPS patients (one 
NLRP3 mutation-negative with chronic infantile neurological, cutaneous and articular (CINCA) 
syndrome-like phenotype including skin involvement, and one with an I313V NLRP3 mutation 
and lack of urticaria), one patient with delayed pressure urticaria (DPU) and 17 healthy controls 
provided written informed consent after medical ethical approval was obtained. All SchS patients 
had been on treatment with anakinra. This treatment was stopped in the run-in phase to a clinical 
trial with canakinumab, as described elsewhere 5, and they became symptomatic within days. 
Skin biopsies were taken when they were symptomatic: lesional skin for mRNA and histology, and 
clinically uninvolved skin for mRNA, histology and keratinocyte cultures. The extent of infiltrating 
immune cells was rated mild (< 10 cells in field of vision (200x magnification)), moderate (10-50) 
or extensive (> 50). Serum samples were collected from symptomatic SchS patients and healthy 
volunteers. In the CCU patients, lesional and non-lesional skin biopsies were taken 15 minutes 
after the application of an ice cube to the skin. DPU was inflicted by 15 minutes application of a 
250-gram weight on the skin, which was biopsied after six hours. Non-lesional skin biopsies were 
taken from the two CAPS patients when they were asymptomatic during anakinra treatment.
Isolation of epidermal sheets, RNA isolation and real-time quantitative PCR
Isolation of epidermal sheets for mRNA isolation, mRNA extraction, cDNA synthesis, qPCR, and 
normalization to the reference gene ribosomal phosphoprotein P0 were performed as previously 
described.19,20 Primers for qPCR (Biolegio, Nijmegen, the Netherlands) had an efficiency of 100 
± 10%, and corrections were made for primer efficiency. The delta-delta cycle times (∆∆-Ct) 
method was used for the calculation of the relative mRNA expression levels.21
Immunofluorescence and immunohistochemistry
For immunofluorescence (IF), paraffin-embedded formalin-fixed skin sections were blocked for 
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15 minutes with 20% normal rabbit serum (for IL-1b), normal goat serum (for IL-17), or normal 
mouse serum (for myeloperoxidase (MPO) and tryptase) in PBS and subsequently incubated with 
the antibodies rabbit anti-IL-1b 1:50 (Abcam, Cambridge, UK; stains both cleaved and uncleaved 
IL-1b), goat anti-IL-17 1:500 (R&D Systems, Minneapolis, MN), mouse anti-MPO 1:400 (R&D), 
and mouse anti-tryptase 1:2000 (DAKO, Heverlee, Belgium). Skin sections for IL-1b staining were 
pretreated with a citrate pH 6,0 buffer, and for IL-17 staining with a Tris/EDTA pH 9,0 buffer. 
The following fluorochromes were used: Alexa fluor donkey anti-mouse Fab 488 1:200 for MPO 
and tryptase, Alexa fluor donkey anti-goat Fab 594 1:200 for IL-17, and Alexa fluor goat anti-
rabbit Fab 594 1:200 for IL-1b. For immunohistochemistry, paraffin-embedded formalin-fixed 
skin sections were blocked for 15 minutes with 20% normal rabbit serum (for hBD-2 and IL-1b) 
or normal goat serum (elafin, S100A7/psoriasin and S100A8/MRP8) in PBS and subsequently 
incubated with anti-IL-1b 1:50 (Abcam), anti-hBD-2 1:100 (Abcam), anti-elafin 1:500 22, anti-
Figure 15.1. Dermal mast cells express IL-1b in Schnitzler’s syndrome. A. Immunofluorescence of IL-
1b (red) and tryptase (green, mast cells) in skin sections of healthy controls, Schnitzler’s syndrome patients 
(SchS) with or without myeloid NLRP3 mosaicism, cryopyrin-associated periodic syndrome (CAPS) patients 
and cold contact urticaria patients (CCU). Bar: 100 µm. B. Number of dermal IL-1b positive cells in healthy 
controls, SchS, CAPS and CCU, as counted per field of vision. * p < 0.05. Bars: median value.
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Figure 15.2. Neutrophils in SchS and DPU skin lesions are IL-17-positive. Immunofluorent imaging of 
neutrophils (MPO, myeloperoxidase, green) and IL-17 (red) of skin sections of Schnitzler’s syndrome patients 
(SchS), cold contact urticaria patients (CCU), and one patient with delayed pressure urticaria (DPU). Bar: 
100 µm.
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S100A7/psoriasin 1:10000 (kind gift of Dr P. Madsen, University of Aarhus, Denmark), and anti-
S100A8/MRP8 1:10000 (kind gift of Dr G. Siegenthaler, University Hospital, Geneva, Switzerland) 
antibodies for one hour at room temperature. Next, sections were incubated for 30 minutes 
with a secondary antibody (biotinylated rabbit anti-goat or biotinylated goat anti-rabbit in PBS 
containing 1% BSA, Vector laboratories, Burlingame, CA), and for 30 minutes with Avidin-Biotin 
complex (Vector Laboratories).
Cell culture
Primary human epidermal keratinocytes from skin biopsies of seven SchS patients and six age- 
and gender-matched healthy volunteers were cultured and induced to differentiate by growth 
factor depletion as described before.23 At 100% confluence, differentiated cell cultures were 
exposed to either of the following stimuli: poly:IC 5 ng/ml, IL-1b 50 ng/ml, IL-17 30 ng/ml or 
interferon gamma (IFNg) 500 U/ml (Peprotech). We also performed a cross-over experiment using 
the stimuli 10% control serum or 10% serum from the symptomatic patient. After 24 hours the 
cells were harvested for mRNA isolation.
Statistical analysis
The number of IL-1b-positive cells was analyzed by means of two-tailed independent T-test with 
unequal variances. A repeated-measures analysis of variance using SPSS v20.0 with LSD post-
hoc testing was performed on the delta-Ct (∆Ct) values of the qPCR data corrected for primer 
efficiency.
Results
Dermal mast cells express IL-1b in Schnitzler’s syndrome
Numerous IL-1b-positive (mature and uncleaved IL-1b) cells were found throughout the dermis of 
lesional and non-lesional SchS skin, whereas fewer IL-1b-positive cells were found in non-lesional 
skin of CAPS patients, and hardly any in skin of healthy controls and lesional or non-lesional skin 
of CCU patients (Figure 15.1). The extent of the cellular infiltrate in lesional SchS skin did not 
correlate with the number of IL-1b-positive cells. 
In SchS skin, the IL-1b-positive cells contained granules and IF double staining showed that 
most of them were mast cells, and that almost all mast cells contained IL-1b. However, in healthy 
skin or CCU, hardly any mast cells were IL-1b positive, whereas in non-lesional CAPS skin, part of 
them were (Figure 15.1).
Dermal neutrophils and mast cells express IL-17
IL-1b induces IL-17. Neutrophils are the dominant cells in the cellular infiltrate in SchS. Recently, 
it was reported that neutrophils express IL-17 in psoriatic lesional skin.24 Here we found strong 
IL-17 expression in neutrophils in SchS urticaria as well as in DPU lesions (Figure 15.2). Neutrophils 
were absent in CCU. The remaining IL-17 positive cells in SchS and DPU skin samples were mast 
cells, which also expressed IL-17 in non-lesional skin and in CCU lesional and non-lesional skin 
(Figure 15.3).
Epidermal antimicrobial protein expression in SchS lesions
mRNA expression levels of IL1B, IL6, IL8, IL23 and IL33 did not differ in lesional and non-lesional 
SchS epidermis (N=8), data not shown. However, mRNA expression levels of several AMPs were 
elevated in lesional epidermis (Figure 15.4A), especially DEFB4, PI3, S100A7, S100A8 and S100A9. 
Three symptomatic patients whose clinically seemingly uninvolved skin showed neutrophilic 
infiltrates during histological examination, indicated that urticaria had been present on this part of 
their skin on the previous day. Depending on the extent of the infiltrate, these samples had similar 
changes in epidermal gene and protein expression levels as the overtly involved skin samples. 
Hence, for statistical analyses, we grouped the lesions according to the size of the infiltrate rather 
than the clinical appearance at the time of biopsy-taking. 
Validation at the protein level showed that psoriasin (S100A7), elafin (PI3) and human 
beta-defensin-2 (DEFB4) protein expression was increased in the keratinocytes, whereas MRP8 
(S100A8) and MRP14 (S100A9) were only detected in neutrophils (Figure 15.4B; MRP14 not 
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shown). Truly uninvolved skin (both clinically and histopathologically) resembled normal skin of 
healthy volunteers (Figure 15.4B). Such a correlation of AMP mRNA expression and neutrophilic 
infiltrate was not seen in the DPU skin sample (not shown). We also isolated mRNA from the der-
mal compartment from lesional and non-lesional skin of four SchS patients, in which we detected 
S100A8 and S100A9, but not IL1B, IL-6, and IL-17 transcription in lesional dermis (not shown).
IL-1b, IL-17 and poly:IC induce antimicrobial proteins in patient and control 
primary keratinocytes
Next, we studied the influence of IL-1b and IL-17 on epidermal inflammation, and especially 
epidermal AMP expression, as these cytokines are implicated in the pathophysiology of several 
other inflammatory skin diseases with epidermal involvement, such as psoriasis.24 We also used 
the TLR3 agonist poly:IC, which induces potent responses in keratinocytes. Moreover, to find out 
whether keratinocytes from SchS patients respond differently to inflammatory stimuli in vitro, we 
isolated primary human keratinocytes from seven SchS patients as well as six age- and gender-
matched healthy controls. 
IL-1b, IL-17 and poly:IC induced mRNA expression levels of DEFB4 and S100A7, and poly:IC 
induced IL1B mRNA transcription in keratinocytes. There was no difference between patient and 
control cells. A cross-over experiment with 10% serum from either a healthy control or serum from 
the symptomatic patient from whom the keratinocytes were isolated did not show any differences 
in response between patient and control cells (Figure 15.5). The most important in-vitro finding, 
however, was that AMP expression can be induced by IL-1b and IL-17 in keratinocytes, thereby 
offering an explanation for the in-vivo findings.
Figure 15.3. Dermal mast cells express IL-17. Immunofluorescent staining of mast cells (tryptase, green) 
and IL-17 (red) of skin sections of Schnitzler’s syndrome patients (SchS) and cold contact urticaria patients 
(CCU). Bar: 100 µm.
Chapter  15
176
Figure 15.4. Enhanced epidermal antimicrobial protein expression in lesional skin of Schnitzler’s 
syndrome patients. A. In purified epidermal samples from healthy controls (normal skin, NS; N=5), 
uninvolved and involved skin from Schnitzler‘s syndrome (SchS, N=8) patients, DEFB4 (hBD-2), PI3 (elafin), 
S100A7 (psoriasin), S100A8 (MRP8), S100A9 (MRP14) and CAMP (LL-37) mRNA levels correlated with 
the extent of the cellular infiltrate. (The extent of infiltrating immune cells was rated mild (< 10 cells in 
field of vision), moderate (10-50) or extensive (> 50). Delta-delta-Ct method; for graphic representation 
of mRNA data, all data are plotted relative to one normal skin sample of DEFB4. * p < 0,05, ** p < 0,01, 
*** p < 0,001 compared to normal skin. B. Staining of skin biopsies from healthy controls, uninvolved and 
involved skin from SchS patients revealed induction of psoriasin, elafin and human beta-defensin 2 (hBD-2) 
in keratinocytes, whereas myeloid-related protein 8 (MRP8) was only detected in neutrophils. True non-
lesional skin (without infiltrate) resembled normal skin of healthy volunteers. Bar: 100 µm.
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Discussion
In this paper, we report the presence of IL-1b-positive mast cells in lesional and non-lesional 
skin of SchS patients. In addition, we detected IL-17-positive neutrophils in the dermis and 
enhanced AMP expression in the epidermis of SchS skin lesions. SchS has clinical similarities to 
CAPS which is caused by activating NLRP3 mutations, and in which mast cells were identified 
as the main source of IL-1b in the skin.16 This is in line with the constitutive IL-1b production 
found in peripheral blood mononuclear cells (PBMCs) of CAPS patients 25 and of our two SchS 
patients with myeloid-restricted NLRP3 mosaicism.17 Mast cell degranulation is not triggered by 
inflammasome activation, underlining the histamine-independent nature of the CAPS (and SchS) 
skin lesions.16 Further, upon transplantation into mouse skin, NLRP3-mutant mast cells produced 
IL-1b and induced neutrophil migration and vascular leakage.16 Given our NLRP3 findings in SchS, 
we speculate that a low threshold for NLRP3 activation leads to an exaggerated IL-1b response. 
In a previous study, elevated IL6 and IL1B mRNA expression levels were found in full-thickness 
skin biopsies of CAPS patients. Protein expression of IL-1b and IL-6 was found in dermal cells in 
involved skin by means of immunohistochemistry.30 Here, we analyzed epidermal and dermal 
mRNA expression levels separately. In purified epidermal sheets from lesional and non-lesional 
skin of SchS patients we observed no difference in mRNA cytokine expression levels of IL1B, IL6, 
IL8, IL23 and IL33. In the dermal compartment of lesional and non-lesional skin of these patients 
we did not find IL1B, IL-6, and IL17, but we detected S100A8 and S100A9 mRNA in lesional 
dermis. In view of the considerable difference in abundance of IL-1b- and MRP8-positive cells 
in the dermis in lesional skin, and the relatively low mRNA yields from our dermal samples, we 
think the mRNA levels of the cytokines were below the level of detection. Another explanation 
could be the timing of measurement:  two hours after cold exposure in the aforementioned CAPS 
study and several days after disease onset in our SchS study. Interestingly, IL-1b-positive cells (with 
dendritic shapes like that of mast cells) were only found in lesional skin in the CAPS patients in the 
Figure 15.5. Relative mRNA expression 
in primary human keratinocytes upon 
stimulation with inflammatory mediators 
A. DEFB4, B. S100A7, and C. IL1B mRNA expres-
sion. Primary human keratinocytes from seven 
patients and six healthy controls were stimulated 
with poly:IC 5 ng/ml, IL-1b 50 ng/ml, IL-17 30 
ng/ml, interferon gamma (IFNg) 500 U/ml, 10% 
control serum, or 10% serum from a symptomatic 
patient. Delta-delta Ct method; relative expression 
compared to one control sample. 
* p < 0,05, ** p < 0,01 compared to unstimulated 
control. Error bars: standard error of the mean.
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study of Hofmann et al.30, whereas we found IL-1b-positive mast cells in both lesional and non-
lesional skin of SchS patients and a few IL-1b-positive mast cells in uninvolved skin of two CAPS 
patients.16 The CAPS patients in which dermal IL-1b-positive mast cells were previously reported 
were symptomatic at the time of sampling and it is unclear if involved or uninvolved skin was 
biopsied. Possibly, the presence of (a higher number of) IL-1b-positive mast cells in non-lesional 
skin of SchS is another factor that distinguishes it from CAPS. Alternatively, the lower number of 
IL-1b-positive mast cells in our two CAPS patients can be accounted for by the effect of their IL-
1Ra treatment when biopsies were taken, whereas the SchS patients were symptomatic. 
But what drives the NLRP3 activation, as we found IL-1b-positive mast cells in both lesional 
and non-lesional SchS skin? An explanation might lie in the balance between triggering factors 
and negative feedback mechanisms, such as microbial products and IL-1ra, respectively. Indeed, 
primary mast cells secrete IL-1b in an NLRP3-dependent fashion upon stimulation with microbial 
constituents.16 Intriguingly, depletion of the maternal microbiota prevented skin disease in 
neonates of mice carrying Nlrp3 mutations, and antibiotic treatment of these neonatal mice 
reduced disease severity.26 Hence, microbiome constituents may inflict skin inflammation 
in SchS too, and might be responsible for the variation in (skin) disease severity as the skin 
microbiome varies greatly among healthy individuals as well as skin locations.27 Moreover, PBMCs 
from symptomatic SchS patients were hyperresponsive to lipopolysaccharide (LPS), resulting in 
enhanced IL-1b secretion.6,28,29 
In lesional skin of SchS patients, the DPU patient and the reported psoriasis patients neutrophils 
were IL-17-positive, which may be true for other neutrophilic dermatoses as well. Indeed, IL-17 
positive neutrophils were reported in one FCAS patient so far.31 IL-1b, IL-17 and poly:IC strongly 
induced AMPs in SchS and controls keratinocytes. In vivo, only lesional SchS skin displayed strong 
AMP expression, which correlated with the extent of the cellular infiltrate. This suggests that 
neutrophil-derived IL-17 may cause epidermal activation in SchS skin lesions. AMPs have several 
functions, including leukocyte chemotaxis. Hence, AMP induction in SchS lesional epidermis 
could lead to a vicious circle of inflammation in both the epidermal and dermal compartments.
Limitations of the study are that we used relatively small sample numbers, and that we used 
semi-quantitative immunohistology for some of the analyses. However, a sample size of eight 
patients with SchS is quite large for such a rare disease.
To conclude, dermal mast cells of SchS patients produce IL-1b in lesional and non-lesional 
skin. We propose the following course of events causing cutaneous inflammation in SchS: mast 
cells that are hypersensitive to pathogen- or microbiome-associated molecular patterns secrete IL-
1b, which leads to recruitment of neutrophils, that in turn secrete IL-17 which induces epidermal 
AMP production, whereupon AMPs promote leukocyte chemotaxis. Our data suggest that IL-1b 
and IL-17 may play a role in other (neutrophilic) dermatoses, and show epidermal involvement in 
neutrophilic urticarial dermatosis.
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Abstract
Schnitzler’s syndrome (SchS) is a disabling autoinflammatory disorder, characterized by a chronic 
urticarial rash, an M-protein, arthralgia, and other signs of systemic inflammation. Anti-IL-1b 
antibodies are highly effective, but the pathophysiology is still largely unknown. Here we studied 
the effect of in-vivo IL-1 inhibition on serum markers of inflammation and cellular immune 
responses.
Eight patients with SchS received monthly s.c. injections with 150mg canakinumab for six 
months. Blood was drawn several times for measurement of serum markers of inflammation and 
for functional and phenotypic analysis of both freshly isolated and TLR-ligand-stimulated PBMCs. 
All data were compared to results from healthy controls. 
IL-6 levels in serum and in lysates of freshly isolated PBMCs and serum MRP8/14 and S100A12 
concentrations correlated with disease activity. In vitro, LPS stimulation resulted in higher IL-6 and 
IL-1b production in PBMCs from symptomatic SchS patients compared to healthy controls, whereas 
patient cells were relatively hyporesponsive to poly:IC and Pam3Cys. The mRNA microarray of 
PBMCs showed distinct transcriptomes for controls, symptomatic patients and anti-IL-1-treated 
patients. Numbers of T- and B-cell subsets as well as M-protein concentrations were not affected 
by IL-1 inhibition. Serum free light chain levels were elevated in four out of eight patients.
In conclusion, patient PBMCs are hyperresponsive to LPS, and clinical efficacy of IL-1b 
inhibition in patients with SchS is associated with in-vivo and ex-vivo suppression of inflammation. 
Interestingly, patient PBMCs showed divergent responses to TLR2/6, TLR3 and TLR4 ligands. Our 
data underscore that IL-1b plays a pivotal role in SchS.
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Introduction
Schnitzler’s syndrome (SchS) is a chronic disabling autoinflammatory disorder, characterized 
by a chronic urticarial rash, a monoclonal component (M-protein), arthralgia and other 
signs and symptoms of systemic inflammation, with the long-term risk of development of a 
lymphoproliferative disorder.1-3 The mean age of onset is 51 years, and a positive family history has 
never been reported. The etiology is unknown, but a pathophysiological clue has been provided 
by the efficacy of anti-interleukin-1 (IL-1) treatment 1,4-11, and IL-1b inhibition in particular.12-14 
However, when IL-1 inhibition is discontinued, symptoms will rapidly return after stopping the 
IL-1 receptor antagonist (IL-1Ra) anakinra, or will gradually return after stopping canakinumab, 
a monoclonal anti-IL-1b antibody. This implies that the disease process continues upstream of 
IL-1b.13 Also, whereas markers of systemic inflammation all normalize, M-protein concentrations 
remain unaffected during anakinra and canakinumab treatment.13 
Previous case reports showed that peripheral blood mononuclear cells (PBMCs) or monocytes 
from symptomatic SchS patients produced more IL-1b and IL-6 upon LPS-stimulation compared 
to control PBMCs.9,15,16 Here, we studied the effect of several Toll-like receptor (TLR) ligands on 
IL-1b, IL-6 and tumor necrosis factor alpha (TNFa) production by PBMCs of eight classical and 
variant SchS patients, including two variant patients with mosaicism of mutations in NLRP3 that 
were recently described.17 Moreover, we performed these experiments, as well as serum cytokine 
measurements, leukocyte subset analyses and serum free light chain analyses, on blood samples 
collected during a symptomatic episode, anakinra treatment, and at several time points during a 
trial with canakinumab 13 in order to investigate disease-specific characteristics and the effect of 
IL-1 on these markers.
Patients, materials and methods
Patients and patient samples
The study was approved by the local medical ethical committee. Eight patients with SchS, either 
classical or variant type, and 17 healthy controls that were age- and sex-matched as much as 
possible provided written informed consent. Patients stopped anakinra in order to enter the 
canakinumab trial and multiple blood samples were collected.13 Polymorphonuclear cells (PMNs) 
and PBMCs were isolated during anakinra treatment, during disease relapse after discontinuation 
of anakinra (symptomatic episode), 14 days and six months after the first monthly canakinumab 
injection, and upon disease relapse after discontinuation of canakinumab. At each time point, 
blood samples from a matched healthy donor control were collected too. B- and T-cells were 
isolated from blood samples collected during anakinra, canakinumab and during the symptomatic 
phase. Serum samples were also taken at those occasions, as well as three and seven days and 
then monthly after the first canakinumab injection. 
PBMC and PMN processing
PBMCs were isolated from EDTA-blood using Ficoll-paque Plus (GE Healthcare, Eindhoven, The 
Netherlands) separation, and PMNs were isolated from the pellet by lysing erythrocytes with a 
hypotonic 155 mM NH4Cl, 10 mM KHCO3 lysis buffer. For RNA isolation, five million cells of each 
sample were dissolved in 1 ml Trizol (Invitrogen, Bleiswijk, The Netherlands) and stored until 
further processing. For protein analysis, five million cells were lysed with a lysisbuffer (50 mM 
Tris (pH 7,4), 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 10% glycerol, 1% Triton X-100, 40 mM 
b-glycerophosphate, 50 mM sodium fluoride, 200 mM sodium vanadate, supplemented with 
protease inhibitor cocktail (Roche, Mannheim, Germany)) and stored at -80°C until measurement. 
PBMC culture
PBMCs isolated at the five indicated time points were also used for in vitro experiments. Patient 
(N=8) and control (N=17) cells were stimulated for 24 hours with LPS (TLR4 ligand, 0,1, 1, 10 
ng/ml) (Sigma, St Louis, MO, USA; Escherichia coli serotype 055:B5, purified in our own lab), 
Pam3Cys (TLR2/6 ligand, 10 µg/ml) (EMC Microcollections, Tubingen, Germany), poly:IC (TLR3 
ligand, 5 µg/ml) (InvivoGen, Toulouse, France), or no ligand. For IL-17 assays, cells were stimulated 
for seven days with heat-killed Candida albicans (106/ml). Supernatants were collected and stored 
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at -80°C. Cytokine concentrations in serum, supernatants and lysates were measured by means 
of enzyme-linked immunosorbent assays (ELISAs): IL-1b (R&D, DY 201E), IL-6 (Sanquin, M9316), 
TNFa (R&D, DY210E), IL-17 (R&D, DY317E), MRP8/14  and S100A12 as previously described.18,19
RNA extraction and quantitative real-time polymerase chain reaction (qPCR)
mRNA was extracted and first-strand cDNA was generated and amplified by means of qPCR 
as previously described. Specific qPCR primers were designed with Primer Express 1.0 Software 
(Applied Biosystems) and purchased from Biolegio (Nijmegen, The Netherlands). By means of 
the comparative delta-delta cycle times (∆∆Ct) method, relative mRNA expression levels of all 
examined genes were calculated.
Microarray 
A microarray using the Illumina Direct Hybridization Assay (performed by ServiceXS, Leiden, 
The Netherlands) was performed on purified whole blood RNA samples from two classical SchS 
patients and one IgG variant case with myeloid-restricted NLRP3 mosaicism. Integrity of the RNA 
samples was confirmed by Eukaryote Total RNA Nano Bioanalyzer analysis. The microarray data 
were further analyzed by loading the log expression values into Partek Genomics Suite Software 
(Version 6.4; Partek, Inc., St Louis, MO). To correct for large overall expression differences between 
the arrays a quantile normalization was performed including all arrays. In addition, to adjust for 
the baseline expression level of each of the individual patients in the different subgroups, a 
correction for the factor ‘individual’ was performed, as one would do for a batch correction, 
using the batch removal option from the software. 
Flow cytometric analysis
T-lymphocyte subsets
To detect intracellular expression of the transcription factors Foxp3, RORgt and Tbet in CD3+CD4+ T 
cells, Ficoll-isolated PBMCs were first labeled with CD3(UCHT1)-ECD and CD4(SFCI12T4D11)-PC7 
(Beckman Coulter), and subsequently fixed and permeabilized using Fix/Perm buffer (eBioscience), 
labeled with FoxP3(PCH101)-FITC (eBioscience), RORgt(AFKJS-9)-APC and T-bet(4B10)-PE (Santa 
Cruz Biotechnology, Santa Cruz, CA) and measured by five-color flow cytometry (FC500, Beckman 
Coulter). Data were analyzed using CXP software (Beckman Coulter). Isotype controls were used 
for gate settings.
B-lymphocyte subsets
Cells from heparinized blood were phenotypically analyzed in a 10-color MoAb conjugate 
combination using a NaviosTM instrument with 10-color PMTs and three solid-state lasers 
(Beckman Coulter, Fullerton, FL). The list mode data files were further analyzed using KaluzaTM 
software (Beckman Coulter). In order to guarantee that the optics, laser, fluidics and fluorescence 
intensity were stable during all measurements calibration was performed using Flow Check Pro 
Fluorospheres (Beckman Coulter) and Cyto-Cal Multifluor + Violet Fluorescence Alignment Beads 
(Thermo Scientific, Fremont, CA). After erythrocyte lysis (BD Pharm-Lyse, BectonDickinson) cells 
were washed with PBS with 1% bovine serum albumin before being labeled with fluorochrome-
conjugated mAbs. After incubation for 30 min at 4°C in the dark, cells were washed twice to 
remove unbound antibodies and analyzed. For cell surface staining, the following mAbs were 
used: IgD-FITC, IgM-PE (both from Dako, Denmark) and CD3-ECD, CD4-PECy5.5, CD27-PECy7, 
CD20-PacB, CD45-KromeOrange, CD56-APC, CD8-APC-Alexa Fluor700 and CD19-APC-Alexa 
Fluor750 (all from Beckman Coulter, Marseille, France). Subsequently, the various lymphocyte 
subpopulations were analyzed on the flow cytometer using CD45/SSC to gate the lymphocyte 
population.
M-protein and free light chain analyses
To detect and quantify the presence of an M-protein, agarose gel electrophoresis and 
immunofixation were performed on the Hydrasys (Sebia, Evry, France) according to the 
manufacturer’s protocol. Serum free light chain analysis was performed on a BNII analyzer 
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 16Figure 16.1. Serum concentrations of IL-6, MRP8/14 and S100A12, and PBMC-associated IL-6 correlate with disease activity. A. Serum IL-6 levels in controls, and in Schnitzler’s syndrome (SchS) 
patients with or without NLRP3 mosaicism during anakinra (IL-1Ra) treatment, a symptomatic episode, at 
several time points during a canakinumab (anti-IL-1b antibody) trial, and during relapse after canakinumab 
withdrawal. B. IL-6 concentration in lysates of freshly isolates peripheral blood mononuclear cells (PBMCs)
of SchS patients with or without NLRP3 mosaicism. C. Correlation of serum and cell-associated IL-6 
concentrations in SchS patients. D. Serum MRP8/14 and E. S100A12 concentrations during anakinra 
treatment, a symptomatic episode, and 28 days after a single injection with canakinumab.
(Siemens, Marburg, Germany) using Freelite reagents (The Binding Site Ltd, Birmingham, UK) 
according to the manufacturer’s protocol.
Statistical analysis
A repeated-measures analysis of variance (ANOVA) using SPSS v16.0 (SPSS Inc) was performed on 
the delta-Ct (∆Ct) values of the qPCR data corrected for primer efficiency. ∆Ct is the difference 
between the Ct of the target gene and the reference gene (RPLP0). The ELISA data were analyzed 
by a Student’s T-test with unequal variances. Fold changes and p-values of the microarray data 
for the contrast, patients versus controls, were calculated by conducting a multifactorial ANOVA 
on the factor ‘treatment’.
Results
Proinflammatory cytokines and S100 proteins in serum, PBMCs and PMNs
Proinflammatory cytokine concentrations were measured in serum from patients under anakinra, 
during symptoms, and several time points upon initiating canakinumab treatment.
Compared to controls, serum IL-6 was elevated in all patients during active disease, to 
become undetectable or very low during anakinra or canakinumab treatment (Figure 16.1A). The 
Chapter  16
186
presence or absence of NLRP3 mosaicism did not make a difference. IL-17 was undetectable in 
all and TNFa in most serum samples (data not shown). Serum IL-1b was undetectable or very low 
in the samples taken during anakinra treatment and during active disease. Since binding to the 
administered antibodies probably interferes with detection, IL-1b could not be reliably measured 
during canakinumab treatment. Interestingly, clinical relapse was not associated with a rise in IL-6 
concentrations. Cell-associated IL-6 concentrations (measured in lysates from PBMCs that were 
directly lysed after sampling) were also high during the symptomatic phase, and correlated with 
serum IL-6 concentrations (R2=0,86, Figure 16.1B,C). We could not detect any IL-1b, IL-6 or IL-17 
protein in neutrophil lysates (data not shown). 
Myeloid-related protein 8 (MRP8, or S100A8), MRP14 (S100A9) and S100A12 are known 
indicators of systemic inflammation.20-22 Serum MRP8/14 and S100A12 concentrations 
corresponded with disease activity in all SchS patients as they were increased during symptomatic 
episodes and decreased during in-vivo IL-1 inhibition (Figure 16.1D,E). The clinical relapse in 
patient 8 and presence of minimal symptoms in patient 7 at day 28 after the first canakinumab 
dose were reflected by relatively high MRP8/14 and S100A12 concentrations, whereas serum 
IL-6 concentrations were only marginally increased (Figure 16.1A,D,E).13 MRP8/14 and S100A12 
concentrations in active SchS (median 3905 and 485 ng/mL) were higher than in reported healthy 
Figure 16.2. Microarray data. A. Unsupervised clustering of microarray data of peripheral blood 
mononuclear cells from healthy controls (ctr), Schnitzler’s syndrome patients with active disease (nil = 
no treatment), and Schnitzler’s syndrome patients treated with anakinra (IL-1 receptor antagonist, ana) 
or canakinumab (anti-IL-1b antibody, can). Controls and patients as well as symptomatic patients and 
treated patients cluster separately. B. Clustering of the samples for the most significantly upregulated and 
downregulated genes in the symptomatic patients.
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controls (median 340ng/mL and 120 ng/mL) 22,23, and in anakinra-treated patients (median 945 
and 133 ng/mL) and canakinumab-treated patients (median 1195 and 125 ng/mL). Interestingly, 
MRP8/14 serum levels during IL-1 inhibition were significantly higher than in the reported healthy 
controls. The patient data showed considerable heterogeneity. The S100A12 data correlate with 
the MRP8/14 data (R2 0,92, 0,94 and 0,85, respectively).
As neutrophils were reported to possess IL-1b processing capacity 24, we measured cytokine 
mRNA expression levels of circulating PMNs of controls and of patients with active disease or 
during IL-1 inhibition. Both during attacks and during treatment episodes, we found moderate 
expression of IL1B and IL1RN mRNA in neutrophils from two out of two SchS patients, and these 
levels were similar in two control samples (data not shown).
Microarray of circulating PBMCs
As an unbiased approach, we performed a transcriptome analysis of RNA from PBMCs from three 
patients with SchS (one with the NLRP3 mosaicism in myeloid cells) and three matched controls. 
To investigate the effect of IL-1 inhibition on gene expression, we analyzed patient samples drawn 
during symptomatic disease, anakinra and canakinumab treatment. Assessment of unsupervised 
clustering of gene expression levels, normalized for the effect of the individual, revealed that 
controls, symptomatic patients, and treated patients were in separate clusters, with the largest 
difference between control and symptomatic patient samples (Figure 16.2). 
Figure 16.2B shows the clustering of the samples for the most significantly upregulated and 
downregulated genes in the symptomatic patients. Comparison of symptomatic patients to 
patients during IL-1 inhibition showed that S100A12 and IL1B are among the most differentially 
expressed genes during active disease. Both genes are significantly higher expressed in 
symptomatic patients than in anti-IL-1-treated patients and in controls, but mRNA levels during 
canakinumab or anakinra therapy did not differ significantly from those in controls. qPCR analysis 
confirmed the corresponding microarray data (Figure 16.3).
Differential production of proinflammatory cytokines by patient PBMCs 
stimulated with TLR ligands
We assessed the proinflammatory response to LPS, Pam3Cys and poly:IC stimulation of control 
PBMCs and patient PBMCs, sampled either in the symptomatic phase or during treatment with 
anakinra or canakinumab. As PBMCs from our two patients with myeloid mosaicism of NLRP3 
variants constitutively produced high levels of IL-1b and IL-6, whereas PBMCs of controls and 
patients without this mosaicism did not 17, we analyzed the results of the former separately 
(see below). In PBMCs of all patients sampled during a symptomatic episode, IL-1b, IL-6 and 
TNFa production was higher than in healthy controls when the cells were exposed to LPS 1 
ng/mL (Figure 16.4). There was a clear dose response for cells exposed to 0,1 and 1 ng/mL 
LPS (data not shown). During treatment with anakinra or canakinumab, the IL-1b production 
induced by LPS was lower (Figure 16.4). LPS-induced IL-6 production was significantly elevated in 
Figure 16.3. qPCR validation 
of IL1B and S100A12 mRNA 
expression. IL1B and S100A12 
mRNA expression in PBMCs from 
controls (N=17) and patients 
(N=8) during anakinra treatment, 
canakinumab treatment, during 
symptoms, or during relapse after 
canakinumab withdrawal were 
evaluated by means of quantitative 
polymerase chain reaction assays. 
Quantities are depicted relative to 
the mean of controls. 
* p < 0,05, ** p < 0,01. 
Bars: mean +/- SEM. 
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Figure 16.4. LPS-induced production of IL-1b, IL-6, TNFa in PBMCs sampled during active disease 
and IL-1-blocking treatment. PBMCs of patients with Schnitzler’s syndrome without NLRP3 mosaicism were 
sampled during anakinra treatment, a symptomatic episode, at several time points during a canakinumab 
trial, and during relapse after canakinumab withdrawal. These PBMCs and those of healthy controls were 
stimulated with lipopolysaccharide (LPS) 1 ng/mL for 24 hours, and supernatants were collected for ELISAs 
of IL-1b, IL-6 and TNFa concentrations. Bars: median values. * p < 0,05.
Figure 16.5. Pam3Cys- and poly:IC-induced production of IL-1b, IL-6, TNFa in PBMCs sampled 
during active disease and IL-1-blocking treatment. PBMCs of patients with Schnitzler’s syndrome 
without NLRP3 mosaicism were sampled during anakinra treatment, a symptomatic episode, at several time 
points during a canakinumab trial, and during relapse after canakinumab withdrawal. These PBMCs and 
those of healthy controls were stimulated with A. Pam3Cys 10 µg/mL or B. poly:IC 5 µg/mL for 24 hours, 
and supernatants were collected for ELISAs of IL-1b, IL-6 and TNFa concentrations. Bars: median values. 
*** p < 0,001; **** p < 0,0001.
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PBMCs during the symptomatic phase compared to during anti-IL-1 treatment (Figure 16.4). The 
patients with the highest responses were all classical IgM type and had a more severe phenotype 
than the others. No clear difference in proinflammatory cytokine production between patients 
and controls was found upon stimulation with LPS 10 ng/mL. In-vitro addition of IL-1Ra only 
marginally inhibited IL-1b and IL-6 production (only tested at the highest LPS concentration (10 
ng/mL)) in PBMCs of all SchS patients (data not shown).
When cells from SchS patients and controls were exposed to Pam3Cys and poly:IC, production 
of IL-1b and IL-6 was significantly lower in the patients than in controls. Interestingly, the treatment 
condition did not affect this production (Figure 16.5). 
In PBMCs from the two patients with myeloid NLRP3 mosaicism (patients 7 and 8), high 
baseline (hence unstimulated) IL-1b and IL-6 production was seen, as previously reported. 
Addition of IL-1Ra in vitro inhibited this production, pointing to autocrine or paracrine cytokine 
production mediated by IL-1.17 In one of these patients (patient 7), the unstimulated production 
of IL-6 and IL-1b was lower during IL-1 blocking treatment than during the symptomatic phase. 
LPS, Pam3Cys and poly:IC induced production of both cytokines during the symptomatic episode 
in this patient. This was also reduced during both anakinra and canakinumab treatment. The data 
of patient 8 were inconsistent (Figure 16.6). However, in both patients, the production of IL-1b 
and IL-6 was dose-dependent over a range of 0,1 to 10 ng/mL LPS (data not shown).
After 7 days stimulation with heat-killed Candida albicans, IL-17 production by PBMCs of 
patients and controls was similar, irrespective of the disease status of the patients (data not 
shown).
T- and B-lymphocyte analyses
Circulating T-and B-lymphocyte subsets were analyzed by means of flow cytometry during active 
disease and under anakinra and canakinumab treatment. 
Numbers of CD4+ and CD8+ T cells were similar in patients during different treatment settings. 
Also, there was no difference in numbers of FOXP3+ cells, RORgt+ cells and CD25+CD127- (T 
regulatory) cells between patients during IL-1 inhibition, symptomatic patients, and controls 
(Figure 16.7). Regulatory T cell suppressor function as studied in a co-culture suppression assay, 
appeared unaffected: we found no difference between patient and control cells (N=1 ; data 
not shown). There were no B-lymphocyte subset changes either during the different treatment 
settings (Figure 16.8).
Figure 16.6. Spontaneous and TLR2/6-/3-/4-stimulated production of IL-1b and IL-6 in PBMCs of 
NLRP3 mosaic patients. PBMCs of patients with Schnitzler’s syndrome with NLRP3 mosaicism that were 
sampled during a symptomatic episode, anakinra treatment, and canakinumab treatment were exposed 
to LPS 1 ng/mL, Pam3Cys 10 µg/mL poly:IC 5 µg/mL, or no stimulus for 24 hours, and supernatants were 
collected for ELISAs of A. IL-1b, and B. IL-6 concentrations.
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M-protein and serum free light chain concentrations
In our patients, the serum concentration of the M-protein, the diagnostic hallmark of SchS syndrome, 
was not related to disease activity. IL-1 inhibition did not affect paraprotein concentrations in our 
patients either during several years of anakinra treatment or during canakinumab treatment of 
six months. Moreover, in our two patients with the most severe phenotype and in which NLRP3 
somatic mosaicism was found in myeloid cells, only an unquantifiable IgG kappa was found 
(Table 16.1).
The ratio of serum kappa and lambda free light chain levels was reported to be a prognostic 
factor for disease progression in multiple myeloma and other monoclonal gammopathies.25-27 
Hence, we measured this ratio in eight patients, in two of which it was abnormal, especially in 
a female patient with strongly elevated kappa light chain levels. In these and two other patients 
that had increased free light chain levels, we tested free light chains during symptoms and during 
treatment with IL-1 inhibition. We observed no significant changes in serum free light chain 
concentrations in symptomatic SchS patients versus patients in remission due to IL-1 inhibition 
(Table 16.1). 
Discussion
Here, we described the inflammatory response during the symptomatic phase of SchS, during 
treatment with either anakinra or canakinumab, and during relapse after canakinumab withdrawal. 
During the symptomatic phase, the circulating concentrations of IL-6 were elevated, as were the 
protein concentrations of IL-6 and mRNA levels of IL1B in circulating PBMCs. In this phase there 
Figure 16.7. No correlation of treatment status with absolute numbers in several T-cell subsets
CD4+ and CD8+ T-cell subsets were assessed by means of fluorescence-assisted cell-sorting during 
a symptomatic episode, during anakinra or canakinumab treatment, and at the time of relapse after 
canakinumab withdrawal. FOXP3+ cells, RORgt+ cells and CD25+CD127- (T regulatory) cells were measured 
in healthy controls (N=12) and in Schnitzler’s syndrome patients (SchS) during canakinumab treatment (N=8) 
or relapse (N=4). (The triangle indicating 0% RORgt+ cells in SchS canakinumab represents 6 individuals.)
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was also augmented LPS-induced production of IL-1b and IL-6. Finally, the MRP8/14 and S100A12 
concentrations in serum and S100A12 mRNA levels in PBMCs were elevated. All of these were 
normalized during treatment with either IL-1Ra or anti-IL-1b antibodies, and both therapies led 
to a shift of the PBMC transcriptome towards the mRNA signature of healthy controls. Clinical 
relapse several months following canakinumab withdrawal was not associated with a rise in IL-6 
serum concentrations, nor with increased ex-vivo cytokine production by PBMCs. Interestingly, 
irrespective of the treatment condition, PBMCs from SchS patients produced less IL-1b and IL-6 
when exposed to Pam3Cys or poly:IC when compared to controls.
Taken together, our data point to an IL-1b-driven disorder, which is in line with the clinical 
efficacy of IL-1b inhibition and with the few reports on in-vitro findings. Recently, we reported 
two variant SchS patients with NLRP3 mosaicism in the myeloid lineage, whose PBMCs produced 
high constitutive levels of IL-1b and IL-6, which was abolished by in-vitro addition of IL-1Ra.17 
Previously, a few SchS cases were described in which PBMCs or monocytes from symptomatic 
patients produced more IL-1b and IL-6 upon LPS-stimulation compared to control PBMCs 9,15,16, 
and that this could be reversed by in-vivo anakinra treatment.15 Spontaneous IL-1b production by 
PBMCs was present in one more patient 16, but absent in others.15 
In our patients with NLRP3 mosaicism, the hyperproduction of IL-1b is probably due to an 
overactive NLRP3 inflammasome. In those without this genetic defect the trigger of the enhanced 
IL-1b production is still unclear. The increased IL-1b concentrations in turn lead to production 
of IL-6 and an autocrine or paracrine production of more IL-1b. The latter became clear from 
the striking reduction in spontaneous IL-1b and IL-6 production by PBMCs from the two NLRP3 
Figure 16.8. No correlation of treatment status with absolute numbers in several B-cell subsets 
Several B-cell subsets were assessed by means of fluorescence-assisted cell-sorting during a symptomatic 
episode, during anakinra or canakinumab treatment, and at the time of relapse after canakinumab 
withdrawal. In patient 3 (IgMκ stable 3,4 mg/L, died in accident before relapse occurred) higher IgM+ 
cells were present, especially on Day 168; not in others even though some had higher IgM M-component 
concentrations.
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Table 16.1. M-protein and serum free light chain levels during IL-1 inhibition
Patient Sex  Treatment M-protein Serum free light chains
number   subtype g/L κ (mg/L) l (mg/L) Ratio κ / l
1 M anakinra IgMκ & IgMl 10,1 14,4 46,8 0,31
none (Day 4 after 
anakinra withdrawal) 7,7 14,7 53,9 0,27
canakinumab Day 28 10,6 18,6 51,0 0,36
relapse (post-
canakinumab (canak.)) 9,3    
2 F none (pre-anakinra) IgGκ 6,8 88,3 12,4 7,12
anakinra 5 59,9 9,4 6,35
none (Day 5 after 
anakinra withdrawal) 4,1 69 13,5 5,11
canakinumab Day 28 4,3 59,1 11,6 5,09
relapse (post-canak.) 3,7 78,4 12,2 6,43
3 M none (Day 5 after 
anakinra withdrawal) IgMκ 2,7    
canakinumab Day 28 3,5 19,1 19,8 0,96
4 M anakinra IgGκ 2,9    
none (Day 5 after 
anakinra withdrawal) 2,8    
canakinumab Day 28 3,2 14 10,3 1,36
relapse (post-canak.) 2,5    
5 M anakinra IgMκ 4,4    
none (Day 6 after 
anakinra withdrawal) 4,5 19,4 12,4 1,56
canakinumab Day 28 5    
relapse (post-canak.)     
6 M anakinra IgMκ 6,8 25,5 20,6 1,24
none (Day 4 after 
anakinra withdrawal) 6,1 29,2 15,8 1,85
canakinumab Day 28 5,6 29,3 17,9 1,64
relapse (post-canak.) 6,3    
7 F anakinra IgGκ n.d.    
none (Day 3 after 
anakinra withdrawal) n.d. 15,3 15,1 1,01
canakinumab Day 28 n.d.    
relapse (post-canak.) n.d.    
8 M anakinra IgGκ n.d. 17 13,5 1,26
none (Day 5 after 
anakinra withdrawal) n.d. 26,9 18,7 1,44
canakinumab Day 14 p.n.q. 18,4 18,1 1,02
canakinumab Day 28 
(relapse) p.n.q. 23,9 23,2 1,03
Free light chains in the serum were measured with the Freelight assay, reference values: serum free kappa 
chains (3,3 - 19,4 mg/L); serum free labda chains (5,7 - 26,3 mg/L); ratio kappa / labda light chains (0,26 - 
1,65). Abnormal values are indicated in bold. n.d. is not detectable; p.n.q. is present but not quantifiable.
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mosaic patients when IL-1Ra was added in vitro 17, the reduced IL1B mRNA and IL-6 protein levels 
in circulating PBMCs during in-vivo IL-1 inhibition, and the lower LPS-induced IL-1b and IL-6 
production in PBMCs sampled during treatment. 
The increased downstream production of cytokines leads to an enhanced acute phase 
response with elevation CRP. The amount of IL-6, which is readily measurable in the circulation, is 
probably responsible for the fever and other signs of systemic inflammation. 
How should we envisage the lack of a rise in serum IL-6 and the still downregulated cytokine 
production when the patients relapsed several months after canakinumab withdrawal? Probably 
the best explanation is that the relapse is compartmentalized in its early phase, possibly at the 
level of the skin, which is continuously exposed to pathogen-associated molecular patterns as 
well as endogenous ligands of pattern recognition receptors (PRRs). Indeed, PRRs were implicated 
in the pathophysiology of other inflammatory skin diseases, such as AIM2 (absent in melanoma 
2) and dectin-1 in psoriasis.28-30 The IL-1b-positive mast cells we recently identified in SchS skin 
might not only be involved in the chronic urticarial rash (Chapter 15), but also in the induction of 
systemic inflammation.
As the triggers of the IL-1b production are currently unclear, it is of great interest that we found 
that TLR4 plays a clear role - and not TLR2, TLR3 and TLR6. It implies that either exogenous TLR4 
ligands (such as LPS) or putative endogenous TLR4 ligands (like heat-shock proteins, minimally 
modified LDL, HMGB1, SAA3, MRP8/14, and S100A12 31,32) function as triggers for the attacks. 
Especially MRP8/14 and S100A12 are interesting in this regard, as serum levels are associated 
with disease activity in SchS. Several in-vitro studies and mouse models of other inflammatory skin 
diseases have demonstrated a role for TLR4, e.g. nickel-induced allergic contact dermatitis and 
graft versus host disease.30 Intriguingly, expression of both TLR4 and NLRP3 mRNA is extremely 
low in healthy epidermis, which one might consider a protective strategy preventing continuous 
stimulation by constituents of the microbiome, for example.29 We detected a relatively decreased 
responsiveness to Pam3Cys (TLR2/6 ligand) and poly:I:C (TLR3 ligand) of the SchS patient PBMCs 
(sampled both during symptoms and anti-IL-1 treatment) compared to control PBMCs. To our 
knowledge, such divergent responses to TLR2, TLR3, TLR6 and TLR4 ligands have not been 
reported in inflammatory diseases before. We speculate that the relative hyporesponsiveness 
to TLR2/6 and TLR3 ligands might be a protective mechanism in response to the enhanced 
proinflammatory response to TLR4 ligands.
Our findings regarding elevated spontaneous cytokine production are reminiscent of findings 
in patients with CAPS in which systemic inflammation is caused by activating NLRP3 mutations. 
CAPS patient PBMCs constitutively produce IL-1b, and treatment with IL-1Ra results in both a 
dramatic clinical improvement and substantive downregulation of LPS-induced IL-1b secretion 
by the patients’ cells in vitro.33 Typically, the enhanced proinflammatory response to lower LPS 
concentrations we found in SchS, is also seen in other autoinflammatory diseases, whereas at the 
relatively high concentration of 10 ng/mL, the difference is much smaller or absent.34
Hence, current and previous findings suggest that an inflammasome is primed in PBMCs in 
SchS like in CAPS, which explains a substantial IL-1b release in the absence of the ‘second hit’ 
which is usually required. Also, the relative hyporesponsiveness to TLR2/6 and TLR3 agonists (this 
study) and ATP 16, and low IL18 mRNA levels in monocytes despite high IL-18 serum levels 35 
suggest the presence of several negative feedback mechanisms.
We previously reported that in the two patients with NLRP3 mosaicism in the myeloid cell 
lineage, high constitutive IL-1b and IL-6 production by PBMCs was blocked by in-vitro addition 
of IL-1Ra.17 Here we show that this high baseline production was not or only partially impaired 
while patients were treated with IL-1 inhibitors. This implies ongoing activation of IL-1b, and 
may explain why these two patients had the most severe phenotypes and their disease quickly 
relapsed upon cessation of anti-IL-1 treatment.13 TLR2/6 and TLR4 ligands induced the production 
of IL-1b and IL-6 in these two patients, but a TLR3 ligand did not. 
In this study we additionally monitored S100 proteins, B- and T-cell subsets, M-proteins 
and serum free light chains. S100A8/A9 (MRP8/14) and S100A12 are released from monocytes 
and granulocytes during activation of the innate immune system and are regarded as markers 
of systemic inflammation.20-22 In CAPS, both MRP8/14 and S100A12 levels mirrored disease 
activity, and were suggested as a sensitive marker even for subclinical disease.21,36 In our study, 
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S100A12 mRNA levels were significantly higher in circulating PBMCs of symptomatic patients 
than in PBMCs of treated patients and controls, and serum protein levels of both MRP8/14 and 
S100A12 correlated with disease activity. In a previous report, serum S100A12 protein levels 
did not correlate with disease activity in SchS, which might have to do with the higher levels 
found in that study.5 Our patient data showed considerable heterogeneity, and in several patients 
persistent elevated MRP8/14 levels under treatment were found compared to healthy controls, as 
was previously reported in CAPS patients.22,36 This may indicate subclinical disease activity that is 
not detected by CRP or IL-6 measurements.
Previously, an increase in transitional B cells, decrease in switched-memory B cells and low levels 
of peripheral blood plasma cells were reported in one SchS patient when compared to healthy 
controls. IL-1Ra treatment had no effect on the patient’s B lymphocytes or the IgM M-protein.37 
Our analyses on T- and B-cell subsets showed no differences between active disease and anti-IL-1 
treatment, nor were there any differences in T-cell subsets between patients and controls. We do 
not know if long-term IL-1 inhibition would affect the T- and B-cell compartments.
An M-protein is one of the diagnostic hallmarks of SchS. We demonstrated that it is not a 
marker for disease activity as the serum concentration of the M-protein was not affected by 
IL-1 inhibition. Moreover, in our two most severely affected patients, only an unquantifiable IgG 
kappa was once found. Still, it cannot be excluded that long-term anti-IL-1 treatment could halt 
a progressive increase in M-protein concentration in view of the B-cell activating property of IL-1b 
(the longest treatment duration of SchS patients on continuous anti-IL-1 treatment is currently 
10 years). Moreover, long-term follow-up of many SchS patients is needed to determine if IL-1 
inhibition can prevent progression to a lymphoproliferative disorder. Indeed, in some patients with 
smoldering or indolent multiple myeloma who were at risk of progression to active myeloma, 
concomitant treatment with IL-1Ra and dexamethasone decreased the myeloma proliferative 
rate.38
The ratio of serum immunoglobulin kappa and lambda light chain levels is a prognostic factor 
for multiple myeloma disease progression.14,15 No such correlation was seen in our SchS patient 
cohort, but in one case, the highest free light chain level was found prior to starting treatment 
with IL-1 inhibition. More measurements comparing pre- and post-IL-1 inhibition serum light 
chain levels are needed to examine a possible association. We conclude that both the intact 
M-protein and the free light chain concentrations are stable biomarkers in SchS patients not 
affected by disease status or therapeutic intervention.
To conclude, clinical efficacy of IL-1b inhibition in patients with SchS is associated with 
suppression of inflammation. We identified MRP8/14 and S100A12 as markers for disease activity 
in SchS. Our collective data underscore that IL-1b plays a pivotal role in SchS, and that TLR4 is 
involved in the enhanced IL-1b production, possibly triggered by MRP8/14 or S100A12, among 
others. Future studies should be directed at the mechanism behind the differential responses to 
different TLR ligands and what drives the pivotal TLR4 response in the disease process. 
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Introduction
This thesis deals with many different topics, with pattern recognition receptors (PRRs) in the 
skin and Schnitzler’s syndrome (SchS) as the common denominators. Fortuity led to this joint 
project of dermatology and internal medicine, two disciplines that are interrelated at many levels. 
Indeed, molecular biology and clinical internal medicine coalesced at several points, and resulted 
in a multifaceted scientific approach to SchS. The cherry atop the pie was the finding of genetic 
variants in NLRP3, an inflammasome-related PRR, in two patients with variant SchS (Chapter 14). 
Here I summarize and discuss the major findings per chapter. 
Part 1. Epidermal responses to skin barrier disruption
Inspired by the skin barrier abnormalities in psoriasis and atopic dermatitis (AD), we analyzed the 
effect of experimental skin barrier disruption on the expression of cornified envelope structural 
proteins and keratinocyte differentiation-regulating proteins in Chapter 2. We found that skin 
barrier disruption induces a temporary imbalance between cornification and desquamation in the 
upper epidermal layers, resulting in barrier recuperation. This imbalance is also seen in lesional 
psoriatic and AD skin, in which the epidermis is trapped in what could be regarded as a chronic 
barrier repair phase. Therefore, therapies should be directed at improving barrier function by 
resolving the imbalance between cornification and desquamation. However, a decades-long 
supremacy of the immunological paradigm in psoriasis and AD has led to the dominance of 
immunosuppressive therapies for these diseases. The application of emollients to the skin is the 
foundation of psoriasis and AD treatment, and a simple means of artificially restoring the skin 
barrier. As it is very time-consuming and bothersome to patients, more sophisticated agents di-
rected at restoring normal epidermal differentiation are required for treatment compliance. Oral 
acitretin is one of the few therapies capable of restoring epidermal proliferation and differentia-
tion, but its mechanism of action is unclear, and side effects include lipid spectrum disturbance 
and elevated liver enzymes. Coal tar is a highly effective ancient topical therapy for AD, and is 
effective in psoriasis as well. Unfortunately, the daily application of this malodorant substance im-
pairs the willingness of many doctors and patients to prescribe or use it. Our group recently elu-
cidated the mechanism of action of coal tar in AD. Coal tar induces skin epidermal differentiation 
through the activation of the aryl hydrocarbon receptor, and interferes with T-helper 2 (Th2) cell 
signaling.1 Regardless of toxicological hurdles that need to be overthrown, the aryl hydrocarbon 
receptor is a potential therapeutic target for the development of more patient-friendly mecha-
nism-based therapies for AD and psoriasis.
Deficiencies in skin barrier formation or repair expose epidermal cells to environmental stimuli 
such as microbial components. In Chapter 3 we investigated the effect of experimental skin 
barrier disruption on the expression of host defense genes in uninvolved epidermis of psoriasis 
and AD patients and healthy controls. Skin barrier disruption only marginally affected the mRNA 
expression levels of PRRs, but mRNA and protein expression levels of antimicrobial proteins 
(AMPs) were strongly elevated. This increase was similar in psoriasis and AD patients and healthy 
controls. This proves that non-lesional epidermis of AD patients is equally capable of producing 
massive amounts of AMPs upon skin barrier perturbation as uninvolved skin of psoriasis patients, 
although in AD lesional skin, AMP levels are much lower than in psoriatic plaques. This can be 
explained by our finding that Th2 cytokines partly reduced the Th1 cytokine-mediated induction 
of several AMPs in cultured keratinocytes of healthy controls, AD and psoriasis patients alike. 
Part 2. Pattern recognition receptors in skin
In Chapter 4, we reviewed the current knowledge on the role of PRRs in fungal, (myco)bacterial, 
viral, and parasitic skin infections, and in the treatment of skin infections. Even though a large 
number of studies address the role of PRRs in skin diseases, an even greater challenge awaits since 
the exact mechanisms often remain unknown, or need to be verified in models with primary human 
cells or in vivo. A fascinating topic is the role of the skin microbiome in modifying host defense 
responses. Instead of constantly fighting the entire resident microbiota, the skin can discriminate 
between harmless commensal microorganisms and harmful pathogenic microorganisms. Recent 
studies have started to shed light on the underlying mechanisms and point towards the induction 
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of immune tolerance by commensals. Inhibition of PRR signaling is a means of achieving immune 
evasion, as was shown for fungi.2 The human skin microbiome varies greatly among individuals 
and contains many different bacterial species with distinct predilection for certain body sites.3,4 
The particular composition of the local skin microbiome may also modulate the response to skin 
barrier disruption, and influence primary immune disorders of the skin. 
The roles of PRRs in immune disorders affecting the skin were reviewed in Chapter 5. PRRs 
evolved to protect organisms against pathogens, but excessive signaling can induce immune 
responses that are harmful to the host. Putative PRR dysfunction is associated with numerous 
immune disorders that affect the skin, such as systemic lupus erythematosus, the cryopyrin-as-
sociated periodic syndrome (CAPS), and primary inflammatory skin diseases including psoriasis 
and AD. As yet, the evidence is often confined to genetic association studies without additional 
proof of a causal relationship. However, insight in the role of PRRs in the pathophysiology of some 
disorders has already resulted in new therapeutic approaches based on immunomodulation of 
PRRs. The prototype of a PRR-targeting therapy is imiquimod, a synthetic agonist of TLR7 and to a 
lesser extent TLR8.5,6 Imiquimod has potent antitumor and antiviral properties and is an approved 
topical therapy for superficial basal cell carcinoma, actinic keratosis and genital warts.7,8 However, 
the disadvantage of such immunomodulation is excessive immune responses, as imiquimod often 
induces local skin inflammation at the application site, it can aggravate psoriatic lesions and even 
induce de novo psoriasis.9-12 In the universe of PRRs, it is all about keeping the balance.
Chapter 6 provides a comprehensive overview of the expression of PRRs in the skin. We found 
that most PRRs that were known at that time were present in normal epidermis, and that mRNA 
expression levels of the potent PRRs NLRP3 and TLR4 were hardly detectable. Only a few genes 
were differentially induced in psoriasis (CLEC7A (dectin-1), TLR4 and MRC1) or AD (MRC1, IL1RN 
and IL1B) compared to normal epidermis. A remarkably high expression of CLEC7A mRNA was 
observed in psoriatic epidermis and this was corroborated by immunohistochemistry. In cultured 
primary human keratinocytes, CLEC7A expression was induced by the psoriasis-associated cyto-
kines interferon-g (IFNg), IFNa and IL-17. Keratinocytes were unresponsive, however, to dectin-1 
ligands such as b-glucan or heat-killed Candida albicans, nor did we observe synergy with TLR2 or 
TLR5 ligands. Thus, the role of dectin-1 in the biology of skin inflammation and infection remains 
to be explored.
Right at the onset of this PhD project, three high-ranking papers emerged that identified 
AIM2 as an inflammasome-related PRR.13-15 At that time, we found a dramatic increase in AIM2 
mRNA expression in the epidermis of psoriatic lesions. As several commercially available antibodies 
appeared to lack specificity for immunohistochemical staining of skin sections, we set out to 
produce our own specific anti-AIM2 antibody. Meanwhile, we tried to elicit IL-1b production by 
stimulation of keratinocytes with the AIM2 ligand poly-dAdT, but failed to find any response. 
Then, Dombrowski et al. published a paper on AIM2 in psoriasis, that showed functionality in 
keratinocytes 16, although we could not replicate these findings. Our expression studies revealed 
interesting data. AIM2 appears to be induced in keratinocytes in various inflammatory skin 
conditions, as diverse as wound healing and allergic contact dermatitis. It is also quickly induced 
by superficial skin barrier disruption. The exact mechanisms have yet to be unraveled, but we 
found that IFNg and IFNa are the main cytokines that caused AIM2 induction (Chapter 7). 
Since AIM2 is a dsDNA-receptor and human papilloma virus (HPV) is a dsDNA virus, we tested 
AIM2 expression in genital and common warts. Surprisingly, AIM2 expression was enhanced in 
the basal cell layers of the epidermis, but not in the stratum granulosum, in which HPV numbers 
are the highest. As AIM2 was relatively strongly induced in the basal layer of the epidermis 
in several proliferative conditions, we wondered if proliferation was a stimulus. Indeed, we 
found strong induction of AIM2 in proliferating keratinocytes in epidermal constructs. Next, we 
observed basal induction of AIM2 in cutaneous squamous cell carcinoma. Interestingly, prior to 
its identification as a PRR, AIM2 was associated with growth control in several malignancies.17-28 
We hypothesized that AIM2 would be induced in proliferating cells as a tumor suppressor, and 
that loss of AIM2 expression (or function) could be found in poorly differentiated cutaneous 
squamous cell carcinoma and its metastases. Indeed, this appeared to be true (Chapter 8).
“Absent in melanoma 2” received its name as it was absent in a melanoma cell line.28 
In normal skin, we found that Langerhans cells and melanocytes express AIM2. Hence we 
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investigated AIM2 expression in benign and malignant melanocytic skin tumors and hypothesized 
that loss of AIM2 would be seen in melanoma and melanoma metastases. AIM2 appeared to be 
present in most melanomas, but reduced or absent in most melanoma metastases, especially in 
those localized in the lymph nodes (Chapter 8). We suggest that constitutive AIM2 expression in 
melanocytes may be required to maintain growth control, and to prevent metastasizing which 
melanocytes may be more prone to because of the inherent migratory potential of these cells. In 
both keratinocytic and melanocytic tumors, AIM2 may help to prevent metastasizing. These are 
hypotheses at present, but these findings could kindle several new lines of research and revive 
interest in the putative tumor-suppressive role of AIM2. 
First, we have to find out if and how exactly AIM2 influences growth control. Is it an active 
tumor suppressor? Or is its high expression in melanocytes and several skin diseases merely an 
epiphenomenon? We studied expression levels, but functionality should obviously be studied, 
as well as the effect of mutations in certain domains. It would be highly interesting to find out 
if and how the inflammasome-activating function and tumor-suppressive function are related. 
An inflammasome-unrelated effect of AIM2 on tumorigenesis could for example be tested in a 
model that lacks caspase-1, the crucial enzyme for inflammasome activation, e.g. by means of 
caspase-1 siRNA. Knockdown and knockin of AIM2 in multiple (tumor) cell lines could show the 
effect of presence or absence of AIM2 on proliferation and tumorigenesis. In mouse models, 
one could cross Aim2 knockout mice with mice that are prone to tumor development, or expose 
Aim2 knockout mice and controls of the same background to several oncogenic stimuli, such as 
UV-radiation. These are just the first few ideas that come to my mind, and I hope that others will 
be able to elaborate on this topic. In the end, I am happy to add even the slightest grain of sand: 
“Adde parvum parvo magnus acervus erit”, “Add little to little and there will be a big pile”.
Part 3. Schnitzler’s syndrome, a systemic interleukin-1-beta-driven 
disease: a 12-year quest at the Radboudumc*
When I started collecting SchS cases at the end of my first year as a medical student, I could 
not have envisioned how much we would learn about this enigmatic disorder in the following 
years. Based on an index patient, Professor Dr. Jos van der Meer had identified this disease as a 
promising research topic, and under guidance of Dr. Anna Simon and him, I published my first 
scientific paper on the beneficial effect of anakinra in three patients (Chapter 10), and I set out 
to collect cases which we published in a review (Chapter 9). At the start of my full-time PhD 
trajectory, the research gained momentum and was fueled by the expertise of the dermatology 
laboratory, most notably from Professor Dr. Joost Schalkwijk and Dr. Patrick Zeeuwen. The trial 
with anti-IL-1b antibodies offered a unique opportunity to collect patient samples during different 
treatment settings. In hindsight, we are fortunate that we collected all of these samples, since 
now we can correlate in-vitro data with the newly identified data on somatic mosaicism. Also, the 
keratinocytes and fibroblasts we collected for in-vitro stimulation provided a source of non-bone-
marrow-derived DNA for assessment of NLRP3 mosaicism.
We identified IL-1, and later IL-1b in particular, as the key cytokine involved in the pathogenesis 
of SchS (Chapters 10-16). The phenotypical similarities to CAPS and the therapeutic effect of 
IL-1 inhibition offered the first clues. Technological advances in genetic testing enabled us to 
investigate somatic mosaicism in SchS. Indeed, whereas in 2004, conventional Sanger sequencing 
of whole blood DNA of our SchS patient 7 showed no NLRP3 mutations, in 2012 a p.F523L 
mutation was found in 17% of NLRP3 copies in whole blood of this patient by means of exome 
sequencing. Hence, this unbiased approach revealed a mutation in the very gene that is mutated 
in CAPS. Moreover, the p.F523L mutation caused a severe neonatal-onset phenotype in two 
patients with CAPS.29 The late onset and milder phenotype in the SchS patient is probably due to 
the restricted occurrence of the NLRP3 mutation in 10% of the myeloid cells, which we identified 
by means of next-generation sequencing (NGS). In addition, we identified a p.K435E variant in 
exon 3 of NLRP3 in about 30% of the myeloid cells of our most severely affected SchS patient. This 
variant is predicted to be pathogenic, and peripheral blood mononuclear cells (PBMCs) of both 
patients spontaneously produce high amounts of IL-1b. Interestingly, the variants are not present 
in T- or B-lymphocytes, keratinocytes, or fibroblasts of these patients, and present as myeloid-
lineage-restricted mosaicism. This is the first time that myeloid-lineage-restricted mosaicism was 
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found in a non-malignant disease (Chapter 14).
Somatic mosaicism of NLRP3 has also been reported in neonatal-onset CAPS patients.30,31 In 
these CAPS patients, there was no significant difference in mutation frequency between seve-
ral leukocyte subsets and buccal mucosa.31 In contrast, in our two SchS patients, the mosaicism 
was restricted to the granulocytes and monocytes. We speculate that in the CAPS patients, the 
mutation occurred rather early in embryogenesis, as both mesenchymal and ectodermal tissues 
were equally affected. In our patients, the mutational event took place soon after differentia-
tion of the myeloid precursor cells, leading to mosaicism in both granulocytes and monocytes. 
The myeloid-confined NLRP3 mosaicism, late age of onset, lack of family history, and (transient) 
gammopathy differentiate these two SchS patients from the known spectrum of CAPS patients. 
However, as the name CAPS implies association with NLRP3 mutations, we propose that SchS 
patients with NLRP3 mosaicism should be added to the spectrum of CAPS, as ‘Schnitzler’s syn-
drome variant CAPS’.
Genetic analyses of NLRP3 in other SchS patients by other investigators previously showed 
three variants of which the pathogenic potential is unclear. In two cases, a p.V198M variant was 
detected, but both had unaffected family members carrying this variant.32,33 It was also reported 
in families with classical CAPS phenotypes 33, and in patients with autoinflammatory phenotypes 
who concurrently had mutations in the Mediterranean fever gene 34 or a low-penetrance mutation 
in the TNFRSF1A gene.35 The population allele frequency of this variant is about 0,5%, and as it 
shows variable expressivity and reduced penetrance, the pathophysiological significance of this 
variant remains to be determined.33 In another patient, the p.Q703K polymorphism was found 
36, which is the most common NLRP3 polymorphism with an allele frequency of 5% in healthy 
Caucasians.37 This polymorphism is thus not suspected to play a major inflammation-initiating 
role, but it could modify inflammation under certain circumstances, as it was reported to lead to 
gain-of-function alterations.38 
Deeper insight in the pathophysiological role of IL-1b was gained from in-vitro studies with 
PBMCs (Chapters 13,14,16). PBMCs from patients without NLRP3 mosaicism that were sampled 
during symptoms produced more IL-1b and IL-6 upon stimulation with the TLR4 ligand lipopoly-
saccharide, and this effect was abolished in PBMCs that were sampled during anti-IL-1 therapies. 
Interestingly, PBMCs from the two patients with NLRP3 mosaicism constitutively produced more 
IL-1b and IL-6, regardless of the in-vivo treatment status, and this was largely to completely 
abolished by in-vitro addition of IL-1Ra. These data imply a strong positive feedback loop, and 
complete dependence of IL-6 overproduction on IL-1 in SchS. The excessive spontaneous in-vitro 
production of IL-1b in the NLRP3 mosaics correlates with their severe phenotype.39 Fascinatingly, 
patient PBMCs showed decreased responses to stimulation with TLR2/6 and TLR3 ligands, which 
could indicate compensatory suppression of other inflammatory pathways than the TLR4 path-
way. Finally, our study of the skin pathophysiology identified mast cells as the main source of IL-1b 
production in the skin and provided a model for the chain of events leading to the neutrophilic 
urticarial dermatosis (Chapter 15). 
The presence of the paraprotein is the most puzzling aspect of SchS. Accumulating data 
suggest that the M-protein is caused by the systemic inflammation rather than vice versa. IgM 
depositions in skin were present in only 30% of cases, and the partial or entire lack of efficacy 
of rituximab in 80% (16/20) of cases shows that lowering the paraprotein concentration rarely 
attenuates the systemic inflammation.40 Further, the calculations of Jain et al. show that accidental 
concomitant occurrence of IgM monoclonal gammopathy and chronic urticaria is not a probable 
explanation in all of these patients.41 The third option is that the systemic inflammation instigates 
the formation of a plasma cell clone. This hypothesis is supported by different lines of evidence. 
First, several cases have been reported in which an M-protein became detectable several years 
after the onset of symptoms.40 In a Norwegian patient, for example, this was 13 years.42 Indeed, a 
few cases have been reported that lacked the M-protein.43-46 These are not (yet) regarded as SchS 
patients, as they do not fulfill the Strasbourg diagnostic criteria 47, but these may well develop 
a monoclonal gammopathy over time. Further, in nine cases, more than one M-protein was 
present, which suggests a common factor capable of inducing plasma cell clones. IL-6 and IL-1b 
have been implicated in the development of hematological malignancies. IL-6 is a growth factor 
for B-lymphocytes, and crucial to the growth, proliferation and survival of myeloma cells. Through 
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its stimulation of osteoclast function it also influences the tumor microenvironment in the bone 
marrow of patients with myeloma.48 In myeloma, IL-1 was found to stimulate IL-6 release from 
marrow stromal cells, which stimulates the survival and proliferation of plasma cells. Anakinra 
decreased IL-6 levels but left numbers of myeloma cells unaffected. However, combination 
therapy of anakinra with dexamethasone (which induces apoptosis) induced myeloma cell 
death. Moreover, in some patients with smoldering or indolent multiple myeloma who were at 
risk of progression to active myeloma, concomitant treatment with IL-1Ra and dexamethasone 
decreased the myeloma proliferative rate.49 Thus, speculatively, combination therapy of anakinra 
with dexamethasone in SchS might clear the malignant clone and M-protein. To date, only one 
case of reduction of the M-protein concentration during anakinra treatment has been reported 
in SchS.50 Neither several years of monotherapy with IL-1Ra, nor several months of treatment 
with IL-1b antibodies or an IL-1R fusion protein led to a decrease in the monoclonal gammopathy 
in any other patient.39,51 As in general, M-protein levels remain rather stable during anti-IL-1 
treatment, one could speculate that IL-1 inhibition is capable of blocking further growth of the 
plasma cell clone, but cannot induce its demise. The short follow-up during anti-IL-6 treatment 
did not show a reduction in M-protein concentrations.52 Long-term follow-up in more patients is 
needed to determine if IL-6 inhibition can affect the plasma cell clones in SchS. Indeed, anti–IL-6 
treatment has been successfully used in Castleman’s disease, a rare lymphoproliferative disorder.53
During our 12-year quest, we learned much about SchS from the 270 cases and 
pathophysiologic studies reported by our international colleagues, and the additional 11 patients 
we have personally seen and studied, without whose clinical data, blood and skin samples this 
thesis would not have come about. Still, many questions remain. Awareness is rising worldwide, 
and many more cases remain to be identified. The variety in phenotypes hampers proper 
diagnosing, and the clinical presentation of patients that fulfill all criteria except for the mandatory 
monoclonal gammopathy, has led us to think that a monoclonal gammopathy may well surface 
during follow-up. It also remains to be further established whether the monoclonal gammopathy 
has any pathophysiological role in itself or whether it is merely an effect of the chronic IL-1b 
overproduction. In that case, we might have to reconsider the classification of the monoclonal 
gammopathy as a major criterium. This would however be problematic, as other disorders such 
as CAPS, adult-onset Still’s disease and Sweet’s syndrome would fit the diagnosis too, and it 
would also be harder to distinguish some cases of chronic spontaneous urticaria. In fact, CAPS 
and some cases of SchS might even be part of a disease spectrum, just as the phenotypically 
diverse familial cold-associated periodic syndrome, Muckle-Wells syndrome and neonatal-onset 
multiorgan inflammatory disease were all placed under the common denominator CAPS, even 
though several cases are NLRP3-mutation-negative. CAPS usually starts during childhood, but a 
few adult-onset CAPS patients are known.54 One could argue that these could be SchS patients, 
or in case of the lack of a monoclonal gammopathy ‘Schnitzler-like syndrome’. This intricate 
matter will have to be discussed, and insights may change along with scientific progress. 
Another question that arose from the bedside was how to explain the minimal systemic in-
flammation and the still downregulated proinflammatory cytokine production by PBMCs when 
the patients relapsed several months after canakinumab withdrawal. I speculate that the auto-
stimulatory loop of IL-1b production is profoundly impaired by the long-acting IL-1b antibodies, 
and that the extremely gradual rise in unbound IL-1b caused the very gradual development of 
symptoms. In contrast, the relapse after IL-1Ra withdrawal is characterized by acute massive 
systemic inflammation, which is due to the sudden availability of the IL-1R for binding of the 
circulating IL-1b. Probably the best explanation for the mild, delayed relapse after canakinumab 
cessation is that the relapse is compartmentalized in its early phase. The skin is a potential first 
focus for reinstituted IL-1b overactivation, as it is continuously exposed to pathogen-associated 
molecular patterns as well as endogenous ligands of PRRs. In Chapter 16, we showed increased 
production of proinflammatory cytokines in PBMCs from symptomatic SchS after triggering of 
TLR4. This may also be the case in dermal mast cells, that were identified as the source of IL-1b 
in SchS skin in Chapter 15. By inciting local inflammation, IL-1b production by dermal mast cells 
could possibly incite systemic inflammation as well. Further, as indicated in Part 2, PRRs are im-
plicated in the pathophysiology of other inflammatory skin diseases, such as AIM2 and dectin-1 
in psoriasis.
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A fascinating question is why solely NLRP3 mutations have been found in both CAPS en SchS, 
and not in other genes of the NLRP3 or other inflammasome pathways. Would these be lethal? 
Would the phenotype be entirely different? Would carriers be asymptomatic? Intriguingly, in 
CAPS, long-term excessive IL-1b signaling does not result in a monoclonal gammopathy, but the 
number of patients over the age of 50 years diagnosed with CAPS is currently small. Further, I 
can only speculate that in SchS the high age of onset makes the aging bone marrow cells more 
vulnerable for malignant conversion. Hypothetically, the presence of mutant (myeloid) cells in the 
bone marrow of SchS patients produces high local concentrations of IL-1b and IL-6, facilitating 
the development of a lymphoproliferative disorder.
Somatic mosaicism is currently a hot topic, and advances in genetic testing have enabled us 
to catch these subtle changes that might have significant clinical consequences. I foresee that 
many (late-onset) disorders that used to be classified as acquired or at least ‘non-genetic’ will turn 
out to be caused by somatic mosaicism. Also, even though rare diseases may be of less interest 
to policymakers, funding sources and the general public, research in these niches often results in 
knowledge that can be extrapolated to more common diseases. Gout patients that respond well 
to IL-1 inhibition, for example, benefit from insights that were generated by research on CAPS 
patients.
We still do not know what triggers or perpetuates the chronic systemic inflammation, but 
the presence of mosaicism of NLRP3 mutations in myeloid cells of two variant SchS patients 
suggests that (mosaicism of) mutations of genes in the IL-1 pathway may be responsible for 
disease in other cases. NGS will facilitate the detection of even low percentages of mutant cells. 
The efficacy of anti-IL-6 treatment in three patients who were unresponsive to IL-1 inhibition 
suggests that in some cases, the defect is downstream of IL-1.52 This could include aberrant 
IL-1R signaling or overproduction of IL-6. In a landmark paper in 2012, Treon et al. described 
a p.L265P mutation in the MyD88 gene in bone marrow samples from 49 out of 54 patients 
with Waldenströms macroglobulinemia. MyD88 is a crucial adaptor protein for the function of 
many Toll-like receptors and the IL-1R, and the p.L265P mutation triggered IRAK-mediated NF-κB 
signaling. In addition, it was associated with a more severe phenotype.55,56 As 12% of SchS cases 
develop WM, the MyD88 p.L265P mutation might be present in a subset of SchS patients as well, 
and perhaps even correlate with malignant progression.
Future investigations on SchS should focus on further genetic studies (NGS) in more patients, 
the functional characterization of genetic variants, and the matching of phenotype, treatment 
and pathogenesis. Functional studies on PBMCs of more patients are needed to show if the 
TLR4-hypersensitivity and TLR2/6- and TLR3-hyposensitivity we found are consistent. The role 
of the monoclonal gammopathy needs to be investigated: is it an epiphenomenon, an effect of 
chronic inflammation, and / or does it contribute to the pathophysiology? We will have to further 
characterize the skin lesions (neutrophilic urticarial dermatosis) and assess which differences and 
similarities exist with other chronic urticarial and neutrophilic skin disorders, such as CAPS and 
adult onset Still’s disease. And last but definitely not least, we will have to optimize treatment 
with IL-1 blockers. Our clinical experience suggests that treatment should be more tailored to the 
individual patient in terms of dose and dosing interval because of variations in disease severity 
and treatment response.
During the past 43 years, SchS has evolved from an elusive little-known disorder to an 
autoinflammatory disorder that is recognized by increasing numbers of dermatologists, 
rheumatologists, allergologists, hematologists and other specialists. Diagnostic criteria have been 
revisited, effective treatments have been identified (IL-1 (and IL-6) inhibition), as well as the risk 
of development of lymphoproliferative disorders, and novel genetic techniques have partially 
shed light on the pathophysiology of SchS. Figure 17.1 summarizes the current knowledge of 
pathophysiological factors that cause the various disease manifestations. Presumably, during the 
next decade, (mosaicism of) mutations of genes in the IL-1 pathway in several other cases of 
SchS will be uncovered. Finally, long-term follow-up will teach us if IL-1 inhibition is capable of 
preventing the development of lymphoproliferative disorders. 
Altogether, we gained some answers, and each of them generated a multitude of new questions. 
That’s the beauty of science.
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*Parts of the discussion of Part 3 were adapted from the latest review on 281 SchS cases.40
Figure 17.1. Schematic overview of the pathophysiology of Schnitzler’s syndrome 
A. We propose the following pathophysiological course of events causing cutaneous inflammation in 
SchS: mast cells that are hypersensitive to pathogen- or microbiome-associated molecular patterns (e.g. 
based on genetic causes such as NLRP3 mutations) secrete IL-1b, which leads to recruitment of neutrophils, 
that in turn secrete IL-17. IL-17 and IL-1b induce epidermal antimicrobial protein (AMP) production by 
keratinocytes, whereupon AMPs promote leukocyte chemotaxis. Neutrophils also release S100A12 and 
myeloid-related protein (MRP) 8/14, putative endogenous TLR4 ligands that can further stimulate IL-1b 
secretion by mast cells.
B. As evidence is lacking, I can only speculate about the factors that cause the arthralgias (and rarely overt 
arthritis) in SchS. IL-1b and IL-6 derived from serum or synovial macrophages may cause synovitis.  
C. Bone pain often occurs at sites of osteosclerosis. IL-1b and IL-6 may be involved in this process too. Serum 
vascular endothelial growth factor (VEGF) levels are elevated in SchS, and VEGF may induce osteosclerosis 
via angiogenesis.
D. Possibly, in the bone marrow, (mutant) myeloid cells produce IL-1b and IL-6, which can both induce 
plasma cell proliferation, and thus might lead to an M-protein-producing clone. IL-1b induces IL-6 release 
from stromal cells, and IL-6 induces the release of neutrophils from the bone marrow into the circulation.
E. In the circulation, neutrophils release MRP8/14 and S100A12, putative endogenous TLR4 ligands, that 
could trigger IL-1 and IL-6 production by monocytes, which would in turn induce IL-6 production by 
endothelial cells.
F. IL-1b and IL-6 cause fever by changing the temperature setpoint in the hypothalamus, and induce the 
production of acute phase reactants C-reactive protein (CRP) and serum amyloid A (SAA) in the liver.
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Introductie
Dit proefschrift bevat een verscheidenheid aan onderwerpen, met als rode draad de zogenaamde 
‘patroonherkenningreceptoren’ in de huid en het Schnitzlersyndroom. In Hoofdstuk 1 worden 
de onderwerpen kort ingeleid, te weten de bouw en functies van de huid; de onderdelen van 
het immuunsysteem; en de ziekten atopisch eczeem, psoriasis en het Schnitzlersyndroom. In 
dit proefschrift hebben wij voornamelijk onderdelen van het aangeboren immuunsysteem 
onderzocht, vandaar dat de titel start met “Innate immunity in the skin”. Gaandeweg het 
proefschrift dringen we steeds dieper in de huid door, tot we bij het Schnitzlersyndroom ook 
uitgebreid het bloed onderzoeken.
Deel 1. Reacties van de opperhuid op verstoring van de huidbarrière
In Deel 1 beginnen we aan de buitenkant van de huid en onderzoeken we wat er gebeurt in 
de opperhuid als we de beschermende barrière die de huid vormt beschadigen. Bij twee veel 
voorkomende ontstekingsziekten van de huid, te weten psoriasis en atopisch eczeem, is er 
namelijk sprake van een verminderde barrièrefunctie van de huid. We verstoren de huidbarrière 
op twee manieren: 1) we verwijderen de hoornlaag door plakband herhaaldelijk op dezelfde plek 
aan te brengen en eraf te trekken, of 2) we lossen een deel van de beschermende vetten van de 
hoornlaag op met een sterke zeep, natriumdodecylsulfaat. In Hoofdstuk 2 beschrijven we dat het 
verstoren van de huidbarrière leidt tot een tijdelijke toename van verhoorning en vermindering 
van afschilfering van de opperhuidcellen, zodat de hoornlaag zich kan herstellen. De verstoring 
van deze balans wordt ook in aangedane huid van patiënten met psoriasis en atopisch eczeem 
gezien, wat betekent dat behandelingen gericht op het herstellen van deze balans een mooi 
supplement of alternatief zouden kunnen vormen voor de huidige behandelingen, die veelal 
gericht zijn op het onderdrukken van ontsteking. 
Door het verstoren van de huidbarrière worden de opperhuidcellen blootgesteld aan allerlei 
omgevingsfactoren, zoals (onderdelen van) micro-organismen. In Hoofdstuk 3 laten wij zien 
dat het verstoren van de huidbarrière leidt tot een sterke toename van eiwitten die bacteriën 
en schimmels kunnen doden (de zogenaamde antimicrobiële eiwitten) in de opperhuid. Deze 
toename is bij gezonde controles en patiënten met psoriasis of atopisch eczeem gelijk. In de 
zieke huid van psoriasispatiënten zijn deze eiwitten ook sterk verhoogd aanwezig, terwijl dat 
veel minder het geval is bij atopisch eczeem. Wij tonen aan dat de productie van antimicrobiële 
eiwitten in gekweekte opperhuidcellen toeneemt als we een ontstekingsstof die bij psoriasis 
een rol speelt toevoegen. Het toevoegen van ontstekingsstoffen die een rol spelen bij atopisch 
eczeem daarentegen doet deze toename weer teniet. Mogelijk is dit de reden dat infecties met 
bacteriën zoals Staphylococcus aureus wel veel op eczeemplekken gezien worden, maar niet op 
psoriasisplekken.
Deel 2. Patroonherkenningreceptoren in de huid
In dit deel behandelen we uitgebreid de patroonherkenningreceptoren. Dit zijn eiwitten van het 
aangeboren immuunsysteem die op en in vele soorten cellen voorkomen en stukjes bacterie, 
virus, of schimmel kunnen herkennen. Ook sommige stoffen die ons eigen lichaam maakt 
worden hierdoor herkend. Na binding van zo’n stof aan de receptor komt een ontstekingsreactie 
op gang, wat onder andere kan leiden tot de productie van de sterk werkzame ontstekingsstof 
interleukine-1 beta (IL-1b). Die stof speelt een sleutelrol in ons onderzoek naar het Schnitzler-
syndroom. In Hoofdstukken 4 en 5 behandelen wij de huidige kennis met betrekking tot de 
rol van patroonherkenningreceptoren in respectievelijk infectieziekten en ontstekingsziekten van 
de huid. Hoofdstuk 6 geeft een overzicht van welke van deze receptoren aanwezig zijn in de 
opperhuid van gezonde controles, psoriasisplekken en atopisch-eczeemplekken. We laten onder 
andere zien dat de receptor dectin-1 meer aanwezig is in aangedane huid van psoriasispatiënten, 
en dat ontstekingsstoffen die bij psoriasis een rol spelen de aanwezigheid van dectin-1 
kunnen oproepen in gekweekte opperhuidcellen. Verder vonden we dat NLRP3 en TLR4, twee 
receptoren die sterke ontstekingsreacties kunnen veroorzaken in witte bloedcellen, vrijwel niet 
voorkomen in opperhuidcellen. In de eerste maand van mijn promotietraject ontdekten wij dat 
de patroonherkenningreceptor AIM2 zeer sterk aanwezig is in de opperhuid in psoriasisplekken, 
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terwijl deze zo goed als afwezig is in gezonde opperhuid. Wij vonden dit dermate interessant 
dat we vervolgens een test hebben ontwikkeld om AIM2 aan te kunnen tonen. We ontdekten 
daarmee dat AIM2 meer voorkomt in verschillende acute en chronische ontstekingsziekten 
van de huid (Hoofdstuk 7). Aangezien er in verschillende van deze huidziekten sprake is van 
toegenomen celvermeerdering, onderzochten wij de aanwezigheid van AIM2 ook in goedaardige 
(wratten) en kwaadaardige (plaveiselcelcarcinoom) tumoren van opperhuidcellen (Hoofdstuk 
8). Daarbij vonden wij een sterke toename van AIM2 in deze tumoren. In zogenaamde slecht 
gedifferentieerde plaveiselcelcarcinomen en uitzaaiingen van deze vorm van huidkanker bleek 
AIM2 echter te zijn afgenomen. Het zou kunnen dat AIM2 een rol speelt bij het (pogen tot) 
onderdrukken van celvermeerdering en uitzaaiing. 
AIM2 staat voor ‘absent in melanoma 2’ (‘afwezig in kwaadaardige moedervlekken 2’). Wij 
tonen aan dat deze naam niet klopt, want AIM2 is juist sterk aanwezig in zowel goedaardige 
als kwaadaardige moedervlekken (melanomen). Ook bij de melanomen was AIM2 beduidend 
afgenomen in de uitzaaiingen, hetgeen past bij de hierboven genoemde mogelijke rol van AIM2. 
Een kankeronderdrukkende rol van AIM2 wordt ook in de literatuur beschreven. Daarnaast 
brengt AIM2 ontstekingsreacties tot stand. Of die twee functies met elkaar verband houden, is 
nog niet bekend.
Deel 3. Interleukine-1 beta speelt een sleutelrol in het Schnitzlersyn-
droom: een zoektocht van 12 jaar in het Radboudumc
Deel 3 beslaat het grootste deel van dit proefschrift. Dit komt doordat ik reeds in 2003 tijdens mijn 
studie Geneeskunde ben gestart met het verzamelen van ziektegeschiedenissen van patiënten 
met het Schnitzlersyndroom. Sindsdien hebben we veel geleerd over deze intrigerende ziekte. 
Bij het Schnitzlersyndroom is er sprake van spontane ontsteking in het lichaam. Zo’n ziekte met 
spontane ontsteking noemen we een ‘auto-inflammatoire’ (‘vanzelf ontstekende’) ziekte. De 
ontsteking uit zich in rode, soms branderig aanvoelende vlekken op de huid (netelroos, ‘urticaria’), 
koorts, gewrichtspijn en botpijn. In het bloed zijn ontstekingscellen en -stoffen verhoogd en 
wordt een abnormaal eiwit gevonden. Dit abnormale eiwit, een zogenaamd M-proteïne, behoort 
tot de antistoffen (immunoglobulinen). 
We hebben het Schnitzlersyndroom op vele manieren bestudeerd: literatuurstudie, 
behandeleffecten, ontstekingsstoffen en afweercellen uit het bloed, ontstekingskenmerken in de 
huid, en, niet in de laatste plaats, genetische afwijkingen die aan de ziekte ten grondslag liggen. 
Ook hebben we in een internationale werkgroep de klinische verschijnselen, de diagnostiek en 
behandelingen besproken. Bij die gelegenheid had ik de eer om professor dr. Liliane Schnitzler te 
ontmoeten, naar wie de ziekte is vernoemd. In 1972 beschreef zij de eerste patiënt. Zij heeft het 
voorwoord bij dit proefschrift geschreven.
In Hoofdstuk 9 beschrijven we de klinische kenmerken, behandelingsresultaten en prognose 
van de 94 patiënten met het Schnitzlersyndroom die in 2006 bekend waren. Dergelijke 
samenvattingen van de literatuur (reviews) vormen een praktisch houvast voor artsen. In 2014 
heb ik wederom een review geschreven over 281 patiënten, aangezien er inmiddels veel meer 
ervaring was opgedaan met nieuwe behandelingen; ook was er meer onderzoek gepubliceerd 
dat de ontstaanswijze van de ziekte onder de loep had genomen. Terwijl voorheen de meeste 
behandelingen niet erg aansloegen, zagen wij 11 jaar geleden een zeer goed effect van anakinra 
(Hoofdstuk 10). Anakinra is een geneesmiddel dat de receptor blokkeert van het eerder genoemde 
krachtige ontstekingseiwit IL-1. Professor dr. Jos van der Meer was op het idee gekomen dit 
medicijn uit te proberen, aangezien in een tijdschrift was beschreven dat anakinra zeer effectief 
was in enkele patiënten met het cryopyrine-geassocieerde periodieke syndroom (CAPS), waarvan 
de klachten deels overeenkomen met die van patiënten met het Schnitzlersyndroom. Omdat 
anakinra dagelijks ingespoten moet worden, gingen we op zoek naar langerwerkende middelen 
tegen IL-1. Canakinumab, dat specifiek de werking van IL-1b (en niet ook IL-1a) blokkeert, 
is effectief in CAPS en hoeft maar eens per een tot twee maanden ingespoten te worden bij 
CAPS-patiënten. Tijdens een studie van zes maanden met maandelijkse canakinumabinjecties 
zagen wij ook bij patiënten met het Schnitzlersyndroom een zeer goed effect op de klachten 
van de patiënten. De tekenen van ontsteking in het bloed verdwenen eveneens grotendeels 
(Hoofdstukken 11 en 12). Dit was het bewijs dat IL-1b (en niet IL-1a) een sleutelrol speelt in 
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het ontstaan van de klachten. Bij één patiënt keerden de klachten al binnen enkele weken weer 
terug; hij werd weer klachtenvrij na herstart van de behandeling met anakinra. Bij de andere 
patiënten bleven de klachten tot zes maanden na de laatste canakinumabinjectie weg. Er zijn dus 
grote verschillen tussen patiënten. Bij iedere patiënt moeten we dus een persoonlijk behandelplan 
opstellen. Dit laatste had mijn vader 30 jaar geleden in een stelling bij zijn proefschrift ook al 
gezegd (zie ‘Stellingen’ behorend bij dit proefschrift). 
Het succes met IL-1b-remming gaf aan dat we ons op deze ontstekingsstof moesten richten 
om het ontstaan van de klachten bij het Schnitzlersyndroom te begrijpen. Dankzij onze toegewijde 
patiënten konden wij vele experimenten uitvoeren: zij stonden tijdens perioden met klachten 
en tijdens behandeling met anakinra of canakinumab vele buizen bloed af, zodat wij konden 
onderzoeken wat er met de ontstekingsstoffen en ontstekingscellen in het bloed gebeurde. 
Iedere keer werd bij deze experimenten ook bloed van gezonde controles onderzocht, zodat we 
de uitkomsten ook hiermee konden vergelijken. Wij vonden dat verschillende ontstekingsstoffen 
in het bloed van de patiënten verhoogd waren tijdens klachten en weer normaal werden tijdens 
behandeling met IL-1-remmers (Hoofdstukken 10, 11, 12 en 16). Verder ontdekten wij dat 
bepaalde groepen witte bloedcellen van patiënten in het laboratorium meer IL-1b produceerden 
dan cellen van controlepersonen indien de patroonherkenningreceptor TLR4 werd geactiveerd. 
Dit was alleen het geval bij cellen die waren afgenomen tijdens een periode van klachten, en niet 
tijdens behandeling met IL-1-remmers. Verder vonden wij dat deze bloedcellen van patiënten juist 
minder sterk reageerden op prikkeling van de patroonherkenningreceptoren TLR3 en TLR2/6 dan 
cellen van controles (Hoofdstukken 13 en 16). Wij denken dat de verhoogde gevoeligheid voor 
prikkeling van TLR4 tijdens klachten leidt tot een vicieuze cirkel van ontsteking en dat de andere 
receptoren mogelijk als reactie hierop minder gevoelig zijn.
In de stukjes huid die de patiënten hadden afgestaan bleek IL-1b aanwezig te zijn in mestcellen, 
een bepaald soort ontstekingscel die zich in weefsels bevindt. In mestcellen van controles was 
dit niet het geval (Hoofdstuk 15). IL-1b kan IL-17, een andere ontstekingsstof, oproepen. We 
vonden dat IL-17 wordt geproduceerd door granulocyten (de witte bloedcellen die het meest 
voorkomen in de ontstoken huid van patiënten met het Schnitzlersyndroom) in de huid van onze 
patiënten, maar ook door mestcellen in de huid van zowel patiënten als controles. IL-1b en IL-17 
kunnen productie van de eerdergenoemde antimicrobiële eiwitten in de opperhuid stimuleren. 
In de aangedane huid van patiënten vonden wij inderdaad een forse toename van veel van 
deze eiwitten in de opperhuid, terwijl voorheen werd gedacht dat de ontsteking in de huid bij 
deze ziekte zich tot de onderliggende lederhuid beperkte. In gekweekte opperhuidcellen van 
patiënten en controles zetten IL-1b en IL-17 aan tot de productie van meerdere antimicrobiële 
eiwitten, waarbij geen verschil tussen patiënten en controles werd gevonden.
Het zeer goede effect bij patiënten met het Schnitzlersyndroom van behandeling met de IL-
1-remmers anakinra en canakinumab is de belangrijkste klinische bevinding van dit proefschrift. 
De belangrijkste wetenschappelijke bevinding is de ontdekking van genetische veranderingen 
(mutaties) in het NLRP3-gen in bloedcellen van twee patiënten met de IgG variant van het 
Schnitzlersyndroom (Hoofdstuk 14). NLRP3 is een patroonherkenningreceptor waarvan de 
activatie leidt tot de productie van IL-1b. In de reeds genoemde ziekte CAPS zijn mutaties in het 
NLRP3-gen ook de oorzaak van de ziekte. Het meest fascinerende van onze bevinding is dat de 
mutaties alleen gevonden werden in een deel van de witte bloedcellen, de zogenaamde myeloïde 
lijn, terwijl ze niet voorkwamen in andere witte bloedcellen, opperhuidcellen of bindweefselcellen 
van deze patiënten. Wanneer mutaties alleen in een deel van de lichaamscellen voorkomen, noemt 
men dat genetisch mozaïcisme. Dit komt veel voor bij kankercellen. In de huid is het eveneens 
een bekend fenomeen, omdat mozaïcisme van mutaties in opperhuidcellen of pigmentcellen tot 
uiting kan komen in specifieke streepvormige patronen in de huid. Mozaïcisme in bloedcellen is 
echter veel lastiger te onderscheiden. De zeer gevoelige methoden die wij hebben gebruikt voor 
het vinden van genetisch mozaïcisme zijn pas kort geleden beschikbaar gekomen. Zodoende 
waren wij de eersten die dit fenomeen hebben beschreven in de myeloïde lijn bij een niet-
kwaadaardige aandoening. Wij verwachten dat de komende jaren in vele andere aandoeningen 
mozaïcisme van mutaties gevonden gaat worden.
Het M-proteïne is een belangrijk criterium voor de diagnose Schnitzlersyndroom. Wij 
vonden geen effect van IL-1-remming op de concentraties van het M-proteïne of van vrije lichte 
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ketens, die deel uitmaken van het M-proteïne (Hoofdstuk 16). Het is tot nu toe niet duidelijk 
of het M-proteïne bijdraagt aan de ziekte, of dat de aanwezigheid hiervan het gevolg is van 
de jarenlange ontsteking in het lichaam. Wij denken dat continue productie van IL-1b leidt tot 
‘ontsporing’ van plasmacellen, die vervolgens het M-proteïne gaan produceren. Een dergelijk 
effect van IL-1b en de ontstekingsstof IL-6 (die door IL-1b opgeroepen wordt) is beschreven in 
andere ziekten. Hoewel het bij de meeste patiënten met het Schnitzlersyndroom blijft bij de 
aanwezigheid van het M-proteïne, ontwikkelt zich na 10 jaar bij 15% van de patiënten een vorm 
van witte-bloedcelkanker (Hoofdstuk 9). Daarom moeten deze patiënten levenslang door de 
behandelaars vervolgd worden. Aangezien de behandeling met anakinra pas sinds 2004 wordt 
toegepast, is nog niet duidelijk of remming van IL-1 het ontstaan van deze vormen van kanker 
kan voorkomen.
Gedurende de afgelopen 43 jaar is het Schnitzlersyndroom uitgegroeid van een ongrijpbare 
onbekende ziekte naar een auto-inflammatoire ziekte die wordt herkend door steeds meer 
dermatologen, reumatologen, internisten, hematologen en andere specialisten. De diagnostische 
criteria zijn herzien, effectieve behandelingen zijn gevonden, het risico op het ontstaan van 
witte-bloedcelkanker is duidelijk geworden, en verschillende studies hebben stukjes van de 
ontstaanswijze van de ziekte ontrafeld. In dit proefschrift hebben wij gepoogd een bijdrage 
te leveren aan de kennis omtrent de ontstaanswijze van het Schnitzlersyndroom en effectieve 
behandelingen voor onze patiënten. Ik verwacht dat de komende jaren meer genetische 
afwijkingen die verband houden met de functie van IL-1b in andere patiënten zullen worden 
ontdekt. Tot besluit, het vervolgen van patiënten op de lange termijn zal ons leren of behandeling 
met IL-1-remmers de ontwikkeling van witte-bloedcelkanker kan voorkomen. 
Al met al hebben wij enkele antwoorden gekregen, die ieder weer vele nieuwe vragen opriepen. 
Dat is het mooie van wetenschap.
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flow cytometry.
Verpleegkundigen van poli Blauw (Algemene Interne Geneeskunde) van het Radboudumc; beste 
Sarah, Anne-Marie, Annemieke, Marga, Yvonne, Riëtte, Angela, Marijke, Marti, Mieke, Mariëtte 
en Ria, hartelijk dank voor de bloedafnames, het oplossen van de canakinumabsamples en voor 
de gezelligheid op de poli tijdens de canakinumabtrial.
Dr. Evelien Bodar, beste Evelien, jou leerde ik in de periodieke-koortswerkgroep kennen als een 
perfectionistische en betrokken arts en onderzoeker en fijne collega. Mede dankzij jou hebben 
de eerste Schnitzlersyndroompatiënten in 2004 anakinra gekregen. 
Professor dr. Jeroen van der Hilst, beste Jeroen, bedankt voor de samenwerking in de periodieke-
koortswerkgroep. Ik herinner mij zowel je bloedserieuze gedachtengangen over ‘jouw’ amyloid 
als je hilarische grappen.
Professor dr. Joost Drenth, beste Joost, bedankt voor de samenwerking in de periodieke-
koortswerkgroep, waarbij ik je scherpe, opbouwende kritiek en spitsvondige humor kon 
waarderen.
Beste dr. Sanne Smeekens, dr. Marije Oosting, (bijna dr.) Mark Gresnigt, Thijs Remijn, dr. James 
Cheng, dr. Frank van de Veerdonk en dr. Theo Plantinga, bedankt voor de samenwerking in het 
lab Experimentele Interne Geneeskunde.
Professor dr. Gosse Adema, beste Gosse, dank voor de prettige evaluatiegesprekken en verfrissende 
inhoudelijke discussies in het kader van het RIMLS PhD mentorprogramma. Bedankt voor het 
ter beschikking stellen van samples voor de pilotexperimenten met betrekking tot expressie van 
AIM2 in virusgeïnfecteerde dendritische cellen en in tumorcellijnen, waarvoor ik ook dr. Barbara 
te Riet-Schulte en dr. Marleen Ansems wil bedanken.
Dr. Sandra Tjabringa, beste Sandra, bedankt dat ik gebruik heb mogen maken van samples van 
jouw 3D-huidmodellen. Beste Lilie Ong, dank voor je hulp bij het maken van de AIM2-bevattende 
vectoren.
Dr. Marijke Kamsteeg, beste Marijke, bedankt dat ik gebruik heb mogen maken van de 
huidsamples die jij afnam na barrièreverstoring van de huid.
Hanna Niehues, beste Hanna, met jou werd ons lab een gezellige, hardwerkende promovenda 
rijker. Bedankt dat je de LCE3A inductie die we vonden na poly:IC-stimulatie gaat opnemen in 
jouw project: ik ben erg benieuwd naar je verdere bevindingen.
Dr. Hans Jacobs, beste Hans, dank voor het uitvoeren van en je uitleg omtrent de metingen van 
de vrije lichte ketens.
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Beste dr. Hans Koenen, Esther van Rijssen en Esther Fasse van het Laboratorium Medische 
Immunologie, bedankt voor jullie inbreng en het verrichten van de T-cel experimenten. Beste dr. 
Frank Preijers en Eugène Verwiel, bedankt voor jullie bijdragen aan het grote pathofysiologie-
artikel (respectievelijk B-cel-analyses en analyse microarray).
Beste mede-AIOS en mede-arts-onderzoekers van de afdeling Dermatologie van het Radboudumc, 
met erg veel plezier werk ik met jullie samen. Collegialiteit staat hoog in het vaandel en daarmee 
hebben we elkaar door drukke perioden heen geholpen. Tijdens de COCOM en met ons Morbus-
Bowlen-team bleek telkens wat een prettig team we zijn. 
Graag wil ik de medewerkers van de administratie van Dermatologie van het Radboudumc, in het 
bijzonder Anja van der Cruijsen, Diny de Heus, Eelke Engelen, Manon van Zandvoort en Wendy 
Peters-Boekhoorn, hartelijk danken voor alle hulp op vele vlakken.
Ook wil ik alle medewerkers van de kliniek en polikliniek Dermatologie van het Radboudumc 
hartelijk danken voor de prettige samenwerking die we gelukkig nog een paar jaar zullen 
voorzetten.
Beste Jan Meeuwissen, Anja Prischmann en Annie Naus, bedankt voor het maken van de mooie 
medische foto’s.
Beste Wilma Janssen, Jeroen Mooren and Henk Arnts van het Centrale dierenlaboratorium, 
hartelijk dank voor de technische ondersteuning bij de dierenexperimenten.
Dr. Mariëlle van Gijn, beste Mariëlle, het duurde even voordat ons enthousiasme over het belang 
van onze bevinding van somatisch mosaïcisme van NLRP3 mutaties in de myeloide lijn door 
editors van een tijdschrift werd gedeeld, maar nu staat het mooi in de JACI. Hartelijk dank voor 
de samenwerking en voor je uitleg over de genetica.
Beste dr. Martin Elferink, dr. Isaac Nijman en dr. Kornelia Neveling, hartelijk dank voor jullie 
bijdragen aan het mosaïcisme-artikel.
Dear Professor Dr. Hiroshi Ichimura and Dr. Raphael Lwembe, thank you very much for your 
hospitality and for teaching me various laboratory techniques during our study on the HIV env 
gene in your laboratory in Kanazawa, Japan, in 2005.
Dr. Daniel Kastner and Dr. Richard Siegel, dear Dan and Richard, thank you very much for your 
kind welcome and guidance during my internship at NIAMS, USA, in 2006. I still benefit from 
the techniques I learned, and it is a pleasure to catch up at the Autoinflammation conferences.
Dear Dr. Michel Simon, Dr. Julie Henry, Professor Dr. Akemi Ishida-Yamamoto, Dr. Noriko Takashita, 
and Professor Dr. Kiyotaka Hitomi, thank you very much for the collaboration on the epidermal 
response to skin barrier disruption.
Dear Dr. Dirk Holzinger, thank you for our collaboration concerning S100 protein levels in serum 
from patients with Schnitzler’s syndrome.
Dear Dr. Ken Abrams and Pauline Pernot from Novartis, thank you for the collaboration during 
the canakinumabtrial.
Lieve Maartje (Katzenbauer), Carolien (Cuijpers), Michelle (van Tongerloo) en Aafke (Derks), al 12 
tot 22 jaar steunen wij elkaar op alle mooie en moeilijke momenten. Bij jullie mocht ik trots zijn op 
mijn hoge cijfers en de eerste gevechten met mascara aangaan. Dank voor jullie aanmoedigingen, 
warme vriendschap en relativerende humor. Ik ben enorm trots op jullie. Mich en Car, lief dat 
jullie af en toe voor Sunera zorgden als ik een manuscript af moest maken - jullie “bijdrage aan 
de wetenschap”, zoals Carolien het noemde.
Lieve Anne (de Bruijn), hartelijk dank voor het zorgen voor Sunera als ik af en toe door moest 
werken. Lieve Loes (van Aken), bedankt voor de sportieve afleiding (mens sana in corpore sano 
est). Lieve Krystelle (Nganou Makamdop) en Anna (Krijger), bedankt voor jullie overzeese steun. 
Krystelle, ik vond het bijzonder dat ik jouw paranimf mocht zijn en fijn om ervaringen te delen. 
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Lieve opa Jan Willems, oma Maria Willems-Lieben, opa Dick de Koning en oma Jeanne de 
Koning-Klein, dank voor jullie stimulerende woorden en warme belangstelling. Als leraar Frans 
(opa Willems) en leraar aardrijkskunde en tevens rector van het Christelijk Lyceum in Zwijndrecht 
(opa De Koning) zouden jullie vast van mijn promotie genoten hebben. Ik mis jullie.
Lieve overige familieleden De Koning, Willems, Coats, Lewis, Pollack, Den Hartog, Heijltjes, 
Welling, Van der Sluijs en De Bruin, dank voor jullie belangstelling. Lieve Lucy (Coats-Lewis), ik 
ben er enorm trots op dat mijn schoonmoeder tegelijk met mij aan het promoveren is. Succes 
met de laatste loodjes van uw proefschrift betreffende de sociaal-culturele determinanten van 
suïcide(pogingen) in Suriname.
Lidwine de Koning, lieve grote zus, jij hebt altijd de weg voor mij gebaand: qua sportclub, 
middelbare school en studiestad vertrouwde ik blind op jouw keuzes. Bedankt voor je nooit 
aflatende zorgzaamheid voor ons allemaal en voor je bemoedigende woorden. Rachid Nejjari, 
beste zwager, bedankt voor je interesse in mijn werk en je betrokkenheid. Lieve Marouan, ik vind 
het heerlijk te zien hoe jij met ongebreideld enthousiasme de wereld bestormt. Lieve Safiya, vier 
weken na Sunera kwam jij ter wereld. Ik wens je alle geluk met je lieve ouders en broer.
Marijn de Koning en Loek van den Boom, lieve zus en zwager, bedankt voor jullie belangstelling 
en gezelligheid. Marijn, ik vind het heel bijzonder dat jij mijn paranimf bent. Van mijn kleine zusje 
ben je uitgegroeid tot een geweldige vrouw en lieve vriendin. Met jouw organisatietalent wordt 
het promotiefeest zeker onvergetelijk. Loek, jij maakt de familie-exercitie compleet: bedankt voor 
het prachtige ontwerp op de omslag van dit proefschrift.
Dr. Rudolf de Koning en Hyacinthe de Koning-Willems, lieve papa en mama, door middel van zowel 
‘nature’ als ‘nurture’ hebben jullie een aanzienlijke bijdrage geleverd aan de persoon die ik ben en 
aan dit proefschrift. Ik prijs mij zeer gelukkig dat ik in jullie warme gezin heb mogen opgroeien. 
Die geborgenheid ervaar ik nog steeds en jullie staan mij geregeld met raad en daad bij. Papa, 
van jou leerde ik om mijn talenten te benutten. Uit ervaring kon je mij vertellen dat promoveren 
10% inspiratie en 90% transpiratie is en dat 200% inzet geen succesvolle data garandeert, maar 
dat promoveren bovenal een cruciale fase is in iemands wetenschappelijke vorming. Ik vind het 
heel bijzonder om te promoveren 30 jaar na jouw verdediging van het proefschrift “Human 
hepatocellular membrane antigens, studies on PLC/PRF/5 cells” te Maastricht op 15 maart 1985. 
Als internist en maag-darm-leverarts heb jij voor vele patiënten individueel veel betekend, en als 
hoofdopleider Interne Geneeskunde van het Canisius Wilhelmina Ziekenhuis heb jij je ingezet 
voor de opleiding van arts-assistenten en je tevens op landelijk niveau ingezet in het Concilium 
Medicinae Internae. Mama, van jou leerde ik multi-tasken en met bewondering zag en zie ik 
hoe je de vele ballen in de lucht hield als arts met een gezin en toenemend zorgbehoevende 
(schoon)ouders. Ik ben er trots op dat jij 40 jaar geleden tot de (slechts) 10% vrouwelijke 
geneeskundestudenten behoorde. Als verpleeghuisarts / specialist ouderengeneeskunde zette jij 
je volledig in voor optimale zorg op maat voor je patiënten en heb jij geholpen de extramurale 
zorg voor ouderen te ontwikkelen in Nijmegen. Tijdens en na mijn zwangerschapsverlof heb je 
meerdere keren heel lief voor Sunera gezorgd als ik aan dit proefschrift werkte. Nu ik moeder 
ben geworden zie ik nog meer hoeveel jullie altijd voor mij gedaan hebben en kan ik alleen maar 
hopen dat ik Sunera net zo’n goede basis kan geven als jullie mij hebben gegeven.
Lieve Ian Pollack, mi gudu, je bent mijn alles. Hoewel jij het vanzelfsprekend vindt, wil ik je 
hier graag bedanken voor je luisterend oor, je wijze adviezen, je relativerende humor, je nooit 
aflatende zorgzaamheid voor Sunera, mij en onze naasten en je onvoorwaardelijke steun. Zonder 
jou had ik dit allemaal niet voor elkaar gekregen. Je maakt mij intens gelukkig en na bijna 7 jaar 
huwelijk is iedere dag samen weer een cadeau. Mi lobi yu.
En tenslotte wil ik jou, onze lieve prachtige Sunera, bedanken dat ik van zo dichtbij mag 
meegenieten van hoe jij onze wondere wereld verkent. In mijn buik en vanuit de box gaf je mij 
de inspiratie voor de eindsprint van dit proefschrift. Je bent mijn zonnetje.
